0001558370-24-01463210-Q Generation Bio Co. 20241106202411061616301616301616301616301616300 0001558370-24-014632 10-Q 66 20240930 20241106 20241106 Generation Bio Co. 0001733294 2834 814301281 DE 1231 10-Q 34 001-39319 241431208 301 BINNEY STREET CAMBRIDGE MA 02142 857-529-5908 301 BINNEY STREET CAMBRIDGE MA 02142 10-Q 1 gbio-20240930x10q.htm 10-Q 0001733294--12-31Q3false0P10YP12Yhttp://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense006620555066753508P2Y1M6D0.060.060001733294us-gaap:CommonStockMember2024-07-012024-09-300001733294us-gaap:CommonStockMember2024-01-012024-09-300001733294us-gaap:CommonStockMember2023-07-012023-09-300001733294us-gaap:CommonStockMember2023-01-012023-09-300001733294us-gaap:RetainedEarningsMember2024-09-300001733294us-gaap:AdditionalPaidInCapitalMember2024-09-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001733294us-gaap:RetainedEarningsMember2024-06-300001733294us-gaap:AdditionalPaidInCapitalMember2024-06-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001733294us-gaap:RetainedEarningsMember2023-12-310001733294us-gaap:AdditionalPaidInCapitalMember2023-12-310001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001733294us-gaap:RetainedEarningsMember2023-09-300001733294us-gaap:AdditionalPaidInCapitalMember2023-09-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001733294us-gaap:RetainedEarningsMember2023-06-300001733294us-gaap:AdditionalPaidInCapitalMember2023-06-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001733294us-gaap:RetainedEarningsMember2022-12-310001733294us-gaap:AdditionalPaidInCapitalMember2022-12-310001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001733294us-gaap:CommonStockMember2024-09-300001733294us-gaap:CommonStockMember2024-06-300001733294us-gaap:CommonStockMember2023-12-310001733294us-gaap:CommonStockMember2023-09-300001733294us-gaap:CommonStockMember2023-06-300001733294us-gaap:CommonStockMember2022-12-310001733294gbio:TwoThousandAndTwentyStockIncentivePlanMember2024-01-310001733294gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember2024-01-310001733294gbio:TwoThousandAndTwentyStockIncentivePlanMember2023-12-310001733294gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember2023-12-310001733294gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember2024-01-012024-09-300001733294gbio:CertainEmployeesDirectorsAndConsultantsMembergbio:ServiceBasedOptionsMember2024-01-012024-09-300001733294gbio:TwoThousandAndTwentyStockIncentivePlanMember2024-01-012024-09-300001733294us-gaap:LetterOfCreditMember2021-07-310001733294us-gaap:ContractsAccountedForUnderPercentageOfCompletionMembergbio:CollaborationAndLicenseAgreementMember2024-09-300001733294us-gaap:EmployeeSeveranceMember2024-09-300001733294us-gaap:EmployeeSeveranceMember2023-12-3100017332942023-11-012023-11-300001733294us-gaap:LeaseholdImprovementsMember2024-09-300001733294us-gaap:FurnitureAndFixturesMember2024-09-300001733294us-gaap:ConstructionInProgressMember2024-09-300001733294gbio:LaboratoryEquipmentMember2024-09-300001733294gbio:ComputerEquipmentAndSoftwareMember2024-09-300001733294us-gaap:LeaseholdImprovementsMember2023-12-310001733294us-gaap:FurnitureAndFixturesMember2023-12-310001733294us-gaap:ConstructionInProgressMember2023-12-310001733294gbio:LaboratoryEquipmentMember2023-12-310001733294gbio:ComputerEquipmentAndSoftwareMember2023-12-310001733294us-gaap:RetainedEarningsMember2024-07-012024-09-300001733294us-gaap:RetainedEarningsMember2024-01-012024-09-300001733294us-gaap:RetainedEarningsMember2023-07-012023-09-300001733294us-gaap:RetainedEarningsMember2023-01-012023-09-300001733294gbio:ModernatxIncMember2024-01-012024-09-300001733294gbio:ModernatxIncMember2023-01-012023-09-300001733294us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001733294us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001733294us-gaap:ConstructionInProgressMember2024-01-012024-09-300001733294gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember2024-01-012024-09-300001733294gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember2024-01-012024-09-300001733294gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember2024-09-300001733294gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember2024-09-300001733294us-gaap:ContractsAccountedForUnderPercentageOfCompletionMembergbio:CollaborationAndLicenseAgreementMember2024-07-012024-09-300001733294us-gaap:ContractsAccountedForUnderPercentageOfCompletionMembergbio:CollaborationAndLicenseAgreementMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember2024-07-012024-09-300001733294gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember2024-01-012024-09-300001733294gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember2024-09-300001733294gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember2024-09-300001733294gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember2024-09-300001733294gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember2024-09-300001733294gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember2024-09-300001733294gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember2024-09-300001733294gbio:TwoThousandAndTwentyStockIncentivePlanMember2024-09-300001733294gbio:AdditionalFrom2017PlanMembersrt:MaximumMembergbio:TwoThousandAndTwentyStockIncentivePlanMember2020-06-110001733294gbio:TwoThousandAndTwentyStockIncentivePlanMember2020-06-1100017332942023-09-3000017332942022-12-310001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001733294us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001733294us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001733294us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001733294us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001733294us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001733294us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001733294us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001733294us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001733294us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001733294us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001733294us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001733294us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001733294us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001733294us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001733294us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001733294us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000017332942023-07-012023-09-300001733294us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001733294gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember2023-03-310001733294gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember2023-03-310001733294gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember2023-03-310001733294gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember2023-03-310001733294gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember2023-03-310001733294gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember2023-03-310001733294gbio:ModernatxIncMembergbio:SharePurchaseAgreementMemberus-gaap:BeneficialOwnerMembergbio:CollaborationAndLicenseAgreementMember2023-03-012023-03-310001733294gbio:AnnualIncrease2021To2030Membersrt:MaximumMembergbio:TwoThousandAndTwentyStockIncentivePlanMember2020-06-112020-06-110001733294gbio:AnnualIncrease2021To2030Membersrt:MaximumMembergbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember2020-06-112020-06-110001733294srt:MaximumMember2024-08-012024-08-310001733294gbio:AtMarketOfferingMember2024-08-012024-08-310001733294gbio:ActiveLeaseMember2024-09-3000017332942021-07-012021-07-3100017332942023-01-012023-09-300001733294srt:MaximumMember2021-07-012021-07-310001733294gbio:ModernatxIncMembergbio:SharePurchaseAgreementMemberus-gaap:BeneficialOwnerMembergbio:CollaborationAndLicenseAgreementMember2023-03-3100017332942021-07-310001733294gbio:AtMarketOfferingMember2024-08-310001733294gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember2023-04-300001733294gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember2023-03-310001733294gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember2023-03-012023-03-310001733294gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember2024-09-300001733294gbio:ModernatxIncMembersrt:MinimumMembergbio:CollaborationAndLicenseAgreementMember2023-03-012023-03-3100017332942024-09-3000017332942023-12-3100017332942024-07-012024-09-3000017332942024-11-0100017332942024-01-012024-09-30xbrli:sharesiso4217:USDgbio:itemgbio:productgbio:securityxbrli:pureiso4217:USDxbrli:sharesTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 10-Qâ€‹QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934 â€‹For the quarterly period ended SeptemberÂ 30, 2024ORâ€‹TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934 â€‹For the transition period from Â toÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words â€œanticipate,â€ â€œbelieve,â€ â€œcontemplate,â€ â€œcontinue,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œmight,â€ â€œplan,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œshould,â€ â€œtarget,â€ â€œwill,â€ â€œwould,â€ or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.The forward-looking statements in this Quarterly Report include, among other things, statements about:â—our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over which we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements;â—the potential achievement of milestones and receipt of payments under our collaboration with ModernaTX, Inc., or Moderna;â—the potential advantages of our non-viral genetic medicine platforms;â—the initiation, timing, progress and results of our research and development programs and preclinical studies and clinical trials;â—the timing of and our ability to submit applications and obtain and maintain regulatory approvals for any product candidates we may develop;â—our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;â—our estimates regarding the potential addressable patient populations for our programs;â—our commercialization, marketing and manufacturing capabilities and strategy;â—our expectations regarding our ability to obtain and maintain intellectual property protection;â—our intellectual property position;â—our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;â—the impact of government laws and regulations;â—our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or may become available; andâ—our ability to maintain and establish collaborations or obtain additional funding. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and stockholders should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report, particularly in the â€œRisk Factorsâ€ Â Table of Contentssection in this Quarterly Report and our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover, we operate in a competitive and rapidly changing environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into.Stockholders should read this Quarterly Report and the documents that we file with the SEC with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.Except where the context otherwise requires or where otherwise indicated, the terms â€œwe,â€ â€œus,â€ â€œour,â€ â€œour company,â€ â€œthe company,â€ and â€œour businessâ€ in this Quarterly Report refer to Generation Bio Co. and its consolidated subsidiary.â€‹â€‹<3 Table of ContentsGeneration Bio Co.INDEXâ€‹â€‹â€‹â€‹<Page(s)PART I â€” FINANCIAL INFORMATIONItemÂ 1.Financial Statements (unaudited)â€‹<5â€‹<Condensed Consolidated Balance Sheetsâ€‹<5â€‹<Condensed Consolidated Statements of Operations and Comprehensive Lossâ€‹<6â€‹<Condensed Consolidated Statements of Stockholdersâ€™ Equity â€‹<7â€‹<Condensed Consolidated Statements of Cash Flowsâ€‹<9â€‹<NotesÂ to Condensed Consolidated Financial Statementsâ€‹<10ItemÂ 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€‹<22ItemÂ 3.Quantitative and Qualitative Disclosures About Market Riskâ€‹<33ItemÂ 4.Controls and Proceduresâ€‹<33PART II â€” OTHER INFORMATIONItemÂ 1.Legal Proceedingsâ€‹<34ItemÂ 1A.Risk Factorsâ€‹<34Item 5.Other Informationâ€‹<34ItemÂ 6.Exhibitsâ€‹<35â€‹<Signaturesâ€‹<36â€‹â€‹â€‹<4 Table of ContentsPARTÂ Iâ€”FINANCIAL INFORMATIONItemÂ 1. Financial Statements (unaudited)Generation Bio Co.Condensed Consolidated Balance Sheets(In thousands, except share and per share amounts)(Unaudited)â€‹â€‹â€‹

funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, pipeline expansion or commercialization efforts, which could adversely affect our business prospects. Although management will continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations when needed or at all.10 Table of ContentsThe accompanying condensed consolidated financial statements reflect the operations of Generation Bio and our wholly owned subsidiary, Generation Bio Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.2. Summary of Significant Accounting PoliciesUse of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the measurement of proportional performance of the performance obligation of our collaboration agreements, accrual of research, and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and otherÂ market-specificÂ or other relevant factors that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.Unaudited interim financial informationThe condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited financial statements as of SeptemberÂ 30, 2024 and for the three and nine months ended SeptemberÂ 30, 2024 and 2023 have been prepared by us pursuant to the rulesÂ and regulations of the Securities and Exchange Commission, or SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rulesÂ and regulations. These financial statements should be read in conjunction with our audited financial statements included in our Annual Report on FormÂ 10-K that was most recently filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of our financial position as of SeptemberÂ 30, 2024, the results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023, and cash flows for the nineÂ months ended SeptemberÂ 30, 2024 and 2023 have been made. The results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of the results of operations that may be expected for theÂ year ending DecemberÂ 31, 2024 or any other period.Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. Updates to our significant accounting policies are discussed below.EmployeeÂ RetentionÂ CreditUnder the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, passed by the United States Congress and signed by the President, we are eligible for a refundable Employee Retention Credit, or ERC, subject to certain criteria. ASC 105, Generally Accepted Accounting Principles, describes the decision-making framework when no clear guidance exists in GAAP for a particular transaction. Specifically, ASC 105-10-05-2 instructs companies to look for guidance for a similar transaction within GAAP and apply that guidance by analogy. As such, forms of government assistance, such as the ERC, provided to business entities would not be within the scope of International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, but it may be applied by analogy under ASC 105-10-05-2. We accounted for the ERC as a government grant in accordance with IAS 20 by analogy under ASC 105-10-05-2. 11 Table of ContentsWe recognized a $2.3 million ERC upon completion of an analysis providing reasonable assurance that we met the conditions set forth in the CARES Act and it was reasonably assured that we will receive the employee retention credit. We recorded the ERC in other long-term assets on our condensed consolidated balance sheet as of September 30, 2024 related to labor costs recognized during 2020 and 2021. The ERC was recorded in research and development expenses and general and administrative expenses proportionately in the manner in which the qualified wages and related costs were classified. We have filed for refunds of the ERC and as of the date of this Quarterly Report, we have not received any refunds.â€‹3. Marketable Securities and Fair Value MeasurementsThe following tables present our marketable securities by security type: â€‹As of September 30, 2024â€‹Â Â Â Â â€‹â€‹Â Â Â Â GrossÂ Â Â Â GrossÂ Â Â Â â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹Gainsâ€‹Lossesâ€‹ValueU.S. treasury securitiesâ€‹$ 177,836â€‹$ 319â€‹$ â€”â€‹$ 178,155â€‹As of December 31, 2023â€‹Â Â Â Â â€‹â€‹Â Â Â Â GrossÂ Â Â Â GrossÂ Â Â Â â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹Gainsâ€‹Lossesâ€‹ValueU.S. treasury securitiesâ€‹$ 197,644â€‹$ 274â€‹$ â€”â€‹$ 197,918â€‹The following table summarizes our marketable securities by contractual maturity as of September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As of September 30, 2024â€‹â€‹Amortizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹ValueLess than one yearâ€‹$ 162,932â€‹$ 163,113Greater than one year but less than two yearsâ€‹â€‹ 14,904â€‹â€‹ 15,042Totalâ€‹$ 177,836â€‹$ 178,155â€‹Our marketable securities as of December 31, 2023 consisted of investments that mature within one year of their purchase date. We assess our available-for-sale securities under the available-for-sale security impairment model inÂ ASC 326, â€œFinancial Instruments - Credit Lossesâ€, or ASC 326,Â as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on our available-for-sale securities is the result of a credit loss. We also evaluate our available-for-sale securities for impairment using a variety of factors including our intent to sell the underlying securities prior to maturity and whether it is more likely than not that we would be required to sell the securities before the recovery of their amortized basis. During the nine months ended September 30, 2024 and 2023, we did not recognize any impairment or realized gains or losses on sales of available-for-sale securities, and we did not record an allowance for, or recognize, any expected credit losses.â€‹12 Table of ContentsThe following tables present our assets that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques that we utilized to determine such fair value:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â FairÂ ValueÂ MeasurementsÂ atÂ SeptemberÂ 30,Â 2024Â Using: (inÂ thousands)â€‹LevelÂ 1â€‹LevelÂ 2â€‹LevelÂ 3â€‹TotalCash equivalents:Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Money market fundsâ€‹$ 5,460â€‹$ â€”â€‹$ â€”â€‹$ 5,460Marketable securities:â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â U.S. treasury securitiesâ€‹Â â€”â€‹Â 178,155â€‹Â â€”â€‹Â 178,155Totalsâ€‹$ 5,460â€‹$ 178,155â€‹$ â€”â€‹$ 183,615â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â FairÂ ValueÂ MeasurementsÂ atÂ DecemberÂ 31,Â 2023Â Using: (inÂ thousands)Â Â Â Â LevelÂ 1Â Â Â Â LevelÂ 2Â Â Â Â LevelÂ 3Â Â Â Â TotalCash equivalents:â€‹â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Money market fundsâ€‹$ 38,210â€‹$ â€”â€‹$ â€”â€‹$ 38,210Marketable securities:â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â U.S. treasury securitiesâ€‹Â â€”â€‹Â 197,918â€‹Â â€”â€‹Â 197,918Totalsâ€‹$ 38,210â€‹$ 197,918â€‹$ â€”â€‹$ 236,128â€‹â€‹â€‹4. Collaboration and License AgreementModerna Collaboration and License AgreementIn March 2023, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Moderna to collaborate on developing treatments for certain diseases by targeting delivery of nucleic acids to liver cells and certain cells outside of the liver. Under the Collaboration Agreement, the parties have agreed to collaborate on preclinical research programs relating to lipid nanoparticle, or LNP, delivery systems and nucleic acid payloads, with each party obtaining certain rights to intellectual property used in and arising out of such research programs. Each party will be solely responsible for its own clinical development and commercialization of products under the Collaboration Agreement. Moderna will reimburse us for the internal and external costs incurred by us in conducting the research programs, to the extent consistent with such research plans and budgets.Moderna has exclusive options, upon payment of option exercise fees, to obtain worldwide, exclusive, sublicensable licenses under specified company intellectual property to develop, manufacture and commercialize (a) products comprising LNP delivery systems and nucleic acid payloads that are directed to (i) up to two liver targets, (ii) up to two non-liver targets and (iii) a third liver or non-liver target and (b) Exclusive Targets, which are Independent Program Products (as defined below) that include messenger RNA, or mRNA, that are directed to gene and protein targets in any of certain agreed-upon immune cell types, referred to as the Cell Target Types. Subject to the exclusivity obligations described below, each party has granted to the other a worldwide, non-exclusive, sublicensable license under certain LNP-related intellectual property arising out of the non-liver ctLNP program, or the Joint Collaboration ctLNP Intellectual Property, to develop, manufacture and commercialize products comprising LNP delivery systems and nucleic acid payloads directed to gene and protein targets in any of the Cell Target Types, or Independent Program Products.Each party is obligated to use commercially reasonable efforts to complete the activities assigned to it under the research plans, and Moderna is further obligated to use commercially reasonable efforts to develop, seek regulatory approval for and commercialize at least one product directed to each target for which Moderna exercises its exclusive license option in at least one indication in the United States and in specified European countries.We have agreed not to, directly or indirectly, alone or with, for or through any third party, develop, manufacture, commercialize or exploit (a) products containing mRNA that are directed to any of the Cell Target Types, during an agreed-upon exclusivity period, which may be extended by payment of extension fees, (b) products directed to any liver 13 Table of Contentstarget or non-liver target during the option periods for those targets, (c) products directed to any liver target or non-liver target for which Moderna has exercised its exclusive license option or (d) products containing mRNA that are directed to any Exclusive Target for which Moderna has exercised its exclusive license option.Under the terms of the Collaboration Agreement, in April 2023, Moderna made an upfront payment to us of $40.0 million, and paid us $7.5 million in prepaid research funding. In addition, we are eligible to receive up to $1.8 billion in milestone payments upon the achievement of specified development, regulatory, commercial, and sales milestone events, research term extension fees and exclusivity extension fees. Subject to reductions in specified circumstances, we will also be entitled to receive tiered royalties: (i) ranging from high-single-digits to low-double-digits on sales of licensed products that are directed to any liver target or non-liver target with respect to which Moderna has exercised its exclusive license option, and (ii) in the single digits on sales of Independent Program Products, including the exclusively licensed Independent Program Products directed to the Exclusive Targets. In consideration for the non-exclusive license granted by Moderna to us under the Joint Collaboration ctLNP Intellectual Property, we have agreed to pay Moderna tiered royalties in the single digits on sales of Independent Program Products that include mRNA, subject to reductions in specified circumstances. Royalties will be paid by each party, on a licensed product-by-licensed product and country-by-country basis, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; or (iii) ten years after the first commercial sale of the applicable licensed product. In addition, in connection with the execution of the Collaboration Agreement, we entered into a Share Purchase Agreement, or the Share Purchase Agreement, with Moderna, pursuant to which we issued and sold 5,859,375 shares of our common stock to Moderna, at a price of $6.14 per share, for an aggregate purchase price of $36.0 million, which closed concurrently with the execution of the Collaboration Agreement and resulted in Moderna becoming a related party. Under the Share Purchase Agreement, Moderna has the right, subject to certain terms and conditions, to purchase up to 3.06% of the outstanding shares of our common stock (on a post-closing basis) in connection with a future equity financing of at least $25.0 million by us.â€‹Moderna Agreement Assessmentâ€‹We assessed the promised goods and services under the Collaboration Agreement, in accordance with ASC 606. At inception, the Collaboration Agreement included one combined performance obligation, which includes the license to the ctLNP technology to target indications outside of the liver and the related research services to develop such technology, as the two items are not distinct in context of the contract. The Collaboration Agreement also provides Moderna with options to receive additional research services and options to receive exclusive licenses. The options to receive exclusive licenses allow Moderna to develop and commercialize product candidates that utilize our ctLNP and ceDNA technology for targets within the liver, as well as utilizing the ctLNP technology to be developed as part of the Collaboration Agreement and our ceDNA technology for targets outside the liver. These options are considered to be a priced at a discount to its standalone selling price and therefore are considered to be material rights.â€‹The initial transaction price included a $40.0 million upfront fee, premium paid over the fair value of the common stock of $13.3 million in connection with shares issued and sold to Moderna under the Share Purchase Agreement, and estimated revenue associated with the payment for research services, including $7.5 million in prepaid research services. We utilized the expected amount method to determine the amount of reimbursement for these activities. We utilized the most likely amount method to determine the amount of consideration to include in the transaction price related to any variable consideration related to exclusivity fees, and milestones, and the royalty payments are constrained based on the royalty constraint. No amounts are included in the transaction price related to these elements.â€‹14 Table of ContentsWe initially allocated the transaction price to each unit of account as follows: â€‹Performance Obligations (in thousands)â€‹Standalone Selling Priceâ€‹Transaction Price Allocated ctLNP technology and research licenseâ€‹$ 52,500â€‹$ 42,576First liver program commercialization option licenseâ€‹â€‹ 7,000â€‹â€‹ 5,677Second liver program commercialization option licenseâ€‹Â 7,000â€‹Â 5,677First non-liver program commercialization option licenseâ€‹Â 11,700â€‹Â 9,488Second non-liver program commercialization option licenseâ€‹Â 11,700â€‹Â 9,488Third liver or non-liver program commercialization option licenseâ€‹â€‹ 6,150â€‹â€‹ 4,987Totalâ€‹$ 96,050â€‹$ 77,893â€‹The transaction price was allocated to each unit of account based on the relative estimated standalone selling prices, over which management has applied significant judgment, of each element. We developed the estimated standalone selling price for combined performance obligation and each of the options to receive licenses primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program and an estimate of the costs to provide services including a reasonable return. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, the probability of success and the time needed to commercialize a product candidate pursuant to the associated license.â€‹On a quarterly basis, we measure proportional performance of the combined performance obligation over time using an input method based on cost incurred relative to the total estimated costs by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is then applied to the transaction price allocated to the combined performance obligation and each of the options to receive licenses. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. All allocated consideration for the material rights is deferred until such time that Moderna exercises its options or the right to exercise the options expires. Upon exercise, we will determine the appropriate revenue recognition methodology and any other implications on the accounting treatment for the arrangement.â€‹During the three months ended September 30, 2024, we recorded additional revenueÂ related to aÂ change in estimate due to revisions in the research plan resulting in a reduction in the estimated timeline of future research services and total estimated costs. The change in estimate resulted in a $6.8 million decrease in the allocated transaction price and a $3.8Â million increase in collaboration revenue, a $3.8 million decrease in deferred revenue and a $0.06 decrease in net loss per share, basic and diluted, for both the three and nine months ended September 30, 2024.â€‹15 Table of ContentsThe following table provides a summary of the transaction price allocated to each unit of account, in addition to revenue activity during the period:â€‹Performance Obligationsâ€‹Transaction Price Allocated â€‹Revenue Recognized Duringâ€‹Revenue Recognized Duringâ€‹Deferred Revenue(inÂ thousands)â€‹As of September 30, 2024â€‹Three Months Ended September 30, 2024â€‹Nine Months Ended September 30, 2024â€‹As of September 30, 2024ctLNP technology and research licenseâ€‹$ 40,409â€‹$ 7,554â€‹$ 15,704â€‹$ 14,549First liver program commercialization option licenseâ€‹â€‹ 5,388â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 4,526Second liver program commercialization option licenseâ€‹Â 5,388â€‹Â â€”â€‹Â 4,526First non-liver program commercialization option licenseâ€‹Â 9,006â€‹Â â€”â€‹Â â€”â€‹Â 7,565Second non-liver program commercialization option licenseâ€‹Â 9,006â€‹Â â€”â€‹Â â€”â€‹Â 7,565Third liver or non-liver program commercialization option licenseâ€‹â€‹ 4,734â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 3,976Totalâ€‹$ 73,931â€‹$ 7,554â€‹$ 15,704â€‹$ 42,707â€‹â€‹5. Property and equipment, netProperty and equipment, net consisted of the following:â€‹September 30,â€‹â€‹ DecemberÂ 31,Â (inÂ thousands)â€‹2024â€‹2023Laboratory equipmentâ€‹$ 14,543â€‹$ 14,859Computer equipment and softwareâ€‹Â 1,422â€‹Â 1,447Furniture and fixturesâ€‹Â 1,293â€‹Â 1,293Leasehold improvementsâ€‹Â 20,909â€‹Â 20,865Construction in progressâ€‹Â 112â€‹Â 7,030â€‹â€‹â€‹ 38,279â€‹â€‹ 45,494Less: Accumulated depreciation and amortizationâ€‹â€‹ (22,269)â€‹â€‹ (19,695)Totalâ€‹$ 16,010â€‹$ 25,799â€‹Depreciation and amortization expense for the three and nine months ended September 30, 2024 was 1.2 million and $3.8 million, respectively. Depreciation and amortization expense for the three and nine months ended September 30, 2023 was $1.3 million and $3.9 million, respectively.In July 2021, we entered into a lease agreement for a manufacturing facility in Waltham, Massachusetts, or the Seyon Lease. On January 31, 2024, we notified Waltham CenterPoint I Investment Group, LLC, or Landlord, of termination of the Seyon Lease due to Landlordâ€™s breach of its obligations to us under the Seyon Lease and returned possession of the premises to Landlord, effective January 31, 2024. On February 14, 2024, Landlord sent us a notice of the termination of the Seyon Lease due to our non-payment of rent. On February 20, 2024, Landlord served us with a complaint, filed in Massachusetts Superior Court, or the Court, with respect to the Seyon Lease. The complaint sought declaratory judgment that

we unlawfully terminated the Seyon Lease and also asserted a claim for breach of contract damages. Following receipt of the complaint, we filed a counterclaim against Landlord asserting breach of contract and violation of Massachusetts General Law Chapter 93A. On October 29, 2024, the Court determined that although we did not have the right to terminate the Seyon Lease, Landlordâ€™s subsequent termination was effective, and that we had alleged sufficient facts to state a claim for breach of contract and violation of Massachusetts General Law Chapter 93A by Landlord. We will continue to vigorously defend our rights with respect to this matter. During the nine months ended September 30, 2024, in connection with the termination of the Seyon Lease, we recorded a non-cash charge of $6.2 million in an impairment of construction in progress. For additional information, refer to Note 7, Leases. 16 Table of Contentsâ€‹6. Accrued ExpensesAccrued expenses and other current liabilities consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹September 30,â€‹
DecemberÂ 31,Â (inÂ thousands)Â Â Â Â 2024â€‹2023Accrued employee compensation and benefitsâ€‹$ 4,505â€‹$ 13,208Accrued external research and development expensesâ€‹Â 600â€‹Â 1,169Accrued professional feesâ€‹Â 654â€‹Â 908Property and equipmentâ€‹â€‹ 33â€‹â€‹ 838Otherâ€‹Â 405â€‹Â 406Totalâ€‹$ 6,197â€‹$ 16,529â€‹In November 2023, following a review of strategic priorities and a determination by our management and board of directors to implement a strategic reorganization, to invest in our ctLNP delivery platform to develop wholly-owned programs for extrahepatic cell types and to develop our iqDNA platform for our lead program in hemophilia A and other programs, we announced a reduction in our workforce of approximately 40%, or RIF, and implemented reductions in operational expenditures including Good Manufacturing Practice readiness and manufacturing expenses. We completed the RIF during the second quarter of 2024. In connection with the RIF, affected employees were eligible to receive one-time severance benefits, including cash severance, temporary healthcare coverage, to the extent they were eligible for and elected such coverage, and transition support services, subject to each such employee entering into an effective separation agreement, which included a general release of claims against us. We offered a retention bonus to certain affected employees if such employees remained in continuous employment with us through their respective separation dates and executed a general release of claims against us.Below is a summary of accrued restructuring costs recorded and included in accrued expenses and other current liabilities during the year ended September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹â€‹Severance and Benefits CostsBalance at December 31, 2023â€‹$ 5,291Cash paymentsâ€‹Â (5,055)Restructuring expensesâ€‹â€‹ 380Adjustmentsâ€‹â€‹ (402)Balance at September 30, 2024â€‹$ 214â€‹During the nine months ended September 30, 2024, we recorded $0.4 million of restructuring expenses in our condensed consolidated statements of operation and comprehensive loss all of which was classified as general and administrative expense. We did not recognize any restructuring expense during the nine months ended September 30, 2023.â€‹â€‹7. Leasesâ€‹We lease our office and laboratory space under a noncancelable operating lease that expires in 2029, or the Office and Lab Lease. We have an option to extend the Office and Lab Lease term for one additional term ofÂ five yearsÂ at the greater of the then-current base rent or the then-current fair market value. Exercise of this option was not determined to be reasonably certain and thus was not considered in determining the operating lease liability on the consolidated balance sheet as of September 30, 2024. We posted a letter of credit in the amount of approximately $2.1 million as a security deposit. The letter of credit is subject to increase if we were to sublease any portion of the leased premises. The Office and Lab Lease does not include any restrictions or covenants that had to be accounted for under the lease guidance.17 Table of ContentsFuture lease payments for our noncancelable operating leases as of September 30, 2024 and a reconciliation to the carrying amount of the operating lease liabilities presented in the condensed consolidated balance sheet as of September 30, 2024 are as follows: â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended SeptemberÂ 30,Â â€‹(in thousands)2024 (remaining 3 months)â€‹$ 1,9352025â€‹Â 7,8382026â€‹Â 8,0592027â€‹Â 8,2752028â€‹Â 8,535Thereafterâ€‹Â 2,834Total undiscounted payments due under operating leasesâ€‹â€‹ 37,476Less imputed interestâ€‹â€‹ (5,673)Totalâ€‹$ 31,803â€‹â€‹â€‹â€‹Current operating lease liabilityâ€‹$ 5,707Non-current operating lease liabilityâ€‹ 26,096Totalâ€‹$ 31,803â€‹The following table presents our costs included in operating expenses related to our noncancelableÂ operating leases:â€‹Three Months Ended September 30, â€‹Nine Months Ended September 30, (in thousands)â€‹2024â€‹2023â€‹2024â€‹2023Operating lease costâ€‹$ 1,467â€‹$ 3,280â€‹$ 4,401â€‹$ 9,842Variable lease costâ€‹â€‹ 528â€‹â€‹ 832â€‹â€‹ 1,575â€‹â€‹ 2,542Totalâ€‹$ 1,995â€‹$ 4,112â€‹$ 5,976â€‹$ 12,384â€‹Net cash paid for the amounts included in the measurement of the operating lease liability on the condensed consolidated balance sheet and operating activities in our consolidated statement of cash flows was $5.7 million and $9.6 million for the nine months ended September 30, 2024 and 2023, respectively.Â The weighted-average remaining lease term and weighted-average incremental borrowing rate for all leases as of September 30, 2024 was approximately 5 years and 7.1%, respectively.The Seyon Lease commenced in December 2021, when we were granted access to the facility, and monthly rent payments began in September 2022; the total rent payment was expected to be approximately $104.3 million for the 12-year lease term. We had an option to extend the Seyon Lease term for two additional terms of five years each at the greater of the then-current base rent or the then-current fair market value. Exercise of this option was not determined to be reasonably certain and thus was not considered in determining the operating lease liability. In connection with the Seyon Lease, we provided a security deposit of $3.6 million in the form of a letter of credit. We paid an initial monthly base rent of approximately $0.4Â million that increased annually, up to a monthly base rent of $0.6 million. We were obligated to pay operating costs, taxes and utilities applicable to the facility. We were responsible for costs of constructing interior improvements within the facility that exceed a construction allowance of $26.0Â million provided by the landlord. As previously disclosed in our most recent Annual Report on Form 10-K and in this Quarterly Report, the termination of the Seyon Lease is the subject of pending litigation with the landlord. As of September 30, 2024, the landlord has collected $3.6 million from our security deposit in lieu of rent payments and has fully utilized such deposit. In connection with the termination of the Seyon Lease, during the nine months ended September 30, 2024, we recorded a material impairment loss of non-cash charges of $45.8 million in an impairment of the Seyon Lease right-of-use asset, $6.2 million in an impairment of construction in progress, and the write-off of $3.9 million in tenant improvement allowance receivable from the landlord. In addition, during the nine months ended September 30, 2024, we recognized 18 Table of Contents$3.7 million in accretion and other lease related expenses, which resulted in a $59.6 million loss on termination of lease in our condensed consolidated statement of operations and comprehensive loss. Accretion and other lease related expenses related to the Seyon Lease will continue to be recognized in loss on lease termination on our condensed consolidated statement of operations and comprehensive loss. As of September 30, 2024, as we have not met the criteria to extinguish the lease liability pursuant to ASC 405 Liabilities, and we had $62.0 million in operating lease liability related to the Seyon Lease on our condensed consolidated balance sheet. Additionally, in accordance with ASC 450 Contingencies, we have assessed the probability of realizing a material loss contingency for the potential losses, including obligations to pay any future variable lease costs, under the Seyon Lease. Based on this assessment, we have determined that it is not probable that we will be obligated to pay any such amounts. As a result, we have not accrued for any amounts related to the potential losses, primarily variable lease costs, such as common area fees and other charges, as they relate to the Seyon Lease.â€‹8. EquityAs of September 30, 2024, our amended and restated certificate of incorporation authorizes us to issue 150,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000Â shares of preferred stock, par value $0.0001 per share, all of which preferred stock is undesignated.In August 2024, we entered into an â€œat-the-marketâ€ sales agreement pursuant to which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $237.0Â million. Upon our entry into this sales agreement, we terminated our prior at-the-market program pursuant to a prior sales agreement that we entered into in August 2021. At the time of termination, approximately $237.3 million out of an aggregate of $250.0 million remained unsold under the prior sales agreement. As of November 6, 2024, the issuance date of these condensed consolidated financial statements, we have not issued and sold any shares of our common stock pursuant to the August 2024 sales agreement.Each share of common stock entitles the holder to one vote on all matters submitted to a vote of our stockholders. Holders of common stock are not entitled to receive dividends, unless declared by the board of directors.9. Stock-Based CompensationStock incentive plansOur 2017 Stock Incentive Plan, or the 2017 Plan, provided for us to grant incentive stock options or nonstatutory stock options, restricted stock, restricted stock units and other equity awards to employees, non-employees, and directors.In MayÂ 2020, our board of directors adopted, and in JuneÂ 2020, our stockholders approved, the 2020 Stock Incentive Plan, or the 2020 Plan, and together with the 2017 Plan, the Plans, which became effective on JuneÂ 11, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the 2020 Plan is the sum of (1)Â 2,547,698 shares; plus (2)Â the number of shares (up to a maximum of 7,173,014 shares) as was equal to the sum of (x)Â the number of shares of common stock reserved for issuance under the 2017 Plan that remained available for grant under the 2017 Plan on JuneÂ 11, 2020 and (y)Â the number of shares of common stock subject to outstanding awards granted under the 2017 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right; plus (3)Â an annual increase, to be added on the first day of each fiscalÂ year, beginning with the fiscalÂ year ending DecemberÂ 31, 2021 and continuing until, and including, the fiscalÂ year ending DecemberÂ 31, 2030, equal to the lesser of (i)Â 4% of the number of shares of common stock outstanding on such date, and (ii)Â an amount determined by the board of directors. In January 2024, the number of shares of common stock authorized for issuance under the 2020 Plan was increased from 16,813,962 shares to 19,462,688â€¯shares. Upon the effectiveness of the 2020 Plan, we ceased granting additional awards under the 2017 Plan.The Plans are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions on any award under the Plans are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted under the Plans with service-19 Table of Contentsbased vesting conditions generally vest over fourÂ years and expire after tenÂ years. The exercise price for stock options granted is not less than the fair value of common stock as of the date of grant. Prior to our initial public offering, or IPO, in June 2020, the fair value of our common stock was determined by the board of directors. Subsequent to our IPO, fair value of common stock is based on quoted market prices.As of September 30, 2024, 790,738 shares remained available for future issuance under the 2020 Plan. Shares subject to outstanding awards granted under the Plans that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right will be available for future awards under the 2020 Plan.Grant of stock optionsDuring the nineÂ months ended September 30, 2024, we granted time-based options to certain employees for the purchase of an aggregate of 3,693,074 shares of common stock with a weighted average grant date fair value of $1.87 per share that vest over a weighted average period of approximately fourÂ years.Employee stock purchase planIn MayÂ 2020, our board of directors adopted, and in JuneÂ 2020, our stockholders approved, the 2020 Employee Stock Purchase Plan, or the 2020 ESPP, which became effective JuneÂ 11, 2020. The 2020 ESPP is administered by our board of directors or by a committee appointed by the board of directors. The number of shares of common stock authorized for issuance under the 2020 ESPP automatically increases on the first day of each fiscalÂ year, beginning with the fiscalÂ year that commenced on JanuaryÂ 1, 2021 and continuing for each fiscalÂ year until, and including the fiscalÂ year commencing on, JanuaryÂ 1, 2030, in an amount equal to the lowest of (1)Â 1,302,157 shares of common stock, (2)Â 1% of the number of shares of common stock outstanding on such date, and (3)Â an amount determined by the board of directors. In January 2024, the number of shares of common stock authorized for issuance under the 2020 ESPP was increased from 2,115,792 shares toÂ 2,777,974 shares. As of September 30, 2024, 2,204,771 shares remained available for issuance under the 2020 ESPP.Stock-based compensationStock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: â€‹Three Months Ended September 30,â€‹â€‹Nine Months Ended SeptemberÂ 30,Â (inÂ thousands)2024Â Â Â Â 2023â€‹2024Â Â Â Â 2023Research and development expenses$ 1,520â€‹$ 2,874â€‹$ 4,452â€‹$ 8,608General and administrative expensesÂ 2,232â€‹Â 3,130â€‹Â 6,997â€‹Â 9,685Total$ 3,752â€‹$ 6,004â€‹$ 11,449â€‹$ 18,293â€‹â€‹As of September 30, 2024, total unrecognized compensation cost related to unvested time-based stock options and restricted stock units was $14.7 million, with $13.2 million expected to be recognized over a weighted average period of 2.1Â years and $1.5 million expected to be recognized over a weighted average period of 2.2Â years, respectively. â€‹20 Table of Contents10. Commitments and Contingencies401(k)Â PlanWe have a defined-contribution plan under SectionÂ 401(k)Â of the Internal Revenue Code of 1986, as amended, or the 401(k)Â Plan. The 401(k)Â Plan covers all employees who meet defined minimum age and service requirements and allows participants to contribute a portion of their annual compensation on a pre-tax and/or after-tax basis. In SeptemberÂ 2020, we adopted a match program, beginning on January 1, 2021, for employee contributions to the 401(k)Â Plan up to a maximum of fourÂ percent of the employeeâ€™s salary, subject to the maximums established under the U.S. Internal Revenue Code of 1986, as amended.Indemnification agreementsIn the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and our officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.â€‹Legal proceedingsWe, from time to time, may be party to litigation arising in the ordinary course of business. On February 20, 2024, our Landlord served us with a complaint, filed in the Court with respect to the Seyon Lease. The complaint sought declaratory judgment that we unlawfully terminated the Seyon Lease and also asserted a claim for breach of contract damages. Following receipt of the complaint, we filed a counterclaim against Landlord asserting breach of contract and violation of Massachusetts General Law Chapter 93A. On October 29, 2024, the Court determined that although we did not have the right to terminate the Seyon Lease, Landlordâ€™s subsequent termination was effective, and that we had alleged sufficient facts to state a claim for breach of contract and violation of Massachusetts General Law Chapter 93A by Landlord. We will continue to vigorously defend the action and our rights with respect to this matter. As a result, we may continue to incur costs and expenses relating to this facility, and we may remain responsible for payments under the Seyon Lease, which may have a material adverse effect on our business, results of operations or financial condition.â€‹11. Net Loss per ShareWe have generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. We excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹September 30,â€‹Â Â Â Â 2024Â Â Â 2023Unvested restricted stock unitsâ€‹374,076â€‹1,179,349Stock options to purchase common stockâ€‹13,215,012â€‹9,676,685Totalâ€‹13,589,088â€‹10,856,034â€‹â€‹â€‹â€‹â€‹â€‹21 Table of ContentsItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.The following discussion and analysis of our financial condition and results of operations is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amounts and uncertainties of cash flows from operations and from outside resources, so as to allow investors to better view our company from managementâ€™s perspective. It should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on FormÂ 10-Q, or Quarterly Report, and our consolidated financial statements and related notes appearing in our most recently filed Annual Report on Form 10-K, or Annual Report, with the Securities and Exchange Commission, or SEC. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the â€œRisk Factorsâ€ section of this Quarterly Report, in our Annual Report and in the other documents filed with the SEC, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.OverviewWe are innovating non-viral genetic medicines to provide durable, redosable treatments for potentially hundreds of millions of patients living with rare and prevalent diseases. We are developing two distinct and complementary platforms that we believe will enable highly differentiated therapeutic applications. Our first platform is a potent, highly selective cell-targeted lipid nanoparticle, or ctLNP, delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. The identification and optimization of new ligands to target new tissues and cell types is an efficient, flexible, and modular process, which we believe may allow us to rapidly expand our portfolio. We have demonstrated selective delivery of a T cell-targeted ctLNP carrying messenger RNA, or mRNA, cargo encoding a CAR with expression that was efficient and dose dependent. We plan to assess the efficacy of T cell-targeted ctLNPs delivering immune-quiet DNA, or iqDNA, in mice. Our second platform is our novel iqDNA, a partially single-stranded DNA, which is an optimized variant of our closed-ended DNA, or ceDNA, designed to enable long-lasting high levels of gene expression from non-integrating episomes, while avoiding innate immune sensors that have long prevented DNA from use in non-viral systems. Underpinning the iqDNA platform is our highly scalable capsid-free manufacturing process that uses our

proprietary cell-free rapid enzymatic synthesis, or RES, to produce highly pure iqDNA at scale. We continue to leverage RES to advance our iqDNA platform as it allows for precise chemical and structural changes to DNA, enabling the enhancement of DNA functionality through the engineering of molecular design and components. We have developed a second generation of iqDNA that achieved greater luciferase expression than a first generation iqDNA.Â We are advancing a portfolio of programs guided by the potent and highly selective delivery of mRNA and/or iqDNA to T cells, hematopoietic stem cells, or HSCs, and hepatocytes. Our work in T cells initially focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases. Our HSC research is focused initially on in vivo gene editing of HSCs for hematologic disorders, prioritizing sickle cell disease and beta-thalassemia. Our work in hepatocytes prioritizes hemophilia A, a rare monogenic disease that results from mutations in a single gene, has significant unmet need, and clear biomarkers for development. We plan to expand our portfolio to include programs for additional indications in other tissues, including retina, skeletal muscle, and the central nervous system, or CNS, by developing discrete ctLNPs, each with a unique targeting ligand engineered to provide targeted delivery of mRNA and/or iqDNA to T cells, HSCs and hepatocytes or delivery of antibody genes to direct the liver to produce therapeutic antibodies from patientsâ€™ own cells, which we refer to as endogenous therapeutic antibody production, or ETAP.In November 2023, following a review of strategic priorities and a determination by our management and board of directors to implement a strategic reorganization to invest in our ctLNP delivery system to develop wholly-owned programs for extrahepatic cell types and to develop our iqDNA platform for our lead program in hemophilia A and other programs, we 22 Table of Contentsannounced a strategic reorganization, pursuant to which we undertook a reduction in force, or RIF, and implemented reductions in operational expenditures including current Good Manufacturing Practice readiness and manufacturing expenses. We completed the RIF during the second quarter of 2024. As part of the restructuring, we are prioritizing investment in the development of our ctLNP delivery system for wholly-owned programs in extrahepatic cell types and to develop iqDNA for our lead program in hemophilia A. In July 2021, we entered into a lease agreement to build out a current Good Manufacturing Practice-compliant manufacturing facility, in Waltham, Massachusetts, or the Seyon Lease. On January 31, 2024, we notified Waltham CenterPoint I Investment Group, LLC, or Landlord, of termination of the Seyon Lease due to Landlordâ€™s breach of its obligations to us under the Seyon Lease and returned possession of the premises to the Landlord, effective January 31, 2024. On February 14, 2024, Landlord sent us a notice of the termination of the Seyon Lease due to our non-payment of rent. On February 20, 2024, Landlord served us with a complaint, filed in Massachusetts Superior Court, or the Court, with respect to the Seyon Lease. The complaint sought declaratory judgment that we unlawfully terminated the Seyon Lease and also asserted a claim for breach of contract damages. Following receipt of the complaint, we filed a counterclaim against Landlord asserting breach of contract and violation of Massachusetts General Law Chapter 93A. On October 29, 2024, the Court determined that although we did not have the right to terminate the Seyon Lease, Landlordâ€™s subsequent termination was effective, and that we had alleged sufficient facts to state a claim for breach of contract and violation of Massachusetts General Law Chapter 93A by Landlord. We will continue to vigorously defend the action and our rights with respect to this matter.In March 2023, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Moderna to collaborate on developing treatments for certain diseases by targeting delivery of nucleic acids to liver cells and certain cells outside of the liver. Under the Collaboration Agreement, the parties have agreed to collaborate on preclinical research programs relating to lipid nanoparticle, or LNP, delivery systems and nucleic acid payloads, with each party obtaining certain rights to intellectual property used in and arising out of such research programs. The research programs will be conducted pursuant to research plans and associated research budgets established by governance committees formed by the parties. Moderna will reimburse us for the internal and external costs we incur in conducting the research programs, to the extent consistent with such research plans and budgets. Each party will be solely responsible for its own clinical development and commercialization of products under the Collaboration Agreement.In addition, Moderna has exclusive options, upon payment of option exercise fees, to obtain worldwide, exclusive, sublicensable licenses under certain of our specified intellectual property to develop, manufacture and commercialize (a) products comprising LNP delivery systems and nucleic acid payloads that are directed to (i) up to two liver targets, (ii) up to two agreed-upon non-liver targets and (iii) a third liver or non-liver target and (b) Independent Program Products, which are products comprising LNP delivery systems that include mRNA that are directed to gene and protein targets in any of the agreed-upon immune cell types, or Cell Targets Types.Under the terms of the Collaboration Agreement, in April 2023, Moderna made an upfront payment to us of $40.0 million, and paid us $7.5 million in prepaid research funding. In addition, we are eligible to receive up to $1.8 billion in milestone payments upon the achievement of specified development, regulatory, commercial, and sales milestone events, research term extension fees and exclusivity extension fees. Subject to reduction in specified circumstances, we will also be entitled to receive tiered royalties: (i) ranging from high-single-digits to low-double-digits on sales of licensed products that are directed to the liver targets and non-liver targets with respect to which Moderna has exercised its exclusive license options, and (ii) in the single digits on sales of Independent Program Products, including the exclusively licensed Independent Program Products. In consideration for the non-exclusive license granted by Moderna to us under the LNP-related intellectual property arising out of the research program focused on the discovery and development of ctLNPs directed to agreed-upon immune cell types, we have agreed to pay Moderna tiered royalties ranging from low-single-digits to mid-single-digits on sales of Independent Program Products that include mRNA, subject to reductions in specified circumstances. In connection with the Collaboration Agreement, we entered into a Share Purchase Agreement with Moderna, pursuant to which we issued and sold 5,859,375 shares of our common stock to Moderna, at a price of $6.14 per share, for an aggregate purchase price of $36.0 million. In addition, under the Share Purchase Agreement, Moderna has the right, subject to certain 23 Table of Contentsterms and conditions, to purchase up to 3.06% of the outstanding shares of our common stock (on a post-closing basis) in connection with a future equity financing of at least $25.0 million by us. For additional information on our collaboration with Moderna and the accounting thereunder, refer to Note 4, Collaboration and License Agreement.Since our inception in OctoberÂ 2016, we have focused substantially all of our resources on building our non-viral genetic medicine platforms, establishing and protecting our intellectual property portfolio, conducting research and development activities, developing our manufacturing process, organizing and staffing our company, business planning, raising capital and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. We expect that any revenue recognized for the next several years will be derived primarily from our current collaboration with Moderna and any additional collaborations that we may enter into in the future. Historically, we have funded our operations with proceeds from the sale of instruments convertible into convertible preferred stock (which converted into convertible preferred stock in 2017), sales of convertible preferred stock (which converted into common stock in 2020), and sales of common stock in underwritten public offerings, â€œat-the-marketâ€ offerings, and in a private placement, as well as collaboration revenue under our collaboration with Moderna. In JuneÂ 2020, we completed our initial public offering, or IPO, pursuant to which we issued and sold 12,105,263 shares of our common stock, including 1,578,947 shares sold by us pursuant to the full exercise of the underwritersâ€™ option to purchase additional shares. We received net proceeds of $210.7Â million, after deducting underwriting discounts and commissions and other offering expenses. In JanuaryÂ 2021, we issued and sold 9,200,000 shares of our common stock, including 1,200,000 shares sold by us pursuant to the full exercise of the underwritersâ€™ option to purchase additional shares, in a follow-on public offering, resulting in net proceeds of $211.3Â million after deducting underwriting discounts and commissions and other offering expenses. In August 2024, we entered into an â€œat-the-marketâ€ sales agreement pursuant to which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $237.0Â million. Upon our entry into this sales agreement, we terminated our prior at-the-market program pursuant to a prior sales agreement that we entered into in August 2021. At the time of termination, approximately $237.3 million out of an aggregate of $250.0 million remained unsold under the prior sales agreement. As of November 6, 2024, the issuance date of this Quarterly Report, we have not issued and sold any shares of our common stock pursuant to the August 2024 sales agreement. Historically, we have incurred significant operating losses. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more product candidates we may develop. For theA nine months ended September 30, 2024 and 2023, we reported net losses of $110.3 million and $91.4 million, respectively. As of September 30, 2024, we had an accumulated deficit of $681.7 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next severalÂ years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:â—continue our current research programs and conduct additional research programs, including pursuant to our collaboration with Moderna;â—expand the capabilities of our proprietary non-viral genetic medicine platforms;â—advance any product candidates we identify into preclinical and clinical development;â—obtain, expand, maintain, defend and enforce our intellectual property portfolio;â—seek marketing approvals for any product candidates that successfully complete clinical trials; â—hire additional clinical, regulatory and scientific personnel;â—establish additional manufacturing sources and secure supply chain capacity sufficient to provide necessary quantities of any product candidates we may develop for clinical or commercial use; 24 Table of Contentsâ—ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; andâ—add operational, legal, compliance, financial and management information systems and personnel to support our research, product development, and future commercialization efforts.We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for any product candidates we may develop. If we obtain regulatory approval for any product candidates we may develop, we expect to incur significant expenses related to developing our commercial capability to support product sales, marketing and distribution. Further, we expect to continue to incur additional costs associated with operating as a public company.As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements, including our collaboration with Moderna. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements when needed or on terms acceptable to us, we would be required to delay, limit, reduce or terminate our product development or future commercialization of one or more of our product candidates.Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.We believe that our existing cash, cash equivalents, and marketable securities will enable us to fund our operating expenses and capital expenditures into the second half of 2027. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong. We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. See â€œâ€”Liquidity and Capital Resources.â€Components of Our Results of OperationsCollaboration revenueOur revenue consists of collaboration revenue, including amounts recognized as payments for licenses, research funding and milestone payments earned under our collaboration and license agreements.Operating expensesResearch and development expensesResearch and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our programs, which include:â—personnel-related costs, including salaries, benefits, stock-based compensation and severance expense, for employees engaged in research and development functions;â—expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants, contractors and contract research organizations, or CROs, and regulatory agency fees;25 Table of Contentsâ—the cost of developing and scaling our manufacturing process and capabilities and manufacturing drug substance and drug product for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors and contract development organizations, or CDOs;â—laboratory supplies and research materials;â—facilities, depreciation and amortization and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; andâ—payments made under third-party licensing agreements.We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.Our external research and development expenses consist of costs that include fees and other costs paid to consultants, contractors, CDOs and CROs in connection with our research, preclinical and manufacturing activities. We do not allocate our research and development costs to specific programs because costs are deployed across multiple programs and our platforms and, as such, are not separately classified. We expect that our research and development expenses will increase substantially as we advance our programs into clinical development and expand our discovery, research and preclinical activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop. The successful development of any of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following:â—the timing and progress of preclinical studies, including investigational new drug, or IND, -enabling studies;â—the number and scope of preclinical and clinical programs we decide to pursue;â—our ability to raise additional funds necessary to complete preclinical and clinical development of any product candidates we may develop;â—the timing of the submission and acceptance of IND applications or comparable foreign applications that allow commencement of future clinical trials for any product candidates we may develop;â—the successful initiation, enrollment and completion of clinical trials, including under Good Clinical Practices;â—our ability to achieve positive results from our future clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended patient populations of any product candidates we may develop;â—our ability to scale RES to produce clinical and initial commercial supply;â—our ability to establish arrangements with third-party manufacturers for preclinical, clinical and initial commercial supply;â—the availability of specialty raw materials for use in production of any product candidates we may develop;â—our ability to establish new licensing or collaboration arrangements;â—the receipt and related terms of regulatory approvals from the U.S. Food and Drug Administration and other applicable regulatory authorities;26 Table of Contentsâ—our ability to establish, obtain, maintain, enforce and defend patent, trademark, trade secret protection and other intellectual property rights or regulatory exclusivity for any product candidates we may develop and our technology; â—our ability to maintain a continued acceptable safety, tolerability and efficacy profile of our product candidates following approval; andâ—the terms and timing of any existing or future collaboration, license or other arrangement, including the terms and timing of any achievement of milestones and the receipt of payments thereunder.A change in the outcome of any of these variables with respect to any product candidates we may develop could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidates we may develop.General and administrative expensesGeneral and administrative expenses consist primarily of personnel-related costs, including salaries, benefits, stock-based compensation and severance expense, for employees engaged in executive, legal, finance and accounting and other administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, investor and public relations and accounting and audit services as well as direct and allocated facility-related costs.We anticipate that our general and administrative expenses will increase in the future as our research progresses toward clinical studies and we will increase our headcount. We also anticipate that we will continue to incur substantial accounting, audit, legal, regulatory, compliance, director and officer insurance costs and investor and public relations expenses associated with operating as a public company.Loss on lease terminationLoss on termination of lease consists of expenses recognized for the impairments of right-of-use asset and construction in progress, write-off of tenant improvement allowance receivable, accretion and other lease-related expenses in connection with the termination of the Seyon Lease. Other income and interest income, netOther income and interest income, net consists of interest income earned on our invested cash balances andÂ other miscellaneous income unrelated to our core operations.â€‹27 Table of ContentsResults of OperationsComparison of the three and nine months ended September 30, 2024 and 2023The following table summarizes our results of operations for the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹

59,596Total operating expensesâ€‹Â 25,438â€‹Â 33,503â€‹Â (8,065)â€‹Â 134,531â€‹Â 103,168â€‹Â 31,363Loss from operationsâ€‹Â (17,884)â€‹Â (31,357)â€‹Â 13,473â€‹Â (118,827)â€‹Â (100,142)â€‹Â (18,685)Other income:â€‹Â Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â Other income and interest income, netâ€‹Â 2,571â€‹Â 3,091â€‹Â (520)â€‹Â 8,541â€‹Â 8,716â€‹Â (175)Net lossâ€‹$ (15,313)â€‹$ (28,266)â€‹$ 12,953â€‹$ (110,286)â€‹$ (91,426)â€‹$ (18,860)â€‹Collaboration revenueDuring the three months ended September 30, 2024, we recognized $7.6 million in collaboration revenue, compared to $2.1 million for the three months ended September 30, 2023. During the nine months ended September 30, 2024, we recognized $15.7 million in collaboration revenue, compared to $3.0 million for the nine months ended September 30, 2023. The increase in collaboration revenue during the three and nine months ended September 30, 2024 was due to increased reimbursable activity under our Collaboration Agreement with Moderna, which commenced in the second quarter of 2023 and additional revenue related to the change in estimate, during the three months of September 30, 2024, due to revisions in the research plan resulting in a reduction in the estimated timeline of future research services and total estimated costs. The change in estimate resulted in an increase of $3.8 million in collaboration revenue and a decrease in net loss per share, basic and diluted, of $0.06 for both the three and nine months ended September 30, 2024. For additional information on our collaboration with Moderna and the accounting thereunder, refer to Note 4, Collaboration and License Agreement.Research and development expensesâ€‹The following table summarizes our research and development expenses for the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹

achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our President and Chief Executive Officer and our ChiefÂ Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in Internal Control over Financial ReportingThere were no other changes in our internal control over financial reporting (as defined in Rules 13aâ€“15(f) and 15dâ€“15(f) under the Exchange Act) during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.33 Table of ContentsPARTÂ IIâ€“OTHER INFORMATIONItem 1. Legal Proceedings.For a discussion of material legal proceedings, see Note 10. Commitments and Contingenciesâ€“Legal Proceedings in Part I, Item 1, Financial Statements of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.. â€‹Item Â 1A. Risk Factors.In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, Item 1A Risk Factors in our Annual Report, which could materially affect our business, financial condition, or future results.Item 5. Other Information.â€‹Director and Officer Trading Arrangementsâ€‹None of our directors or officersÂ adoptedÂ orÂ terminatedÂ a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report.â€‹â€‹â€‹â€‹34 Table of ContentsItemÂ 6. Exhibits.ExhibitNumberÂ Â Â Â DescriptionÂ ofÂ ExhibitÂ Â Â Â 10.1â€‹Sales Agreement, dated as of August 7, 2024, by and between the registrant and TD Securities (USA) LLC (incorporated by reference to Exhibit 1.2 to the registrantâ€™s Registration Statement on Form S-3, File No. 333-281335, filed August 7, 2024)â€‹â€‹â€‹â€‹Â Â Â Â Â 31.1*Â Â Certification of Principal Executive Officer pursuant to RuleÂ 13a-14(a)Â of the Securities Exchange Act, as adopted pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002Â Â Â Â Â 31.2*Â Â Certification of Principal Financial Officer pursuant to RuleÂ 13a-14(a)Â of the Securities Exchange Act, as adopted pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002Â Â Â Â Â 32.1**Â Â Certification of Principal Executive Officer pursuant to 18Â U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002Â Â Â Â Â 32.2**Â Â Certification of Principal Financial Officer pursuant to 18Â U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002101.SCHÂ Â Inline XBRL Taxonomy Extension Schema Document101.CALÂ Â Inline XBRL Taxonomy Extension Calculation Linkbase Document101.DEFÂ Â Inline XBRL Taxonomy Extension Definition Linkbase Document101.LABÂ Â Inline XBRL Taxonomy Extension Label Linkbase Document101.PREÂ Â Inline XBRL Taxonomy Extension Presentation Linkbase Documentâ€‹â€‹â€‹â€‹104â€‹Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)â€‹*Filed herewith.**Furnished herewith.â€‹â€‹â€‹â€‹â€‹35 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.GENERATION BIO CO.Date: November 6, 2024By:Â Â /s/ Geoff McDonoughâ€‹Geoff McDonough, M.D.â€‹President and Chief Executive Officerâ€‹(Principal Executive Officer)Date: November 6, 2024By:Â Â /s/ Matthew Norkunasâ€‹Matthew Norkunas, M.D., M.B.A.â€‹Chief Financial Officerâ€‹(Principal Financial and Accounting Officer)â€‹â€‹â€‹â€‹36 EX-31.1 2 gbio-20240930xex31d1.htm EX-31.1 Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Geoff McDonough, hereby certify that: 1. I have reviewed this Quarterly Report on FormÂ 10-QÂ of Generation Bio Co.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â andÂ 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â (c)Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 6, 2024 Â /s/ Geoff McDonoughÂ Geoff McDonough, M.D.President and Chief Executive Officer(Principal Executive Officer)â€‹ EX-31.2 3 gbio-20240930xex31d2.htm EX-31.2 â€‹â€‹Â Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Norkunas, hereby certify that: 1. I have reviewed this Quarterly Report on FormÂ 10-QÂ of Generation Bio Co.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â andÂ 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â (c)Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 6, 2024 Â Â Â /s/ Matthew NorkunasÂ Matthew Norkunas, M.D., M.B.A.Chief Financial Officer(Principal Financial and Accounting Officer)â€‹â€‹â€‹ EX-32.1 4 gbio-20240930xex32d1.htm EX-32.1 Â Exhibit 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Geoff McDonough, certify pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on FormÂ 10-QÂ of Generation Bio Co. for the quarter ended September 30, 2024 fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such FormÂ 10-QÂ fairly presents, in all material respects, the financial condition and results of operations of Generation Bio Co. Â â€‹â€‹ /s/ Geoff McDonoughÂ Geoff McDonough, M.D.President and Chief Executive Officer(Principal Executive Officer)November 6, 2024â€‹ EX-32.2 5 gbio-20240930xex32d2.htm EX-32.2 â€‹Â Exhibit 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Matthew Norkunas, certify pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on FormÂ 10-QÂ of Generation Bio Co. for the quarter ended September 30, 2024 fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such FormÂ 10-QÂ fairly presents, in all material respects, the financial condition and results of operations of Generation Bio Co. Â â€‹â€‹Â Â /s/ Matthew NorkunasÂ Matthew Norkunas, M.D., M.B.A.Chief Financial Officer(Principal Financial and Accounting Officer)November 6, 2024â€‹â€‹â€‹â€‹ EX-101.SCH 6 gbio-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of marketable securities by contractual maturity (Detail) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of assets measured at FV on a recurring basis (Detail) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Leases - Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Leases - Future Lease Payments (Details) Calc2 link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Leases - Costs included in operating expenses related to the operating lease (Detail) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Marketable Securities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Collaboration and License Agreement link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Property and equipment, net link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Collaboration And License Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Property and equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Nature of the Business and Basis of Presentation - Additional information (Detail) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Detail) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of marketable securities (Detail) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Collaboration and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Collaboration and License Agreement - Schedule of Allocated Transaction Price and Revenue Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Property and equipment, net - Summary of Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Property and equipment, net - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Accrued Expenses - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Accrued Expenses - Schedule of accrued restructuring costs (Detail) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Stock-Based Compensation (Detail) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Stock-Based Compensation - Expense Classification (Detail) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Stock-Based Compensation - Unrecognized Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Net Loss per Share - Summary of Potential Dilutive Securities (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gbio-20240930_cal.xml EX-101.CAL EX-101.DEF 8 gbio-20240930_def.xml EX-101.DEF EX-101.LAB 9 gbio-20240930_lab.xml EX-101.LAB Cover [Abstract] Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Period Focus Amendment Flag Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities Accounts Receivable, after Allowance for Credit Loss, Current Collaboration receivable Nontrade Receivables, Current Tenant receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Marketable Securities, Noncurrent Marketable securities, net of current portion Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Restricted Cash, Noncurrent Restricted cash Other Assets, Noncurrent Other long-term assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities and Other Liabilities Total Accrued expenses and other current liabilities Deferred Revenue, Current Deferred revenue Operating Lease, Liability, Current Operating lease liability Current operating lease liability Liabilities, Current Total current liabilities Deferred Revenue, Noncurrent Deferred revenue, net of current portion Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Non-current operating lease liability Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 10) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Common Stock, Value, Issued Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 66,753,508 and

66,205,550 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Equity, Attributable to Parent Ending balance Beginning balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value per share Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value per share Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Revenues [Abstract] Revenues: Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Gain (Loss) on Termination of Lease Loss on lease termination Loss on lease termination Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income: Nonoperating Income (Expense) Other income and interest income, net Net loss and net loss attributable to common stockholders Net loss Net loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, diluted (in shares) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive (loss) income: OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Unrealized gains on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Shares, Outstanding Ending balance, shares Beginning balance, shares Stock Issued During Period, Value, New Issues Sale of common stock in connection with the Moderna Share Purchase Agreement Stock Issued During Period, Shares, New Issues Sale of common stock in connection with the Moderna Share Purchase Agreement, shares Shares issued during the period Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, shares Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Vesting of restricted common stock Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Vesting of restricted common stock, shares Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock under ESPP Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock under ESPP, shares APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gains on marketable securities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Statement of Cash Flows [Abstract] Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to ModernaTX, Inc. ModernaTX, Inc [Member] ModernaTX, Inc Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amount of non-cash adjustment of gain (loss) on termination of lease before expiration of lease term. Gain (Loss) On Termination Of Lease, Non Cash Loss on lease termination Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Depreciation, Depletion and Amortization Depreciation and amortization expense Investment Income, Net, Amortization of Discount and Premium Amortization (accretion) of premium (discount) on marketable securities, net Other Operating Activities, Cash Flow Statement Other Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable, Related Parties Collaboration receivable Amount of increase (decrease) during the reporting period in the amount due from the landlord for tenant improvements. Increase Decrease In Tenant Improvements Allowance Receivable Tenant receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets The increase (decrease) during the reporting period in the aggregate amount of assets used to generate operating income. Increase (Decrease) in Operating Lease Right of Use Assets Operating lease right-of-use assets Increase (Decrease) in Other Noncurrent Assets Other noncurrent assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Operating Lease Liability Operating lease liability Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of property and equipment Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Payments of Stock Issuance Costs Payment of share issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance/sale of common stock Proceeds from Stock Options Exercised Proceeds from exercise of stock options and ESPP, net Payment, Tax Withholding, Share-Based Payment Arrangement Tax withholding payments related to net share settlements of restricted stock units Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of noncash investing and financing information: Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment included in accounts payable and accrued expenses Marketable Security, Unrealized Gain (Loss) Unrealized gains on marketable securities Nature of the Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Nature of the Business and Basis of Presentation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Marketable Securities and Fair Value Measurements Marketable Securities [Table] Marketable Securities [Line Items] Fair Value Disclosures [Text Block] Marketable Securities and Fair Value Measurements Collaboration and License Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaboration and License Agreement Collaborative Arrangement Disclosure [Text Block] Collaboration and License Agreement Property and equipment, net. Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment Disclosure [Text Block] Property and equipment, net Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Leases Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Operating Leases [Text Block] Leases Equity Equity, Capital Unit or Share [Table] Capital Unit [Line Items] Equity [Text Block] Equity Stock-Based Compensation Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Payment Arrangement [Text Block] Stock-Based compensation Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Net Loss per Share Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Earnings Per Share [Text Block] Net Loss per Share Use of Estimates, Policy [Policy Text Block] Use of estimates Basis of Accounting, Policy [Policy Text Block] Unaudited interim financial information Disclosure of accounting policy for employee retention credit. Employee Retention Credit [Policy Text Block] Employee Retention Credit Marketable Securities [Table Text Block] Summary of marketable securities by security type The tabular disclosure of marketable securities by contractual maturity. Schedule Of Marketable Securities By Contractual Maturity [Table Text Block] Schedule of marketable securities by contractual maturity Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of assets measured at fair value on a recurring basis Tabular disclosure of information pertaining to allocation of transaction price to each unit of account. Summary Of Allocation Of Transaction Price To Each Unit Of Account [Table Text Block] Summary of allocation of transaction price to each unit of account Tabular disclosure of transaction price allocated to each unit of account in addition to revenue activity. Summary Of Transaction Price Allocated With Revenue Activity [Table Text Block] Summary of transaction price allocated with revenue activity Property, Plant and Equipment [Table Text Block] Summary of Property and equipment, net Schedule of Accrued Liabilities [Table Text Block] Summary of accrued expenses Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Summary of accrued restructuring costs recorded and included in accrued expenses and other current liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Future lease payments for noncancelable operating lease Lease, Cost [Table Text Block] Costs included in operating expenses related to the operating lease Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of stock-based compensation expense was classified in the statements of operations and comprehensive loss Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of potential dilutive securities, presented based on amounts outstanding Entity Incorporation, Date of Incorporation Date of incorporation Other Employee-related Liabilities Employee retention credit recognized Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring Asset Class [Axis] Asset Class [Domain] US Treasury Securities [Member] U.S. treasury securities Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Total Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Debt Securities, Available-for-Sale Fair Value Debt Securities, Available-for-sale, Fair Value Marketable securities Debt Securities, Available-for-Sale, Amortized Cost [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Current Less than one year Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Greater than one year but less than two years Debt Securities, Available-for-Sale [Abstract] Fair Value Debt Securities, Available-for-Sale, Current Less than one year Debt Securities, Available-for-Sale, Noncurrent Greater than one year but less than two years Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Money Market Funds [Member] Money Market Funds Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and Cash Equivalents [Abstract] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Marketable Securities [Abstract] Marketable securities: Assets, Fair Value Disclosure Total Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to collaboration and license agreement. Collaboration and License Agreement [Member] Collaboration and License Agreement Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate, Type [Domain] Contracts Accounted for under Percentage of Completion [Member] Contracts Accounted for under Percentage of Completion Related Party Transaction [Axis] Related Party Transaction [Domain] Represents information pertaining to share purchase agreement. Share Purchase Agreement [Member] Share Purchase Agreement Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Related Party [Member] Related Party Beneficial Owner [Member] Beneficial Owner Counterparty Name [Axis] Counterparty Name [Domain] Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum The number of products to be commercialized under collaborative arrangements. Collaborative Arrangement, Number of Products to be Commercialized Number of products to be commercialized The amount of upfront payments received under collaborative arrangements. Collaborative Arrangement, Upfront Payments Upfront payments The amount of research services prepayments received under collaborative arrangements. Collaborative Arrangement, Prepaid Research Services Funding Prepaid research services funding The amount of milestone payments receivable under collaborative arrangements. Collaborative Arrangement, Milestone Payments Receivable Milestone payments receivable The term for payment of royalty under collaboration agreement. Collaborative Agreement, Royalty Payment Term Royalty payment term Shares Issued, Price Per Share Shares issue price (in dollars per share) The shares to be purchased under share purchase agreement as percent of outstanding shares. Share Purchase Arrangement, Share Purchase as Percent of Outstanding Shares Percent of shares to be issued The amount of equity financing. Equity Financing Amount Equity financing The number of performance obligations under collaborative arrangements. Collaborative Arrangement, Number of Performance Obligations Number of performance obligations The amount of premium paid over fair value of common stock under share purchase agreement. Share Purchase Arrangement, Premium Paid on Common Stock Premium paid on common stock The amount of variable consideration included in transaction price of collaborative arrangements. Collaborative Arrangement, Variable Consideration Included in Transaction Price Variable consideration Revenue, Remaining Performance Obligation, Amount Transaction Price Allocated Represents the information about ctLNP technology and research license. Ctlnp Technology And Research License [Member] ctLNP technology and research license Represents the information about First liver program commercialization option license. First Liver Program Commercialization Option License [Member] First liver program commercialization option license Represents the information about Second liver program commercialization option license. Second Liver Program Commercialization Option License [Member] Second liver program commercialization option license Represents the information about First non-liver program commercialization option license. First Non-liver Program Commercialization Option License [Member] First non-liver program commercialization option license Represents the information about Second non-liver program commercialization option license. Second Non-Liver Program Commercialization Option License [Member] Second non-liver program commercialization option license Represents the information about Third liver or non-liver program commercialization option license. Third Liver Or Non-Liver Program Commercialization Option License [Member] Third liver or non-liver program commercialization option license The amount of standalone selling price. Standalone Selling Price Standalone Selling Price Contract with Customer, Liability, Revenue Recognized Revenue Recognized Contract with Customer, Liability Deferred Revenue Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Laboratory Equipment [Member] Laboratory equipment Computer Equipment And Software [Member] Computer equipment and software Furniture and Fixtures [Member] Furniture and fixtures Leasehold Improvements [Member] Leasehold improvements Construction in Progress [Member] Construction in progress Property, Plant and Equipment, Gross Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation and amortization Property and equipment, net Impairment Charge on Reclassified Assets Impairment charge Employee-related Liabilities, Current Accrued employee compensation and benefits Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development expenses. Accrued External Research And Development Expenses Current Accrued external research and development expenses Accrued Professional Fees, Current Accrued professional fees The amount of accrued expense on property and equipment. Accrued Expense on Property and Equipment Property and equipment Other Liabilities, Current Other Restructuring Reserve Ending Balance Beginning Balance Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Reduction in workforce Restructuring and Related Cost, Incurred Cost Restructuring expenses Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Cost [Table] Restructuring Type [Axis] Type of Restructuring [Domain] Employee Severance [Member] Severance and Benefits Costs Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring costs Payments for Restructuring Cash payments Restructuring Charges Restructuring expenses Restructuring Reserve, Accrual Adjustment Adjustments Credit Facility [Axis] Credit Facility [Domain] Letter of Credit [Member] Maximum [Member] Maximum Lessee, Operating Lease, Existence of Option to Extend [true false] Lease existence of option to extend Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Operating lease agreement option to renewal term Letter of credit for security deposit. Letter of Credit for Security Deposit Letter of credit for security deposit Lessee, Operating Lease, Term of Contract Operating lease term Lessee, Operating Lease, Liability, to be Paid Total undiscounted payments due under operating leases Total rent payments Initial monthly base rent on operating lease. Initial Monthly Base Rent on Operating Lease Initial monthly base rent on operating lease Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend Option to extend lease Construction allowance in operating lease. Construction Allowance in Operating Lease Construction allowance in operating lease Operating Lease, Payments Operating lease payments Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Weighted-average

incremental borrowing Estimated monthly base rent on operating lease Estimated Monthly Base Rent On Operating Lease Estimated monthly base rent on operating lease Security Deposit Security deposit Security Deposit Liability Security deposit liability Operating Lease, Impairment Loss Impairment of right-of-use asset Payments for Tenant Improvements Tenant improvement allowance receivable write-off Accretion Expense Accretion and other lease related expenses Operating Lease, Liability Total Lease Contractual Term [Axis] Lease Contractual Term [Domain] Represents information related to active lease with Company. Active Lease [Member] Active Lease Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 (remaining 3 months) Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, to be Paid, after Year Four Thereafter Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Operating Lease, Cost Operating lease cost Variable Lease, Cost Variable lease cost Lease, Cost Total Represents information pertaining to at the market offering. At the Market Offering [Member] At the Market Offering Amount of common stock remained unsold upon termination. Common Stock, Capital Shares Reserved For Future Issuances, Remained Unsold Upon Termination Termination of shares reserved for future issuances Cash inflow form gross proceeds form issuance of common stock. Proceeds from Issuance of Common Stock, Gross Aggregate gross offering price Number of vote per common shares. Number of Vote Per Common Share Number of vote per common share Plan Name [Axis] Plan Name [Domain] Two thousand and twenty stock incentive plan. Two Thousand And Twenty Stock Incentive Plan [Member] 2020 Stock Incentive Plan Represents information related to employee stock purchase plan two thousand and twenty. Employee Stock Purchase Plan Two Thousand And Twenty [Member] Employee Stock Purchase Plan 2020 Pertains to information relating to service based options. Service Based Options [Member] Service Based Options Title and Position [Axis] Title and Position [Domain] Certain Employees Directors And Consultants [Member] Certain Employees Directors And Consultants [Member] Certain Employees Directors And Consultants Date [Axis] Date [Domain] Additional From 2017 Plan [Member] Additional From 2017 Plan [Member] Additional From 2017 Plan Annual Increase 2021 To 2030 [Member] Annual Increase 2021 To 2030 [Member] Annual Increase 2021 To 2030 Common Stock, Capital Shares Reserved for Future Issuance Stock reserved for future issuance Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of common stock outstanding. Share Based Compensation Arrangement By Share Based Payment Award Number of Additional Shares Authorized Percentage Percentage of common stock shares additionally reserved for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share based compensation by share based payment arrangement number of shares authorized for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Stock based compensation vesting period service based Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Stock based compensation period of expiry Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Shares issued Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Number of share instruments newly issued under a share-based compensation plan Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share based compensation by share based payment weighted average period Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and development expenses Selling, General and Administrative Expenses [Member] General and administrative expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expense Stock-based compensation expense Scenario [Axis] Scenario [Domain] Represents information pertaining to share based compensation expected to recognize over a weighted average period one. Share Based Compensation Expected to Recognize Over a Weighted Average Period One [Member] Share based compensation expected to recognize over a weighted average period one Represents information pertaining to share based compensation expected to recognize over a weighted average period two. Share Based Compensation Expected to Recognize Over a Weighted Average Period Two [Member] Share based compensation expected to recognize over a weighted average period two Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized Expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock compensation on account of unvested options remaining period over which the compensation is to be recognized Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Defined contribution plan, percentage Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Restricted Stock Units (RSUs) [Member] Unvested restricted stock units Stock options to purchase common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive net loss per share EX-101.PRE 10 gbio-20240930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover Page - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Transition Report false Â Securities Act File Number 001-39319 Â Entity Registrant Name GENERATION BIO CO. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 81-4301284 Â Entity Address, Address Line One 301 Binney Street Â Entity Address, City or Town Cambridge Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02142 Â City Area Code 617 Â Local Phone Number 655-7500 Â Title of 12(b) Security Common Stock, $0.0001 Par Value Â Trading Symbol GBIO Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 66,792,822 Entity Central Index Key 0001733294 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 21,657 $ 66,446 Marketable securities 163,113 197,918 Collaboration receivable 2,212 0 Tenant receivable 0 3,960 Prepaid expenses and other current assets 4,272 4,294 Total current assets 191,254 272,618 Marketable securities, net of current portion 15,042 0 Property and equipment, net 16,010 25,799 Operating lease right-of-use assets 21,220 69,852 Restricted cash 2,152 5,791 Other long-term assets 3,106 698 Total assets 248,784 374,758 Current liabilities: Â Â Accounts payable 1,659 2,346 Accrued expenses and other current liabilities 6,197 16,529 Deferred revenue 11,512 12,919 Operating lease liability 10,797 8,120 Total current liabilities 30,165 39,914 Deferred revenue, net of current portion 31,195 41,942 Operating lease liability, net of current portion 82,982 89,774 Total liabilities 144,342 171,630 Commitments and contingencies (Note 10) Stockholders' equity: Â Â Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2024 and December 31, 2023 0 0 Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 66,753,508 and 66,205,550 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 7 7 Additional paid-in capital 785,779 774,224 Accumulated other comprehensive income 319 274 Accumulated deficit (681,663) (571,377) Total stockholders' equity 104,442 203,128 Total liabilities and stockholders' equity $ 248,784 $ 374,758 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NontradeReceivablesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value per share $ 0.0001 $ 0.0001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value per share $ 0.0001 $ 0.0001 Common stock, shares authorized 150,000,000 150,000,000 Common stock, shares issued 66,753,508 66,205,550 Common stock, shares outstanding 66,753,508 66,205,550 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Collaboration revenue $ 7,554 $ 2,146 $ 15,704 $ 3,026 Operating expenses: Â Â Â Â Research and development 15,088 21,862 45,811 65,694 General and administrative 9,181 11,641 29,124 37,474 Loss on lease termination 1,169 0 59,596 0 Total operating expenses 25,438 33,503 134,531 103,168 Loss from operations (17,884) (31,357) (118,827) (100,142) Other income: Â Â Â Â Other income and interest income, net 2,571 3,091 8,541 8,716 Net loss $ (15,313) $ (28,266) $ (110,286) $ (91,426) Net loss per share, basic (in dollars per share) $ (0.23) $ (0.43) $ (1.66) $ (1.43) Net loss per share, diluted (in dollars per share) $ (0.23) $ (0.43) $ (1.66) $ (1.43) Weighted average common shares outstanding, basic (in shares) 66,738,468 65,907,000 66,568,326 63,951,508 Weighted average common shares outstanding, diluted (in shares) 66,738,468 65,907,000 66,568,326 63,951,508 Comprehensive loss: Â Â Â Â Net loss $ (15,313) $ (28,266) $ (110,286) $ (91,426) Other comprehensive (loss) income: Â Â Â Â Unrealized gains on marketable securities 599 19 45 79 Comprehensive loss $ (14,714) $ (28,247) $ (110,241) $ (91,347) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic

10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Total Beginning balance at Dec. 31, 2022 $ 6 $ 727,335 $ (83) $ (444,765) $ 282,493 Beginning balance, shares at Dec. 31, 2022 59,505,437 Â Â Â Â Sale of common stock in connection with the Moderna Share Purchase Agreement $ 1 22,555 Â Â 22,556 Sale of common stock in connection with the Moderna Share Purchase Agreement, shares 5,859,375 Â Â Â Â Vesting of restricted common stock Â (448) Â Â (448) Vesting of restricted common stock, shares 455,463 Â Â Â Â Issuance of common stock under ESPP Â 367 Â Â 367 Issuance of common stock under ESPP, shares 107,681 Â Â Â Â Stock-based compensation expense Â 18,293 Â Â 18,293 Unrealized gains on marketable securities Â Â 79 Â 79 Net loss Â Â Â (91,426) (91,426) Ending balance at Sep. 30, 2023 $ 7 768,102 (4) (536,191) 231,914 Ending balance, shares at Sep. 30, 2023 65,927,956 Â Â Â Â Beginning balance at Jun. 30, 2023 $ 7 762,228 (23) (507,925) 254,287 Beginning balance, shares at Jun. 30, 2023 65,784,250 Â Â Â Â Vesting of restricted common stock Â (130) Â Â (130) Vesting of restricted common stock, shares 143,706 Â Â Â Â Stock-based compensation expense Â 6,004 Â Â 6,004 Unrealized gains on marketable securities Â Â 19 Â 19 Net loss Â Â Â (28,266) (28,266) Ending balance at Sep. 30, 2023 $ 7 768,102 (4) (536,191) 231,914 Ending balance, shares at Sep. 30, 2023 65,927,956 Â Â Â Â Beginning balance at Dec. 31, 2023 $ 7 774,224 274 (571,377) 203,128 Beginning balance, shares at Dec. 31, 2023 66,205,550 Â Â Â Â Issuance of common stock upon exercise of stock options Â 31 Â Â 31 Issuance of common stock upon exercise of stock options, shares 22,517 Â Â Â Â Vesting of restricted common stock Â (172) Â Â (172) Vesting of restricted common stock, shares 369,414 Â Â Â Â Issuance of common stock under ESPP Â 247 Â Â 247 Issuance of common stock under ESPP, shares 156,027 Â Â Â Â Stock-based compensation expense Â 11,449 Â Â 11,449 Unrealized gains on marketable securities Â Â 45 Â 45 Net loss Â Â Â (110,286) (110,286) Ending balance at Sep. 30, 2024 $ 7 785,779 319 (681,663) 104,442 Ending balance, shares at Sep. 30, 2024 66,753,508 Â Â Â Â Beginning balance at Jun. 30, 2024 $ 7 782,030 (280) (666,350) 115,407 Beginning balance, shares at Jun. 30, 2024 66,702,734 Â Â Â Â Issuance of common stock upon exercise of stock options Â 13 Â Â 13 Issuance of common stock upon exercise of stock options, shares 9,680 Â Â Â Â Vesting of restricted common stock Â (16) Â Â (16) Vesting of restricted common stock, shares 41,094 Â Â Â Â Stock-based compensation expense Â 3,752 Â Â 3,752 Unrealized gains on marketable securities Â Â 599 Â 599 Net loss Â Â Â (15,313) (15,313) Ending balance at Sep. 30, 2024 $ 7 $ 785,779 $ 319 $ (681,663) $ 104,442 Ending balance, shares at Sep. 30, 2024 66,753,508 Â Â Â Â X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (110,286) $ (91,426) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Loss on lease termination 59,085 0 Stock-based compensation expense 11,449 18,293 Depreciation and amortization expense 3,755 3,938 Amortization (accretion) of premium (discount) on marketable securities, net (6,312) (6,699) Other 84 24 Changes in operating assets and liabilities: Â Â Collaboration receivable (2,212) 0 Tenant receivable 0 (265) Prepaid expenses and other current assets 694 1,408 Operating lease right-of-use assets 2,799 4,794 Other noncurrent assets (2,840) 931 Accounts payable (79) 1,386 Accrued expenses and other current liabilities (9,526) (2,633) Deferred revenue (12,154) 44,474 Operating lease liability (7,236) (1,992) Net cash used in operating activities (72,779) (27,767) Cash flows from investing activities: Â Â Purchases of property and equipment (2,023) (2,817) Proceeds from sale of property and equipment 149 0 Purchases of marketable securities (115,881) (295,967) Maturities of marketable securities 142,000 291,000 Net cash provided by (used in) investing activities 24,245 (7,784) Cash flows from financing activities: Â Â Payment of share issuance costs 0 (179) Proceeds from exercise of stock options and ESPP, net 278 367 Tax withholding payments related to net share settlements of restricted stock units (172) (448) Net cash provided by financing activities 106 35,740 Net (decrease) increase in cash, cash equivalents and restricted cash (48,428) 189 Cash, cash equivalents and restricted cash at beginning of period 72,237 98,863 Cash, cash equivalents and restricted cash at end of period 23,809 99,052 Supplemental disclosure of noncash investing and financing information: Â Â Purchases of property and equipment included in accounts payable and accrued expenses 47 1,330 Unrealized gains on marketable securities 45 79 ModernaTX, Inc Â Â Cash flows from financing activities: Â Â Proceeds from issuance/sale of common stock $ 0 $ 36,000 X - DefinitionAmount of non-cash adjustment of gain (loss) on termination of lease before expiration of lease term. + ReferencesNo definition available. + Details Name: gbio_GainLossOnTerminationOfLeaseNonCash Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of assets used to generate operating income. + ReferencesNo definition available. + Details Name: gbio_IncreaseDecreaseInOperatingLeaseRightOfUseAssets Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) during the reporting period in the amount due from the landlord for tenant improvements. + ReferencesNo definition available. + Details Name: gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accretion (amortization) of purchase discount (premium) on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=gbio_ModernatxIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of the Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Nature of the Business and Basis of Presentation Â Nature of the Business and Basis of Presentation Generation Bio Co.Notes to Condensed Consolidated Financial Statements(Unaudited)â€‹1.Â Nature of the Business and Basis of PresentationGeneration Bio Co., or Generation Bio, was incorporated on OctoberÂ 21,Â 2016 as Torus Therapeutics,Â Inc.Â and subsequently changed its name to Generation Bio Co. Generation Bio Co. and its consolidated subsidiary, or the company, we, our or us, are innovating non-viral genetic medicines to provide durable, redosable treatments for potentially hundreds of millions of patients living with rare and prevalent diseases. We are developing two distinct and complementary platforms that we believe will enable highly differentiated therapeutic applications. Our first platform is a potent, highly selective cell-targeted lipid nanoparticle, or ctLNP, delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. The identification and optimization of new ligands to target new tissues and cell types is an efficient, flexible, and modular process, which we believe will allow us to rapidly expand our portfolio. Our second platform is our novel immune-quiet DNA, or iqDNA, a partially single-stranded DNA, which is a variant of our closed-ended DNA, or ceDNA, designed to enable long-lasting high levels of gene expression from non-integrating episomes, while avoiding innate immune sensors that have long prevented DNA from use in non-viral systems. Underpinning the iqDNA platform is our highly scalable capsid-free manufacturing process that uses our proprietary cell-free rapid enzymatic synthesis, or RES, to produce highly pure iqDNA at scale. We are headquartered in Cambridge, Massachusetts.We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, we have funded our operations with proceeds from the sale of instruments convertible into convertible preferred stock (which converted into convertible preferred stock in 2017), sales of convertible preferred stock (which converted into common stock in 2020), and sales of common stock in underwritten public offerings, â€œat-the-marketâ€ offerings, and in a private placement, as well as collaboration revenue under our collaboration with ModernaTX, Inc., or Moderna. We have incurred recurring losses, including net losses of $110.3Â million for the nineÂ months ended September 30, 2024 and $91.4 million for the nine months ended September 30, 2023. As of September 30, 2024, we had an accumulated deficit of $681.7Â million. We expect to continue to generate operating losses in the foreseeable future. As of November 6, 2024, the issuance date of these condensed consolidated financial statements, we expect that our cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12Â months.We will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We may not be able to obtain financing on acceptable terms, or at all, and we may not be able to enter into additional collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of our stockholders. Arrangements with collaborators or others may require us to relinquish rights to certain of our technologies or programs. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, pipeline expansion or commercialization efforts, which could adversely affect our business prospects. Although management will continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations when needed or at all.The accompanying condensed consolidated financial statements reflect the operations of Generation Bio and our wholly owned subsidiary, Generation Bio Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesUse of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the measurement of proportional performance of the performance obligation of our collaboration agreements, accrual of research, and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and otherÂ market-specificÂ or other relevant factors that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.Unaudited interim financial informationThe condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The

accompanying unaudited financial statements as of SeptemberÂ 30, 2024 and for the three and nine months ended SeptemberÂ 30, 2024 and 2023 have been prepared by us pursuant to the rulesÂ and regulations of the Securities and Exchange Commission, or SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rulesÂ and regulations. These financial statements should be read in conjunction with our audited financial statements included in our Annual Report on FormÂ 10-K that was most recently filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of our financial position as of SeptemberÂ 30, 2024, the results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023, and cash flows for the nineÂ months ended SeptemberÂ 30, 2024 and 2023 have been made. The results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of the results of operations that may be expected for theÂ year ending DecemberÂ 31, 2024 or any other period.Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. Updates to our significant accounting policies are discussed below.EmployeeÂ RetentionÂ CreditUnder the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, passed by the United States Congress and signed by the President, we are eligible for a refundable Employee Retention Credit, or ERC, subject to certain criteria. ASC 105, Generally Accepted Accounting Principles, describes the decision-making framework when no clear guidance exists in GAAP for a particular transaction. Specifically, ASC 105-10-05-2 instructs companies to look for guidance for a similar transaction within GAAP and apply that guidance by analogy. As such, forms of government assistance, such as the ERC, provided to business entities would not be within the scope of International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, but it may be applied by analogy under ASC 105-10-05-2. We accounted for the ERC as a government grant in accordance with IAS 20 by analogy under ASC 105-10-05-2. We recognized a $2.3 million ERC upon completion of an analysis providing reasonable assurance that we met the conditions set forth in the CARES Act and it was reasonably assured that we will receive the employee retention credit. We recorded the ERC in other long-term assets on our condensed consolidated balance sheet as of September 30, 2024 related to labor costs recognized during 2020 and 2021. The ERC was recorded in research and development expenses and general and administrative expenses proportionately in the manner in which the qualified wages and related costs were classified. We have filed for refunds of the ERC and as of the date of this Quarterly Report, we have not received any refunds.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities and Fair Value Measurements 9 Months Ended Sep. 30, 2024 Marketable Securities and Fair Value Measurements Â Marketable Securities and Fair Value Measurements 3. Marketable Securities and Fair Value MeasurementsThe following tables present our marketable securities by security type: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of September 30,
2024â€‹Â Â Â Â â€‹â€‹Â Â Â Â GrossÂ Â Â Â GrossÂ Â Â Â â€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹Gainsâ€‹Lossesâ€‹ValueU.S. treasury securitiesâ€‹$ 177,836â€‹$ â€”â€‹$ 178,155â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of December 31,
2023â€‹Â Â Â Â â€‹â€‹Â Â Â Â GrossÂ Â Â Â GrossÂ Â Â Â â€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹Gainsâ€‹Lossesâ€‹ValueU.S. treasury securitiesâ€‹$ 197,644â€‹$ 274â€‹$ â€”â€‹$ 197,918â€‹The following table summarizes our marketable securities by contractual maturity as of September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As of September 30, 2024â€‹â€‹Amortizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹ValueLess than one yearâ€‹$ 162,932â€‹$ 163,113Greater than one year but less than two yearsâ€‹â€‹ 14,904â€‹â€‹ 15,042Totalâ€‹$ 177,836â€‹$ 178,155â€‹Our marketable securities as of December 31, 2023 consisted of investments that mature within one year of their purchase date. We assess our available-for-sale securities under the available-for-sale security impairment model inÂ ASC 326, â€œFinancial Instruments - Credit Lossesâ€, or ASC 326,Â as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on our available-for-sale securities is the result of a credit loss. We also evaluate our available-for-sale securities for impairment using a variety of factors including our intent to sell the underlying securities prior to maturity and whether it is more likely than not that we would be required to sell the securities before the recovery of their amortized basis. During the nine months ended September 30, 2024 and 2023, we did not recognize any impairment or realized gains or losses on sales of available-for-sale securities, and we did not record an allowance for, or recognize, any expected credit losses.â€‹The following tables present our assets that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques that we utilized to determine such fair
value:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

an input method based on cost incurred relative to the total estimated costs by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is then applied to the transaction price allocated to the combined performance obligation and each of the options to receive licenses. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. All allocated consideration for the material rights is deferred until such time that Moderna exercises its options or the right to exercise the options expires. Upon exercise, we will determine the appropriate revenue recognition methodology and any other implications on the accounting treatment for the arrangement.â€‹During the three months ended September 30, 2024, we recorded additional revenueÂ related to aÂ change in estimate due to revisions in the research plan resulting in a reduction in the estimated timeline of future research services and total estimated costs. The change in estimate resulted in a $6.8 million decrease in the allocated transaction price and a $3.8Â million increase in collaboration revenue, a $3.8 million decrease in deferred revenue and a $0.06 decrease in net loss per share, basic and diluted, for both the three and nine months ended September 30, 2024.â€‹The following table provides a summary of the transaction price allocated to each unit of account, in addition to revenue activity during the period:â€‹â€‹â€‹

-Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Stock-Based compensation 9. Stock-Based CompensationStock incentive plansOur 2017 Stock Incentive Plan, or the 2017 Plan, provided for us to grant incentive stock options or nonstatutory stock options, restricted stock, restricted stock units and other equity awards to employees, non-employees, and directors.In MayÂ 2020, our board of directors adopted, and in JuneÂ 2020, our stockholders approved, the 2020 Stock Incentive Plan, or the 2020 Plan, and together with the 2017 Plan, the Plans, which became effective on JuneÂ 11, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the 2020 Plan is the sum of (1)Â 2,547,698 shares; plus (2)Â the number of shares (up to a maximum of 7,173,014 shares) as was equal to the sum of (x)Â the number of shares of common stock reserved for issuance under the 2017 Plan that remained available for grant under the 2017 Plan on JuneÂ 11, 2020 and (y)Â the number of shares of common stock subject to outstanding awards granted under the 2017 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right; plus (3)Â an annual increase, to be added on the first day of each fiscalÂ year, beginning with the fiscalÂ year ending DecemberÂ 31, 2021 and continuing until, and including, the fiscalÂ year ending DecemberÂ 31, 2030, equal to the lesser of (i)Â 4% of the number of shares of common stock outstanding on such date, and (ii)Â an amount determined by the board of directors. In January 2024, the number of shares of common stock authorized for issuance under the 2020 Plan was increased from 16,813,962 shares to 19,462,688â€¯shares. Upon the effectiveness of the 2020 Plan, we ceased granting additional awards under the 2017 Plan.The Plans are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions on any award under the Plans are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted under the Plans with service-based vesting conditions generally vest over fourÂ years and expire after tenÂ years. The exercise price for stock options granted is not less than the fair value of common stock as of the date of grant. Prior to our initial public offering, or IPO, in June 2020, the fair value of our common stock was determined by the board of directors. Subsequent to our IPO, fair value of common stock is based on quoted market prices.As of September 30, 2024, 790,738 shares remained available for future issuance under the 2020 Plan. Shares subject to outstanding awards granted under the Plans that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right will be available for future awards under the 2020 Plan.Grant of stock optionsDuring the nineÂ months ended September 30, 2024, we granted time-based options to certain employees for the purchase of an aggregate of 3,693,074 shares of common stock with a weighted average grant date fair value of $1.87 per share that vest over a weighted average period of approximately fourÂ years.Employee stock purchase planIn MayÂ 2020, our board of directors adopted, and in JuneÂ 2020, our stockholders approved, the 2020 Employee Stock Purchase Plan, or the 2020 ESPP, which became effective JuneÂ 11, 2020. The 2020 ESPP is administered by our board of directors or by a committee appointed by the board of directors. The number of shares of common stock authorized for issuance under the 2020 ESPP automatically increases on the first day of each fiscalÂ year, beginning with the fiscalÂ year that commenced on JanuaryÂ 1, 2021 and continuing for each fiscalÂ year until, and including the fiscalÂ year commencing on, JanuaryÂ 1, 2030, in an amount equal to the lowest of (1)Â 1,302,157 shares of common stock, (2)Â 1% of the number of shares of common stock outstanding on such date, and (3)Â an amount determined by the board of directors. In January 2024, the number of shares of common stock authorized for issuance under the 2020 ESPP was increased from 2,115,792 shares toÂ 2,777,974 shares. As of September 30, 2024, 2,204,771 shares remained available for issuance under the 2020 ESPP.Stock-based compensationStock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: â€‹â€‹â€‹

Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Use of estimates Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the measurement of proportional performance of the performance obligation of our collaboration agreements, accrual of research, and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and otherÂ market-specificÂ or other relevant factors that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Unaudited interim financial information Unaudited interim financial informationThe condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited financial statements as of SeptemberÂ 30, 2024 and for the three and nine months ended SeptemberÂ 30, 2024 and 2023 have been prepared by us pursuant to the rulesÂ and regulations of the Securities and Exchange Commission, or SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rulesÂ and regulations. These financial statements should be read in conjunction with our audited financial statements included in our Annual Report on FormÂ 10-K that was most recently filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of our financial position as of SeptemberÂ 30, 2024, the results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023, and cash flows for the nineÂ months ended SeptemberÂ 30, 2024 and 2023 have been made. The results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of the results of operations that may be expected for theÂ year ending DecemberÂ 31, 2024 or any other period.Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. Updates to our significant accounting policies are discussed below. Employee Retention Credit EmployeeÂ RetentionÂ CreditUnder the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, passed by the United States Congress and signed by the President, we are eligible for a refundable Employee Retention Credit, or ERC, subject to certain criteria. ASC 105, Generally Accepted Accounting Principles, describes the decision-making framework when no clear guidance exists in GAAP for a particular transaction. Specifically, ASC 105-10-05-2 instructs companies to look for guidance for a similar transaction within GAAP and apply that guidance by analogy. As such, forms of government assistance, such as the ERC, provided to business entities would not be within the scope of International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, but it may be applied by analogy under ASC 105-10-05-2. We accounted for the ERC as a government grant in accordance with IAS 20 by analogy under ASC 105-10-05-2. We recognized a $2.3 million ERC upon completion of an analysis providing reasonable assurance that we met the conditions set forth in the CARES Act and it was reasonably assured that we will receive the employee retention credit. We recorded the ERC in other long-term assets on our condensed consolidated balance sheet as of September 30, 2024 related to labor costs recognized during 2020 and 2021. The ERC was recorded in research and development expenses and general and administrative expenses proportionately in the manner in which the qualified wages and related costs were classified. We have filed for refunds of the ERC and as of the date of this Quarterly Report, we have not received any refunds.â€‹ X - DefinitionDisclosure of accounting policy for employee retention credit. + ReferencesNo definition available. + Details Name: gbio_EmployeeRetentionCreditPolicyTextBlock Namespace Prefix: gbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities and Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Marketable Securities and Fair Value Measurements Â Summary of marketable securities by security type â€‹As of September 30, 2024â€‹Â Â Â Â â€‹â€‹Â Â Â Â GrossÂ Â Â Â GrossÂ Â Â Â â€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹Gainsâ€‹Lossesâ€‹ValueU.S. treasury securitiesâ€‹$ 177,836â€‹$ 319â€‹$ â€”â€‹$ 178,155â€‹As of December 31, 2023â€‹Â Â Â Â â€‹â€‹Â Â Â Â GrossÂ Â Â Â GrossÂ Â Â Â â€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Unrealizedâ€‹Fair(inÂ thousands)â€‹Costâ€‹Gainsâ€‹Lossesâ€‹ValueU.S. treasury securitiesâ€‹$ 197,644â€‹$ 274â€‹$ â€”â€‹$ 197,918 Schedule of marketable securities by contractual maturity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

- DefinitionTabular disclosure of information pertaining to allocation of transaction price to each unit of account. + ReferencesNo definition available. + Details Name: gbio_SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock Namespace Prefix: gbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of transaction price allocated to each unit of account in addition to revenue activity. + ReferencesNo definition available. + Details Name: gbio_SummaryOfTransactionPriceAllocatedWithRevenueActivityTableTextBlock Namespace Prefix: gbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Property and equipment, net (Tables) 9 Months Ended Sep. 30, 2024 Property and equipment, net. Â Summary of Property and equipment, net â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹September 30,â€‹ DecemberÂ 31,Â (inÂ thousands)â€‹2024â€‹2023Laboratory equipmentâ€‹$ 14,543â€‹$ 14,859Computer equipment and softwareâ€‹Â 1,422â€‹Â 1,447Furniture and fixturesâ€‹Â 1,293â€‹Â 1,293Leasehold improvementsâ€‹Â 20,909â€‹Â 20,865Construction in progressâ€‹Â 112â€‹Â 7,030â€‹â€‹â€‹ 38,279â€‹â€‹ 45,494Less: Accumulated depreciation and amortizationâ€‹â€‹ (22,269)â€‹â€‹ (19,695)Totalâ€‹$ 16,010â€‹$ 25,799 X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Accrued Expenses Â Summary of accrued expenses â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹September 30,â€‹ DecemberÂ 31,Â (inÂ thousands)Â Â Â Â 2024â€‹2023Accrued employee compensation and benefitsâ€‹$ 4,505â€‹$ 13,208Accrued external research and development expensesâ€‹Â 600â€‹Â 1,169Accrued professional feesâ€‹Â 654â€‹Â 908Property and equipmentâ€‹â€‹ 33â€‹â€‹ 838Otherâ€‹Â 405â€‹Â 406Totalâ€‹$ 6,197â€‹$ 16,529 Summary of accrued restructuring costs recorded and included in accrued expenses and other current liabilities â€‹â€‹â€‹â€‹â€‹â€‹(in thousands)â€‹â€‹Severance and Benefits CostsBalance at December 31, 2023â€‹$ 5,291Cash paymentsâ€‹Â (5,055)Restructuring expensesâ€‹â€‹ 380Adjustmentsâ€‹â€‹ (402)Balance at September 30, 2024â€‹$ 214 X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases Â Future lease payments for noncancelable operating lease â€‹â€‹â€‹â€‹â€‹Three Months Ended SeptemberÂ 30,Â â€‹(in thousands)2024 (remaining 3 months)â€‹$ 1,9352025â€‹Â 7,8382026â€‹Â 8,0592027â€‹Â 8,2752028â€‹Â 8,535Thereafterâ€‹Â 2,834Total undiscounted payments due under operating leasesâ€‹â€‹ 37,476Less imputed interestâ€‹â€‹ (5,673)Totalâ€‹$ 31,803â€‹â€‹â€‹â€‹Current operating lease liabilityâ€‹$ 5,707Non-current operating lease liabilityâ€‹â€‹ 26,096Totalâ€‹$ 31,803 Costs included in operating expenses related to the operating lease The following table presents our costs included in operating expenses related to our noncancelableÂ operating leases:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended September 30, â€‹Nine Months Ended September 30, (in thousands)â€‹2024â€‹2023â€‹2024â€‹2023Operating lease costâ€‹$ 1,467â€‹$ 3,280â€‹$ 4,401â€‹$ 9,842Variable lease costâ€‹â€‹ 528â€‹â€‹ 832â€‹â€‹ 1,575â€‹â€‹ 2,542Totalâ€‹$ 1,995â€‹$ 4,112â€‹$ 5,976â€‹$ 12,384 X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Summary of stock-based compensation expense was classified in the statements of operations and comprehensive loss â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended September 30,â€‹Nine Months Ended SeptemberÂ 30,Â (inÂ thousands)2024Â Â Â Â 2023â€‹2024Â Â Â Â 2023Research and development expenses$ 1,520â€‹$ 2,874â€‹$ 4,452â€‹$ 8,608General and administrative expensesÂ 2,232â€‹Â 3,130â€‹Â 6,997â€‹Â 9,685Total$ 3,752â€‹$ 6,004â€‹$ 11,449â€‹$ 18,293 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Net Loss per Share Â Summary of potential dilutive securities, presented based on amounts outstanding â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹September 30,â€‹Â Â Â Â 2024Â Â Â Â 2023Unvested restricted stock unitsâ€‹374,076â€‹1,179,349Stock options to purchase common stockâ€‹13,215,012â€‹9,676,685Totalâ€‹13,589,088â€‹10,856,034â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of the Business and Basis of Presentation - Additional information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Summary of Significant Accounting Policies Â Â Â Â Â Â Date of incorporation Â Â Â Â Oct. 21, 2016 Â Â Â Â Net loss and net loss attributable to common stockholders $ 15,313 $ 28,266 $ 110,286 $ 91,426 Â Accumulated deficit $ 681,663 Â $ 681,663 Â $ 571,377 X - DefinitionDate when an entity was incorporated + ReferencesNo definition available. + Details Name: dei_EntityIncorporationDateOfIncorporation Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -

Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Detail) $ in Millions Sep. 30, 2024 USD ($) Summary of Significant Accounting Policies Â Employee retention credit recognized $ 2.3 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligations incurred for employer-related costs classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities and Fair Value Measurements - Summary of marketable securities (Detail) - Fair Value, Recurring - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Marketable Securities [Line Items] Â Â Amortized Cost $ 177,836 Â Fair Value 178,155 Â U.S. treasury securities Â Â Marketable Securities [Line Items] Â Â Amortized Cost 177,836 $ 197,644 Gross Unrealized Gains 319 274 Gross Unrealized Losses 0 0 Fair Value $ 178,155 $ 197,918 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities and Fair Value Measurements - Summary of marketable securities by contractual maturity (Detail) - Fair Value, Recurring $ in Thousands Sep. 30, 2024 USD ($) Amortized Cost Â Less than one year $ 162,932 Greater than one year but less than two years 14,904 Debt Securities, Available-for-sale, Amortized Cost, Total 177,836 Fair Value Â Less than one year 163,113 Greater than one year but less than two years 15,042 Debt Securities, Available-for-sale, Fair Value $ 178,155 X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Marketable Securities and Fair Value Measurements - Summary of assets measured at FV on a recurring basis (Detail) - Fair Value, Recurring - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Marketable securities: Â Â Marketable securities $ 178,155 Â Total 183,615 $ 236,128 Level 1 Â Â Marketable securities: Â Â Total 5,460 38,210 Level 2 Â Â Marketable securities: Â Â Total 178,155 197,918 Level 3 Â Â Marketable securities: Â Â Total 0 0 Money Market Funds Â Â Cash equivalents: Â Â Cash equivalents 5,460 38,210 Money Market Funds | Level 1 Â Â Cash equivalents: Â Â Cash equivalents 5,460 38,210 Money Market Funds | Level 2 Â Â Cash equivalents: Â Â Cash equivalents 0 0 Money Market Funds | Level 3 Â Â Cash equivalents: Â Â Cash equivalents 0 0 U.S. treasury securities Â Â Marketable securities: Â Â Marketable securities 178,155 197,918 U.S. treasury securities | Level 1 Â Â Marketable securities: Â Â Marketable securities 0 0 U.S. treasury securities | Level 2 Â Â Marketable securities: Â Â Marketable securities 178,155 197,918 U.S. treasury securities | Level 3 Â Â Marketable securities: Â Â Marketable securities $ 0 $ 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration and License Agreement (Details) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Nov. 06, 2024 shares Mar. 31, 2023 USD ($) item product $ / shares shares Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) $ / shares Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) $ / shares Apr. 30, 2023 USD ($) Collaboration and License Agreement Â Â Â Â Â Â Â Sale of common stock in connection with the Moderna Share Purchase Agreement, shares | shares 0 Â Â Â Â Â Â Collaboration revenue Â Â $ 7,554 $ 2,146 $ 15,704 $ 3,026 Â Deferred revenue Â Â Â Â $ (12,154) $ 44,474 Â Net loss per share, basic (in dollars per share) | $ / shares Â Â $ (0.23) $ (0.43) $ (1.66) $ (1.43) Â Net loss per share, diluted (in dollars per share) | $ / shares Â Â $ (0.23) $ (0.43) $ (1.66) $ (1.43) Â Collaboration and License Agreement | ModernaTX, Inc Â Â Â Â Â Â Â Collaboration and License Agreement Â Â Â Â Â Â Â Upfront payments Â $ 40,000 Â Â Â Â $ 40,000 Prepaid research services funding Â $ 7,500 Â Â Â Â $ 7,500 Milestone payments receivable Â Â $ 1,800,000 Â $ 1,800,000 Â Â Number of performance obligations | item Â 1 Â Â Â Â Â Premium paid on common stock Â $ 13,300 Â Â Â Â Â Variable consideration Â 0 Â Â Â Â Â Transaction Price Allocated Â $ 77,893 73,931 Â 73,931 Â Â Collaboration and License Agreement | ModernaTX, Inc | Minimum Â Â Â Â Â Â Â Collaboration and License Agreement Â Â Â Â Â Â Â Number of products to be commercialized | product Â 1 Â Â Â Â Â Royalty payment term Â 10 years Â Â Â Â Â Collaboration and License Agreement | Share Purchase Agreement | Beneficial Owner | ModernaTX, Inc Â Â Â Â Â Â Â Collaboration and License Agreement Â Â Â Â Â Â Â Sale of common stock in connection with the Moderna Share Purchase Agreement, shares | shares Â 5,859,375 Â Â Â Â Â Shares issue price (in dollars per share) | $ / shares Â $ 6.14 Â Â Â Â Â Proceeds from issuance/sale of common stock Â $ 36,000 Â Â Â Â Â Percent of shares to be issued Â 3.06% Â Â Â Â Â Â Equity financing Â $ 25,000 Â Â Â Â Â Collaboration and License Agreement | Contracts Accounted for under Percentage of Completion Â Â Â Â Â Â Â Collaboration and License Agreement Â Â Â Â Â Â Â Transaction Price Allocated Â Â (6,800) Â (6,800) Â Â Collaboration revenue Â Â 3,800 Â 3,800 Â Â Deferred revenue Â Â $ (3,800) Â $ (3,800) Â Â Net loss per share, basic (in dollars per share) | $ / shares Â Â $ (0.06) Â $ (0.06) Â Â Net loss per share, diluted (in dollars per share) | $ / shares Â Â $ (0.06) Â $ (0.06) Â Â X - DefinitionThe term for payment of royalty under collaboration agreement. + ReferencesNo definition available. + Details Name: gbio_CollaborativeAgreementRoyaltyPaymentTerm Namespace Prefix: gbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe amount of milestone payments receivable under collaborative arrangements. + ReferencesNo definition available. + Details Name: gbio_CollaborativeArrangementMilestonePaymentsReceivable Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of performance obligations under collaborative arrangements. + ReferencesNo definition available. + Details Name: gbio_CollaborativeArrangementNumberOfPerformanceObligations Namespace Prefix: gbio_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe number of products to be commercialized under collaborative arrangements. + ReferencesNo definition available. + Details Name: gbio_CollaborativeArrangementNumberOfProductsToBeCommercialized Namespace Prefix: gbio_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe amount of research services prepayments received under collaborative arrangements. + ReferencesNo definition available. + Details Name: gbio_CollaborativeArrangementPrepaidResearchServicesFunding Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of upfront payments received under collaborative arrangements. + ReferencesNo definition available. + Details Name: gbio_CollaborativeArrangementUpfrontPayments Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of variable consideration included in transaction price of collaborative arrangements. + ReferencesNo definition available. + Details Name: gbio_CollaborativeArrangementVariableConsiderationIncludedInTransactionPrice Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of equity financing. + ReferencesNo definition available. + Details Name: gbio_EquityFinancingAmount Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of premium paid over fair value of common stock under share purchase agreement. + ReferencesNo definition available. + Details Name: gbio_SharePurchaseArrangementPremiumPaidOnCommonStock Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe shares to be purchased under share purchase agreement as percent of outstanding shares. + ReferencesNo definition available. + Details Name: gbio_SharePurchaseArrangementSharePurchaseAsPercentOfOutstandingShares Namespace Prefix: gbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-

41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=gbio_ModernatxIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=gbio_SharePurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ContractsAccountedForUnderPercentageOfCompletionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration and License Agreement - Schedule of Allocated Transaction Price and Revenue Activity (Detail) - ModernaTX, Inc - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Mar. 31, 2023 Collaboration and License Agreement Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â $ 96,050 Transaction Price Allocated $ 73,931 $ 73,931 77,893 Revenue Recognized 7,554 15,704 Â Deferred Revenue 42,707 42,707 Â ctLNP technology and research license Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â 52,500 Transaction Price Allocated 40,409 40,409 42,576 Revenue Recognized 7,554 15,704 Â Deferred Revenue 14,549 14,549 Â First liver program commercialization option license Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â 7,000 Transaction Price Allocated 5,388 5,388 5,677 Revenue Recognized 0 0 Â Deferred Revenue 4,526 4,526 Â Second liver program commercialization option license Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â 7,000 Transaction Price Allocated 5,388 5,388 5,677 Revenue Recognized 0 0 Â Deferred Revenue 4,526 4,526 Â First non-liver program commercialization option license Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â 11,700 Transaction Price Allocated 9,006 9,006 9,488 Revenue Recognized 0 0 Â Deferred Revenue 7,565 7,565 Â Second non-liver program commercialization option license Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â 11,700 Transaction Price Allocated 9,006 9,006 9,488 Revenue Recognized 0 0 Â Deferred Revenue 7,565 7,565 Â Third liver or non-liver program commercialization option license Â Â Â Collaboration and License Agreement Â Â Â Standalone Selling Price Â Â 6,150 Transaction Price Allocated 4,734 4,734 $ 4,987 Revenue Recognized 0 0 Â Deferred Revenue $ 3,976 $ 3,976 Â X - DefinitionThe amount of standalone selling price. + ReferencesNo definition available. + Details Name: gbio_StandaloneSellingPrice Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=gbio_ModernatxIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_CtlnpTechnologyAndResearchLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_FirstLiverProgramCommercializationOptionLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_SecondLiverProgramCommercializationOptionLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_FirstNonLiverProgramCommercializationOptionLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_SecondNonLiverProgramCommercializationOptionLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=gbio_ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Property and equipment, net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross $ 38,279 $ 45,494 Less: Accumulated depreciation and amortization (22,269) (19,695) Property and equipment, net 16,010 25,799 Laboratory equipment Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 14,543 14,859 Computer equipment and software Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,422 1,447 Furniture and fixtures Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,293 1,293 Leasehold improvements Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 20,909 20,865 Construction in progress Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross $ 112 $ 7,030 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Property and equipment, net - Additional Information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Line Items] Â Â Â Â Depreciation and amortization expense $ 1,200 $ 1,300 $ 3,755 $ 3,938 Construction in progress Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Impairment charge Â Â $ 6,200 Â X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 35 -Paragraph 44 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482190/360-10-35-44 + Details Name: us-gaap_ImpairmentChargeOnReclassifiedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Expenses Â Â Accrued employee compensation and benefits $ 4,505 $ 13,208 Accrued external research and development expenses 600 1,169 Accrued professional fees 654 908 Property and equipment 33 838 Other 405 406 Total $ 6,197 $ 16,529 X - DefinitionThe amount of accrued expense on property and equipment. + ReferencesNo definition available. + Details Name: gbio_AccruedExpenseOnPropertyAndEquipment Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development expenses. + ReferencesNo definition available. + Details Name: gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Narrative (Detail) - USD ($) $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended Nov. 30, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Accrued Expenses Â Â Â Â Reduction in workforce 40.00% Â Â Â Restructuring expenses Â $ 0.0 $ 0.4 $ 0.0 Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Â Â General and Administrative Expense Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostIncurredCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes restructuring charges. + ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Schedule of accrued restructuring costs (Detail) - Severance and Benefits Costs $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Restructuring costs Â Beginning Balance $ 5,291 Cash payments (5,055) Restructuring expenses 380 Adjustments (402) Ending Balance $ 214 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveAccrualAdjustment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Narrative (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jul. 31, 2021 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2022 Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Lease existence of option to extend Â Â Â true Â Â Operating lease agreement option to renewal term 5 years 5 years Â 5 years Â Â Letter of credit for security deposit Â $ 2,100 Â $ 2,100 Â Â Operating lease term Â Â Â Â Â 12 years Total rent payments Â Â Â Â Â $ 104,300 Initial monthly base rent on operating lease $ 400 Â Â Â Â Â Option to extend lease two Â Â Â Â Â Construction allowance in operating lease $ 26,000 Â Â Â Â Â Operating lease payments Â Â Â $ 5,700 $ 9,600 Â Weighted-average remaining lease term Â 5 years Â 5 years Â Â Weighted-average incremental borrowing Â 7.10% Â 7.10% Â Â Security deposit liability Â $ 3,600 Â $ 3,600 Â Â Impairment of right-of-use asset Â Â Â 45,800 Â Â Tenant improvement allowance receivable write-off Â Â Â 3,900 Â Â Accretion and other lease related expenses Â Â Â 3,700 Â Â Loss on lease termination Â (1,169) $ 0 (59,596) $ 0 Â Operating Lease, Liability Â $ 62,000 Â 62,000 Â Â Construction in progress Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Impairment charge Â Â Â $ 6,200 Â Â Maximum Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Estimated monthly base rent on operating lease 600 Â Â Â Â Â Letter of Credit [Member] Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Security deposit $ 3,600 Â Â Â Â Â X - DefinitionConstruction allowance in operating lease. + ReferencesNo definition available. + Details Name: gbio_ConstructionAllowanceInOperatingLease Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEstimated monthly base rent on operating lease + ReferencesNo definition available. + Details Name: gbio_EstimatedMonthlyBaseRentOnOperatingLease Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInitial monthly base rent on operating lease. + ReferencesNo definition available. + Details Name: gbio_InitialMonthlyBaseRentOnOperatingLease Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLetter of credit for security deposit. + ReferencesNo definition available. + Details Name: gbio_LetterOfCreditForSecurityDeposit Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_AccretionExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFor the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 35 -Paragraph 44 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482190/360-10-35-44 + Details Name: us-gaap_ImpairmentChargeOnReclassifiedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForTenantImprovements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing. + ReferencesNo definition available. + Details Name: us-gaap_SecurityDepositLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Future Lease Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2022 Lessee, Lease, Description [Line Items] Â Â Â Total undiscounted payments due under operating leases Â Â $ 104,300 Current operating lease liability $ 10,797 $ 8,120 Â Non-current operating lease liability 82,982 $ 89,774 Â Total 62,000 Â Â Active Lease Â Â Â Lessee, Lease, Description [Line Items] Â Â Â 2024 (remaining 3 months) 1,935 Â Â 2025 7,838 Â Â 2026 8,059 Â Â 2027 8,275 Â Â 2028 8,535 Â Â Thereafter 2,834 Â Â Total undiscounted payments due under operating leases 37,476 Â Â Less imputed interest (5,673) Â Â Current operating lease liability 5,707 Â Â Non-current operating lease liability 26,096 Â Â Total $ 31,803 Â Â X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: gbio_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=gbio_ActiveLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Costs included in operating expenses related to the operating lease (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases Â Â Â Â Operating lease cost $ 1,467 $ 3,280 $ 4,401 $ 9,842 Variable lease cost 528 832 1,575 2,542 Total $ 1,995 $ 4,112 $ 5,976 $ 12,384 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Equity - Additional Information (Detail) $ / shares in Units, $ in Millions 1 Months Ended 9 Months Ended Nov. 06, 2024 shares Aug. 31, 2024 USD ($) Sep. 30, 2024 security $ / shares shares Dec. 31, 2023 $ / shares shares Capital Unit [Line Items] Â Â Â Â Common stock, shares authorized | shares Â Â 150,000,000 150,000,000 Common stock, par value per share | $ / shares Â Â $ 0.0001 $ 0.0001 Preferred stock, shares authorized | shares Â Â 5,000,000 5,000,000 Preferred stock, par value per share | $ / shares Â Â $ 0.0001 $ 0.0001 Shares issued during the period | shares 0 Â Â Â Number of vote per common share | security Â Â 1 Â Maximum Â Â Â Â Capital Unit [Line Items] Â Â Â Â Aggregate gross offering price | $ Â $ 237.0 Â Â At the Market Offering Â Â Â Â Capital Unit [Line Items] Â Â Â Â Termination of shares reserved for future issuances | $ Â 237.3 Â Â Aggregate gross offering price | $ Â $ 250.0 Â Â X - DefinitionAmount of common stock remained unsold upon termination. + ReferencesNo definition available. + Details Name: gbio_CommonStockCapitalSharesReservedForFutureIssuancesRemainedUnsoldUponTermination Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of vote per common shares. + ReferencesNo definition available. + Details Name: gbio_NumberOfVotePerCommonShare Namespace Prefix: gbio_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCash inflow form gross proceeds form issuance of common stock. + ReferencesNo definition available. + Details Name: gbio_ProceedsFromIssuanceOfCommonStockGross Namespace Prefix: gbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CapitalUnitLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe

maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=gbio_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Detail) - $ / shares 9 Months Ended Nov. 06, 2024 Jun. 11, 2020 Sep. 30, 2024 Jan. 31, 2024 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Shares issued during the period 0 Â Â Â Â Service Based Options | Certain Employees Directors And Consultants Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Shares issued during the period Â Â 3,693,074 Â Â Weighted average grant date fair value Â Â $ 1.87 Â Â Share based compensation by share based payment weighted average period Â Â 4 years Â Â 2020 Stock Incentive Plan Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock reserved for future issuance Â 2,547,698 790,738 Â Â Share based compensation by share based payment arrangement number of shares authorized for issuance Â Â Â 19,462,688 16,813,962 Stock based compensation vesting period service based Â Â 4 years Â Â Stock based compensation period of expiry Â Â 10 years Â Â 2020 Stock Incentive Plan | Maximum | Additional From 2017 Plan Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock reserved for future issuance Â 7,173,014 Â Â Â 2020 Stock Incentive Plan | Maximum | Annual Increase 2021 To 2030 Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Percentage of common stock shares additionally reserved for issuance Â 4.00% Â Â Â Employee Stock Purchase Plan 2020 Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Share based compensation by share based payment arrangement number of shares authorized for issuance Â Â Â 2,777,974 2,115,792 Shares issued Â Â 2,204,771 Â Â Employee Stock Purchase Plan 2020 | Maximum | Annual Increase 2021 To 2030 Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Percentage of common stock shares additionally reserved for issuance Â 1.00% Â Â Â Number of share instruments newly issued under a share-based compensation plan Â 1,302,157 Â Â Â X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement, as a percentage of common stock outstanding. + ReferencesNo definition available. + Details Name: gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage Namespace Prefix: gbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=gbio_ServiceBasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=gbio_CertainEmployeesDirectorsAndConsultantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: gbio_DateAxis=gbio_AdditionalFrom2017PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: gbio_DateAxis=gbio_AnnualIncrease2021To2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Expense Classification (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Stock-based compensation expense $ 3,752 $ 6,004 $ 11,449 $ 18,293 Research and

development expenses Â Â Â Â Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Stock-based compensation expense 1,520 2,874 4,452 8,608 General and administrative expenses Â Â Â Â Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Stock-based compensation expense $ 2,232 $ 3,130 $ 6,997 $ 9,685 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Unrecognized Expense (Detail) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Unrecognized Expense $ 14.7 Share based compensation expected to recognize over a weighted average period one Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Unrecognized Expense $ 13.2 Unrecognized stock compensation on account of unvested options remaining period over which the compensation is to be recognized 2 years 1 month 6 days Share based compensation expected to recognize over a weighted average period two Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Unrecognized Expense $ 1.5 Unrecognized stock compensation on account of unvested options remaining period over which the compensation is to be recognized 2 years 2 months 12 days X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementScenarioAxis=gbio_ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=gbio_ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies. Â Defined contribution plan, percentage 4.00% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Summary of Potential Dilutive Securities (Detail) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Anti-dilutive net loss per share 13,589,088 10,856,034 Unvested restricted stock units Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Anti-dilutive net loss per share 374,076 1,179,349 Stock options to purchase common stock Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Anti-dilutive net loss per share 13,215,012 9,676,685 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}3(AP]@7_MOX!A0H+Q4[E.J.H8)3L;HDKG-! MF,.:EO(,\/"QW%P2A]K"WQ3'S2O)3?5CD,!D8&T\7"D?=T<'AI?D;.3A=;?KTJX-$@VM"$F=8DEUT*(-8QUH,\4L K-@0(.. M>60=C25"'X?CX6/_:?0P)G>C!S)XN+3!XB)5:5\9"'H*[2CVI(*^RDVWO2!3 M#1,0D8H,Y#K6:@?_?7L5X.KW0RLR&E05F17([!3D)_Y"1CX,V& >>"DWTIM+ M)*]HO>DZE%U99R4\N"IO87\H:C@.O'W?!_7DXG!!/L%WY"&VMRLN":SD+HAC ML8.NHL"]6K'/X8- H880H;F7>8P_,'73I)[F-K@ZG1 NK1'&'\QYT(A,-5N*O8'5\AL(5 M'4:,S$IZ#J]$"[-$<8>3]M8^;.V/@^$";=JQ8IW#(M'"(U'0HTN"(Y)Y3]//N%["W3S@J)*PUD%,&2 M--72> [X@/SJ7#G@FV.HK\I6']ET,KEB1G17&B>%^'!WRO'\0+,MU%,QG:DL M/H)-LJ8+SF&16&&1&&YB#HU(AB_>DL<+<=00E@B-^]/[OG5[C0=6)2P<$3O) M$0W62ID-3+9K29L2%A+ [_JQ$\9LU$37 HZIR%DZ(G>2$1K$6*LM FITV/X!; M.7'%8YSGL#ZLL#[L).MC=FA@X<$+*2RSD$E.F,9U[GG"9 !$\3\3M/*>P_^P MPO^PD_S/-.)A2.[6";Q.[+VV6GH(#ZN*5[@>=I+K&49"+@G& (%KQ MV-ZNN.#1] (>5Q6T,#T,]RR'=EP*:$<,#YUAJL;&P64"OQ=[(U^WK(U%JIFCDJVO3:[4Z773&PPAL8V& &&Y#HPP MG2IP>J/8%R_D=V%OQK(&PO=V]R:W-H965T M&ULK5GSIM]I/"'2/L,D M9&%"$@P RG&_O@M2%B4"A.W6#[9XV5V>70![#LCS>R&_J0UC&OVHREI=S#9: M-V>+A+50C&2TZIZIJ2U^Q:(M56%94/'U@I[B]F>/9XX3._VVAS8;$Z;^@=NV'Z:W,MX6RQCU+P MBM6*BQI)MKZ8O<=GER$Q#IW%7YS=JX-C9%*Y%>*;.?FCN)@%!A$K6:Y-" H_ M6W;)RM)$ AS?=T%G^V<:Q\/CQ^B_=H8&O:EOJS MN/^=[1**3;QR2- -40S!UUM.F_(AM=F&&^TA+L<_/3J4M0%# HK M$!PI4?*"':CCY0$M:YPS=F, *G:"O-U?HUS=OT1O$:_1E(UI%ZT*=+S1@,)$6 M^>YY'_KGD8GGW;#F%(7!')& 1 [W2[_[%9ZY\^@"1.X!996>JH3F[F,$R4DQNV6SU\T\X"=ZYLGNE8$>Y MAOM<0U_TU255&P2CAG)SP+ZW?$M+2-XYBGVHI ME6L%V17 2I^>+[6$ZME62 M1%&RMSK"&>UQ1EZ<'ZG\QC2]+1E2+&\EUYPY,?9AXH.GXR3$.!R!=)AE:8:7 M;I3Q'F7LKZ8H2WHK)-5]0\L9E!,PNX#&%@)",!G!M(T"-\)DCS#Q(OS":@I3 MVP\M\3RUQV5;A%DR 2W=0TN]T*XE:R@O$/O1F.:CNFDI](9)Z'F'*](%.;4 M120=5]-EE$5NU,L]ZJ6_H$+3\AD EXX)ATD)$ZH=N,ICVU(!.!'KDQ9.IN?& M+NH1'$R(A=HV2[)E3"90#W2'O0RS^LR4ECPW%&]8P(F0.!#&X_%W6$%5\02^ M@:*PGZ,^=3V@%/7=B6:R\\A4RM/L2#I(Q3-L*ZCB!HOA%XL-F40Z)E MNAQW (==F$9I/ 5PX"8\)K 4YM@[T<]U)Q\UK1CI,>Z [[^>Y] MGHL6Y QJZ,,4W6&;S4#69.-QL:U(."5K\$!ZV,]Z %"VS,MZ!P/FA&_36@)B M9@S?MH(DR53+&^@/^_GOBJT9P"Q 4FQ9W;H+[" _'%MBQV5&,CP%<2 _[&>_ M<5=^K.>#$ZN#ZH+4+J=MML1D@N[0('?$3W?':N*)@2770H;IZD)/; B\/BI:@JKHUF MZSM;+FI3=U;G@!C]^J?0#.'@K1.[-[*:.9!S?_W_ QUG/U N\5/NC1;YMXTH M"R;5+YU\U0_N]PFORKFO%>TXZX%SB9]S82.WZPS*Y#]';X+3(@P<+!$6UJV M[!V*YW#%_"&UH=+07JLW0O)_P,O,DUH\WN!*&7X4$HE6*PTWS;JE&MVP1K/J M%HCR\=51YWD%6]O^JO.-T* [>3V]QO2;'E1G(GOC)WJP&47O* KLJ7V&>G_0[ME"3S- [G<;#L+."4!/$\CH-183N]\=\J.X?6KQK6O70MG6Q*;-4Q9E*OR7&= M!U%" *+D?5%PT[:A09I7"B>\AIU-PZ%A.D':NB-=QFDZ5H NNS0B9*J5#P*% M^ 4*:,"V:LON)>M.^HD*EN;&O!G?,L1K.'*96C%SL!VYH# M!U%D4:;#C@0A)A/[M' 0)Z%?G%C$WBV^9\,G]DM:ÙS;38>?<9BX./B.8;S@? MJ;SCM0+AM ;'X#2% LC^LTA_HD73?5FX%5J+JCO<, JPC0'<7PO@_-V)^5BQ M_SBU^A=02P,$% @ "X)F6?DS=R/P @ 0H !@ !X;"]W;W)KNJY(,"J9ZHH(2K\R%+)C&J5RXJI+ 4BLJG-'(+QDLG'MFUJ8Q'8JES M7L)4$K4L"B9_WT NUF/':JSL3-T2 ISMLSUG5A_@B:AT/@E(E?V MFZSKVC@D&2IM"@:,1(4O*Q_V6-3B V!U]\C\!N!?ZH@: 2!3;0FLVG=,LWB MD11K(DTTNIF!K8U58S:\- +=QIB5>Y:C3\424*=X42 F.E,AYRC1.;EC.R@3(MS!@K\G;*))0Z \T3EK\C[\EKXA*5X:H:N1HYC)N;-'O>U'OZ>_:<0=4C ;T@ M/O7['?+)8?DM)"CWK#S8EKN8?5L"ORV!;_V"?

3@:4\;.U$3,R4=>8N*=]N/Z7FF)_?:S*]7:N]_M;1["*U6Q!,8./F4*Y J<^,TK+Z(?NA+_3V9; M90C:,@2'W.,I/C\@)=Y\;+KDX8)43)(5RY= *I#US>XJ0.TZL*[F3V,5TQZE MU!NYJ\W4CH9M0?
=;Z/YYT'5/$K;4F9#\#Z1=R+5GN,$24OO983X>MP4=MM#A MBZ"Y4LMNX/ 9R"[JH8@MR*B%C%X$B:\"I5F9\G+111H=)3T4L44Z:$D'!TDG
MHBCP,3VO:P>G=>W1L"WB84L\/(XI)8=/JN:U_3B;GU/B=RBOFRI+\^GWM^S ME\\XHF@0!B$=[@!W!?HT#,,]O![]]VZCYQ,?:>#&\@3NSLA.<'?C_6P.1U^8 M7/!2D1SF**6]
7K(^KQ13[2H["O[7F@\ -AAAFGX]@% J' & 'AL+W=0=[3.5HZB_RBWGBGPKBTI>S[9*[2[G M<[G:\C*5%V+'*WBS%G69+KBM-W.YJWF:-49E,6>.$\S\+-*]FBZOFV<=Z<27V MJL@K_K$FW.6;K=
(/YHNK7;KA]UQ]WGVLX6Y^9,GR MDE)HQI@P;Q1\X?Y\)72%"G\ M._!;7A2:">;Q9T9^]=P2 ,VA^-X%;IBI=7-7BD=0:#6SZHHE^8PWQRBN= M*/>JAK$;B2HLBS5,'-O8)_D
]*KFO^]XG>IUE22M-+*$ MI-SJ;#EP\JN0DKPCG^^7Y/6K-^05R2OR:2OV$J#R:JY@DGJH^;J;T$T[(79F M0B[Y("JUE22!B66(_=)N'UOLYQ"<8X384X1NF)7PGN\NB.N\);
MNY@[_V_TY#^//@B&>TP7M^%SS_#=\0.O]EQ>8@O;FGJXJ:YXEW*7KOCU#+)' M\OK 9XOOOZ.!\P,6U2G)EE.2)1.1#>+O'>/OV=AANQ9%^B#:W0B%NED-;"U: MF]"AT7Y$J9%[8U3@!
[&')U]X=#FTNOP3KR#[MBL;C-(/.FTNEL_& ;K=P-(681L8\;\<@2@//0"W'*!939NZW,)T)4J.]I'.?J)&,BG;N3EV_0J+1#1*>3U[M\3/['H)#^Q[&A_8]!&CI>ZP7V\QYAN)<#7+PM7;_C4V&,JN"?
VDR3LJVG0)M8FIMN#S]@8!99>[BQ7.["I\7!M1/QFRB[R0F@=!# >[TC,/ M@B@?[,J1\L: ,9R50\O^GQP];[YG..\?R& M7MY2Y/F27B;M9ZN>OOV*]B&M-SIO"KZ&H9R+$!:H;C],M3=*
[)HO+P]"*5$V MEUN>9KS6 'B_%D(]W>@!CI\'% _\ 4$L#!!0 (N"9EFWK4T3<@D +]. M 8 >&PO=V]R:W-H965T&ULO5QKD^(V%OTK+C:53:K" M8#ULPZ2[JV; JDPJV>U*9[*?/:!N7&-
L8ION27Y]9,-@].*Z#;?V2S>&JR/I M'DG6.1;U]V61Y=3M:U_7V[612+==RDU1OBJW,U2>/1;E):G59 M/DVJ;2F355MHDTVH[X>339+FH[N;]KW[\NZFV-59FLO[TJMVFTU2_O5>9L7+
M[8B,OK[Q6_JTKILW)G3(\HJW0*=>2MX MU!1H(_Y(Y4MU\MIKNO!I*#XW%Q]6MR. :9',Y+)N(!+U[UG.998U2*H=?QY M1\WXZF(\\E'Y-=5O]6O/PD#QT*&KQE MD57M7^_E$.N/O.6NJHO-
H;!JP2;-]_^3+X=$G!0@[$P!>BA C0(T.E. '0HP MHP /SQ3@AP+"U?0@/!<(V]_MDM9E>)'5R=U,6+U[91"NTYD5+ MU5UM:)3C-FY'U4)?JTU25]^_F1;Y2XT2N//6J*K)TE=3JXJ%6_]0 JBNO>%17 MQ?
+SNLA6LJS^[<5_[M+Z+V_L?7Q8>-]]\[WWC9?FWN_K8E;=)^EJK-HR3[9IG60.K$4/ MUG*YV^RR-@7_K=>R5%G9J!F[;J;2L_0^Y,MB([WO?BFJZGL'?/QZ^(5\3)=I M[0
1,.COA=6UB2+]R#P],D];"X&Y[U\2O,\S9_4S,R2?"F]I%:M6K[Q&/G! MHSZE+B;WF&&+V:Q:SW?AS>3YE"T[(J18X$>MK##QE.FQ\2.&,YY%!I8PHZC
M4\IG'9R6('9,$!N6H!^\:IV4LGI5HO;8P4F;@EG@!YQ%1K[1C0WEK?5-EG* MVY$:AY4LG^7H[MM_D=#_T36\,<%B3#"!!*8QR8],X(%1UJ"_QLM7^>FBY[GHK38,8B(_US ML+5#9R(F6(P))I# -
,K#(^4A2/D?LJJ;%56QKL#K,ETV]\+3 > B$,0/U35KMW)F8QJ3FWR2R]^N+]W$0B"#IU>4VLTL-#8\BPP M*XPQP03<>HV4V9&4V;6D0+-K9K6(^%$X-3<88!N&SBY,L!@33""!:402O]/*
M/KQA:7@;-T9&NSINE2I,VFV* -*\E[I"'T(.G5T'-&TX3.G,6&L7J)7&J&BB MMPLZ.2=&!@')^9B7,LG2OQ4W357:5Y[B99.4GV6=?%+[S$HN=V5:I^Y9!F,/ M9@D3;7% .TU8-#.4,Fj- JY1YZ>S&PCL-
_Q'UEY65.[T@'4'1Q\3;8&*%A_0 MM/W;C'1]N"BB/TZGH3,U".QJQ/G*\'P>Y/:-Q_S6RF!.=IAMZ1BW'V+;'HU/;IS]7ME(.@QF- 9H'ID\%M&#*Q*4;T#5#2!A::SV;D,!+89G$;GS[N\A\B@?]#;QD(44DI-
,>F(M&U/3ZW0%!7XTHZ;9Z0BD :?3,]M4TDES FMST._LSYB>1F')X3FQW8$R8;\X05#V/BB;Z>]"3TTEU FOU MZSP78@M5PEGD6S<93'6\0$6+4=$$%II.9R?R":SR+Y*&F-)X3FRG(/1];LXT
M5&V/BB;Z>J _YNQ4.X55^U7"$,8>RA$JVH(ZE+01#%%K%"-.C^=<*>P<(>$ M(5QT,4AHY 2!C23CS3(>)YD#"DME@](PSA-@P>I:A' E#1!!::SF8G\RDL M\WM/P+B)M)_V6X/>-@&BB%-JWHP=
<32R1KT=- XBPJ+('/4.-)\1>N;A(.T$ M-!THH,\=A''GR]:K84C](+"$(=R,P0,?]0D*IK 0M,)[90^A97^^4=2VW;' M*LME6K6?[M\NMLU6UGV#1GTV3VT3@1%STJ *?E0T ;=?
9ZN3\126\1>R!3]A26]MS@Y@L!UPX2$9 M&'7H9&.VD*;%L0>SA/LE*-MJX<93U!BU1@'7J//3V1,,MB<@7Q0N.CC]J$<14-%BYK _ M"/'IU#1&7Q&H$]'Y'PSV/V!GE#OYZ3\]P!RG!Z9!9!
[M6CCBF&7S.&+&X92$ MYBELX0@D/N?\S"Z9=9X"@SV%UUFC[F0YC@Z$4< "?VKF#/7H "I:C(HFL-!T M-CO/@<&>0^^9&3>14?^HMYV':$I]ZT2 0,[IXY[!U1H1KTIK4H'(&$!-P_
MMV/ME#N#E?NK#\VX$V8K5C7RU8:5F?(0;L;@D8^JXE'1!!::3FBG]MFEQ_4' M>Z-P38-OTHYO ICGOE%KC%'1!-Q^_7N=G9CGEXKYB[U1;BO;66BN/'.X74/G M(RI:C(HFL-!TACM+@,.6P&76*
PZ=.IQQS-W8NP_%ZA5QJAHHJ<#.C6=NN>P MNK_.&.6VK.7$GYDW/K@-@R<:JLY'11-8:#J;G1W 83O@$J\&AAP\S6P5S:+ M? *!6F>,BB;Z>]!3<_+S!; 3<)53
V,/Y@C5*N"%9K5+T5*DSU%D$ M'+8(/*\&+CJ8 -1#$]AH,7>X$"1@YC95],?I-'0F!!]B0KS*?#@=0IK5%>)R M:AQQME/C"!([-8Y R*GAG;;GL+:_PJGAMHP^X]3 ;1@\3%&/#]"B"2RT/9N3
MDY_R:G[:[=>D?&I6_$P^*GC_3:1R7^Y_+6U_41?;]M>)/A5U76S:EVN9K&39 M!*C/'XNB_GK1_\3?K[OX!4$L#!!0 (N"9EEQQ8Q2P@< ,XB 8 M >&PO=V]R:W-
H965T&ULM5I1]LX$OXKA&]Q2(&Z%DG9 MDG*)@33=Q2UPW09-NWNOC$3;O$JBEZ2<9']DI)BVB+%Q(#O)9'DX>B;X4*0!4E;6\GFR4VE[.9C+?T(K(#WQ+:_W+BHN**'TJUC.Y%904
M[:*JG*$H6LPJPNK)[JJ]=B>65[Q1):OIG0"RJ2HBGZ_2DC]>3^#DV>)7MMXH MG(#+V_C=D$K\3NCC_+@&!A3 M'CC_84Y^+:XGD4%$2YHKHX+H?SMZ2\O2:-(X_NR53O;W- L/CU^T_]:(KXUY
M()+>\O(/5JC-]22=@(*N2%.JK_SQW[0W:&[TY;R4[5_PV,M&$Y W4O&J7ZP1 M5*SN.I.GWA$'"[0> P+4+T##!?'(MPOP*VA';+6K$]$D>65X() &&FMS1RT
MOFE7:VM8;;;Q7@G]*]/KU/*6UX7>%%H ?21YR0JB],F]TO_T;BD)^ K<$KD! MO^@=EV *OM]_A<_O0,_ 5:#;QO>2%(7\FJF-!JCC%E(\HJ/">;C\ '+T'*$*Q!_MVY?C !R\]RQN]>$Q
MSQJGK5JGK02O@,X\012KUUWH,L6HO/2YK5,;^]6:M+Z46Y+3ZXG.6TG%CDZ6 M__P'?$3_\ME\)F5'HCW'HA#VI>_Z2I4V3RX-S?%_W1J=?
&MN"Y'.:]S5E)0]Y#-57.3XO@#O['N$(7VY+J2@D4%;H"$5-^?59WJN8'6S7/ MHG0^V%!7*O+O9;+'F 0QWBN>_YB:4EZ G%>:WV0+$= GJ12E&$_W'0/-PW"_43U/N6L@Z@K)R
5%XK]]2KFU$&#D_G0QQMA#*=^Q-D> M<19$?',((+DN:#F\)UA!FU+Q9H*7!1,YKRIU3L3+KHA^$$5>=)6G>B#93 MWIN$\AF6.9BG"PS1P#*?U!*+ *;!R-)?
%#3NB]I0X26OR+EA&@\P>610/(+H M@)!AF#1KUM,(30-]@'FA1T[!:9DPFN$(RCD<(# M+4W#(+LMO^P3H&,@89KR*5]--26'(,_=O$RR87GW2,5)-I:_EC)AF#/;B@]J MW5"\[EJ7#*]RX;3;
(Z&+:9/#"WP",]#2YLPS)N?Z(IJG(4N M"SM:-WX'>V@-(CAW\LN5B^,X&0E69.D/O4)_@P1[\>BS#RQRZ6Z:(#STIT\, M9AD:P6J)$06YIATG7NW'O;BA#W?B!+)/3HLMDA'DEL40.FD49/6.RK<,$BC(
MCJ=R^;FT'7O!DB0*D^1=(_(-,9G<-HYF]1SF]7TSX9MS33F]8&/$]L1_7CS M?&(I'-L[RYWH->[D.:5%OW.2Z)[V-/@^9G0BSQ4:Z4F0Y4X4YLXC=WL[AMQE21BC*!JRJ4<.9?!0[ADWM) 504)M1]?
=+!L6.%KE$/S^"B+U;OO$GOM<.E4Q2C>#CI><2F29*.,8*E792> M5*M6>N*O\[?4JB"=GURKSJ3MV N6NU&8N^_(LTEH$X!R0P0%3,I&^X&"G$M_M,X=@D MCCWS);(.C/ (X;&DQY;
<<9CF6:P;0-P>)CU%@A??GF1 MNV,KC(:MET<(SY-XI+3A@T?98>HVR"*F@O3))I2UAV9)LP8]+XSR_#@3A-D MW3^I.-@6\[O7*@]KQVF,G*!SY6 ZECB6VW&8VV_?C!T0!1[HFM6UV2G3 %#!
M>.$UR>7R!"&<#"URQ;(T78Q,'=C2/@[3_FDV43-3!:WQC-(XC88-C$61&R=EV$CC<27SF M!14U^?;?]^#7.O="'RHX.1#/I.WXC9_M1>+H_]_^QL$>YU0OG$O;L1=L-Q.'
MNYGCCNRE=YRJ3(\YKRH=O&VOXO4%=-YZ#EM)CPA>N$/,[.#+@(J*=?O!A 1M M\G=OUO=7]Q]EW+2?(@RN?X27MJVG%59-]Z7'9R+6)AM+NM(JHP^)SA_1?3S1 MG2B^;;_>.!*\:HJW%"BL\
((Z-]7G*N7$W.#_2&PO=V]R:W-H965T&ULM5EK M;QLW%OTKA!H4#:"793=/VX#M)MT F]2(Z^U^I68X$M<<C.1FDC"HB29#XMU%7RA@2!#.^9)FC7B4=''[N
MI+]GW^'+4@9UY25S@3^*_8IKTGKT>B M:$-T=3X,'VIMTW_Y-<=A<.#5_!L'%OG @NU.BMC*7V24YZ?>;86GW9!&'JA5 M/@WCM*6DW$2/IQKGXOOG&5NOA*M$7"MQWO04\#T%
(6XI+&72@)]=>!66CI#*> MSB*TTME9D35<)@V+;VAX+3XZ&]=!0+.E*N^?G\':WN1%9_+EXDF!-ZJ9BN/Y M6"SFBY,GY!WW(3AF>'-5!CO0F-+-39]"%!?J-
&YS_^DOZ7V/^TAE^559[/BDOMQ)6;BD\NJB B?4%:;5 E?0K.Z%)&?'FO MK;2%ED;<0*M"&\<@?KJULBTUGC\7/_[P:C$_?BN.(.L['1"/{1D+YQ\LC\56 M!J%MX7SC/!N%![\5T2V5%XLCJI^C%P()?[?
G>^Q=\U#C>JC;H(8_!%E.V(+3+ MH+ZTT&UVHEA+NX(@#6>LK!4%X$!P#BR1*#15#-($LG6I 89L/WE?N+J1%M^W M"FNMI_46]D@$2%OK-A!K5\(Z.]EHC_"NH LFBUJ5N]# D4V-
=QM=*E&V7BX- M)'E5ND ?101TQY0.0+IHD$<;D2=XMVYMB8T<[UH;_OYOH.8PO(A\C1PW7!=P7C9&1 M)@RL7L(Y\52&8WC4&:.4)9M7P-B86>IJTIY-INB&/>)$[IC"XX]#*C-\2O MTC[$7KY -
^0L M)X\C 8TK?)N4'NM6)+LX:PXFJ$)7$!YU"*U*;4EQ$G'74*[1-P*UAFQ4.?*\ MQ351U_K/M(BLAC020V;GWVGU<.".5-6J I2-6>K,NJKYFJFG;4KX:JG4B^ M%EVP'U8.AP =1#I1);I$"-37ABULJ?
PJZ@*5GHHE*/1G>]:.!:?3AFAZ[JU M:O*EU3#\ET\77 SZ"W]"35&) 2N9-%7>U0P5VD:U M\@DZ5*.#]U6*& 1R/=(#P OZ*;N)4 "H?.['M=PDS=SMR$8R-2EH T'3))2 M/:
(T;N&31 M;KB6J$XK6H_!VE5E(PRX6L@$L3BJO%*B.;2M0M]9KUL{)3D9! M;SJ/U<8C*00DW,%\DK.-J/VY W=#_88=6 CB&3C G]_=C#-2EFW10TM#@RA9 M"0UDD>K1;
W.^Z5%FH$])7E\)>NEU^4*%?E1AB"+-4R*<8]_P/=_H=FX]G2X M2R7>HM-J!%T&J-(\J&MDBO(KO=FA:D"%\Q2@YU!#@5MJ-&JQMLZXU0Z+)9@A M30W J6DI>V.Q;-
%.CGJYU&R+&;MP!,*$(4O0-16-'RFMNR5X}M?T$P;H28<; M*DH")EAXIW:,.9X<[[Z ='$3TV*.H$/,,?8P\?$< M62 BX0:A&F"PS.4>&;71MMF(PT[4KJ6A3^<>!0V(5^(,X45?%(GCV,H#G'Q;
M,*>CI;U;^W*8>$70RR---BE-FJ;).QI .B'C@7#EMBHHSU4+,W0D%.E["IA& M\Q("<-83B^JR1(&X[R C6:L2B.7 B("RRD--%IF,L94]S;W'X*J>YH8]S66T
M7&)P4QXQ%Q+SY#;NZ"R$P/F6:I/&0%]YXVSI/F6HY[@OZ('@2H^/T8TN]CU M':(SO98D_%C:;>I#\-B>2 L?G4$2K-R+UUJ8FYS8@F M[$3VD\YBV,KO_A!)P# M?7_Y?)PREF/ZW0H8?
<2^_/GB5X,I-[?PS"P]3I&RF\+F"J(S"(*2/KC6+ M^5L9)PC),:3D5>.WH[W)9:A1M2;[B+#*Z'-?,6OG[/],=AH==7N.YQ-E%PEN.CB=49/ $"PGJ'ASA7I%7 M*0[/CH[FT^/N7L",DE*/T0X83A?
\1&%/P/4'TU/_IOCQU-Q MP18\%IS+M22BB&YM:\)#13A+I)$9UK,7KXZF+SN]' $0I#R4?*5+)4OMT%]#Y"P>YVU MQ'@XY3*LQ_Q7$&BGJU>NJ%1N;"&/NX0+#(!+@LV.2^']WKZ]>?
XT9%E&DCP= M>1'P3VB>Q\3^]@B;<'G!+>1HD;/($6:-5B7>ZI8,S(,90JH3(_2N!8'MNLCW MW4!Z&!K[ABG5,G9!XH5[I8_O1+=!WM=@M\=$D"F'0JW5.XJ.]5*?+;@Z*(*/L$-<,1NK=\0_!\
MT/0GS*;9Q%;P?+"[@:ED@RP!<;CEX1/"QZ6#)G&&0AZZUPR>7E:&[@K"X$9; MJ&6X)#*)34IQ1@D4J,ES&Y8Y?V&+BFA2S6E\L+$ M-;< B*Q,(4_-,T0FW$D"?6+XP)S(A)DN*@$51Q2A3>\/NG)
(+"-34L=9>SREC141;:/& $X%O@"LE[M\&*MN\5O4;L(MMO:!R_5'NR_V8/B57XKR$/A_5I-A8@.'Q+=&O*Z
MOKIXBN\]8FE_-7=,&NC"3)B8[E'L%_FG%Q35*T5(O\WLU9H2YWFSWGC>_6:.Z6+7P@'() ;&9RK6)]M"6B[V],,N6TI>4E;) B\2V7=Q<)8]N/VV MH4CFC;?C[@KR_MWSP5.7#O_XT/N+F\OIH3?
PL\$/*HC4BG\V(CH&8>FWE7ZU M_V7J(OT@L]^>?M;Z*/T*O!ASLL+1^?3ESZ,$C=V7Z!K^>6;I8G0U?Z0W#Z\W\#4$L#!!0 (N"9EEIB(B$Z@< 'L4 8 M>&PO=V]R:W-H965T&ULM5AM<]NX$?
XK&%WG/BF2+#O7-+4] MHRB^--.YUK6:WF>(7$E(0(!0,OJK^^S"Y*B4\F3Z?6^V"2T[R_/+GB]]^%+ MW!$E]519%V]&NY3JM]-I+'94Z3CQ-3G\LO&AT@FO83N-=2!="E-EI_/9[*=I
MI8T;W5[+V7VXO?9-LL;1?5"QJ2H=#N_(^OW-Z&+4'3R8[2[QP?3VNM9;6E'Z M5-\'O$U[*:6IR$7CG0JTN1DM+MZ^NV)Z(?B7H7T__0JT_KUE>X6V4OVJ?:\:N1ZIH8O)5RPP+*N/R?_W4QF'
\&9VAF'> M,LS%[JQ(K'ROD[Z]#GZO E-#&C^(J\(-XXSCI*Q2P*\&?.EVE9.A_$:MS-:9 MC2FT2VI1%+YQR;BMNO?6%(;B]31!'W--BU;VNRQ[?D;VG]0OWJ5=5'>NI/(Y M_Q1V]L;..V/?
S5\4N*)ZHBYG8S6?S:]>D'?9.W\I\BY_%^>S[*O3LKF9WL9: M%W0S0K=$"H\TNOWQAXN?9G]^P?*KWO*KEZ3_1LM?ECV?J.\7KSY%8C**R:!' M_PX\8X[0JCK8H)-.CI%)5QJO".8<6D ZH^[=2'Q>
(>G?ZU M,8@8JMP!%IA8)8^W+S30HEVI= 24U*PDJX332>G-!LV.9X*4VH=$(*K8Y,AF M@)Y29K5&KXTU"1Z,A;XTL; ^-D&\@6'L):L^S:1T5E/"&&;@GY->,M\Y>^@)
MT!HAK&P^Q_1(QVU!>/+.'F6@?,!)@QTD$# @M)2 N*%E!R4\1^6-KRW/9 M*&Q3TEBM&_B,*#B?X#!R X[D':VM MV?8%X9L FZS5:]]6B=X&RJ;,U2>GF])D5Q*B4 U,-BX(N;A2COCXUI;49L'
MFY9POZ>"JC4%=7DA'"*I]OBAA()'CDKPE>KTG@P11Z;T"#V'IHV7TM8.:B=V MU0L+#E+.$[%2HW&J6KL#)[9Q+ZK)Q@+J4FMMBW>2<3@OH4T[A$M.'+I751EG MB7'V'*MXO-./I-
9$KFW1;&@35=V$V.C<:E*'C6V+*-'VL3H769O8%16HV-P' MH+A[*G8:W:*6OJI,Y'D]5C!T=;<@.<;B6$0PUJ/F.3G#B,2FV!T.B>0WGFG^
MN/.-182YK779(M[GQN6%1"SA3GBQ'(9^,O'"N084#X(3"F)X.5$7LU=_S1C(M-5WYF*"R@ !$:F,LV$(;).]N.5$?!2.4KXUK6_*(MF,I:EU^QO;1=B3WEHD" M2]Y9F0LY$:RE"8)>
P;EH#M&GB"34GZG_<8N/ M$?N6D& Q#6U=_L:V&,M3H>-.;;"E'N7]K\U5Z9)RY_][6UQN0NOD3XH,1IX MM>VZ\[1**8Y*'[@:>?#(J.CL.) .K);S^"U,7G%3 +J4!V5HQ])$_1W9BX/)
MI(^[0=WM!FQO2;$(9IT+^&_ 1/H9O/5&+ MU1(Q?CU6\BAL!B&L1)RG9;/=D/@06%JR[M5E_Z8#U/+DDC:MIO8[M(V#4LNEN&U,1FMZ NS(KBB0G3T"K"=3
($1PZ!=U(*G6)10U5*.,&S< M&?L*18& _<\B(*30%I.59;'+M65P816ZO,RN)V'V^T2#5TYDB^U==VT,NN)X; M:0&26K\](%Y1)H<,P4KJ9^L?*;BJ72SA& _.,\WS1.4:2![FZ4E8O[!T1X! 9
M%U(>BGL9*XP$:^J,8M98H.%9S4<>N$ZWJ]D@-:@GU$(H(SI;DOYQL9+' 0W[M_^%HYP<$H%UDWS];D@J$],J$!6YQN#DN4>0KA_!]%N[SJ@GG63\R*/2C8O>]_:/BS3P0> M<'.
M*1'LKZ6(NCO3OS#-L-1[LFRPDZ#5L\SL:<;7%82R=S,5QKMP,MO^YTI M\FSXBM$"'.%Q@96H6_FR8]F?/:$%"LLMS'02:IG^>&%+),/;^:SRY-?$Z:##T(5A:U\ M]F+@0W?
E;T/]:?]E;9$_*!W)\V>Y7W38 CJ5I0U89Y_ OAZID#]UY9?D:_F\ MM/8I^4H>=]AV*3 !?ND9%E^*>G0-1_VQ1:/ M][[?D2>=+81\4 FBAF]9FJMS)]&Z,.GW591@QE1%)C3SDS(C&E:RGE?%1)9 M;
(6RM!]XWJB?,9X[DS-+NY63,U'JE.=X*T&56<;D\A)3L3AW?&=%^,3GB3:$ M_N2L8'.\0WU?W$I:]1LM,<\P5USD('%V[ESX)Y<#PV\9OG!,9AS#%2!L-C/Z>\ K3U"@B-
QYKG4YCT@BVGU?:/]C8*98I4W@ETJ\\ MULFY,W8@QADK4_U)+/[.IZAT1>)5-E?6%2\0\^!J%1:9+4P>9#QO/IGW^H\ MM 3&AP2"6B"P?E>&K)?OF6:3,RD6(TW:3,/-
E0K3<[QW!3E3DO:Y22G)S=, M/]!FTQ3A#]-2E.^3NXW/P.T%G\MK\-?F"ZV55KOO>70^TM$5;MFNP8OL%_*,C=QR.6I30/VZM MS),?G&Y(C%U_.'SUJFU6[SU&=?%\6[SP?U&\XR-W-!BT*,%1>
[6G>'1Q[(\; MRIX>KF]PBDMU=W%$Y[ZD>[=D*3'IJJ/9@5[Z<5W^XF[=+>*+RU-5X!H)(CIA M.8@<88E,MC,Y"MSC,-B@A*[OAP0M9)H"$O>A:_<(^]W6#\ MH>L- O@L-
&6[JWVWV_.O@R5D!QJ'ZJJXTI0WVN;Y$RI=']CDN:XJC33'Z(2W MPB-6G2"EMRAEE- @!3$EH0=?D>PH$[?!$GMB/#5°*.!\YUBFPZ5-$&8M&$' MWQ)X5E
9C4>0B1A3.R[GZ847NU+X^A.QAYG9?%+J62N=EW MG#SOS;,7VK:]?9/&OGV;GJ[0MA7MO1GY!H3OR7V^LZ<#7[A&]'UXK6*W@M(+1 MOX7/BV 4CMW
_UX!-7OU885R.#>S9(HS$O5Z1T,'9/6QHEIH M4=@/!%.AM MCOA(#P 0S(!D !X;"]W;W)K&ULK5MI<]M& M$OTK**TW95=!%"62.GQ5R8E3ZZW$45GVYO,0&)(3 Q@& XAF?OV^[IX!AH=H MR7
87D00&/7V^/@9ZN;+U9[?0NDF^E$7E7ATMFF;Y .3$90M=*C>P2UWASLS6 MI6KPLYZ?N&6M5N>A[0I),K?U,/][EKXZ&Q) N=-80!86/._VS+@HB!#;^]C2/ MNBWIP?
A[H/XKRPY9ILKIGVWQI\F;Q:NCRZ,DUS/5%LT'N_J/]O),B%YF"\=_ MDY6L'9T?)5GK&EOZA\%!:2KY5%^\'J('+H?W/'#F'SACOF4CYO(7U:C7+VN[
M2FI:#6KTA47EI\&\>)!\0@!\112ZN51U8\#,0MWI1-&]?(]4*H,%C29 M*A)R,%;SLK;S6I4.5PK%0C"K2Y,GE:HL4X8@K-+?WM^DO8QN[1I=BBRQL:F M75C@NU>S5K0:2$ M4Y*8-
@G"UX1ZKI2#%XH V+9@#UPM-3W1.K8\;Z)JX^A9 MJ(K4Y%K0W9%CD+SM]UN9HBDF.G&VT,6:%B\M\L&TT&Q,@YWM"A8(6O%V9T=D
M$]FRU'5F5&'^$<5C7^R4MQD>;;]FG$'G8LQ(K4TY;6MX:BO.1(^2V%A1\'[Z MB_^168<-3)6U-;G^E!1!:LAL17NSF?#PCO0I:9+N$"4(D9&XCK^R+;9T5JA* M[#=M<[BPZQE>*
<:6=$Z&#NQ2Q(,U-LE^9%:LX:@"[F!E:0E"#;36G@02U-* M+7)D)/A/1RT%%.]8U:1)>2K#OIT2VV9F=&L ;6JUO=X!C;QYDJ1T*IVA@3=
MUGK';CIYJI[U1B.BWH @SH_P9JA5P2NP0VX02(V$V%/S#$IAK:]"B L>0]/ MS<;=RE;'&RMX,RS"*J#0PM2YIP#?V%XL:Z?;D%2=>53Z&?58+ VL2:^^@0M1; M.9GG1GR"/D7TI[I"@Y@.
Q.Y=0SD0EN5K2 GE([IZLYMOSP_IH#ON0O>P6? MZTIT#^[=HP3"]%&;.H4?RN:PVTR!A&],/^30T4GD)B(S%GQK* MC_R4%/\U7_6N&@2$(QTS?$J6VN.L6]!%6_<&SAKR1!_"7>
[ZKP6I+621E>_B M+6[\%NDC N(!,,C76&O45G40QZ[@>7&!4/+KL@,D5B,[LK9BLVD9X!722LD M8J&1 (D%KN$+ITKEG)E70LHT$990HF/*@Q&4! ^SMF:?^1>,O,XK3]CC/$%
MSUCH6RVANCM8D[+"KKT0?@4(PG6JSG@;%F G]SA!) 00 M-I!;G ,W>KQ^VY(O*LI2;=74AL+V3[U1E%26 M(CCUS$-1E(6K\ O*+FAGD@#9*F59.!QJVX7[$P"D^P2Z5Y_3[>4A^?UEV5A
M8>2M1%"%8H1@;C_*'7;?O*WI<;4)<3$T(32-S0-"EVI-U0CGYES2>I1+^3(W MJY)%">P[;K>9VD@-^]*%YXU!3NPKO(3*P\+P?:+*OF>K78^3ZD&\+C_L=7CV M:?XM9MG.@]_%1EQIHP0#]
6KWU=VP_.O@9V%[U/"EJ7*"0N1)6EB"^T:QA+ASDE=)PBY, BJX)-[<>$ E M<1I!5QQM(HU3H![M@>>JAM.\EX+TN^7LOOCMXV;S]D;V1Z709I+L-] G,W76 MEJY154;1 ZUPT:T*9SGHJL8TA;A/4
\2 =4=M5VK@I+"M?+>J>]UXJ_&%E?MU+=XZ;_5 MP=-0:SX+8*Y")7OX/Y224U\M!FSI]BO6O=P']!8!41AIYYE]^;&!4)*W(5F M::,VZR0,-1W@-&KIV[A!>W0QM=+;S31BI2>_Y3C?I].M*IQK;O=
(AQ\D'SIF M0M?+X &E]"5P2CRI'0<]GJZ/MZ_Y,H02^9KN^Z\TPC34""*<"IE44#' C-H, M[2J$E3!"TC5UUS3+2M<<-_:8[^A->.FW5]RMRES@A7CL)JFH;HH@XP5G$NZE M0& 3(:5QKOP@ET-*?
%=G;.BG2G4[8+"^:8%H*F]HZ?[%\2SIS19MK5K M514%-S8SSK78B^'4%GDR22\G5^GH8I(X(LL>9:%KPE[RLL9FGXE 1Y7@!I:$ M4CGGG
].QY3_Y?'4EYEP;G!%12QQ(7SVSXS.XSPEK&6%==R8RV"BH@KNT>ID ML2!$6TB_U%755$,>+JB2T$VQU\;)^7ZUQIC(=3QYT$8@A79-$KSX=R4^(D.+ M3@N2-T>#X?F_@S TGT.H,?
=,,)3#K"EA:>3LF@U1\RS?4ZHD-&Y1=-_MY3U MT)HCF+E/G/6U^).S26\)&04-DI_^=7DV'+WHI.ZU>XTFWCG^&A:A"%=\E9!L MP2U$R1EC;JD@9#?3]1TL_X"A%H>3RC);YX0\
(LGU[<_)^?!\D%PSD&F?[G'L-Z'#*6^KP_^YY]Q?D0]_SB,!YH[-%90L[YP%Z13Z)] M)[-_SLH:D-Y/W*ZK53JU]-V;S-#Z?=(PM* 1CY&VN=;3&-6"Y\;9O4-6$ M?>:EGC89ED'P\%"E4O%!K:$CH?I@(C?
N17%$.!,"+Q[N= "3BGF=VLJD3CAZT M%/RA$HJ3;M#1O3.')*,8RKF!Y+0'Q) VK0V#$)F-_T*U?V],K@#\)6('D]PF7 MS<<66%%[AD^A%\J3?4Z!S.C9)(AUC#$/@2SF\!!?P;6B^3U4Z7IEDE^$PD:*
M"O#B<3NT7S(;+<*:5L81+&'.D*W:0D.02B/8N6VMPH/=3+J'EVI W<#+M0>,C MSYWA*[@'+ZR<$E 2REU@JLUFI>M9I4)*QU-RJ4IBVER+!W'C-FRM3)G2I:W3MZ MA(Z45TY'@U'K[5EXB*
<>WJ]SGQJ74O.JDHU;:C3@N00,92- GW1?9ZK%'[S19]'-YS!2A_H(V_6/)*^A;E3\#'J.*9*D|L9=>F,:U>(+3>";QK&CP0G')+C,0_M;/FRA) M_A$-OY^RE+9UT"06X\A-|QKAP>1%'+GNI-
R!T%]J28N'W)PH/0D MF9RED^$PNC#&A8OSY%=3LW<24OA1][[C-1D*;9,-GQ?I,*(=/B?I^<4%1*-J M[EMWV*0L%(7EOB5_--'3T_0BHGJ5CB\O Y_FNS'^XZ/OEG9Y^GI9%?9X_3J
M\B+Y:!ODCM[(5^?I(BO;P:;62E M2#I?(6$V6NEYH*FU"&HY;*&OI,. ="!9M2!_=7F<]_#$805CP4,M7W-P(C^ MU>WE=8'#=:VD*=HI=!F[95=7;(%]*:PMUIL:(7VG:HHTT*R/5_P2$3?QB%"(
MU*7B+@/YCB-3;I', "(YVDB+S$YPBAG&Z[COVK'K/IBO.GWT:=_]J,Q7KWTA MVB=4%1 3U!I\53S[B=Z^X%H[T)91)Y7$4:G#ALR8!+3S63=14^>QJM!W9%Z> M
*Z/.PGHO,#66Q,M&HO[&U*RE\MPKI=4>FZ1!;K3=[7U$D9O"/]Z L1U76Z# M#.@*M,[#NQD;)SR[J?'&9("WZ^WDK=.GJ#^HZ_R[126KZZ(;TJSH3%= M1-
K:=P<;SMB5:0<=52H\$J%U_LS#5,NVJS ZER3#]N=.'J96@8-_K@$3=! M3QO*DZ#;GE_V7CY#Z\E2 !.GT$*#]&8AA+(L7(622]H/&KQ1+6Y-A MDZI#@<#=#D)MH--
#]/2(@$:SC(()E6LUEP,3UQ]>.?T<#P]:H-0_?1DC1SGT M2\ -UP(ET4W6EJW7/-QG4'T.**E' NV?L&[U**2I/)S/R\QVE_R!.[?]A\R M!K$]528FMO
OBL2ZD7D@]/%I&;U+TH_PMTI7.BN%=2A$0EWO-<22B$/VM0H? MX?&1K2D9*CQGX;R#D\S&FUZ=,E1-9P$^!810^Z4_6&L6 "4W?RNHASIW>HE
M,&.*W<+KABP',5AS3Q7WZ('YOIX.1C01HN:M/].Y,RY,@7<.JOU C3BC\4P_ M- ZK^Y@CV]&+?.2B/AOL'Q?L#]8XI4M%R^I@!.Y&%2]\I1OBX"NAM2_QRZ#)
MZ\MK0+HXZ8'6\1FG1,3WEJ8_JA1_2&D=UGSPX MYK'EKI=&9B6?CM^_/;3Z/?G10Q??N_<>XSQ,!T/K^]J,YU,QM'OTPDJY(T+ MXW0ROXDG3<@D':'>WN<0IV?['67?=3!T=OZ=3%-8YGSR
WJ>;]GUQ[=$X_1B-/YNTX_2*S3$VRW4!2Z/3A_CU.BL+X87X<*^ M=|1/HA?[(>F<_WW!R;&>O./?7>W^0^):_C&@7R[_7O&[JN<&P%;H&1X=#BXF
M1Y+6PX_&+OG?!*:V:6S)7Q=:H3B@!;@_L[8)/VB#[O]&7O\?4$L#!!0 (M N"9EF'[VT:NP4 +H. 9 >&PO=V]R:W-H965T^[NN3OQ="O55YTS9LA=[41J-LB-J4Y&(YWDK*!Z*"M6 MXDTF54$-
EFH]TI5B-/5"A1A%83@?%927@^6IW[M1RU-IC> ENU%$VZ*@:G?! MA-R>#<:#=N,37^?&;8R6IQ5=LUMF_JAN%%:C3DO*"U9J+DNB6'8V.!^?7$S=
M>7_@3\ZVNO=,G"91OJ:'+4R6W1+G3T.8>O*M> M&N!XZ9)R:Q3>L&I))&) HC*8']$TZ;R=>W^3G MO1WN

*ME:>JR16KDU&B2DA1MRSF6M8CKGG^;*DFXV&YBMJ_]H,ERT&P%FDZZ8GRYB M-_P_P4P\F*/Q M"JG2P'<=IC /ZZ@V3:AGG:06P96=B*/*^/B-)BM\NB2YD^ H*;D2?.UU:'?: M:F(1^B>^^# KAGB4@%U)K5$#/,&QU[<8$)9E=2*>A,"YH]ME-]%DVF" MT\H2[;P'&NJ#E;#6T(\Y+:V"7/E+17<^C#BI\/ 0:A3NL8JYD#J[6VYR&$_0 M]P2^[-#U,RX\:QXFGMQ:S B.W%S"J.EXT*R\FH:0#M@3BGS&1F<$_=3B&PKM M)!&TZ=)_V73M?0!1C".+07=9E: TVTP@&M?OJCO8#A2I=P). ,CA2?X/0*

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|4:785R3-"30/U80-3ZKLX._+P @DB%T]E*S3O MAB#4=(@R(V?65)L0<&6YTY8/C4N1[G7FT2TEE?\]J*:*93C'E+OF:&,FJ8, M<=Y6;2(GQGE6/3$V.(X+JO4B&_YS$[?7SM,#\21<>[..D[_'Y^GJx@PS': M)CTK=M:.N_-@U9G,ZU?^[F -PW/?_V?1^' DSKE 2AD"M9]3+V=1)N]$E=W MG/9@1';S:1&+T_0K5M:[.!W<- !Z_ZNOUT#4]Q<:C_>EB{UF-)!-%O6]^S\&A MQ791?1X?3+$XYSDG%E+!/FK-8VOBO?`MD]??-A^EW2!%,2S68(T7WLP&PM;?" 7!FS+LZ"OCL?&'1_2FE"P3X/W:&-|> M6$#WT;;|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|&>GXM MM!!]'\BO=OXQJFI&@,_F+?^T#>(./D!!+*06$C.G/*W6X@@<<: ^*@NX04I(T^5(' BL MZ>#R4;!/O1$O@MEBCF0U@,MJV_CPX#BDZ*/-;Y)@OHC?MF2@\@D6$P6[+,ZH.#+7+V#YL%D-7])2RI9GSP.X5QMM"EJ7-FDP"73 MU:U+VH,*Z#"4N0;54;JD15F\7&JO3]) ^OGJI/^,GG%NWTE1]"ZGXAB|Q&=6 M?CT))/GYJ(9F\|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|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|-JXV M9:RZBRN^J'D\|-,F?=I-ZY&+?(@*1 .:T,TET.BV'2,XH%4N.E7:RLHLN8PC5| MF$(KU%::2>AJ3#/JR61L2/V2.BZ*4V9'|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}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|Y_"1515+=-;9:\GB2^E\ MHR->_6H>6D^ZD$5-/5\N%B_FC39VRK/)Q<&K-T<\7R;| M;6@3]IX5>Y(Y]X5? WA5GDP4;1#7EN1:7:M9T277-0#@#CGQYS,F(]" >?!_2W MXRCD2U2I= _,D6LSB;'$U50];LZ?G2;WZGWYSGCY:X.\E]MTMQ#{]AW(;JF M7XSWQMCTJV|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|> M38ANZ5T#V(AFA3U9|**Y7GJKS6!JXW&E1E6[!K?#&8+:+316'8 M4R%6LIDX*V$9T-U7].Y9(4XW(MC 5K)D,J>!CY<"J91-[*%3ZX$*-E8Y8 MC"SM4TYUH%DWCET76F&E76%L;W|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|^&9+MNQ1%WZ#^U#Y9FRIW=W4_9(\C(_'D MKL; D>R->>3)7]4F2ED0*BP],PCZ/>$;5(J)2,:_ V1,L(*CR(3OF/Y00G#O',F*\TRH4OG'K?;!5!V3EOF@%,"AJI M^[)X'O)P!5BF/P#D R /NON-@LJWPHOMVIH36/8F-AZ$4 .:Q$G-A[+SEE8E MX?SV YW[. ^,W@=UUA]2T^(3VC MJ/PLZCZ_2;C#=@)%&D.>YM,;?,489!'XBE|*LN>8? I^#B^/.M:+$342WWZ%] MPFC[\D4V3U_=4#@=%4YOL?]/A;$(XHD8K/%8@0).;8C=) M=:$4>TM3$8HCT^03@Z^1ZL,0 8WXXLL2A*Z@DJICDI&"=W)A) ^&]E?O.B[TB ME('2-T5'MWA\K$VJD+K0 R$3C0$<&$L=:FZ4.7F$ RM\:1"DK(O_7Y4N."P M[*ST$AT5>]?UV]IAPJ/A,7'0+ _!*&HZ4A|OC*,H5NSB2\2AMBO@ M1M&83GL'U,*Z\MCL20X7UJG*1<:? C[I)W0LG9"0DL>!FW0:4D9 M.2.*Q31.%_-QGL798A47TQ7L@K=I.1>.(VP[6]:4V6]"O0"+.,]F<9KEHVD5 MSQ?S>+Z)<6E\$#0=+*816#[MM]/O&E#]]T;3XT[#&MZ M*=&R ZT?#-W#8<(;C&_O]BM02P,$% @ "X)F64S;ZNJ# @ Q < !D M !X;"JW;W)K&ULK55M;]HP$/XK5E9-K;225QAE M$*D0JE5:)U36(;-)#F(UL3/;@?;?SW9""B@@U/5+8I_O>1[?^70WW##^+% (MB5[RC(]1E4I9#&Q;Q"GD6'18 52=+!G/L51;OK)%P0$G!I1GMN8YYJ]CR-AF9+G6UO!(5JG4!CL<%G@%& M"629)E+7^%MS6HVD!NZNM^QW)G85RP(+F+#L*TED.K+Z%DI@B#7 .P0$1P!^#?#/ M50AJ0'"N0K<&F-#M*G:3N A+' XYVR"NO16;7ICL&[3*%Z&Z3N:2JU.B<#*< MX5>T%F@&W-0YA&ZO+A"%XA0]"MEI< T$4-;*FW-8,>U MSKC2\8[H^.B!49D*-*4))"WXZ#3^Y@3>5C$W@7O;P,?>2<(Y%!WD.U^0YWA! MRWTFY\/]MG#^3WWZ;O6]9/A-%? B&SW]/%;0]=D47M-/IWC80!8YA9*GF)8"O MP0H_?W)[SK>V3\D6?219-,/(MM[DZ!YD^ 4>_A3#8E[&K,,%\1*E & M2R7E=+ZJKLFKF5%M)"M,4UPPJ5JL6:9JS +7#NI\R9C<;K1 , [C#?U!+ P04 M " +@F99 'J/JT," "*!@ &0 'AL+W=O=@,A7VT*2,FV57/8*DJV[=G! UAK;&J;L/OO M:QM"TRIAI5S -C//;XP8HD;(9U4 :/12,[YBK]"Z6OJ^2@LHL1J)"KAYD@E9 M8FVF,O=5)0$3EU0R/PR"N5]BRKTDOV6-O%\?*)_=;6;6@Y8P8-@ MORC11>Q]\!"!#-=,[T3S#;IZ9I:7"J;<%35M[.2CA]):::5%VR<:@I+R]XY?N M',X2#.=R0M@EA,Z[W!>ZA&:!+"*

TX80>:DQNU1U M"YU>AMKO9JDJG$+LF0]#@3R"E[Q_-YX'GP:4I[WR=(B>[&H&:!P<9O?CK? %S0KGG_6'$F3NNJ!"J:BY;EM%O]HWVE7;7_Z&MUWZ$&ULM5AM<]NX$?XK&%WGIIU1)%FVTS2U/:,HOC33N=:UFMYGB(1$ M)"# *!E]=? WV05(T:FDR=RU7R2^ /OZ[+,+WNR<_Q(JI:)XKHT-MZ,JQN;M M=!J*2M4R3%RC+-YLG*JEQ*W?3D/CE2QY4VVF\]GL];26VH[N;OC9@[^[<6TT MVJH'+T);U]+OWRGC=K>CBU'WX%%OJT@/IG/NVDOI=2ULD$[M*[S:W(X6%V_?O:;UO.!?6NW"X%J0)VOGOM#-Q_)V-".#E%%%) D2?T]JJ8PA M03#C:Y8YZE72QN%U)_TG]AV^K&502V=^T66L;D=O1J)4&]F:^.AV?U'9GVN2 M5S@3^%?LTMKKJY$HVA!=G3?#@EK;]"^? #>.TI:2LHL=;C7WQ;I62(=Q&K/36ZHTNI(UB412NM5'; MK7AP1A=:!?'[[NH/-],(U21@6F0U[Y*:^0DU? Q(_.QNK(.YMJO9W\^8_E5;_G5.>EWGX(BJU6(&B];M]9"E M!%XWTDNN)[S<:"MMH:41(6(-:C4&H:THG"6ZT'$/-,=*?%@L'E#!7UL-\4"O M1;G38A$= [KZH@19I2R$#**(A)4'$2D8A-QL4,:X5I#3.1X5%-24FD!E8KV+: M:K1<:Z,C\C3F]:4.A7&A]>P-#*-H9E!D@ MK&P](>>PCNX:Y;4KP^0%SDX' "1%# 8- ""PD(2WPHB0%)5T%P)*L+4]EHS!M MJ<9BW<)G1,&Z"(>1&^R(+@6I5I(BQ"F!_8UW;*RSD 5SF?IMT0?DQ:..UT=L> M$*[UL,D8N789)7+K53)E+,Z _;H'^_5YL%O9ECI%(R*0#Z/!K'WD%M.?Z^9$06-MB MQ2,3FX 8FI+$Q>S57Q-I$Z9K%R)4%A" 2&VTP7;6QLF[7T[$1R8UX1IM,X<< MVL.802W+SQB#,H50;>G /.JLX7:=$D%:6L]T.]@@+'2'0(V=TB_%1FHON,!M M?,%:!Y<;%W1*_0G\CS.A!PQ^O 03LL^X_(UE,>:K0H9*;# N'^3]VN*J9:E2 MY?]O[1K>E&5[*W5*P>IT_#U0R"*[H*'R/43LR6?/6 MQ>/]*CUI:%#CYD O/EDF*$Y(H'1AO B)"PD#AX4/>*Y+)I&=XOQ#^5:OC08(\:G,#21ZAR41=H!\@AE[:(O=,6>BQK@X8-BX,_85((K?.62$Z-L" MTM)DH%,E&)RC66ZO,RD)&!V_T]R_. M& (,UBX$O-+3IGO@H1#JA-8<%TQC5UC?IF8A?5,=H YI$,"@NZ3U()!UGF#E8R MQ5+[83;J:MKW-5UP3?=N>L91#B:Q.7<5 TIY!934W0'1V7RJ^> [Q_DB_],K(M=. 2?#:"$*K?0;3S41&K9UT?OTB-FQ+WF>;-7#*@XL+=63,JYA$/1' M3WJQ3724:K*L,6&AU%.'[M<-SGI1<1=/)7)IL9?N=I4N4J? ZBD8"J'FA0&M M*T'38\F?G4()%(9*F-9QJ'D623V/T)MHMV\:#&0^\79/#B=O(.H?+3A->=B5 M&BR3.4ND*L_Y+GDHR((GXL_K$P'W\EJY;?\-9" (#]65/IGU3_L/ MCHOTG>VP/'VM_%GZ+:A3&+7!UMGDCSA>^O0%,-U$U_!7M[6+T=5\66'V5IX6 MX#T=*KH;4M!_AKW[#U!+ P04 " +@F99(<40-$\$ "R$ &0 'AL M+W=O+B"0Z)!77^_4[4K*LQ+*<#D/R85]B\67&14X5*L'+D60&/#E*6.[[JADU&6 M6[.)H=V*V807*F4YW HBBRRC8GL)*=],+<_:$;ZS5: (TP9E-UG0%6$K,,#C6Q\$^W)@O,'O?@SGEJN-@A2B)26 M0/'G":X@3;4@-..QDFG5*C5C\WLG_:OQ'7U94 E7//V+Q2J96D.+Q+"D1:J^ M\\T? 4/G3U_(BGDKSEVS*LZ%OD:B0BF<5,UJ0L;S\\3^K.#08ANX1!K]B\(W= MI2)CY1>JZ&PB^(8(?1JEZ0_CJN%&XUBNDS)7 G<9\JG9#14/H.@B!3*'J!!, M,9"$YC'Y2ID@/VA: +D!*@L!F LER:<[?5I^GC@*]6LI3E3INBQU^4=TC<@- MSU4BR>]Y#/%S?@?MKHWW=|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|^@Q\K.2_;H-S5Z< 1]1+Y(87)-_A0II _M/63:T@T:NC?!2< %E%>D[[LD M\((/P!%Z_#;]O\?IGA4\/A7\HZAHT/ Q:U=&U+FD"$P<+18/:@C-]\ZHW\-^? MH!RVE,-3Z--%73Y$K@GE7"8U=9P9186F]68O%89!C"1 DYQL!#-6/TGDYG!$ MIWV^>34,_/Y[F4B(W,;4*.P[(1:?YG5J8"4).;SUSDQD.1"D(],:8/Z6U"83IDI6I!$%@6HA%'.?N[S7MKA,6PSQ[?P6[& MR!W$,8:62*1VH8>'R#5B35E(|<>%H+V>&W=01VXX'#8\7QIVF3/51"_5<^"; M<>#VHJ?)#MW1,"9+:2CO+/)HX/I1=]7CV!V.^B? J,VKK,SJW/I]6)&VWZ8Z9 M'+?E%L0&ZK.)F?M#E7G:VS('LL8F)G=5E9BJ45<)W+(4-*'-66O)H.8I0D>: MA4NP1FF:,FN$2H|YDW2CK&_$+T$QF5Y? W"=>NK^XW3/!?N*G MVSJR|S5N80U*H;Q1/=+@9KK*,!YF!HH5;OGF1/M%.,?3Y|'A>4K[*VZ*LY6/ M^O[=QAGZ;NB/NB7D1E'8F?L'AC7)(CH2" MP3, [\5,FCSUUY[7'9W?J$;;_P=E.<64&T0LT\DN\OGR?#]VX'SY[Z?ON"$_Y MQ^="C.)^[WPE1!/;7NL_]5;:WG-F]>_]+_7Z MDO2%]HQA8^.P1E/_*L;30=47CWIB9&E_JE?2X-7!ON9X5P-5*>#WM92FF50. MVMO?]'J02P,$% @ "X)F670E:Y_R @ '0< !D*

M231]"JW,J/;$&/;$@S3(Z$&Q432*VY;6U=S2 M>D71KBCG0*KJ%6FO3&"OW$^$2/N$LRE"IT,H/)0S%S?1EI7 QZE]1(BT3ST]
M=^(V;^T31>'AG%ON07?!"3]9_!5D1H7@>PWN.C#;=G")XUVBC2FY2.Q!(VS)WJ5"?*-H5=5R% MM&$F)KH02/MHLZ5")T,H/)1S%[3Y/0BD?
>+9I4)]HB@\G'/+U8Z2P([R M;AN*IZ,X+DRID5'K:12-FD*K=|%IA^ID51>#A#RQT?=.@K M#=GD3SJD2E'VB2R:];M/JZBF(B\)'_<>SCV^-@=/]HQ_%5L
B9[2)!-3;RME?F?;(MY"2L0MRR%3 M=!.,IT2]4]ZQ1B2%/"O[^% MA.VG%K;>+WRFFZW4%^S9)"<;6(+\DB^X.K,;E!5-(1.498C#>F]]P7=SU]$) M9<2?
%/;BX!CI4AX9^ZI//]RFEJ,900*QU!!$_>U@#DFBD12/;S6HU3Q3)QX> M/Z,_*XM7Q3P2 7.6_$57M8QT)Q M(21+ZV3%
(*59]4^>:B$,$K!_)L&M$!S_F^#5"5Y9;.6L+.N>2#*;<+9'7$G"VXZ@@NOR.2K1!*VBNQDC>H$QUT&NTK 87 ML37J!/[>!GY2@2_O01*:O%
(97Y;WZ.6+5^@%HAGZ8\L*H>+%Q):*]WZB'=>\ MWE:\W#,\EI#?(L^Y0:[C^H;T>7_Z/<0]'9?I7C?=5@HU,KF-3&Z)Y_U IANT
M2$@FNR*@OQ]4./H@(17_F$]ML'TSMIZH=R(G,4PM-1,%\!U8LU]_P8'SFZGP M@< Z,GB-#%X?^MENV7 FC(- M&2>2]86BX6FBV(MRZ308"*Q3<-
@4'%YQ-0B'E&$@L(X,XT:&\;"KP?BT1]5$ M]XYZU!0U'IWIT:CA&O5RG;,T+R3PEF?)6K"UW!,.)K;]@)>.TT!@G=]QT[]D MG2LV; T^D!)#H76E./ [>-BFK?
&Z_>BZ1TUKC/)#<]/BUG;@WM?Y[%W!,RH+ M#B7=-7W2QV::@YJ,H="Z9;$W.Q% .A=:5H70SNMS&7]^NI'<%N M=+S(_BBJR[;U++C?M#R
^J3:LF2%)ISM@--UDRS%^CB01H(K5MV:X!P<,U^ M'=08#876E:*U1KC7Z$N'JB!T+J%MX8(1]?LV4'=T5!HW6_[UAZYO9[C\IZM\0Z_ M6#$^M@2&H-
#QG*.&M0_V;O3&V4?"-S03*(&U2G-N0]7QO-J+]DXDR\OMG$&PO=V]R:W-H965T1&B%NSF85C MJV4,@A@";1@H_FU@"G%LB-
",NX+3*E4:X/YZQ_XQ\QU|N:$*IB+ ^QD(=C:TS MBX2PI.M87XGM)RC\Z1F^0.0J^R7;0K9ED6"MM$@*,%J0,)[_T_LB#GL Y*D& M= I YS&@^PS
*0#.2S5T"T#WI1IZ!2!SW$KA;LQ2+0)\0CB7ZGER$(3/YI#&9\;PH M37://=*4Q>]0XGKAD>.C=^2(,$Z^1&*MD$B-;(VV&0UV4-@QR>WH/&.'0RX%
MUY$B/@\AK,![]?CS&KR-,2D#T]D%9M*I)5Q >DJ[\ MFW;_K{4?!,,IJ\3)^)P_5,D)F<>4ZZQ8_%VQD. ^?49S,-"3J1U7F<^YN-;=I
MA$.51@#&%G8Z!7(#EOOV3:O?^E 5]B;)O";) ,(:(#A+4+1/4K6-W/4#2@.6O MI\D.3834[&=^ /=XK2BHRDU.V\]HS9VR<=MXQ8SLS7[*X24R%GT.L=
M"OD50N?.62ETX'NO]+U7Z_M4<*7E.K]XL NE4JPPPI5-J);IM:78))G7))G? M$-E!.OIE.OK_L5?
TFTQ0DV1>DV1^0V0'"1J4"1K4OB^S)*5,9MD((BI7E7VA MEN*U>6B2S!L\;2'])QW+;TAC'E][:[Q* -FYEI% K'F.K]#R]-R=+[(0L9' MYY/V<-
JN./=PU,XGX]_T^9Q^B?EA7)$8EJBJ=3K -UOFLV^^T2+-AKL;H7%4 MS)81?BZ - +X?"F$WFV,@O(#Q/T%4$L#!!0 (R"9EE9&PO=V]R:W-H965TK$]>T
_?>SG32B)" N=D/L^+S'SW0B#R9; MQE]$#B#1KJ"EF%]YE-6M;8LDAP*+:U9]J48RQ@LL59>O:5%QP*D1%=3V'">R
M"TQ**YZ8=PL>3U@M*2EAP9&HBP+SMWN@;#NU7.OJQ2-9YU*_L.-)A=>P!/E< M+;CJV5V6E!10"L)*Q"&;6G?N[6RLXTW 'P);L===&VLF*L1?
=^9E.+4<# 85$ MZ@Q8/38P TIU(H7QVN:TNBFU<+_]GOW!>%=>5EC C-&_))7YU!I;*(4,UU0^ MLNT/:/V$.E_"J#"_:-
O&.A9*:B%9T8H504'*YHEW;1WV!&YP1."U N]<@=|* M?&.T(3.VYECB>,+9%G$=K;+IAJF-42LWI-1?<2FY&B5*)^.]).$UI.C[3JT+ M 0)]14NU4M*:
F(9Z@U?SD%B0J]4W/-RCBXOKM %(B5ZREDM<)F*B2T5EDYN M)RW"?8/@'4%80G6-?.<+\APO&)#/3LOGD'BY:^3^1[FMBM%5Q.L]XIE_ID5
M&3+49 B&_^B-=RL]G,#4CM+ -^ %7_^Y$;.MR%[_RG9![-^9]8_E;TS"T5% MV1L 2EBA;>-FCY4I6D$)&9`AR1R:W/BXV<1 ZX<3>[-OK!]F^YXR[J_<
M0<<=G,>]D\!+3)$N#>9);IA3V*CCJ5*C501QS]C,T>XAQ8YS@%^/\9UHYMA
M^K"C#|^BKSC+0.@#43G(8!@R[$.&P0%D/^;F6(6CCC$ZR;C@ZJ;@\LT4%%YK M8LHY!!CU)O?] [Y^R-@_PC?
J^$8G^7[+'/@0S]@W5]|;DT.QT3#/N.,9G^1Y M8A+3(9YQ;_U'ILWH *@?Y$:A=[C,[+US7M^QOS!?DU(@"IG2.= MHA21#0, $$+ 9 >&PO=V]R:W-
H965T/*=B_\,2]5EC*X%T26>4[%GVO(^'IB]:VMX2%= M)DH;;']^_@9U/$/-%_%,5K]D7>]U+!*54O&\!N,)\I29+]W4 M.NP D*<=X-8]ZT
KP9XSP>2X!!#@\]$L7PKZ 7^YY.1^PIV0+RH'T.2U++A:.+G6 MU8WKJB2'DJHK40"G4S(DFJV2;79L&-PHIN8 WZ]7J0.',[EI25P!43G$C(
M%LYR=!//3;P-^,%@IP[&Q&3R+,2+F7Q+%XYG#$$!B38,%%];6$%1&"*T\;OE M=#I) SP<[]F_V-PQEV>J8"6*GRS5^<*9.R2%C-:%?
A2[K]#F$QB^1!3*/LFN MC?49-7]MS. #X_@F WP)\Z[L1LBYOJ:91*.6.2!.-;&9@ M4[5H-,>X*\4R*U#DDJRQ\&E= !$9'E]S+4%I62>Z
MEHQO2"*45N3\%C1EQ86!P!8DY0D0RE,2 X>,8<3*QIT1QLGW7-0*-U7H:K1M MQ-VDM1@W%OT3%]_)O> Z5^2.IY"^Q[N8;I>SO\\Y]@<)UU!=D;'WB?
B>/R%/ MZUMR?G8QP#OOVN@)L><!^/#ZDOVX9DTD]B+N&-JF@""P=OF0*Y!2?Z^&$T M]3X6)QT%B=#[%$,&\:YL1?
3PA2LSV!#,;44YE)OH\" 'H7NMD$5 M53FIZ!O>Y_Y3:>#!@>AEX 5!O^JT4YT.JKZO"+3?>)_\]$A^//?ZQ6>=^&Q0
M?)G^POM[,N'9<<(3S^^7G'>2|\T%)O"'_J>W\]J+;^:/*/]'O03DJ0&]LT%7[0 M-===-9^E6N[Z\;-K1W_"FJ=]3B1^<(@5D"/6N9IBO;!IE,]&BLLWI66AL=7:8
MX[\%I G _4P(O9\8@>YO%?T!4$L#!!0 (R"9EF, LAC00< 4^ 9 M >&PO=V]R:W-H965TL\A])Y MSQ($2BASPKQ$5G(>7RK-L5Z8+D6!RS)2G4-S/&-
ZPFV-:=,;GY;Z/?'S.5C*C!?G(D5CE.>:/ER1CZXN.WWG;\8G. M%U+OZ(]/EWA.;HG\LOS(U59W0YG2G!2"L@)Q,KOH?/#/DF"D \HC_J5D+;8^
M(WT]=JSS6SM>-:EUB4'.E!:!TF)06@)%,P73F'M!Y2W] M@H?. E"O#Y06@M(B4%H,2DN@:*9^&N\P<+MA6VO&=(YW'I_P.UHK130[Q1! M:5%-
VQWH=H<<4)\0BF8JH/$) [=/>(,?:+ZR^L/NR-9UAZ2%H+0(E!:#TA(H MFJF/QC@,!K]LA %U$4%I(2@M]7%H+0$BF;JIW$E [.V#+,&^ M<[?
GY$[3MR)6@L]/%)4%H,2DN@:)4 NELOG>9$K6#U^\0"I6Q5 MR.KEOS3O+'\HW=7?V3_RST+?LC_RSN'HCN<%7+TC?J 4S+82:N/7.<;4AV;)\Y?6.2_!
[_#U!+ P04 M_" ,@F99.ED+\D8$ +& &0 'AL+W=O<$P6E5!66J[CA/;&2*Y-9]6]^]8?$I+D9(3PNTP?=8?" NF"S9K\8-
KH%)YI/2'*GQ9S2Q']0BG>"F4!))_3WB!TU0IR7[\ MUXA:;9LJ\/#Z1?USE;Q,YA%QO*#IWV0EMC,KML *KU&9BF]T]SMN$@J4WI*F
MO/H%N[IN&%I@67)!LR98]B C>?V/?C8@#@*@_TJ VP2X[PWPF@#OO0%^$^!7 M9.I4*@X)$F@^970'F*HMU=1%!;.*ENF37+WW>\'D4R+CQ/PKEM
XN :?2U$R M#*HRN$//\MT*#BX2+!!)^:6L\?T^ 1Z2?>5)N]Q<0,\YPJXCNN/A"_TX0E>RG!8A7LCXHUP+U=.KS!RI0"LI\1?B2EKG *U"\#,=5 MB=43S(!
<^!@2)-^ M!K!8WRU[1S+UZ184HN%E9A:F9_FT/$]QYG:3R/D_):< MKR6W*!F3F/IL0$K0(TF)>!Z#Y(]T)9I$;4_J[(>U8N@ZW4]MG*) ,
(60/CVM!E+,!PD&$I3 MT'MW"ZWXL$%OAFK; M.Q:-(;$,&NCL/:?S%IQ@U#$,4P6"ET(L?C<*06A?%WM-"O:E]V&*&T5I@-@K$'P!Q8_O S'D3!L@
MY_"Y<&]TH=[IFML?P:'W]2(_"OOT#-G:AMXY3#+_<1/)-L_KDN2X(6E1GL8]4")I5EUN, MY(*M*LCG:TK%2T$=[[;G__/_ 5!+ P04 " ,@F99Q?_!=^\" "D"0
M&0 'AL+W=O<>\^UP1!MN'B2 M"8 BSQG+Y=A(E%H/35-&"6147O(UY#BSY"*C"KMB9L ,1VNZ@CFHA_6M MP)Y9]\1I!KE,>4X$+,?
&E3V&Q8.B%@$"FM M0/&UA0DPIH4PC9^5IE&'U,3#]E[]<^$=O2RHA EG/])8)6.C;Y 8EG3#U!W? M?8'*CZ_U(LYD\22["FL9)-I(Q;.*C!ED:5Z^Z7-
5AP,"ZG03G(K@- G>"P2W M(KBOC>!5!.^U$?R*4%@W2^]%X:94T7 D^(X(C48UW2B]7["Q7FFN]\E<"9Q- MD:?":X!5EN0CF7"D)$GSB&UBB+%!
<"*JM)\1> 9MZ6&"6!4X:SB1"5P@&!: MAIQ/0=&47:#2&YZK M1))9CFEU*>G^8,3?!-K51?,V1?LVCDI.(?U)7&M#\2Q'*\CG\GKZ6Z7G?^+ M/OOGZ$?%
<.O=XQ9Z[LG=T[6]<_KYNF?WU"N:01C _]N$L06C/#].SNP/G65 M]"W%IF\I-GLCL:/B>W7QO5/]X??&UQ?A%]RU%*5*4*CH8V,;VE[0&YG;PQ*W M0:
[3MXY!TS;(\RS[K@P9]SZE!1U:]VJI_TNHC%2E=,/B+TU+$/PCM._V& MT3:F[SH-GVV,[??]AL\VR/%?\AG4/H.3/N^YHJS+6=!>P\&@D=&D#?)LN^FM
M#?('O:#AK2.X'Y88RKKLX3J(\DY0=A1?%X?>@BL\0HMF@M&PO=V]R:W-H965TE?=KMN+:2]<<, J8*YMDMYI'WXV."2DQ+U4[HN&!Y_?L?_G8/O
M8D?H,TL1XN ESP]VM%+.RVO:9E&* M6H[L$'Q\9[^2SUX,9@GR-":9'_AF*=+ MZ](",=K *N-?R.Y7I 8TE;R(9*S^#W9-V_G, E'%.,F5L>A!CHOF%[XH(8X,
M//>,@:<,O%,#[XS!6!F,3PPFYSQ,E,'DQ&!\SL-4&=1#MYNQU\(%D$-_0G* HK:#X[> '2'' M;5]-:P_C,Q[6L,1WNL_?>T[@[;86=#A"V
MA!1L858A4*:2"]D/3Q@??)]^4/E-0D+&MC\2#1G) 1S3[1|LUE'V%DK[$PK M[+W8,"!*16Z^*VFU*&]FH0%LU>L..U-
V:?;=72=M[K.A^GZGIS5NABJKDE8 M,/^^G'VS64?;RU;;2ZVV#VI_Q%@E](W%>ETD@*>ULICH$;.R5:A/$F*M]3U4 M)Y.PT!"LH_E5J_F55O//5?
XD\I9LP);P)HK5-[OG/I4U[*')K))6'#U M>L4ZR6%#[CJN\ZA;G"TNM_!%YQ7>9^H>LNAJAJE!49IH2E:-P9'M9MK;I>M
M6*:B8I(6&*6%IFC=]'B']'C:)V.5)!0E4$Q&"26,B:E)++AR)2@ICNJUM3<\ M6NC@\#2TV='TX8WGW0DD,.HR-
$7KJGXH.%UM_>2O>+W2WD'ZC#CX76G>J[31 M>M,H+3!*"TW1NB$YU)SNQ.#T9+3,-$H+C-)"4[1N5 X%JZNO6/] -,=%\W9/ M[)I46:4\Q6!#*-A4O!);)
[F/A44D[IZ;LXS6HKFE>MU):S0^G;9,>@U-T;K1 M.%2YKK[.?>=B8;2\5;3.8C%U3E4WZ3(T16M4MX_>?^>()O6'!R;J@*K@S:OP M[FK[<6-
5O]*W#|V;+R-B_4APP4"&-L+4&M#F8T-SPDE9OTU_(IR3O#Y, M%8P1E0W$_0T198@ZD0[:3S[^_U!+ P04 " ,@F9965^UFN,& "%.0 M&0
'AL+W=O=#],^N,1 =)*8V0ZTT_GQ= MW(_?[B276RX^RQ5C"CVE22:O>BNEUN\& SE?L93*/E^S3/^RX"*E2A^*Y4"N M!:-1&90F
^PXXT%*XZPWNRR_NQ>S2YZK).[8O4 R3U.]GF]8PK=7/:?W\L7' M>+E2Q1>#V>6:+MD#4[^M]X4^&C24*$Y9)F.>(<$65[UK]QW!TR*@+/%[S+9R
MYS,J3N61\|_%P5UTU7.*%K&$$56!H/K?AMVR)"E(NAU_U=!>4V<1N/OYA4[* MD]I(* MIW6P;D$:9]5_^E1?B)T =W@@ -,#@0,ZX#A6VL8U0&CMP:,
MZX!Q>>VKBU5>Z8 J.KL4?(M$45K3B@^2E7&6TOL!Q5F36@O+ZUUC']=F#XO// M%S=:FPC=\E0GK*2EY-|&3-$X^0Y=H*_1
,D5%4Q>#I2NLX@>96DD49A&+S/B!;FO38/S2X!ML!7[@FSYRQM\C[.!A1WMN[>$_Y5D?N6X9
M[G2=CCW\@:W[R',.UAX>J9W]VCWW8#BQAP=LWH1[EFOI->)|)<\[=#:%J!>/
MK\6_%H)F2Z9'$(4>G]%NN7OZ7'Y]O:4B0G_|K)'H3K%4_MEQ/C=5_'+F4A80$D+(2$$2"8D1'#)B.&-GJ5$1+%
M4N9:ZR@7<;9$:L70FHF81UT25\!1"2SFL/]#U4@[WQV1]2@L=WY;UZ/P=E_QP_W46O&I$D/" OLE&:)G M1D77>B.$;
4!@AFRNTZ[KW:L9UGL+U&YNT9WV5Q+&V\8ND]HUB6EG76JE]"T M)06@M((%,W4>,<[<<^|W*H;)48D+0 E!:"T@@4S4P,W"8&MH_Z9;^OR1%:
M<($6N#SK%MD)/%AN_6BWAT= ?3R2F7!MT%/2GCN_ME0M!FT>@ M:*9"K?/E6FV4D^=ENM.CLSQ]9 +Q1>V*(IJK%1?QW[745HU!'3%06@!*"VO:
M;EJYT^$8CR=[B46Z2HXGKC<=XZ:D*7-K9[E'_*RR(W;(O&%2%5NA:GF%9.V? ME"4[=8.TBFY!:
<&1:V!9;X&V@T#13*U;"\P]XH$=TKK66/=7]K2.Q7.GOJ!6 M%R@M.'+>KF,1&-3:@J*9 K?FEFMU2@XOJ=$7])X^Q6F>ZD_74107LM,$$<%3
MA!W7/[SP!O6S0&!*"T11HFID)K:GE^N=>>(.Z8*"T)06@M((%,U.C-8O M<^V&V;|<>(.Z937-6$^[ON>XP_V%-V2U(2B-0-
%,'5O7S+5[1&\|Z[X^(M%W]F<#T$I#4!J!HIDZMW8:MMMI+T\OU#/"?2[F MJV*|+R>$ P]RW=B9)XL(20M :2$HC4#13*U;8PZ?^YDT#&K!@=
("4%H(2B-0 M-#,Q6BL/O^'1M#,XMO9FG9PNH,X?*"W$KQ_EP[[O3_>?KR!=!5UWY$\/^+6X M]?#P$0]O]W&53C5 ?3I06E#3C,N"G:'ONWMW4D"K)5
T4[+6E<-V5^[HY/R? MMFSVRD_6&]2@ Z6%H#0"13,3HC7H\+D-.@QJT('2 E!:"$HC4#0S,5]##ML- MNO]MRP9JX=6T_2V;N[[E S7P0&D$BF;JW!IXV&

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|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

-8?20$3;8T.P6BP^0"X99K>]9!:GO3VTM;"3],!XT7AI-!2&@H]2/+CO]>&0[:232ZFD MW\^R^%^)C'52RTY^%>TLFV;,;CWILKJ:RPE]R+/ZSIMU*O M0S/P%)/D,6(<#K]#$,_M_PFC6:UD(RY-TW="^R&.5J@ J-U&;EW&-._$++LP M.V'9@J]%>"BXRW4[/* 'LB1<]EQ"A;UN(R,ECVZ%=J)E\,\9)5O@:-E[KKAN M!$L@"P2R."+DIR!+!'(\BB0=<"!2Q/("H&LC@@YBN0I GEZ3,@R@3Q#(,]H M(6^Y[ZU@9L7\1K#WO9-:,,>X#N/2R03R%0+YBA:R[KN.VWV@K.5:2[B,:_F M36-Z[5/(UPCD:UK(O[B]%Y#.E6"U:'HKO11#(*^XM&D*>H- OJ$>DTKQI;&Q M)L+=P(4P2-E\;<4HF4^Q;#ZEQ00_;|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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em;*

} XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 165 237 1 false 45 0 false 7 false false R1.htm 995200090 - Document - Cover Page Sheet http://gbio.com/role/DocumentCoverPage Cover Page Cover 1 false false R2.htm 995200100 - Statement - Condensed Consolidated Balance Sheets Sheet http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 995200400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 7 false false R8.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 995210301 - Disclosure - Marketable Securities and Fair Value Measurements Sheet http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurements Marketable Securities and Fair Value Measurements Notes 9 false false R10.htm 995210401 - Disclosure - Collaboration and License Agreement Sheet http://gbio.com/role/DisclosureCollaborationAndLicenseAgreement Collaboration and License Agreement Notes 10 false false R11.htm 995210501 - Disclosure - Property and equipment, net Sheet http://gbio.com/role/DisclosurePropertyAndEquipmentNet Property and equipment, net Notes 11 false false R12.htm 995210601 - Disclosure - Accrued Expenses Sheet http://gbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 995210701 - Disclosure - Leases Sheet http://gbio.com/role/DisclosureLeases Leases Notes 13 false false R14.htm 995210801 - Disclosure - Equity Sheet http://gbio.com/role/DisclosureEquity Equity Notes 14 false false R15.htm 995210901 - Disclosure - Stock-Based Compensation Sheet http://gbio.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 995211001 - Disclosure - Commitments and Contingencies Sheet http://gbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 995211101 - Disclosure - Net Loss per Share Sheet http://gbio.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 99930303 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) Sheet http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables Marketable Securities and Fair Value Measurements (Tables) Tables http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurements 21 false false R22.htm 99930403 - Disclosure - Collaboration And License Agreement (Tables) Sheet http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementTables Collaboration And License Agreement (Tables) Tables 22 false false R23.htm 99930503 - Disclosure - Property and equipment, net (Tables) Sheet http://gbio.com/role/DisclosurePropertyAndEquipmentNetTables Property and equipment, net (Tables) Tables http://gbio.com/role/DisclosurePropertyAndEquipmentNet 23 false false R24.htm 99930603 - Disclosure - Accrued Expenses (Tables) Sheet http://gbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://gbio.com/role/DisclosureAccruedExpenses 24 false false R25.htm 99930703 - Disclosure - Leases (Tables) Sheet http://gbio.com/role/DisclosureLeasesTables Leases (Tables) Tables http://gbio.com/role/DisclosureLeases 25 false false R26.htm 99930903 - Disclosure - Stock-Based Compensation (Tables) Sheet http://gbio.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://gbio.com/role/DisclosureStockBasedCompensation 26 false false R27.htm 99931103 - Disclosure - Net Loss per Share (Tables) Sheet http://gbio.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://gbio.com/role/DisclosureNetLossPerShare 27 false false R28.htm 99940101 - Disclosure - Nature of the Business and Basis of Presentation - Additional information (Detail) Sheet http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of the Business and Basis of Presentation - Additional information (Detail) Details 28 false false R29.htm 99940201 - Disclosure - Summary of Significant Accounting Policies (Detail) Sheet http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetail Summary of Significant Accounting Policies (Detail) Details http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 29 false false R30.htm 99940301 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of marketable securities (Detail) Sheet http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail Marketable Securities and Fair Value Measurements - Summary of marketable securities (Detail) Details 30 false false R31.htm 99940302 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of marketable securities by contractual maturity (Detail) Sheet http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail Marketable Securities and Fair Value Measurements - Summary of marketable securities by contractual maturity (Detail) Details 31 false false R32.htm 99940303 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of assets measured at FV on a recurring basis (Detail) Sheet http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail Marketable Securities and Fair Value Measurements - Summary of assets measured at FV on a recurring basis (Detail) Details 32 false false R33.htm 99940401 - Disclosure - Collaboration and License Agreement (Details) Sheet http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails Collaboration and License Agreement (Details) Details http://gbio.com/role/DisclosureCollaborationAndLicenseAgreement 33 false false R34.htm 99940402 - Disclosure - Collaboration and License Agreement - Schedule of Allocated Transaction Price and Revenue Activity (Detail) Sheet http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail Collaboration and License Agreement - Schedule of Allocated Transaction Price and Revenue Activity (Detail) Details 34 false false R35.htm 99940501 - Disclosure - Property and equipment, net - Summary of Property and Equipment, Net (Detail) Sheet http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail Property and equipment, net - Summary of Property and Equipment, Net (Detail) Details 35 false false R36.htm 99940502 - Disclosure - Property and equipment, net - Additional Information (Detail) Sheet http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail Property and equipment, net - Additional Information (Detail) Details 36 false false R37.htm 99940601 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 37 false false R38.htm 99940602 - Disclosure - Accrued Expenses - Narrative (Detail) Sheet http://gbio.com/role/DisclosureAccruedExpensesNarrativeDetail Accrued Expenses - Narrative (Detail) Details 38 false false R39.htm 99940603 - Disclosure - Accrued Expenses - Schedule of accrued restructuring costs (Detail) Sheet http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail Accrued Expenses - Schedule of accrued restructuring costs (Detail) Details 39 false false R40.htm 99940701 - Disclosure - Leases - Narrative (Details) Sheet http://gbio.com/role/DisclosureLeasesNarrativeDetails Leases - Narrative (Details) Details 40 false false R41.htm 99940702 - Disclosure - Leases - Future Lease Payments (Details) Sheet http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails Leases - Future Lease Payments (Details) Details 41 false false R42.htm 99940703 - Disclosure - Leases - Costs included in operating expenses related to the operating lease (Detail) Sheet http://gbio.com/role/DisclosureLeasesCostsIncludedInOperatingExpensesRelatedToOperatingLeaseDetail Leases - Costs included in operating expenses related to the operating lease (Detail) Details 42 false false R43.htm 99940801 - Disclosure - Equity - Additional Information (Detail) Sheet http://gbio.com/role/DisclosureEquityAdditionalInformationDetail Equity - Additional Information (Detail) Details 43 false false R44.htm 99940901 - Disclosure - Stock-Based Compensation (Detail) Sheet http://gbio.com/role/DisclosureStockBasedCompensationDetail Stock-Based Compensation (Detail) Details http://gbio.com/role/DisclosureStockBasedCompensationTables 44 false false R45.htm 99940902 - Disclosure - Stock-Based Compensation - Expense Classification (Detail) Sheet http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail Stock-Based Compensation - Expense Classification (Detail) Details 45 false false R46.htm 99940903 - Disclosure - Stock-Based Compensation - Unrecognized Expense (Detail) Sheet http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail Stock-Based Compensation - Unrecognized Expense (Detail) Details 46 false false R47.htm 99941001 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://gbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 47 false false R48.htm 99941101 - Disclosure - Net Loss per Share - Summary of Potential Dilutive Securities (Detail) Sheet http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail Net Loss per Share - Summary of Potential Dilutive Securities (Detail) Details 48 false false All Reports Book All Reports gbio-20240930.xsd gbio-20240930_cal.xml gbio-20240930_def.xml gbio-20240930_lab.xml gbio-20240930_pre.xml gbio-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "gbio-20240930x10q.htm": { "nsprefix": "gbio", "nsuri": "http://gbio.com/20240930", "dts": { "schema": { "local": ["gbio-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",

```
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-
31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-
gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-
2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-
2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "gbio-20240930_cal.xml" ] }, "definitionLink": { "local": [
"gbio-20240930_def.xml" ] }, "labelLink": { "local": [ "gbio-20240930_lab.xml" ] }, "presentationLink": { "local": [ "gbio-20240930_pre.xml" ] },
"inline": { "local": [ "gbio-20240930x10q.htm" ] } }, "keyStandard": 208, "keyCustom": 29, "axisStandard": 21, "axisCustom": 1, "memberStandard":
23, "memberCustom": 21, "hidden": { "total": 17, "http://fasb.org/us-gaap/2024": 12, "http://xbrl.sec.gov/dei/2024": 4, "http://gbio.com/20240930": 1
}, "contextCount": 165, "entityCount": 1, "segmentCount": 45, "elementCount": 487, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-
gaap/2024": 523, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role":
"http://gbio.com/role/DocumentCoverPage", "longName": "995200090 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true",
"groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "dei:DocumentType",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role":
"http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance
Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat":
"Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-
gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-
gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm",
"first": true, "unique": true } }, "R3": { "role": "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName":
"995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets
(Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3",
"firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"unitRef": "Unit_Divide_USD_shares_8lxQUL0cc0m8T2aPkxsCiQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef":
"As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:PreferredStockSharesIssued", "unitRef":
"Unit_Standard_shares_i8sSnb_mHUOh8MyKA6WOIw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R4": { "role":
"http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement -
Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations
and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor":
{ "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-
20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-
gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true
} }, "R5": { "role": "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement
- Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
"isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef":
"As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vsDsPef8Y0OnOaWdKqLnKQ", "name": "us-
gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-
gaap_CommonStockMember_vsDsPef8Y0OnOaWdKqLnKQ", "name": "us-gaap:StockholdersEquity", "unitRef":
"Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R6": { "role":
"http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Condensed Consolidated
Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement",
"subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ProfitLoss", "unitRef":
"Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "gbio:GainLossOnTerminationOfLeaseNonCash", "unitRef":
"Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R7": { "role":
"http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation", "longName": "995210101 - Disclosure - Nature of the Business and
Basis of Presentation", "shortName": "Nature of the Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"gbio-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role":
"http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant
Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-
gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-
20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role":
"http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurements", "longName": "995210301 - Disclosure - Marketable Securities
and Fair Value Measurements", "shortName": "Marketable Securities and Fair Value Measurements", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-
gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role":
"http://gbio.com/role/DisclosureCollaborationAndLicenseAgreement", "longName": "995210401 - Disclosure - Collaboration and License
Agreement", "shortName": "Collaboration and License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-
gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "gbio-
20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://gbio.com/role/DisclosurePropertyAndEquipmentNet", "longName":
"995210501 - Disclosure - Property and equipment, net", "shortName": "Property and equipment, net", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef":
```

"Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://gbio.com/role/DisclosureAccruedExpenses", "longName": "995210601 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://gbio.com/role/DisclosureLeases", "longName": "995210701 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://gbio.com/role/DisclosureEquity", "longName": "995210801 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://gbio.com/role/DisclosureStockBasedCompensation", "longName": "995210901 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://gbio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211001 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://gbio.com/role/DisclosureNetLossPerShare", "longName": "995211101 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:Rule10b51ArrTrmntdFlag", "p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:Rule10b51ArrTrmntdFlag", "p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables", "longName": "99930303 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)", "shortName": "Marketable Securities and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementTables", "longName": "99930403 - Disclosure - Collaboration And License Agreement (Tables)", "shortName": "Collaboration And License Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "gbio:SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "gbio:SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://gbio.com/role/DisclosurePropertyAndEquipmentNetTables", "longName": "99930503 - Disclosure - Property and equipment, net (Tables)", "shortName": "Property and equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div",

"body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://gbio.com/role/DisclosureAccruedExpensesTables", "longName": "99930603 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://gbio.com/role/DisclosureLeasesTables", "longName": "99930703 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://gbio.com/role/DisclosureStockBasedCompensationTables", "longName": "99930903 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://gbio.com/role/DisclosureNetLossPerShareTables", "longName": "99931103 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "longName": "99940101 - Disclosure - Nature of the Business and Basis of Presentation - Additional information (Detail)", "shortName": "Nature of the Business and Basis of Presentation - Additional information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetail", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Detail)", "shortName": "Summary of Significant Accounting Policies (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail", "longName": "99940301 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of marketable securities (Detail)", "shortName": "Marketable Securities and Fair Value Measurements - Summary of marketable securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_egSWBd3f80mOn4uGIwkZ8A", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "gbio:ScheduleOfMarketableSecuritiesByContractualMaturityTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vdzPDfzNOE2IJbH_0_FdRQ", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "longName": "99940302 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of marketable securities by contractual maturity (Detail)", "shortName": "Marketable Securities and Fair Value Measurements - Summary of marketable securities by contractual maturity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_egSWBd3f80mOn4uGIwkZ8A", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "gbio:ScheduleOfMarketableSecuritiesByContractualMaturityTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_egSWBd3f80mOn4uGIwkZ8A", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "gbio:ScheduleOfMarketableSecuritiesByContractualMaturityTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "longName": "99940303 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of assets measured at FV on a recurring basis (Detail)", "shortName": "Marketable Securities and Fair Value Measurements - Summary of assets measured at FV on a recurring basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_egSWBd3f80mOn4uGIwkZ8A", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "gbio:ScheduleOfMarketableSecuritiesByContractualMaturityTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_egSWBd3f80mOn4uGIwkZ8A", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R33": { "role": "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "longName": "99940401 - Disclosure - Collaboration and License

Agreement (Details)", "shortName": "Collaboration and License Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2023_srt_CounterpartyNameAxis_gbio_ModernatxIncMember_us-gaap_TypeOfArrangementAxis_gbio_CollaborationAndLicenseAgreementMember_Uxj-kESwqUGtkWoyJ1UxAA", "name": "gbio:CollaborativeArrangementUpfrontPayments", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R34": { "role": "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail", "longName": "99940402 - Disclosure - Collaboration and License Agreement - Schedule of Allocated Transaction Price and Revenue Activity (Detail)", "shortName": "Collaboration and License Agreement - Schedule of Allocated Transaction Price and Revenue Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_3_31_2023_srt_CounterpartyNameAxis_gbio_ModernatxIncMember_us-gaap_TypeOfArrangementAxis_gbio_CollaborationAndLicenseAgreementMember_Uxj-kESwqUGtkWoyJ1UxAA", "name": "gbio:StandaloneSellingPrice", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "gbio:SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2023_srt_CounterpartyNameAxis_gbio_ModernatxIncMember_us-gaap_TypeOfArrangementAxis_gbio_CollaborationAndLicenseAgreementMember_Uxj-kESwqUGtkWoyJ1UxAA", "name": "gbio:StandaloneSellingPrice", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "gbio:SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail", "longName": "99940501 - Disclosure - Property and equipment, net - Summary of Property and Equipment, Net (Detail)", "shortName": "Property and equipment, net - Summary of Property and Equipment, Net (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "longName": "99940502 - Disclosure - Property and equipment, net - Additional Information (Detail)", "shortName": "Property and equipment, net - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "longName": "99940601 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://gbio.com/role/DisclosureAccruedExpensesNarrativeDetail", "longName": "99940602 - Disclosure - Accrued Expenses - Narrative (Detail)", "shortName": "Accrued Expenses - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_11_1_2023_To_11_30_2023_-j2CGV0xZEaTRUz_80jFIw", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Unit_Standard_pure_e6Rjh4i5N0qPqeLURtkLIw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2023_To_11_30_2023_-j2CGV0xZEaTRUz_80jFIw", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Unit_Standard_pure_e6Rjh4i5N0qPqeLURtkLIw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail", "longName": "99940603 - Disclosure - Accrued Expenses - Schedule of accrued restructuring costs (Detail)", "shortName": "Accrued Expenses - Schedule of accrued restructuring costs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_25RL7D7u7Uq-q0PHLwfjJg", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_25RL7D7u7Uq-q0PHLwfjJg", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://gbio.com/role/DisclosureLeasesNarrativeDetails", "longName": "99940701 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "longName": "99940702 - Disclosure - Leases - Future Lease Payments (Details)", "shortName": "Leases - Future Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_12_31_2022_2oX-8etqdkCtAB8zZhCm7A", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_LeaseContractualTermAxis_gbio_ActiveLeaseMember_2YoVfajxHUea_lvLzGjmOw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://gbio.com/role/DisclosureLeasesCostsIncludedInOperatingExpensesRelatedToOperatingLeaseDetail", "longName": "99940703 - Disclosure - Leases - Costs included in operating expenses related to the operating lease (Detail)", "shortName": "Leases - Costs included in operating expenses related to the operating lease (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm",

"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "longName": "99940801 - Disclosure - Equity - Additional Information (Detail)", "shortName": "Equity - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_i8sSnb_mHUOh8MyKA6WOIw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "gbio:NumberOfVotePerCommonShare", "unitRef": "Unit_Standard_security_rmLcRngvZ0mQkE7SA_1Knw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://gbio.com/role/DisclosureStockBasedCompensationDetail", "longName": "99940901 - Disclosure - Stock-Based Compensation (Detail)", "shortName": "Stock-Based Compensation (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_TitleOfIndividualAxis_gbio_CertainEmployeesDirectorsAndConsultantsMember_us-gaap_AwardTypeAxis_gbio_ServiceBasedOptionsMember_CAWuWQ-FiEKj0y32rcTjCg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_i8sSnb_mHUOh8MyKA6WOIw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_TitleOfIndividualAxis_gbio_CertainEmployeesDirectorsAndConsultantsMember_us-gaap_AwardTypeAxis_gbio_ServiceBasedOptionsMember_CAWuWQ-FiEKj0y32rcTjCg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_i8sSnb_mHUOh8MyKA6WOIw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail", "longName": "99940902 - Disclosure - Stock-Based Compensation - Expense Classification (Detail)", "shortName": "Stock-Based Compensation - Expense Classification (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_FMW5totSU06CejfJbW-Zdw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail", "longName": "99940903 - Disclosure - Stock-Based Compensation - Unrecognized Expense (Detail)", "shortName": "Stock-Based Compensation - Unrecognized Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_bRfS44AfB0mRhxtXsCukQg", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "Unit_Standard_USD_PKubLaEO8EughOygMtjHIQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://gbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "99941001 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Unit_Standard_pure_e6Rjh4i5N0qPqeLURtkLIw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Unit_Standard_pure_e6Rjh4i5N0qPqeLURtkLIw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail", "longName": "99941101 - Disclosure - Net Loss per Share - Summary of Potential Dilutive Securities (Detail)", "shortName": "Net Loss per Share - Summary of Potential Dilutive Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_i8sSnb_mHUOh8MyKA6WOIw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dFva21GBlk6KimbngNzw_w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_i8sSnb_mHUOh8MyKA6WOIw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "gbio-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://gbio.com/role/DisclosureAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r32", "r34", "r37", "r670"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r32", "r499"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Collaboration receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r628"] }, "us-gaap_AccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionExpense", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Accretion Expense", "terseLabel": "Accretion and other lease related expenses", "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations." } } }, "auth_ref": ["r478", "r636"] }, "gbio_AccruedExpenseOnPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "AccruedExpenseOnPropertyAndEquipment", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "documentation": "The amount of accrued expense on property and equipment.", "label": "Accrued Expense on Property and Equipment", "terseLabel": "Property and equipment" } } }, "auth_ref": [] }, "gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development expenses.", "label":

"Accrued External Research And Development Expenses Current", "terseLabel": "Accrued external research and development expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total", "verboseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r25", "r95", "r376"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r10", "r11", "r47", "r98", "r372", "r392", "r393"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r6", "r11", "r290", "r293", "r346", "r388", "r389", "r610", "r611", "r612", "r617", "r618", "r619", "r621"] }, "gbio_ActiveLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ActiveLeaseMember", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information related to active lease with Company.", "label": "Active Lease [Member]", "terseLabel": "Active Lease" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r548"] }, "gbio_AdditionalFrom2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "AdditionalFrom2017PlanMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "documentation": "Additional From 2017 Plan [Member]", "label": "Additional From 2017 Plan [Member]", "terseLabel": "Additional From 2017 Plan" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r42", "r499", "r698"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r399", "r617", "r618", "r619", "r621", "r671", "r699"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r561"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r561"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r561"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r561"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r29", "r30", "r235"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r594"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r520", "r530", "r540", "r572"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r523", "r533", "r543", "r575"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r595"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r561"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r568"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r524", "r534", "r544", "r568", "r576", "r580", "r588"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r586"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label":

"Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r264", "r269"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "gbio_AnnualIncrease2021To2030Member": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "AnnualIncrease2021To2030Member", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "documentation": "Annual Increase 2021 To 2030 [Member]", "label": "Annual Increase 2021 To 2030 [Member]", "terseLabel": "Annual Increase 2021 To 2030" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r146"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r18"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r18"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r281"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r67", "r75", "r97", "r118", "r150", "r152", "r157", "r158", "r169", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r283", "r287", "r321", "r367", "r423", "r475", "r476", "r499", "r511", "r640", "r641", "r686"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r90", "r99", "r118", "r169", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r283", "r287", "r321", "r499", "r640", "r641", "r686"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r300", "r301", "r491"] }, "gbio_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "AtMarketOfferingMember", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to at the market offering.", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r166"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r167"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "totalLabel": "Debt Securities, Available-for-sale, Amortized Cost, Total", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r164", "r172", "r366"] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Fair Value" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Fair Value", "verboseLabel": "Marketable securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r165", "r172", "r300", "r360", "r491", "r494", "r629", "r674", "r675", "r676"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Less than one year", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r163", "r172"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Greater than one year but less than two years", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other

comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r93", "r163", "r172"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r583"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r584"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r579"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r579"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r579"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r579"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r579"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r579"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r582"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r581"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r580"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r580"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Unaudited interim financial information", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BeneficialOwnerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BeneficialOwnerMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Beneficial Owner [Member]", "terseLabel": "Beneficial Owner", "documentation": "Any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has shares of the entity with 1) voting power which includes the power to vote, or to direct the voting of, such security, and/or 2) investment power which includes the power to dispose, or to direct the disposition of, such security." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r31", "r58", "r59"] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r15", "r16", "r17"] }, "us-gaap_CapitalUnitLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitLineItems", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Capital Unit [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash equivalents:" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r14", "r92", "r467"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r672", "r673"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r14", "r55", "r115"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel":

"Net (decrease) increase in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r55"] }, "gbio_CertainEmployeesDirectorsAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "CertainEmployeesDirectorsAndConsultantsMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "documentation": "Certain Employees Directors And Consultants [Member]", "label": "Certain Employees Directors And Consultants [Member]", "terseLabel": "Certain Employees Directors And Consultants" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateByTypeAxis", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Estimate by Type [Axis]", "documentation": "Information by type of change in accounting estimate." } } }, "auth_ref": ["r19", "r131"] }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateTypeDomain", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Estimate, Type [Domain]", "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities." } } }, "auth_ref": ["r19", "r131"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r559"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r556"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r554"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r560"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r560"] }, "gbio_CollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborationAndLicenseAgreementMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to collaboration and license agreement.", "label": "Collaboration and License Agreement [Member]", "terseLabel": "Collaboration and License Agreement" } } }, "auth_ref": [] }, "gbio_CollaborationArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborationArrangementAbstract", "lang": { "en-us": { "role": { "label": "Collaboration and License Agreement" } } }, "auth_ref": [] }, "gbio_CollaborativeAgreementRoyaltyPaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeAgreementRoyaltyPaymentTerm", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The term for payment of royalty under collaboration agreement.", "label": "Collaborative Agreement, Royalty Payment Term", "terseLabel": "Royalty payment term" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreement"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "verboseLabel": "Collaboration and License Agreement", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r77", "r79", "r87"] }, "gbio_CollaborativeArrangementMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeArrangementMilestonePaymentsReceivable", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments receivable under collaborative arrangements.", "label": "Collaborative Arrangement, Milestone Payments Receivable", "terseLabel": "Milestone payments receivable" } } }, "auth_ref": [] }, "gbio_CollaborativeArrangementNumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeArrangementNumberOfPerformanceObligations", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The number of performance obligations under collaborative arrangements.", "label": "Collaborative Arrangement, Number of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "auth_ref": [] }, "gbio_CollaborativeArrangementNumberOfProductsToBeCommercialized": { "xbrltype": "integerItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeArrangementNumberOfProductsToBeCommercialized", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The number of products to be commercialized under collaborative arrangements.", "label": "Collaborative Arrangement, Number of Products to be Commercialized", "terseLabel": "Number of products to be commercialized" } } }, "auth_ref": [] }, "gbio_CollaborativeArrangementPrepaidResearchServicesFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeArrangementPrepaidResearchServicesFunding", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of research services prepayments received under collaborative arrangements.", "label": "Collaborative Arrangement, Prepaid Research Services Funding", "terseLabel": "Prepaid research services funding" } } }, "auth_ref": [] }, "gbio_CollaborativeArrangementUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeArrangementUpfrontPayments", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of upfront payments received under collaborative arrangements.", "label": "Collaborative Arrangement, Upfront Payments", "terseLabel": "Upfront payments" } } }, "auth_ref": [] }, "gbio_CollaborativeArrangementVariableConsiderationIncludedInTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "CollaborativeArrangementVariableConsiderationIncludedInTransactionPrice", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of variable consideration included in transaction price of collaborative arrangements.", "label": "Collaborative Arrangement, Variable Consideration Included in Transaction Price", "terseLabel": "Variable consideration" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaboration and License Agreement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r281"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r38", "r69", "r369", "r410"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {

"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://gbio.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r64", "r184", "r185", "r462", "r633", "r637"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Stock reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r41"] }, "gbio_CommonStockCapitalSharesReservedForFutureIssuancesRemainedUnsoldUponTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "CommonStockCapitalSharesReservedForFutureIssuancesRemainedUnsoldUponTermination", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Amount of common stock remained unsold upon termination.", "label": "Common Stock, Capital Shares Reserved For Future Issuances, Remained Unsold Upon Termination", "terseLabel": "Termination of shares reserved for future issuances" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r501", "r502", "r503", "r505", "r506", "r507", "r508", "r617", "r618", "r621", "r671", "r697", "r699"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r41"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r41", "r411"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r41"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r41", "r411", "r429", "r699", "r700"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 66,753,508 and 66,205,550 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r41", "r371", "r499"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r565"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r564"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r566"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r563"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r12", "r104", "r106", "r110", "r361", "r381", "r382"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "gbio_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer equipment and software" } } }, "auth_ref": [] }, "gbio_ConstructionAllowanceInOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "ConstructionAllowanceInOperatingLease", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Construction allowance in operating lease.", "label": "Construction Allowance in Operating Lease", "terseLabel": "Construction allowance in operating lease" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Deferred Revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r217", "r218", "r221"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r222"] }, "us-gaap_ContractsAccountedForUnderPercentageOfCompletionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractsAccountedForUnderPercentageOfCompletionMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Contracts Accounted for under Percentage of Completion [Member]", "terseLabel": "Contracts Accounted for under Percentage of Completion", "documentation": "Modifications to or changes in assumptions surrounding contracts accounted for under the percentage of completion method of accounting. Percentage of completion is a method of accounting whereby profit on a long-term (construction) contracts is recognized based on reliable estimates as to the degree of completion generally based on contractual relationships (costs incurred to total costs anticipated)." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis",

"presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r121", "r122", "r200", "r205", "r350", "r356", "r365", "r468", "r470"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r190", "r638"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r190", "r638", "r639"] }, "gbio_CtlnpTechnologyAndResearchLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "CtlnpTechnologyAndResearchLicenseMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents the information about ctLNP technology and research license.", "label": "Ctlnp Technology And Research License [Member]", "terseLabel": "ctLNP technology and research license" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "gbio_DateAxis": { "xbrltype": "stringItemType", "nsuri": "http://gbio.com/20240930", "localname": "DateAxis", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Date [Axis]" } } }, "auth_ref": [] }, "gbio_DateDomain": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "DateDomain", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Date [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "terseLabel": "Less than one year", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r172", "r631"] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent", "terseLabel": "Greater than one year but less than two years", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r172", "r631"] }, "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]", "terseLabel": "Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r606"] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r607"] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": ["http://gbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Defined contribution plan, percentage", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r150", "r155", "r158", "r475", "r476"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r233", "r237", "r265", "r266", "r268", "r486"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r515"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r547"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r558"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label":

"Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r111", "r128", "r129", "r130", "r131", "r132", "r133", "r139", "r141", "r143", "r144", "r145", "r149", "r277", "r280", "r297", "r298", "r362", "r383", "r472"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r111", "r128", "r129", "r130", "r131", "r132", "r133", "r141", "r143", "r144", "r145", "r149", "r277", "r280", "r297", "r298", "r362", "r383", "r472"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r138", "r146", "r147", "r148"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34"] }, "gbio_EmployeeRetentionCreditPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gbio.com/20240930", "localname": "EmployeeRetentionCreditPolicyTextBlock", "presentation": ["http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for employee retention credit.", "label": "Employee Retention Credit [Policy Text Block]", "terseLabel": "Employee Retention Credit" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized Expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r267"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock compensation on account of unvested options remaining period over which the compensation is to be recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r267"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Severance and Benefits Costs", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Stock options to purchase common stock", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "EmployeeStockPurchasePlanTwoThousandAndTwentyMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "documentation": "Represents information related to employee stock purchase plan two thousand and twenty.", "label": "Employee Stock Purchase Plan Two Thousand And Twenty [Member]", "terseLabel": "Employee Stock Purchase Plan 2020" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r513"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r513"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r513"] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Date of incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",

"localname": "EntityIncorporationStateCountryCode", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r597"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r513"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r513"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r513"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r513"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r552"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r593"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r593"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r593"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r88", "r107", "r108", "r109", "r123", "r124", "r125", "r127", "r132", "r134", "r136", "r151", "r170", "r171", "r173", "r216", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r346", "r380", "r388", "r389", "r390", "r399", "r449"] }, "gbio_EquityFinancingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "EquityFinancingAmount", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of equity financing.", "label": "Equity Financing Amount", "terseLabel": "Equity financing" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r562"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r520", "r530", "r540", "r572"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r517", "r527", "r537", "r569"] }, "gbio_EstimatedMonthlyBaseRentOnOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "EstimatedMonthlyBaseRentOnOperatingLease", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Estimated monthly base rent on operating lease", "label": "Estimated Monthly Base Rent On Operating Lease", "terseLabel": "Estimated monthly base rent on operating lease" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r568"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r300", "r301", "r314", "r491"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r300", "r301", "r314", "r491"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of assets measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r672", "r673"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r305", "r306", "r307", "r308", "r309", "r310", "r315", "r492"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r305", "r306", "r307", "r308", "r309", "r310", "r315", "r492"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r201", "r224", "r225", "r226", "r227", "r228", "r229", "r299", "r301", "r302", "r303", "r304", "r313", "r314", "r316", "r351", "r352", "r353", "r479", "r480", "r482", "r483", "r484", "r491", "r494"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [

"http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r300", "r301", "r302", "r304", "r491", "r675", "r677"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities and Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Marketable Securities and Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r309", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320", "r359", "r491", "r495"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r201", "r224", "r229", "r301", "r314", "r351", "r482", "r483", "r484", "r491"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r201", "r224", "r229", "r301", "r302", "r314", "r352", "r479", "r480", "r482", "r483", "r484", "r491"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r201", "r224", "r225", "r226", "r227", "r228", "r229", "r301", "r302", "r303", "r304", "r314", "r353", "r479", "r480", "r482", "r483", "r484", "r491", "r494"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r300", "r301", "r302", "r304", "r491", "r675", "r677"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r201", "r224", "r225", "r226", "r227", "r228", "r229", "r299", "r301", "r302", "r303", "r304", "r313", "r314", "r316", "r351", "r352", "r353", "r479", "r480", "r482", "r483", "r484", "r491", "r494"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r491", "r672", "r673", "r674", "r675", "r676", "r677"] }, "gbio_FirstLiverProgramCommercializationOptionLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "FirstLiverProgramCommercializationOptionLicenseMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents the information about First liver program commercialization option license.", "label": "First Liver Program Commercialization Option License [Member]", "terseLabel": "First liver program commercialization option license" } } }, "auth_ref": [] }, "gbio_FirstNonLiverProgramCommercializationOptionLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "FirstNonLiverProgramCommercializationOptionLicenseMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents the information about First non-liver program commercialization option license.", "label": "First Non-liver Program Commercialization Option License [Member]", "terseLabel": "First non-liver program commercialization option license" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r524", "r534", "r544", "r576"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r524", "r534", "r544", "r576"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r524", "r534", "r544", "r576"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r524", "r534", "r544", "r576"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r524", "r534", "r544", "r576"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r557"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and

bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Loss on lease termination", "terseLabel": "Loss on lease termination", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": ["r331"] }, "gbio_GainLossOnTerminationOfLeaseNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "GainLossOnTerminationOfLeaseNonCash", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash adjustment of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) On Termination Of Lease, Non Cash", "negatedLabel": "Loss on lease termination" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r49", "r433"] }, "us-gaap_ImpairmentChargeOnReclassifiedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentChargeOnReclassifiedAssets", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Impairment Charge on Reclassified Assets", "terseLabel": "Impairment charge", "documentation": "For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date." } } }, "auth_ref": ["r23", "r24"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r174", "r175", "r178", "r306", "r310", "r315", "r385", "r387", "r434", "r465", "r493", "r696"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r175", "r178", "r306", "r310", "r315", "r385", "r387", "r434", "r465", "r493", "r696"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Collaboration receivable", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "verboseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r614"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r466"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r603", "r614"] }, "gbio_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of assets used to generate operating income.", "label": "Increase (Decrease) in Operating Lease Right of Use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other noncurrent assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r614"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "IncreaseDecreaseInTenantImprovementsAllowanceReceivable", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) during the reporting period in the amount due from the landlord for tenant improvements.", "label": "Increase Decrease In Tenant Improvements Allowance Receivable", "negatedLabel": "Tenant receivable" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r524", "r534", "r544", "r568", "r576", "r580", "r588"] }, "gbio_InitialMonthlyBaseRentOnOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "InitialMonthlyBaseRentOnOperatingLease", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Initial monthly base rent on operating lease.", "label": "Initial Monthly Base Rent on Operating Lease", "terseLabel": "Initial monthly base rent on operating lease" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r586"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r516", "r592"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r516", "r592"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": {

"role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r516", "r592"] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Amortization (accretion) of premium (discount) on marketable securities, net", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": ["r52"] }, "gbio_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r345", "r602"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r345", "r602"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesCostsIncludedInOperatingExpensesRelatedToOperatingLeaseDetail"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r337", "r498"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://gbio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Costs included in operating expenses related to the operating lease", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r682"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r62", "r344"] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r335", "r345"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r335", "r345"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Lease existence of option to extend", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r336"] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend", "terseLabel": "Option to extend lease", "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": ["r681"] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term", "terseLabel": "Operating lease agreement option to renewal term", "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r681"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://gbio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Future lease payments for noncancelable operating lease", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r683"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted payments due under operating leases", "verboseLabel": "Total rent payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r343"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r343"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r343"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r343"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r343"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024 (remaining 3 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r683"] }, "gbio_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-

gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r343"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r680"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://gbio.com/role/DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r329"] }, "gbio_LetterOfCreditForSecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "LetterOfCreditForSecurityDeposit", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Letter of credit for security deposit.", "label": "Letter of Credit for Security Deposit", "terseLabel": "Letter of credit for security deposit" } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r9", "r33", "r34", "r35", "r36", "r37", "r38", "r39", "r118", "r169", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r284", "r287", "r288", "r321", "r409", "r473", "r511", "r640", "r686", "r687"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r46", "r70", "r374", "r499", "r616", "r632", "r678"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r35", "r91", "r118", "r169", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r284", "r287", "r288", "r321", "r499", "r640", "r686", "r687"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r605"] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities, net of current portion", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": ["r605"] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByContractualMaturityDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Summary of marketable securities by security type", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Marketable Security, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on marketable securities", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": ["r50"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r231", "r270", "r304", "r357", "r384", "r386", "r394", "r401", "r402", "r455", "r456", "r457", "r458", "r459", "r463", "r464", "r477", "r481", "r485", "r494", "r495", "r496", "r497", "r500", "r642", "r688", "r689", "r690", "r691", "r692", "r693"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r560"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r560"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r231", "r270", "r304", "r357", "r384", "r386", "r394", "r401", "r402", "r455", "r456", "r457", "r458", "r459", "r463", "r464", "r477", "r481", "r485", "r494", "r495", "r496", "r500", "r642", "r688", "r689", "r690", "r691", "r692", "r693"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r579"] }, "gbio_ModernatxIncMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ModernatxIncMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to ModernaTX, Inc.", "label": "ModernaTX, Inc [Member]", "terseLabel": "ModernaTX, Inc" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail"],

"lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r643"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r587"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r561"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r114"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r114"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r55", "r56", "r57"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "negatedLabel": "Net loss and net loss attributable to common stockholders", "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r48", "r57", "r71", "r89", "r103", "r105", "r109", "r118", "r126", "r128", "r129", "r130", "r131", "r132", "r135", "r136", "r142", "r169", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r277", "r280", "r298", "r321", "r379", "r431", "r447", "r448", "r509", "r640"] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r560"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r524", "r534", "r544", "r568", "r576"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r551"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r550"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r568"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r587"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r587"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Other income and interest income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r51"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "auth_ref": [] }, "us-gaap_NontradeReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NontradeReceivablesCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Nontrade Receivables, Current", "terseLabel": "Tenant receivable", "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r608"] }, "gbio_NumberOfVotePerCommonShare": { "xbrltype": "integerItemType", "nsuri": "http://gbio.com/20240930", "localname": "NumberOfVotePerCommonShare", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Number of vote per common shares.", "label": "Number of Vote Per Common Share", "verboseLabel": "Number of vote per common share" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r74", "r474", "r622", "r623", "r624", "r625", "r626"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesCostsIncludedInOperatingExpensesRelatedToOperatingLeaseDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by

amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r338", "r498"] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment of right-of-use asset", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": ["r679"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r333"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability", "verboseLabel": "Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r333"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesFutureLeasePaymentsDetails", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion", "verboseLabel": "Non-current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r333"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r334", "r340"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r332"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average incremental borrowing", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r342", "r498"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r341", "r498"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of the Business and Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r96"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gains on marketable securities", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r100", "r101", "r102", "r380"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other comprehensive (loss) income:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gains on marketable securities", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r100", "r102", "r168"] }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetail"], "lang": { "en-us": { "role": { "label": "Other Employee-related Liabilities", "terseLabel": "Employee retention credit recognized", "documentation": "Amount of obligations incurred for employer-related costs classified as other." } } }, "auth_ref": ["r68"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r34", "r499"] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r560"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r522", "r532", "r542", "r574"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r525", "r535", "r545", "r577"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r525", "r535", "r545", "r577"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r549"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "negatedLabel": "Cash payments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r177", "r613"] }, "us-gaap_PaymentsForTenantImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForTenantImprovements", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Payments for Tenant Improvements", "terseLabel": "Tenant improvement allowance receivable write-off", "documentation":

"Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of share issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r13"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Tax withholding payments related to net share settlements of restricted stock units", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r112"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r630"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r54"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r559"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r559"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r551"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r568"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r561"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r550"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r552"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r596"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r551"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r40", "r203"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r40", "r411"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r40", "r203"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r40", "r411", "r429", "r699", "r700"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "definitionGuidance": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r40", "r370", "r499"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r609"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance/sale of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "gbio_ProceedsFromIssuanceOfCommonStockGross": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockGross", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Cash inflow form gross proceeds form issuance of common stock.", "label": "Proceeds from Issuance of Common Stock, Gross", "terseLabel": "Aggregate gross offering price" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the

period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r53"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options and ESPP, net", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r8"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r89", "r103", "r105", "r113", "r118", "r126", "r132", "r135", "r136", "r169", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r277", "r280", "r282", "r285", "r286", "r298", "r321", "r363", "r378", "r398", "r431", "r447", "r448", "r489", "r490", "r510", "r612", "r640"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and equipment, net." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r5", "r344"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNet"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and equipment, net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r61", "r81", "r85", "r86"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r62", "r94", "r377"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r344"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r344", "r364", "r377", "r499"] }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "lang": { "en-us": { "role": { "label": "Property and equipment, net" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and equipment, net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r62", "r344"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r549"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r549"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r223", "r231", "r260", "r261", "r262", "r270", "r304", "r354", "r355", "r357", "r384", "r386", "r394", "r401", "r402", "r455", "r456", "r457", "r458", "r459", "r463", "r464", "r477", "r481", "r485", "r494", "r495", "r496", "r497", "r500", "r503", "r634", "r642", "r675", "r689", "r690", "r691", "r692", "r693"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/DisclosureLeasesNarrativeDetails", "http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r223", "r231", "r260", "r261", "r262", "r270", "r304", "r354", "r355", "r357", "r384", "r386", "r394", "r401", "r402", "r455", "r456", "r457", "r458", "r459", "r463", "r464", "r477", "r481", "r485", "r494", "r495", "r496", "r497", "r500", "r503", "r634", "r642", "r675", "r689", "r690", "r691", "r692", "r693"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r517", "r527", "r537", "r569"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r162", "r230", "r347", "r348", "r368", "r375", "r404", "r405", "r406", "r407", "r408", "r428", "r430", "r454"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r119", "r120", "r347", "r348", "r349", "r350", "r368", "r375", "r404", "r405", "r406", "r407", "r408", "r428", "r430", "r454"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r347", "r348", "r685"] }, "us-

gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r162", "r230", "r347", "r348", "r368", "r375", "r404", "r405", "r406", "r407", "r408", "r428", "r430", "r454", "r685"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r121", "r122", "r200", "r205", "r350", "r356", "r365", "r469", "r470"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r271", "r465", "r475", "r694"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r518", "r528", "r538", "r570"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r519", "r529", "r539", "r571"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r76", "r604", "r615"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesNarrativeDetail"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring expenses", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": ["r176", "r179", "r181", "r183"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesNarrativeDetail"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Reduction in workforce", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Restructuring expenses", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r4", "r180", "r181", "r635"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r176", "r177", "r181", "r182"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r176", "r177", "r178", "r179", "r181", "r182", "r183"] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesNarrativeDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": ["r598", "r599"] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r177", "r182"] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": ["r177", "r182"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring costs", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r43", "r66", "r373", "r391", "r393", "r397", "r412", "r499"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained

Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r88", "r123", "r124", "r125", "r127", "r132", "r134", "r136", "r170", "r171", "r173", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r289", "r291", "r292", "r294", "r296", "r328", "r330", "r388", "r390", "r399", "r699"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Collaboration revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r72", "r73", "r150", "r153", "r154", "r156", "r158", "r159", "r160", "r161", "r219", "r220", "r358"] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Transaction Price Allocated", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r84"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r587"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r587"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r137", "r232", "r600", "r620"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Summary of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://gbio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of potential dilutive securities, presented based on amounts outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfCapitalUnitsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCapitalUnitsTable", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Equity, Capital Unit or Share [Table]", "documentation": "Disclosure of information about capital unit or share, including, but not limited to, authorized, outstanding, and value of capital unit or share." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r281"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r28"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense was classified in the statements of operations and comprehensive loss", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r28"] }, "gbio_ScheduleOfMarketableSecuritiesByContractualMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gbio.com/20240930", "localname": "ScheduleOfMarketableSecuritiesByContractualMaturityTableTextBlock", "presentation": ["http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of marketable securities by contractual maturity.", "label": "Schedule Of Marketable Securities By Contractual Maturity [Table Text Block]", "terseLabel": "Schedule of marketable securities by contractual maturity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://gbio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://gbio.com/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5", "r344"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail"], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r176", "r177", "r178", "r179", "r181", "r182", "r183"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://gbio.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Summary of accrued restructuring costs recorded and included in accrued expenses and other current liabilities", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of

any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r26", "r63"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail", "http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r234", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263"] }, "gbio_SecondLiverProgramCommercializationOptionLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "SecondLiverProgramCommercializationOptionLicenseMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents the information about Second liver program commercialization option license.", "label": "Second Liver Program Commercialization Option License [Member]", "terseLabel": "Second liver program commercialization option license" } } }, "auth_ref": [] }, "gbio_SecondNonLiverProgramCommercializationOptionLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "SecondNonLiverProgramCommercializationOptionLicenseMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents the information about Second non-liver program commercialization option license.", "label": "Second Non-Liver Program Commercialization Option License [Member]", "terseLabel": "Second non-liver program commercialization option license" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r512"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Security Deposit", "terseLabel": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r604"] }, "us-gaap_SecurityDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDepositLiability", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Security Deposit Liability", "terseLabel": "Security deposit liability", "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r514"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationExpenseClassificationDetail"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "General and administrative expenses", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "gbio_ServiceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ServiceBasedOptionsMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "documentation": "Pertains to information relating to service based options.", "label": "Service Based Options [Member]", "terseLabel": "Service Based Options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Stock based compensation vesting period service based", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r486"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share based compensation by share based payment weighted average period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r486"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r252"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail", "http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r234", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of share instruments newly issued under a share-based compensation plan", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://gbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of common stock outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number of Additional Shares Authorized Percentage", "terseLabel": "Percentage of common stock shares additionally reserved for issuance" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Share based compensation by share based payment arrangement number of shares authorized for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r488"] }, "us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average grant date fair value", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r245"] }, "gbio_ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to share based compensation expected to recognize over a weighted average period one.", "label": "Share Based Compensation Expected to Recognize Over a Weighted Average Period One [Member]", "terseLabel": "Share based compensation expected to recognize over a weighted average period one" } } }, "auth_ref": [] }, "gbio_ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to share based compensation expected to recognize over a weighted average period two.", "label": "Share Based Compensation Expected to Recognize Over a Weighted Average Period Two [Member]", "terseLabel": "Share based compensation expected to recognize over a weighted average period two" } } }, "auth_ref": [] }, "gbio_SharePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "SharePurchaseAgreementMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to share purchase agreement.", "label": "Share Purchase Agreement [Member]", "terseLabel": "Share Purchase Agreement" } } }, "auth_ref": [] }, "gbio_SharePurchaseArrangementPremiumPaidOnCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "SharePurchaseArrangementPremiumPaidOnCommonStock", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of premium paid over fair value of common stock under share purchase agreement.", "label": "Share Purchase Arrangement, Premium Paid on Common Stock", "terseLabel": "Premium paid on common stock" } } }, "auth_ref": [] }, "gbio_SharePurchaseArrangementSharePurchaseAsPercentOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://gbio.com/20240930", "localname": "SharePurchaseArrangementSharePurchaseAsPercentOfOutstandingShares", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The shares to be purchased under share purchase agreement as percent of outstanding shares.", "label": "Share Purchase Arrangement, Share Purchase as Percent of Outstanding Shares", "terseLabel": "Percent of shares to be issued" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Stock based compensation period of expiry", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r487"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issue price (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r58", "r116"] }, "gbio_StandaloneSellingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://gbio.com/20240930", "localname": "StandaloneSellingPrice", "crdr": "credit", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "The amount of standalone selling price.", "label": "Standalone Selling Price", "terseLabel": "Standalone Selling Price" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r41", "r44", "r45", "r88", "r107", "r108", "r109", "r123", "r124", "r125", "r127", "r132", "r134", "r136", "r151", "r170", "r171", "r173", "r216", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r346", "r380", "r388", "r389", "r390", "r399", "r449"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r123", "r124", "r125", "r151", "r330", "r358", "r395", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r411", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r430", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r504"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetail"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r137", "r232", "r600", "r601", "r620"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r123", "r124", "r125", "r151", "r162", "r330", "r358", "r395", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r411", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r430", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r504"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r521", "r531", "r541", "r573"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/DisclosureStockBasedCompensationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Sale of common stock in connection with the Moderna Share Purchase Agreement, shares", "verboseLabel": "Shares issued during the period", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r40", "r41", "r66", "r396", "r449", "r460"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted common stock, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r7", "r40", "r41", "r66"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under ESPP, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r7", "r40", "r41", "r66"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r40", "r41", "r66", "r246"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of common stock in connection with the Moderna Share Purchase Agreement", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r40", "r41", "r66", "r399", "r449", "r460", "r510"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted common stock", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r7", "r66"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under ESPP", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r27", "r40", "r41", "r66"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r41", "r44", "r45", "r66"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r41", "r44", "r45", "r60", "r413", "r429", "r450", "r451", "r499", "r511", "r616", "r632", "r678", "r699"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://gbio.com/role/DisclosureEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r65", "r117", "r202", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r295", "r452", "r453", "r461"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://gbio.com/role/DisclosureEquityAdditionalInformationDetail", "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"gbio_SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gbio.com/20240930", "localname": "SummaryOfAllocationOfTransactionPriceToEachUnitOfAccountTableTextBlock", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to allocation of transaction price to each unit of account.", "label": "Summary Of Allocation Of Transaction Price To Each Unit Of Account [Table Text Block]", "terseLabel": "Summary of allocation of transaction price to each unit of account" } } }, "auth_ref": [] },
"gbio_SummaryOfTransactionPriceAllocatedWithRevenueActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gbio.com/20240930", "localname": "SummaryOfTransactionPriceAllocatedWithRevenueActivityTableTextBlock", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of transaction price allocated to each unit of account in addition to revenue activity.", "label": "Summary Of Transaction Price Allocated With Revenue Activity [Table Text Block]", "terseLabel": "Summary of transaction price allocated with revenue activity" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://gbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r567"] },
"gbio_ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember", "presentation": ["http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Represents the information about Third liver or non-liver program commercialization option license.", "label": "Third Liver Or Non-Liver Program Commercialization Option License [Member]", "terseLabel": "Third liver or non-liver program commercialization option license" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r627", "r684"] },
"srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://gbio.com/role/DisclosureStockBasedCompensationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r559"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r566"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r586"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r588"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://gbio.com/role/DocumentCoverPage"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r589" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r590" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r590" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r588" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r588" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r591" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r589" ] }, "gbio_TwoThousandAndTwentyStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://gbio.com/20240930", "localname": "TwoThousandAndTwentyStockIncentivePlanMember", "presentation": [ "http://gbio.com/role/DisclosureStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty stock incentive plan.", "label": "Two Thousand And Twenty Stock Incentive Plan [Member]", "terseLabel": "2020 Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementDetails", "http://gbio.com/role/DisclosureCollaborationAndLicenseAgreementScheduleOfAllocatedTransactionPriceAndRevenueActivityDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r281" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://gbio.com/role/DisclosureAccruedExpensesScheduleOfAccruedRestructuringCostsDetail" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r176", "r177", "r181", "r182" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFvOnRecurringBasisDetail", "http://gbio.com/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r471", "r482", "r484", "r491", "r695" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r585" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://gbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r20", "r21", "r22", "r78", "r80", "r82", "r83" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://gbio.com/role/DisclosureLeasesCostsIncludedInOperatingExpensesRelatedToOperatingLeaseDetail" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r339", "r498" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r555" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r140", "r145" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://gbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r139", "r145" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r553" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "35", "Paragraph": "44", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-44" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-7" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r64": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },

"r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" },

"r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r400": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r490": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":

"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r598": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r601": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 68 0001558370-24-014632-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-014632-xbrl.zip M4$L#!!0 (R"9EDA3K[U:A !>A 1 9V)I;RTR,#(T,#DS,"YX MMOXS82_U[@_@=>OEP/.,=VLMDV07>+/#9%<,DZ2+QM[U-!2[1-5"9= MDDKB^^MOAI)LO5],6BU.7W8=<3B^#P:\7#[? $E8Z_8L(01S%JF$N>N5F2J5RO MJ2!W3"GN>>1"<7?!"!F/#K_'!V>GI#!X/E<4$UU)&"6&9'A^.HX#)D)\49 M&8^'[X='HZ-WY.3L^.CLY'MR?Q? 1W8%HG8HU6*X+4I4\'41?522Y&_6JD!#*$F0>ES\OB5]?GX^M.3(^6@T.AYB M\0Q@BLBQE)?04CO2%49M\LV- 9]+N@A/T/5@IG/ M=,7TFCIL2[J8<7GHR)4E&YT>8_T&/-]:ZE65VQ.?0\8_^%3S_:(K63:S9,+ M;#0>_GIW^VB[143L&I5RLP1F4#S$8I3A:# Z'AR/M[XQ_-51'A1'(_!^PX3F M,X\-D(PI:F!XT8,C'%["AME:,0>[?*&WG Z5]-AP1QD#"DORNX8M24"EV+RP MC?=#* (WWT0+&VZ*DQQA5(CV4;D<59JK4!)*=;7B^VT)!^80D_\D6.)_%J3QJD^S_Z;9D3;QVO1&QW9SK;K7ENGW\?]'F>ZL #-BON MQ%B8',,=MV (=]PTX4# [LT)B+ PJ?/R&$#L%42&DL;Z/CZ*'ZS47-)[2OV"#9WJ7+/A7OI:R-7YR]<7\D5Y2*$ M5!\0#JHUJQ))%*

*[YP7UL!L]+AF+L&M2H12Y$^RS%KTM2_B]Y4KB;$G(MEP2,>^0JD=N6ZLE\LHYF.^QF<@466>)<^,1NI:X%:P-NE9@?U<5\URB1<()K MEE#LU_&&";;<.T4CI[BD>GGMR>?&^.\]5D+]KAW4V *Q3?28)B;8.ZI^9X;" M&O:10;@ 33/LA->4]Y^IY[,[1I',&O+17ZVHVDSF>94N-F!^HZAC8'UU1PT^ MWEP!%??2,_2?TF:Y%/]N=#PZ2L_RNR:(K@T[-*!HQ,I&XL*A)P;RH8^M=M7U MKOIL0YR=D$ 42$F^#>3\9^^/^_OCN=8PA8=% [KFY?IJ(!ZRNN%A<4 WKO]=S MQ-J-57O@\2M[(+6BD54H&Z&&7/^,:2A*5"0AF:&(O?OEN]^YXRB?N9]>UCBE M:(S]7-]C@'JR(-^?&M:NMH -DBGN8"!++OL%;N$OYQ-0] M7; 0\M%;/<0*ZA*LW%NZ6<[NGBJ@6S+#0:?&";QD[1K9O),V MV3SR;:*=OCRY3^] (^4+P.0QQPD#HAUL)8"5Q#QW%X2S[8]Q>K4H\C]DX MQG(0.>9DQY U$['LD6Z>]LE>5:-ZG$6U<3:J!S60:N(MK!*DDRQ($2^+#XNX_8L(UH-3FJ"MR,!6@U$CQ]HCD).XR<^]5-O[NZR]@Z]] ME1-6CH==F:>55OX^:^4^,,K=7@:QH]VLC9L_H+?G!D(%5)4HG.8LE)%5N#T\ MSJS');5R6]VXL6M*NR/(QA!,Y$4U9:15"(U'>>NE+:]P5U",8P]3,J_ #&Z3 MNF?J<4D5RR004L65<.1E"IBQ6[$(K(^(9=-CT" (7L%].H%YNX!0WQ6=>DM5/ M#9!OHU]]OK9]EF"*9'OE"D(.Y5@?O\[VE6^#QGK FV4.\D&N6:L*V'=98)-) MA/.\)$(/9:-L0CZ"Y<15P)UD@2M)+/2 U%RCU6M@"P?I'RB"G0@-LN@DXW- M>ESV>0%_[KI6*.K=B+E4*_LP?ZO;_@S+\7[W&F_M<7K;2D#X3H1^E]L^L7R^ M1S2J6P7^7J_X>W3?^%.K-_ZJO:G* MO&*CS 57O3:U2! 5?,M2M5H5^NYT& M_5<-+=&,?4KD>(>$S)5%%;##E:X5T .M1[8$O,^!*>&/Q5^:?F6355[328 M7,=K4A\Y16*1F%S$"F;KAZ*12+9^!&F4F=K.#07E^5ZU'[,JOVFV928YJR0(M/^T(,7KI/:.)9S2(3UIPJ/:!S-A1[@.QV..FCST:ICT_4X5#\E/!IU85U%58 MOL]BF?-EZY9KCUF[KY4?F#;*=_#$;&P7Z>U^VZYD$\USM4)[^3D3L-B%6^2 M./:+NMX+2E+CJ2Y8D"3/4%4A6+A?+Z]_]LOZW%U\#>;:-Z@I5@!5N_>MGQ%=Y M\5&0?2NCK8*LP3[!'JLF6(5SS*5'M;8)RZ8 EC&H1C6[%ZH(U4$T'9)D4SW< M3>#^(A1SY$+P_V[7,DW +JY>#77]-Y<#$F]GBWL/=-.-P UFU99<*F!OO'NX MGX'W>YV]2R9) XISZEUQS\<%:-6[D?:,JGR@UI;E5$(J:I1$K<;?EOQ_N + ^ M@Z>O/[YL:>(G^'YVQ\.-%^M3QCV3Y;VC.MT3L&T<'*OX&JAR\K+R)!]B4' ML5N'2ELG;#AB0963X9(YY1R8V%P30#2,A#\@P]?2"G!HJE4*N@XJ!4[25*FD M7W50)X_.FNH$59CW)NK\,$R=M!T^2)S';4_C!KVD,D0DC]_7J2/MC^-.-1@? MC@] (<+W$K0S6H[MJ*5VS50^AV5#0$@F*3R,O:CB7W!Y,CC]JMUITEGYIL[E7 M)0R99_2633,I"HZ]KZ5[1(X_FK5:=KE%7M.Y5?"O[:'X WPT&!\-CAOBGKG6 MHF;[405L^*05Z+&K+O; W)ZUOY?QTY<7U#& IU2B%EKA%,T_?M].CMP+,&IU M_9R:]F_=')3=72'U (GH S#PZHKV?2]QL4&+L0? JYK8>7F5BF_]P<'/'P.B$, M*X/_;)24'2K,S0I&^:=@2PR^W7[&/O7'_':?<#=,L)K%>>BWUAR"^T-!"TT"Q?$6;:83AOV^8VLH*,>BCG)MGB PRJM4A M[]".VS=((#H$MP^PX(;ES1*$OV)/S)-6E>B5SZ6]ELC$M&Y7O2, ^'4R"IM@X M-@;,I)O.E:)B8>DN-CN2\/C0PCX)/Y+FM@Z?2Y;Y928?X((EH'0YM% M?)#XD]I+N^$Z*'MM!)HYXO193I?2UU3@!3#39RC9V%PP TT^V: M5>M@!_P$@8O>]#Y\%3;D'F/,TRZK>JW4$K/#+UQ)W L2=KI-4974MH M.JC1%:SO*:AF *[1_$!$)KF8E$IJVO.7+[",TZD5>SMI ZN1DK)'3WLH*5W M@]ZUDJNCT?B[W)&BG*R+>@GA8W8[6##" (G4\E4>CXU%6LPK"3NFV6PLR8W#. MNK3S\[5482YU<\764N.,':XKJ^E2 NVUQ"A9)A0L+$ITO,&4&/7NI#!+;W-A MTTC'3$3R!.#:911D_IM]=VAEU+89;.*??&(O[!Y*_!MUJ M93]!0RN,XFO"VX"^LP#?*^DPYEH<0F^T]K$>=$VY K'L&@0$P&O$ HUK4W=6 MWVAA_;.T#):0H>CF!F3F!CJ44)7IQ8=B"J5=1JT2!Y [!BEYMWYR*CF>//#% MTDSF7S0+;D JS4I55=T+[7;:AT%F4W](?"VS"Z'/0[Z)U$T5:8OU^ELB7O4E M4$YRJEZ%#GKWG70QM61>P%N45=E'"'F/F?6,S!HKD#!EH7UD%Z*B_LEA>F M"%@'8MHF'\/&3/:9>/;JM$TM\F4]5[ZBJ[BJ:%^IL8;CU#;^>D5!ZB$0O>*_MK2EWHU1JF/70U[YP8=RI89$]E^[@>ZXQ[0!P2/,>DH MVQ?3+?ET+9S;&<#INPN18RX9AY? 6//5&4^K&'1N*BER8!@&5]Q?W<-0.!&Q MF+.&[Q=7_=K=XV>]J.(] D0UWPUNT=W>NI;\7K^$OC3E^+29,.D?ATKJ&2.Q$"WM2G:,NB@ M+2RJGU'2_1R6QI'3_1R6-"CS^[,&C@O:9+KD*?'VB]K/+WIPZ;)W=%?+!"38H M^CR]LIG*3]19?A'7C>7VK9743PM:RB[Z@Q2_:,:AB9 MW9217]S!(> 2QWYS+N M)'#P&$+Y$'TX/X'EX"\,7RLS]QQ^TP7NFH"F)SF#ZJMR[:"7[*_?]%F^@=5B M7#MHM7#- \%F]WWU!LSLZ"LH[]$DLM7Q)U]Q$V_8QWZ2>F'LMU;6/1W='FZ>@ M!(5F[A>\5=W]LI8"\VY+#9Y1@7Q\ZMWA">^E0=3°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lOYU%U"OJ:Y4T%C$ I$9H@^#C6@N'J1%)2/J#3E"BX_"NS!]^ M;"*

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

6K/^OP7UY]U7%,U[IU%/S5DD0H1]_Q8%Q-D\(DL59._ M5FK8(1]0&^%K[#N@2QVSW'7;WI0Q /SD]T>BA&TDKD+1]-N'&+_ P'];?0*V M#-\^)#1UY6*K=D${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|RS'\1#UH],,:XF$ZSTX/L& DKVAIWWS=UWI.$=B%P<(X*>Y ?<.+PE,[G M64$(%!:726ZB":$5L:P:8@76O:%D=QO&SI^P%D0/L9Y5B;[*D0O\|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

&%6!S,G0^_9.WM"H^[A(J1Y]GC&Z&Y0^'S)NO7@_?X_MR7R0!"B"_"[-[I0G1M:C(@S|R&)'I)4;++W9OD.\Y%WGZ9+9'-^#5'M'A[_*
*M.IP"AXJH[K@O+H@1A#WKO9H;<{8K:?1)-T.+%X*H%_K85%8WM^^;@V!!3V MY9&9:X;&MB&_]%8% 6&B;K XC01IAPBWXV()JH;%*
<0X\38BNAP76^V-%E?\43>Q7E(]/8/KB@%N$OW(&!_MN!&A[,67,YWF<5QR&)_(K:GR?0&Y@@9Q?X&_(1XBE_)DIF2>OQ4)_$>[^B*
*M,I:6M_2)9CO'BFD"AO,/=O95AZ"'1/$_-E:&A4QJ8%)#8UDQQPE12&A,MXR- M/>_MNN]"PG+/:!+'?-%XB('@IE'/DONJL<7#8B5'BB5O&IO%PGSD`-
*OZBE. MLTW,@\4".DGQWA_C.CGQ.S%!\9AP&?&AN2T>+4C2B8$S0-"QJ[A0"-QZZH-"16N!"PA0:NN_K+=$A M&I,Z7KB#8"K8QH!C1Z>D#. L?
*C&AI#N(0!(T.J)%Z##1'1_B"0NM\2",.) 7 M7$^JC2@6DBTO\HS;$? MAU4YN8EP)5H$"]9//Z("!3C3XJ:H]W.":-ULI"TD:(4 $^,'%0$.P68S@B5=
*M)9FH&_WK+EGRBC#^4VE^'%]OO4O98.6_OO[^]>O7;\@V*L@31_SOY*<%^X3_ M/REE]Y5H5ZWS(OD'P^*..9>4'RKD$++XQVQR:;]J4Y.?7"*5
*M1&"^HW']Z1OQZ8_S&IS-B8R9LKHGC0!>D"LA/'SL5K?9L58=`(#!1FDZE@]# M.Q4&++\X,.J$-6J[^17ZZ<;JM=9@(9H_PYJ?7-I_@;^__G?
*SA#XM_^^G'Q4^O M_R@@V#]_>/W3XJ>?7A_X%)$;,A5%N<;RLO;?:+5]>H^^FJ:BU J MH-F)8P0^R%,.
*(0&5L1C.HRXKKJ%2YROVZ!!)B'S+27TG"BOP4VQ&#]HV)Y>^_M3@7L29\(0M /R*LHR>CR,BHRMA:7"I_OV!8E3LQ/R=V(D(_*?<7J/R]W80$] M-
*/=C2_-26R*2!I-\J^IDC6P^=CM.LI^E9!E]Y*/9S&VT@*HT2PD)_I,;^!*(M'8=Z'VWA.O[T._9$2U9:HZ4T5RB:Y_LNN]A#6@HKMNM(H6\&H>^F+

+,UX;H0S<^6XF3PAA:BU;K7:;D9&:DR$2%F.SB6,VLD,,!,:E9\EM5!/=(BH#"E8JMJ !I<\^,Q'
M7K$%S$#@;ML^F*X3$9"HS$7E1UO4SG%W>@H,_&4IF\B"8(L)TPU]W=:<-4 M]++!P&8I&()>U*"AH3&; D[?=*)@(C2=$KKX%Y1YRG3J9)G!IY(6)
*(N4F9&/M@0:=F!.X4>CGZF#>@QTM(]:=D"*8YS;(BH"']'PV0!9P:/RW"3TC0?.OF>T M/#AW/-QK-L=(S0B\S!O=_R@.,S"NBG0F<1IDC_#
*[<%'$'Q;FX$8[GV-'061 M13AV-#9X'+;ACOGU!H)G)S-*>)*1[&)EW)]+%C;OVKQ$:SDH<_]@&&@_%L0TK
*M+P,=]E,;6W"?)V@GRO03]3A*A]X,P2"S^/0L]W/V^C! &7HZ)C3Y>\(,S[/$
*M0,.!'R#6;+QG2G(ANC"U5^2:GVQ8QY[0XO+KW&ZXWZ;]U)@_[X*K'67>!=BU+%G@$!9=,0F@++1T"PQ98TG-CJ3W4(.!9Q,;+TE1K
M!E_72LK4;GV>+=\QXTQST9NSEL;H':PXH/W\H,(<-/4S(T!U]G-QI.N)W#]_M=ZLM5F,OX('>D2(M.RQ88_F59LQ\4R;(^7*39 DW=?
*X$<+U;4PP,VGBC)^,O%Z^R>%HPM$1%>KT1Y/M,$ M6%$ S<9#E)]+.!A#,;)T%"M&$K]6I:P2%[!X^]F!2,X8[X18G%P+H\L\%AU M;-"V?
*PI18+9;OJ$TJNV5U[8*QW;*>QL%_#+&EW'Y%"8?[)R0J'7W)M\EIPJ) M0+6'C&N5NP.#5>]#/BP*WJOM@$7+G?P+_RU."VM=SS-@'?^49WF?_=I4'2=F
*M'GAP^N\ME&H-3B00V_#D2E?C.A\82XWZ'9[#M;'BR7(OLL0)\/&:4810D5%:.M3)"EX+*0,9:!U1P\5$".IT)D]['G839DUAB4S2H M>0;P-BJ3V""5
*1;.,JW,JQ:J!019F"R<#.O6-"6TVFD$!E:=], ^ M&%F0!PY/ODTRLN19 H7R)7]_D/)WB7IKC+FR1NA\5C$@0 VFZA!45A%CQ,N7.V
*D:/!-.UTF^7@U2G6UK2" -,$L: M)QJ7T$$0*QN!(<#'6YHD)H(D53XW=#PH3&.Y6M2L:-:["9@'B3PJ\N=_|:G M%=>NRO=93#
*5=);L$MC#EDTD,%FSG<=C[1G'LCNQZ!XVK2[3**Q:4RZZ*17M M.+3WP@1]Y^8KV,%S-Q<:U*LW/[YT+\5\RICC[TLUU13PT!GXF-^G4ON-J C+ M/B]X?
*L8[*O_KRCV?@##@5?-DT]*[F3Z:*LQ%]D1L&\[Y/=W"RE](($NT*6CUW^OUTI.EDZ6II,1QZG-MZQ@S1;X,)(0V.C<2SOS0="ZN6#1/'WA?K :9A1(-
*X,-57!OQT@NB)(0N2+1B MRSWI1A&W2O#_5&:>K,\9\T:IZ%;VR&9#9%]NHN)O5.9<94L1[9X@/#1#N@<(MC/VQQ?SSQ/K
5[7'R@M_*]J64KA>C6C1[(4+V:XD0+A^!Q,/1"F)MZ<:;H> M-V4S^!E7K]"^Q$=33J/E5/+%C2;/1$OTKXDIB\:!@T +;<)HM4^' *MU9HX,
*M775(!\NTBT$#:]:! ,_R#0MK3'><>EC .V\;\[T:;QT@S'VWF1.GQI O$AQ8 M991:5QJ%PUQS,' (AZ)H6H]I0Z4T"01='DWEPEH3C7R1H A.>(-Y1]E8V:K9
M#AQT39;-&F]%P-1PV:I-!VV7S[JVRUCL8EJIT'=AMEN/S[]SLL6J_)%QMIM MV:Z7UQ=7QJM&).9VK(@AK:2AR_GT>\|:.3<|$C=WLMFH])
H>B1;=6G8%QF) MD01)H6GE#'PDXIFNABHAS2OE#$=2F6_NU,EK,?MU"/;DOM\@N"G#C-1I*<(M@S[!3BE.U[%;UHI_MRL8>_)>7W0>^42?Q3?
*FHTLO7."^W[!#5J!NQ#ANH/[M<:8Y2.='$!*92&PBT1>R'0Z_NGJ6 ',_)G2M>D?)&;%@-U_UWD@2MBUC&I/1 M6%1&$M5>6<1(/N9+6F21S)TE-
*TR.-2_2<_Y84 I?U\XP"]+GC#3/ 3(Z^S2(MYV&@!YB8+%3+6I")-DLX=AOUE'1"(SU-0."1.'?6T!++\Y+5<7(Z),21(38^T!'$Z ML^
*)X"1X>#_P;;LM^Y/6V/Q:^7&^15!/RNJW)C!O*R%T]NTAMG]'WT5Y\?X<%47D/Z MSNG=1@A==`XC?%*8XZ7YCE"N1YU:O+2?>8'9V!
*M$#HWX2&V]V&##E@HF1^!DTW1F)DEU)PRZG4>W.6F>Q74V@]/DPZ?#O.?(ED$@ MR[N;&Y3&7>^N)K!N.R5TYNTCN/]9 WH#=_/ILO!F.?\G,?
*1^)AXS@6\NZU M;GF?&S)KA>0/AY+?TK_ODC*IZ!TMGI*8RKFZI7'^F DJPC.:D@IG'Q8RVA,W5TA ,M&]+5(2B?>: ,EBJU29J@#6]YDIGF](64*[DI\E52
*M63I"J !PGF3(IFK[W;<@UGHXO+;F]$$]$?;/NA?]35[(F]:#9SV?V*SP=O!Y MFLK^*+*?"+ 5>,@Z(0:&[.5! M.!(16'B*@NP>RF291,6>+XMU_1-;01
S/!BN83H:94)&$:E[-P8$U/K!_L(MBG\H?'^*-NS/>[97+".1)&NM!.*#"*A3WF+UE,N)!:-EGFRYU&V!*TB&/#TDN MM.CUSS^^%IK$/_F!SJ*NOK)X0OO\U
AU>AUQ,,P5P@ RVZ^_S,,=7V9TEQ)6 M7C1/3=F^HA2UA9,]8$V\B1C2PO^TE-D?>=-SOO]?XCX[_MY0SF=9H?)U&<7 M^NWL,;R#]
*]C,0P+G9^2)5V^W7\NZ?(J:YO5GC.^B2WF8Y6KR,(@;;P&RGV M09^_0"HPO2]'LJG=/XF(MR'%TVZ_Y=288_F.=\V7.XIXJLQ/-@MB!E8BYE>; M-
*#.QHY8$<%WIWJ$Y/_',XB2EO2:$[_DT=C_/4$BNO";>.N,UUT3CP%]M32](MIO11.Q0/6=K!R. 0BW_]8CT5W(P6[8RVC6#9I_SOF$_F3L[?#!/L(7HCKOO
*M;;%),A&X7J\^\,O*3WG&YT 7B7FA 6TR D1J=QT>.'#;$&_FAL]WR7?R&"W+ MLS.A85%7.)Y]_"BN:V2_!K9AJ3KZ_-M47%G7MSKTZS8I#K[B\% ;F?
&SHMQ9 MD>N,.CD>D4$@04_@!?^;2;IW!VFCQ228_&?M/NA:FP$U8.\,P+Q)?WVY_4A M2MT+SLZS[;+PFRGN2"X=:1HGRL(+D@UURLD[?
H@4)X(C]G=^]_GV9(Y\;)* M_F$S%#]4.+,)$4TU(A\\$)/R9VR@A"HJS[NHD44;%Q4=V+ FDE"(%2DX.&SM
*M*GNB,@IJFV6H@O%&EF7,8R$#YV"&"#E(JO1!ALN2].?.T+E0=TZU MZ)).2$L%0_[BL=)"K[G]SI+*:5J=9>XX"\A+G"AHK97UA]L8'6TS#V-,MH
*M_1#BVX8$;Q2]F&':/P#+6?'1(E^L^>:Y/#C6+4M:E2)(2)/H(4DQ7&H-13V/ MQ4)>WM*8)D]\$; ^EHA;U351PAKWGS$T(D\7ZBFVW7!<5)!;LQZ;O)3?
42$>. MEVJ0!F\/ADG1RZ8^71I("N=(X4O;WF&4D'[NKG(8MUT%):[S+UGB5^J0%W?)M'ON7 MK%3*#9M_'DD"RQV5B1G\,S;",LV+I7C:6
*GN2**P!W4_..W4M=ZN(4>N^,V1 MD%:E2%]2B@.$O4.:=B)?I2=R=3.$+#=,>:-D^8ZN:%097U-<9I)AC3G(N[R
M7A;\B&$*74+$MX.:=H,E[KEOD\=U=;WZS&31&>](&F@B&3]A+2&,G0"F MV,6'T^&"PV,L>'*XV,A+*D)7%CD4V^\1:)5E9-'FG&>]+(U3\01.9ZP9=2L
*M,<[9!#$BJ[%I^)ALS2'4WWEEC83$OK13T6P[MNM6[^RYDDC(I$Q*W=C#WA:,NB,+DS< MPP.=U"D7LN(,AGD)(? 2BCGH# $?&WGQANF*-
*LQLC7D5I39KG$1DYX-EE*8I M4^$GJ+MB)83.5#W$]C!9"Q5,IN\MD,]2$6X(H]QE,-@N'=5>25FPT=5?I)ZF\ M4GG\]UU24"8U+
*].UOV&2\.791@@!P(]WP6+V*N)Z8\-4S UD;YBN M4!/@%[@U"=+06!!!92'./UI"X%E*OV18>J9QW&GR:;2%*0BTA3#A/$0 ,*6T\J=%D+
*MC=)0#UW1Q_:%9E?RWM>-Z7$1+9PVX:QKI@X1QW)IYLQK>S0R9VI#'8 ADB
*ML:HVXFRST/,NS)U\C"K.VOYZ%6)]X73P+)/>0ML62R<1%$NF)Y<^"R=?-QI: M7+M/:;QC%\^QXM=("5H[]M]H'[U3?QE'2,<=\2$_,IKNJ
*CG:6^8R.*T=ZN* MO&M$UAT3H334\TD69?$$9[]60N@.UT-L#P.V4,%DR$XV0PVZ)?B2SG[#9^'P M['25BHWN[+?NRM&TS>7M-
*%W[53T*_#;5)HIN=ZJ#:]V4FADR[T7;WBAMXV.! MAF8+&BX3%TDT:"9)(U)L%>GDV\Y&F.O5A>@P+23TB.<->#BVE5:A3-M(+1+X
*MMM'"E6.;]'8/E[C2NA!M"L<+UYC3]^9 5>V/CL>ZA$#76_X2LKS\2HLX8:NP MSVY9CX?#NJQ"&0]I=$C@UF7ARG4((Q;J&I6TN(B,:
*[QLM(86]Y>0,Z_E%%ORF1D7M1UNNJ6)#*D+6E\5;0- MW7D;XB*).9AT&KLL@8YT_7?!1V^C7\;YSG'G.LC/7$C^_SR'XHD%\L*3-5Z$?W&>+?L?*)
*WHJ3'X?N!RZ]U!W7VAZBO>K5JCS>IOM&BU!>$!_\&$? M0W)$-*^^%J3EBS2,$H[?YL5ZT,D=XLOS;S.[]WE=CJPA=IE9=V3S38^/JR!112A_W[^J
*M*YZ=8D;NJJBH<,_) WU,,M%OW3TS!VEWM]MNY=XY2IM6#5==AWA'!H$W-F!# MO# !>QWR_%!A6N:%\#:L,Z=@*[U$%)X&@@FE)2W_4GS9+
<1%9\T!,C#KB,!-FS\)X3 3;5(V7U>$'&=RYLZR.? M=$<'1<=D*[^#,D.PE]M+++OZ^7M5'VE':]BES9=Y.1!NP]=Z4D]-KRS<%89B6?=-Q/CR"XX]'
*M1.#)*W^_W95)1DNY47P:E4DIGZ!V8\!:3L/?.UK&1;*MYT PRI^>=FS>TZ_5 MV]2&$)Q-C!=;-8!P$B#:/I;-@6]WRJQ0,BLV^<+I$4$0>G,YV12\+.NN
*MR_6R7>X->Z(4)W:B,G?'R?G"S'_M!U%2_!:E._]N/>]T^7<["IRQ^8BBFI@-'L2PW QY""$T5<,Y,2*HD8\TXK0V
*MUMM&L".N>TNC"@L\KH.LGA"NLZM[L(84#FX\U>N+0#&[9S:!5^1_"Z2NVPPXY M)%5P<*G40!B76K4(:%3K@"-?]>)H1. !ZYC.(;N"4@<.KN71&H):$=
*LD*Y M3%D"%:P3QID>733&R'7:E=_0[:+7.5QY8V*((#UQ@+I9^@K3=]JT(9S41@(X M\RPUNY&;Z^9W^5 M_ 5!GED#SCD& CQ^F&W:>D<5DX\":$T9
*M/Z$..LK8D:!JROAPI:N[HLFV%=55OL>R333*YK?YW%1B:T(8\ )Q?*7BNWC1 SU*7=DX5@S0 M,F\N00XJN9G H8JUV?
*DQMJR_1&6K,XS*VLY&C'HLFE-G-#2W^./(@:>[CMV M-G2YP*&(!.%Q_&FJTVGY:/)&>339*+1"$>E",?ED(#+P#[0L]9(OX%@ES.!P
*M)NH20;5!$RR(D=F9&2B.: F/0ET^R,)0[?,5VV&(%0-:::R"#/5&"PZH.A9^ M--K#,19$X"QZKZ90G&KH)7(=;3BQL&F8]3##@8)(TUS' M0W.&(9F\9CNX
MB+^DD/[5%<.ZD 5SB7.4-],&(#J9F?)]&TMFM0[5*^_1@H&O^3S8Y%J[X@+ M#X'@K$#/KJKU?0@0+=>Q,/CQ)1"6F["ZSLYG7M?<,_-
*QB('AOLLHB"$7\1 < M.JE0SX]!>WAA25G,B2.0O)!5_7&$?(HHKCA/#PI>.D5+NJ9,6 \,LB28AA%C M^2^A,7BB-='2A3=G8"NM5.Y/>47]#Q\#\ '=5*B0/:?
*EBPSCPL*X,S@T3'"=-M-!+!6E7'K>A#UC9)J9NJB#9_8LEXX&U4FI8KCFCP6*)P!C?-=*A&>1Q%$$N= M@N5A(0-
*N+'4W(94HEOA6WRM(S8A^N^]@;J'/GZ-BZ1<-'TT?0^2U!23I(^TC MB0/Y9-P/I2:FKZH_Z'TXU+'4/.42]H<1MNXBX_D#/M/M&Z>?-(>?"?M8<2D
MG<91N6;-%&NG=44A %=TV33TO-)1U.%<483L3TT*_/XW \/MO($WF?>6?) M[FH],GE3->]"+7%2/D_L7+,>VYTR=_METFZX_?
*N_IELEDI7:YGOQ:/T79-"X5#N?W.;J<9!,,!I33I3_%G6($X*/< MZ408)O\KD)5F/0UMV.TZ->FJKFR:^4+?SQ/6:*$-Q
*MI&8PWK894YK+D7/F.L"=CCS@*ZN)IZCW[&HBVC#OL"9EWLL=C,(S/,>[_TPS M!A*&N[;'%G@\@;AUTVL$1A&*.
*[.&=,LQ..SN6(K(KP5;R,8F>_*E_B\>'0^1AS9@P*WU9'>Q M@_XS>_F_SG9ZGLB +?2"Q.NUS?/"A&F5%\#:L#U>TP"N0T=L44>)^CF+=LND
M$OV9V4C)INFG'J5]/_4YZM9?;K9IOJ?TEE8T$PT\'\I8L9M5$"90#?LZPP=I M]GYHLUG3,H]W_*A;_-[C9]V@9\HM ;.KJ.O M97FQ#2-T'H 4C0CD%@,8,X8
*MF\V/'"]Q@TQ:,"+1$;F0&:7$UYC(M5([<'U)K*NRU8$-(V)QC57D:>2"&SG M&-&4QH3:)NP\TZW^UYYPWN=8?[N#:9T(;_?\MI-?:^VB]"-OELMX$7-
*O79HG M(]T:D\V'>V"?C1%N+5^(M8'BG^_IH01VZ5109:]D.!H!W$W% ,28T$%!'-- M2WM]<[TB>K?W=D\4XJ2ACL<=GF9^0A4%2>NZ\[*D55DW
EM>9[><\8%OV+O MYMW-SIL,@@9W@2)K>]YYTH!M@Q?$I*4SWH)(2DV_N"5AL71+K&Y*C\;<)YX&
*M)2'"$Y"QLFEF(*K+BD_0DFNGQ+@ML?]C,R@,G/DMP)!EZ7!VG DW<=RF-6VZ*.M)*;W^644K_E3__;XQ2-"FH@R5)@TZ<1TL=(D9_$#I@GY'T9-
VHA).9[C%T!5 ME/#+(U+E)&IYX'!5QP79QX!%57/,7>-96&35D>?_4@8@ M8@1RGQ, ^AJS=<=V>_N)QNJ>;+:X4XY1H5F=&8]!73YEZ1:W]
*(GFK&%B'W] MY+=7G8(LM:L^?DJ&/G@\300.^%CF/;WOT""B9B"3:3"/3:+E,A$X#*:0S)"H MY@;<_TX^=8KS';K;ECKAY$E-
GS0#8'6[LTV20ZF>^20=J@S2/B:CNY>@V,/Z MB^75J01!?Y+CNI@,822=JX&7Z7[
MQ@_NO6[6CZ$JZ:^I^'N0OL,,FBJ[WOQZ5N2?]$N]RPHKW+R0,E-E"P7"&^# MIY^3]/N*G[RDG +9UH5A1-
*I@QC0Q8LJ8"MGS=LX$*+3I,Q:$/_0S;P.TI E;-M!>B;J184R!0MO.@:12R0KKEAHH@"2KV5LK.'=JTL9+$E[D+8BHG+8KH0H\DL
*MO6.Q11)30^4YY0[DE@4+CUGR#[J\H462RV)2_M'WY.-AB-%GFD1])#_Q8,#Q M_BS2A%9O6S2=#F4(7'<7X&,LR/D&U^TDV!1V>XE2%()[&!2":WP?
>8Y$J=1 M62:K1/1'[@'+BOE#&5 P(K4_S#.Y]^!T"KIFZ/S5CJTGX7]F.-E M&'SBU-,V3RD7)%YP6C%.6+<$I4.<>S8[3[C-Q7.<*"7ME';9L@O"/%K)OF>3
*M*ITE3ZO;R#;#^:YB_C!;LH&G\\O6J]]''!#(<@GM[UA(O%78D_UDE=0RA;PY=B IGT0!>$XW-] M[7T,9*']B[@(DW@)?9\A/38_D/@Q<;10EN MO3]"
*<'5!'T$&9,4>S>= B04ETI Z;PX+/G@ MD+S=UZGU?)ORO[!_W]$LWI]_34QE5KPP$;P3<0NF?1IB1H-]#>+B;_C*M0,G M+3SYPC&
;UNU.NDD>I=OHN0P' O"1!I;L&TNF=&@!4]%U^^NB=Q&8I?V3XJ M^D@W#[0(F) A*B[],XGF4L!#/#0>@^SV1>) ;]RGE@N)1;W=B\=Z
M%_P40>/A?FU]4AA[:'(ASZ?'=? M"*'WW;FQ-0BR(0"6W'2*T2N_:82&*<7I8&=87. ^.-!B]$D8XHIMP<;Z_^YY4 MC4#==0)PA?
BG\&I7^_SXBY*Z3OZ4'4"G6_RHN+G./PJ6?@(PVR$DP&L^#Y2 MY%YE]T .,!7<1S$Y/)=G:(H!+DA+]VR5%V>0R?%CEIH?X1?E3#2C_^/%/>CKLXKK)
*<\6 8:^=CL\\GO[6 =_7A'48+SG4<(KKK1 M$61 /.IH/J2)?&IK0!\3338/G.12D$==.JB?5A34A=@PA="';L(;.'!5NH M8#)@)YM3V.^"U"1Q6F_X'/
*W_*1:1QG),TKV-"I>C $[D]!'TGH19FQ/;!]% M"+LQ.S.^1]ES1_7EF+1S)GXM:,0&[!LV>=A5)&WMO7K.Q<=H#R<<4;8/(L8# M"5L,[<9"=@AQ?
*(2,)R(>+:7'MA5.9\]\@VF@M'(K %/.?R##'A\3AN=<01 MW4XC,+;0UE[^0R3A->V/F[,;R@NS]+EO:7P*8@ $;&EO9[W4RUD+"M#"VL#*\O.3 =2M/
*M(L"Q9/T?*0:2!?7MOOWS?R:T8+JWWG^@3TR%O=XS6I$1++(5>XAE>.EHPH9\] M.EFS.&72XDB??/X;KD>1ZA/AH9S!Y1(L-!#H9XBPSA?
*L)@)XGK+:.0Q46A3/ M"5N)Q"O)4ICA&[^B"CH.!"I\%D2K@$-P6'4S\6.-4R72@@@T\@9+B!$N5"T M/IOX(=@F?L!I$S^$V<0/R&SBAY$V\0-FF[_+50N
*SR9^#+:)'W':Q{]A-O$C M,IOX<:1-_(C9)NQ"U0(@L8DC#J(^)!F]JNC&N5>=9@P$=C?E9$U]PML.\&)/ M>0\DL'H#.8S8D*CM YN1>"UHR_FG&

*(\X0,2,2(;+_+/-GTG<6874;EF,\+_MPSNF/D4IW_Z]I<2'#NQD\\0'S8$6'YL5681T&Y0&&9%M&;GS-S/UZ1WIR*TN4!Q%>L#*

*MOO9LGP1ZIP#;40"O0#U$Z5V$6N!AKD.=#-E>=*K5T+ L3\=)U+U1!5ZA9'SJ MOR)9X $S EU"]!+_3,*

P^7UV;O2U)H&6#^>+]4!9$)39NM_S'M1*"SU+1H ! M%D[MK:[J0IPQ9]<9ZHVN901%3JOV43$I'+V4?"<.>O,%K.MTX2H^^2>_56R%8/W#[0>E =3 ?3&XP3N^>@P$C">>PR/LRCY%#D"CPI)+G3W M]<_OA;ZRS_Y71DIS\1A6T*N\V,B^B5M:5$R_^'EDE9-8'4$H:2K'(%$SR/?S MQB$ZHSQ>^(N!7#4Z:?&A;\).(B3P@=F.^[NK[#R.>7])IG.7994P1:1O]SQV ML(1G?JB QV0!HO5.R#SP8 [`O!D;Z]% Y0V5.V328).'/>'X**(WLY"<16NB MIA\J1H4,H4\9"Q,(1>U.J+(Q:S(,W"&5-.,TN7[O/B<+6EQ0]E< MLMC@D>VP>&/@E'(O:]U5C"4&]+1'B=]3XU&48!3[""%8U,4!-C+34" QVR(I3*

*M(QU!WIJV(PD=^R";"EC[KUN8WD1%M5=VF9; R(H!9\D>@JCF:@$'L4DG/YKM ME2QH+%"(@H,BT#'(8XUP'#CH=,L1U M,F2'!SH/\A&B/06R<.=_;BY&G?B4W*Z9%L3AC_F&2&G0"$ #K(3G0GE0;F$ ME&_WZC?AD8J6 +K%Q2*FQT]CP<:T[!C9,ZY\;2\YKMR3)_*

USTNNUBF:NU">;D&FUG0G/.VH$2#CM? M&.A0"+;A/=QH'? &E2_?X%;/! RG? M >G.(7.M;C1?G/ZW[X\|\/ 3A1V%EE<1L?5'JF\#Y%LZO-H@:;?

OX&P\#I8.O M8'YG^W&7Z9<&L^6/299L=AOCKWWP/,/GPN(V&@{]] M=F?.PGVB2D[PIQWGYWIU4^3+75R5]_E;>I%O-K3@03=O[J$[;SZ&&GRV[L@)

MT&7P!I)"D=4[BN?ARYLU)9E YJD-VO]=7_8\4!+W-3)$'$OY5S)="\19/M. M,RG&5/P%^=.3.U4U_KO]$D>0%3S,=G_5TXY3^[O.6^82LNHGVOO-"IF&*

BLR3 M&41SNJT#/'P^2LN@UB%%&[Y9XPJWDSAD6R.1@L:4D7UYSLA/>HOGJ0F0A@)& M%^,GY.>#'_64CN.FH-LH6=

*[2DO+ZJG>T>$IB6O(:U4GV&"*KBQ(RM^(GN-/+ MV,G@M;.*<)&5))#Z75V6YH\N;@D5?-[00GQG2*

*M52SP<*E+3B'4]"4C,$@*DX,;?:)Z220"WRTP%/ZPCH@O@'.91@J3< 2V&^2B M?)MD9,F-K"CYJPGY5N*[^5_9=)%!__.R?*

K1XO;K>5645B8V)Y%OG'R8@BN] MSA'387C4,X(BEI<_HUG7KNVE5'IV]-\DXS3G'J;G0202YA#7L4#>C5?3P_%V M:+J9.GR0HVXV#KYC4W/338TR@*

0$/>&=:WH4@7OZ)%5I+%=(O'YMM7^?9%$6 M\S+N8E>L$!D ".36K&RWKDH+!>=^+.PXCBBHP"2K!A7+81((&%)"TPD-*39*

*MCF"_G7*0?!5:B,>FS!:N'}+D46A6T'6NBQ**8X)0P?US5+1DL!PAA/'KRDWI M4$G>X;ZXX\M14^&7D:+,D$(2S['#D9/PR:4+I]QMW11TD^PV-*

*U&RO,YX&DV> MW55Y_+>08,I_]E>RB6L<^MD(H!OIV3GU!"%;"4R$=>#^1-3UA6OSOTDJG.S M[V-!CY2YY T6]Z2I#U?O13QEB_*

*M147"KW@NF&=,F*H)4[C*XG2WI,NK3'G3+XZ\0MQW,&ED4=C(J7&&98%T\<5I MHP1P.,6GFB8S!(4H26JJO-1BI10HDL>IPEF^E)!NFEFSQ'C- *0WKE2IE"M M\)21PCV33-1QVD5"KHNO!/-=O26;F2Y)&U@:[A!\,2%K!X1(%R_H(0'(E"- M"6 ,.(4;!.Z"M-B&K=<"]D1H"ED';H6T_C=9:G^>/^/&M3*

*M|^KRY)8V [ZH4+%(F&A=K.&'!QA+A#!H*SQ7K6FO^!Q;0785B:L/GVY(U=(7 M]8':U,NZY0!81'"4[*;=.B$X7?YLTU!?@R5Z8Z3T^LGG,.=O$^^*LOK*

8I#B MIL@?BVBCOG<22G:]Y?_K="XC"0&YFJ/$;AW/"IP;N@(=L.=DAB,:2X_XMG* MX7JOX21L+@:$]E%33HR46Q C-34R(S]) M;A0MR%CN".'[X=P(0L*

1W6B.QP9U69Z=O0RG-_\2/$_M>*_*,\WRUR$]\)\ M8=Y$_N\(8J#!WA0><#0EZ)#OA#ZP7O1?CA.<>H;J">!N\,A&@)//!@Y'>+!.

M"AG<7A<3N<.C20(YQ8FFHG6-1]#&3D^85X*2M?_^25.N+75GES(%\2**')$VJ M?9ON$>>/F.;TZU@B*U^P\35M?CUHP#:VC>$16,?*

*6_+,J)"&S(*TA'C2DB!% M.EI(&OD>)7B 5/ 6.F8BT-I?L+GALZZQQH39< PRO:.K6A1TV;@!6'MAT37O M,+J_83Q6Y]F2/TG<\D#JI?*

*Z>#6MI$.F%"6""2W+//$YZV?5Z6=,,;F%/H'Y?*VA#2"Q.A_@T%\]*_#@V7_AWR%:)_,S;" M_B ?/^3%ON74? 9I 0;.9#O9;_?91LB3JHD/*T/-*

:.%)BX#B&.H(06B#,,\[MP\UVQUAON6&>)>QJN>HL*7E>Y"\[O0[T%4AY^.=",;WB^_*DB6\EHJ+_/ &] MP45A#,*

*<+U]J$R#HO:US8N./[KLB2;E=0)LW[Y"O_J[0V7;4AP$49;C'4X,(_M#1)3N-@9YH0T"$*1&A1H*YE(G%6- FL7'VA4TG6>+J\VVR)_DJ]]K89AQ8"S M#*

]!5-.P@(/8AI.?81#28! 5!8MQ'"-/HJ" GRF65;&+Y:-I<3-)2[MYV%% M3Q2=HAP<!KAHZOQ:Y&7P@6*-A/-1*

*MIR>.US&.P,!U@J.PI*FD(Y$61*")0*5%7!"!"FPT1\DE!**=0(]6@4YB.^=Q MO-OL4OZ^_QU/@HH3D=/_DXI_X.)>+{)BZI.53&*;YBNZ/44Z1:[E2T*

M06Q\6N8'5J.0)RK]!6E'$:ECL&+C?5\R+O1&;R'C_+R21KMN?:'/1]%"*&\]09ZPA@'`]-XKIM;8/L'&M\P;V MO-?*

*&C!YW]'VT=K*M8Y04G)F+=50\TNOLEL9I5);)*]%+<;=DBBW]4.$T,D0T M51=|\$"TT)^Q@?YUJ$3B\A*.*K:\/H2..Z>1,!:XL'9UN=FF^9[26RH6J":!*

M):'EQ:XHS&D!QZ<17D+I9J3PGECRY&I:7K_'."HE(%,P%J7&!K6BL;"R@ M*G9,)%KC\QS^+S0PGMOA05U4%'N>O"Y+44](_6G':U*

MO3C$LF.604ANH1XO3#BEC0]H:'6%V_@END.-/2 G=Y<$^#_JX.?;16BOUN^_M8KMBIMM1^IZZH@P7$N@QE(!HCH#%NO$>(`5W?7R8Z[*

JVB^)1<_%DZC2M!X6LWF]FO5^L?P@'5)O? MQ(CFV:<"2FK8>76;N>(D7'UYFUM] !$N9[ZJH]":,B_BU]3++_M1X#3FZFH4BX.]B[RLFLYX>).-FX3)--

*DO&O;\2TU*UI?>9D+&4D3N"XB3'Z MC'%DX5W,,7P[/%(D"OK+!V],O->NL1F =",LB!RC:0P-WCEDOFE:=FF#SWGQ MMU5>('8>5_4A*/\[?*[ZV"B=@$Y*

*3T-74;$9\Y"W8(-M2(A_XK7'8$EQ',KV M>%)E8$%*)9+NKU?LXWQ#KPO^I*N@.\9U\D3EA_PH,UGW_IQB/*@, 5 M$^[B-5NY4W]]LOBB\IY?"1I^A2 **

<-8U0E#5: +006PAF#^7BC-P\D7 VMH MCR_.5MVLBNUA+?5DG%A(_+Q9(/+']+ >U\33PXMX_FC* K'<$8.3,=:+L8"*

*M#Z=83B%4E3(^RB3@YOA91A7'+;F]M5IDA(PDR5 WM$GML:S7\WZHM.(#9_L M:!! E^>X J:V*CEQ9C.2%IP+.\VP^3HV.=;W;=UF]8OS%M!?*

L+Q(BNH)?P@6B>ZWB+AVTQ/V#,)VZ,ZK:G#)M\X?A$$, 42-;LW>9I^CXO MG]/"5%77B85$"\T"N>X$%11XW3/QY'=32+YP1%)C0COR*02+X?*

WX3;07Q3(8 MVSW>#%;P0&?Z#E$Z#W(,\#"/+^S,C/,+*K!1?9V#P'\86R@)!=1N>;YZ C* MM/371CGTY[6,-J!*

*(5H@#ULUQB82#7PMZC/@=R6+R^:"L([R\;)YCE)XO M_]^NK+@UO@E8[73(2*S!*9XK;!IBPEN,@S6_(&I!:GS2$X<135UH)#5-,VL]\MH#N& ZF>: M&-*

%4Z.&@_&ZB5AOGJ?)X;2F+2M$4]]J.2]@_?O\8?4TVNXU6-33?GUX?C$QR M)1A\>=)?WC#ZX.>N8:#O#@+9A?

9<94GI5NP2&2/HC3K)5M]\HTY7HE6S'> MYR)?QG0L&T@#TM>-$+;O! ,('G'8 ZUAY2ZR:C54XD M,?*

*%;0LH645I:4E3.99I98BJB+GK"UKGC[9F7M225S;)C^EEU(MEW^?%'8UW!=\#T2U_^W$P M*YXX4)V-/(7I&APY$.!*_AQ9MEOQ'*_P:]^RAJ55P?*

*EN%!% (Z6Z:*3J4$E M-2YH2Z<9?RM\"SSW:$S6NCME@)<\1,2U>.O%KJ|'KZ'S!,Q-3]?F3OS=SO2XPA\=EVW91'0&PQI<-'9F9BX@Z.V: M=[-*

*X[X&2FRB9NVEW7D5I<)#K+ ^L]IT]VV3(I8UZBB"[;Y VR9#MT]@U?^/KF M.?-M_1,M'O(1H7VHU+S0R32I*H:(_2I+JB1*/S+:?*

*MT[W;QF/M_QM6];G6Q>G M^&("1>]A@K4QO!\:7"0?PM^PFK-$)AN)31[X.B94C&T/#PP(*JR?1, :FW!T MOMT7-A[X2L@8_V2_(L(17.Z,?*

*14WH<8LN#%6_POYW](#^Q)69W@:,_P%!_A M;F/T;%P?'-=/8.+&]LU=K[;S-,V?^2.@*X^@P!,1K(ES@%A*'VT^^]$'F97:01*

*.3"7>N"H9O$<*80\GL/QOJ,OPE]H\KBNZ/*]",ZM)Y*]03R+:E&+ M5E0LA^Q62=_51Y*W447M)4'#R2"U8(O(WA:LH8'@HU,CK#@AA;AQ!9("G9. M)/W*

*AI,L+D3B2922A[PH\F?;&]$C=]F7995L^-O0$:?7_KA >]50X=KMJB\B MW(XUC,-A=94& ,;@3T'DWKI).#S*OD:U@<7Q8YZFG]$UF"$)$=K)-,H$K*

.>&YOH_U$5,#1J/1 -(MNM[8E/R &:>V=XD=N/3> M6X[: $CJE -@6]>U.?Z0EWY'DXE',6[,^/()MF(XA]Y9+:53-T5!M

MK;PD4@3(5Z3@>ZJS?'6VXYG\O$,WFCI-]S2+LHJQ6^1/U':4[\!!4;')+(RA M;-,0 ;IVDXDC>P$GB454-&";&2-2+47202KW8 6-:?(D&@X_LR6(,G-:P7>5

*MI7Q77':?V,\S$$ RVL2H.6'?8(1/;_I\"K.D B:#!.Q#/O/YE+EKU MR1/RHFY @]/*DR'=U6N91+&_ <A@CJ-@=Q=67MS1TZDV%ZY,\3 Q1(HT=(8C MXI-*

*Y.+*3#S0MQ9?,X)!9BG81^GF(>EB@3$,;,X;W[PJ\?)F$H3:33A)KA28; M BY-,E=K,D.CT29KY2:3/DU1P,G8B;U*GF3^J+;PC@D(K,>Z@5VEH?H!!&3W*

M="TKFK&6S:^V$;7Q!)&]? B:AN""G%JJ>%Y M!++![Y&//!6E!\Y-$29UP\AC?0APS+|SZR+==RMB/\@ZY_X%^(!W,_J)?JWN*

*MGVGZ1,75N7G(,)8<!69A/[T, MD^;S?_^<'SDM+17\!GP@\!B[K4F@-M<>C]-8*2/W0JS4+CRSE3^\(.-D8QY; M#T6A\T(,5!5ZM(ER(OB-M,-*

R(C/E\^2H5HF@%G.O(T<4WW)G""9%D7H:A-MJB*/M5-_[V9=DQ.8Z6:"I@ MU3O'"]S4\PPE_5GA42[QI;B MDX.4?*

5&B^(#LV]W1;4F*WDBM>>&N\IYN@X'CG>%2/I7OOV>7'Z-T]V2\J-V M1B#9B.R'*,OX;0L;)LF7)7E>TZS]OODP*GAFQ#8O.,M<*UKZ)9M#VJ39K9(LMRF)>3$D_Y4F.6;=,=-"&A"YA/>.BDR$\(5&=DY'V;%*DDB:1!(% M;]4Y]53PW,\=%U.L +0$SI/N"\8;5GME.DE +%EO*MOFA#<.A2#7K6/#G>;&*

M85&]#/!B7H91L8WWD^CV;U&I\&QJEVIKX. TV\BT]M@#(!"]-G QT(P&#I%6 M!

*[..1;===NHQ"AZVZ"ZNSKA_\=*KJ+D)MY_3X9&)3TE[U,2K^1JOKU8KR%K.6 MS#T#)%3ZGI7Q+H=/"P;8R&?*

*AQS>;CZV]59U4PA/Z*E*M*=D(LB2OZ8)E\X(7=M=RY9EQBD0<&1W">\'/.4/MUI\NRNRN_.743;A#F%NW7$I*\[0R_?Y\'7[7;4K*

*MZ%59[O@[LSIEB2X_9V6>+C]O\XPG B>9I6+GQ$. E5.=9;J4PJN3THV0=X(6V6UY#>&.&EQIUU-,BAR%B&%8'"('(G*DIBG]*

MDK"QB!R.M,U>93L:SD@X2.294C8NK&GF#T%@NM5*:>M:*:-'_>OY+0ES3!S M^.2;(H!\!79;OF>]!Y.']>MHI^+48EFT(P@3RH&&"M8[1#PW.WX7P-*

*[38]%SS M8"S-G[F";<@C!R;:FJ;\K%&W0V\'YR73>)9JMA_VO&(\GKU6RY]&-9\0>W .*T+L$, M"N<&7#P-*

*5$0B<.5_8BA\%]8:MUAYH*S["$$X"J_WV9HRQP+K337+SP)VV.Q%G'&5\8+$R1/E?)@/ M5,/P@1;Y,4*VRWX(,EP@$,[E<"?*

ZG).JB&RP"I!I3[C2!HZ9.NPH,$B<1L M:!!&A$@]<@= 6CI$V!^&4IP)9&9V_UHKX"PUPS?;--]3*L;]87.QCDK'HDX0 MLV<910:JDOAXD;NBXN$T*

.N+CV5V1+$'6H]5.Z)M/9KP0\Q':9T6E'^:;EX: M2K79-K2D6S+Y,_SNZD13P%W:'-[KCA9/24QYC?6Z96!1]E$68"!/Y&2_]3=&

M2#BOXF!&"++.^22>XF!\ZAOEDM)4]2\7Y)<4H5R#Z$"UO"B,\&R;KQ9HK#R

M222986=;%I6RJV7_ZG:T[!^_WR=52]!75]DR>4J6NRC5G&E8XYOUZFN3T; M@4ZZNW5P,0S$.:Q8LV^:ER&S'7B$JL5?DFI][P(4]-*

ULKW/+UG07.VUIR"C M"!1)3]!C4IF1X=7/Q_^O!1SQB.8"[F*-=%.^2XI;,R02Q8E\?ZCN[2*6'AL MCD("'4"ELHP1LTM4"<$&3$,)9W-*

X.RMID)8(:.F(6%^AZ@.:+DZX]FI$'OR;_>HK0Q?)K:>,.P> MO]@P7CCX"N97LZ[S\G>;LYCLCDK+OW]SG

M/[S^\;7%C!T84(;L)4AGRE9P0&/VX&NH,;@18/%3X_?D/N<<<$1PBWZA CG, M>FJI8--@@I/!#:D?(^C)=.,%EK-MPDF I*2,Y++D8\A5L/'$& -)BU//P%W]*

M),:\@&&6:SO.JJA.\'!AKHA;1VWT'4M<*.W^.BF63JMG%%%+L M\UVUSHOD'PQ:JF,/'K4YS2<:&.HZ\933VEU-GF)4P&O.TXEG232.NB"Z?G04*

MM62$U;8/0':BT+T .I/7]$TQLJCC>4$B1H%G+M<,#%[)Y;NJK)L"?BP%W+F M!4)]_ZF.3I3AR=L]4>%]%HC@@72_G;*

*(]I>6CA'2<0)ZO0PXU3=F)6QAO26> M[OMKU22+U-'AYM&S=5AGAD5_AG$ &Y?/-6F]CN=3#P+3*GT>*?1.[\SA!'YJ MIW>F<7H+Q>L-*

7!UTG_933F=P!2KD\@FKE2^TZS*)&MGS[!(OU!W)_[GEOY] MEY1)1>LDHQM1H?3-U+^:?:P7Z/9\)F\2UV<;Z&6Y/[O:O!4] NJHGXR\T>5Q7='G^1*

NVL[!\RC;924EO>&F)L4O#E!P@#L"FG^B@ ML&RZX7$&:U/+-\I'E@XG6?/"2\Q$\K%;[2P7I,&(U"R1AB=R8ZW;+>H+RNUK2X7T>9=OJF M#L.#AT?

L;">>XDDVOX%CXW2QDPHW2PPJ&"$*)T2P0BK&BJGY8HA4@>>>|%&> M*+;)\UP7S75Z;QOQ!?I(_XF<]#K$/-S+\H2^\LQ[16[&'ZIOF[TS'[JWWTP*

MK]\M#AE]3O>UYZL3')>BD-_8W]L;C'P#H >T3-5TUR:]-M^B_+QQD%F,_2HQ[MA8=K@1,7<-?[?+@SWMHGZC3.*E[3Y8Z_Q&Z+P<@+&<,$ MIH(-*

]M?UZI;&^6-69_DP07@[D?>_]0Q_2;SC 7HON:]HNNS[/E_I$TWS+&:_] ML?:),O FG.X%"*9]H <-B!YZ\Z4IL"DQQ=]JX#:++O1KT8DE7"H24HD\1YVY*

MD-T0%8WN?Z49VZ&E3+SSY2;)DK+BJ29/M)907]]D-W W@2WV:]EYMK7N4I8Z9)NM6G"[O[^+:18Q M3V,H(FV @ZG\:V6ZJ> ^K!3IY%5\+%T/MJ$'

2DC3[M9AYO?N\C4RNGVAQD/L8Y7K3'_:-CUY M5)5DCIHB1[V84;2Q584Y0@C?5CM;68RXZ9=A2D"@-2<D\[;A"J&IZ7?/^=S

*MNG2%_(MUZ8,IFM"EM[1?LDL_$ *#2Z^>\Y?KTEWS.:U+YVW:_CE\;(35&9WEO=Y%:7]]_SX\5->_956W<'D,4>=X\9#?C-PS"0&WQ&, M&0SO;<%X:*

*<+/$=NQFNQL3IQ]6I$]K3]'V!Z*OX2K@PGG[W/6^K:E\\SU97LP MN1Z\SXOZ(PYG>E%R:B;^"7V==;I/X@"U'/QS>46+B'.ZRCI*Y&7XE('_65UG*

*MR"3W_*DLW-]+*MG_17$L,E_S%=DU$UVW=V6\YJ;>_31G!#S>?%XG\9I4.[]G ME8CVL0^T"T^!7[^\HZLDX_.=547RL.-,\MXF]0]3?(RJ>,UDZWTO"]X:?*

*M)C M",*YU..G076/XZF!N+ICV1WVNI($B8HA6N8LFB9T!6FH]H 633UI;FEMO[I_*

*M);\6>5ER#PCLKV:,]5B=J:V8J:V[LO9I\CRR*EDFZ8[GS=W1>%3\#RD&76$0$S2N:?R%X:RGS#P>2N MS"V/ID%0AT Z#!1/=_3"?(HV^NZ-*

*_FC8[&,HDEO).QQ$FGK(E*^ZL2"?8>)Y MP5^;L?1D9R1<89DW2RKU5C@$9P\F830'A(= M L]F*1[E)1U,&D9$\1)\GZFIH8XLJ1D[. MA/&U)*

*(PH/AG%N7?,W% G_&UL[7U;<^.XDN;[1.Q_X-8^ M)F(]2Y9M]NLCNDS(=]Z'.NRM+;J>\Z^=- D)'&:(M4@*5OGUR\DA))$2! M@B((>9,M2SAEID?$D*

B,_'O__&^[]\.OMI\,D GN7;CK?XY5,4 MSC]???J/O_^/?_GW__GY\W]=/S\:MF]%^"%A@6!&0+;>'/"I3'SUVO3,[X# M"'!W7-:ZA8R^_89P-?KKZ;?#3Z-*

*+X_/GOI(UK,T!U?,\@C0U_.DM_N$F:\[V? MC;.S+U^_# ?#"^/RY_/ASY=7QO1[6NX[&MKGKT+3,D3*_LP:"6P"]]*

*M3HMQE]I/AM^/C_]Z3VPTW$=#*N"#/2KPRB_8]#?_\4P8D9#WP7/8&X0&G_ MMVOPRZ? 6,U=W"CY;@G!_)=/BU?'_XS%-1B=#_*

0_]=M@J8;'T%P:BY0!=S8 MC^>'W0API9\L?_4%__"EI,(7&0-Y"1'ZXH8]&W@(I.A#X+N.C5%Y:,J8Y)^[OR(GW,HCM:SM(Y-W8P;+>]=_DRC M3)-2B+EU

LOU@PB")S-$_T[FUU'@>"# $%KG8/ZG$(0H-X);BK5FW![DLEX MB58K$VZ1_)V%AQ9:R_3"L67YD1>B'<$4\=1R0*5 Q-N33,9W$_X)0O/5!2_ MBJ

*3HDX0!^]-!_YFNA'X#DQ$;)$QI.6ESP,OD7FL+QL)877)G*2P&LPXKB@;J75ESYC5RLG)-J ;!>(*

*MRD.'*R$%RFQ$]AH&0KR/F0+XLD3[.8'%JEBQDU6IK=5)B55]AHNUM%;E;1]Y*

MQ1(EB;>]XZQ>HJ.O:;=E4QTL)3JK:QJHF/+USK*TB(Z1'8K[6!MT;%2]G=R M/!K;MH/_:[H/WMR'*_+E+5)C3J6M0FI7G2Q?*

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{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|;*\=S,-/PFYUL?%34TA(A=6C60X\A M;CH>WJ-/O!F B'0BME,QBJ'A@04^;JFZP>#=6.19M]'6(_N@_)OBHU",*:T?KWA.T2O;[DDI)O\YVLH(46;>2W8KXR??\/,%I"F_V M*:*R7E_%7X\P/:XCJ;2+@D IX3>3K :"6,CH^8GB"825:T"NC%(($)G^E43HMD6\>0NK5,.6T+L)FD/:;?'O M_"=1!_9X@U:H!7B*5]\ 3N8'MZ2L^2]4IE^A7S(MNZ4E0!,,E-X/0X$6[$. M-$)=D)K!^EIR|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{3^ZB#<073QMML#_B'CK),Y=J\0;4 MFK!B,04-J6S/&ZHKM)-D?)&%C1[>_OT!X 9<;V>H;^Q#%E3]]QHMZ8&?9N3V MW"#EI2:O++B6.K0K,2!7@*6$/E$M7?'AI;2T!IC@IZN7FKL\V$)4DX\..3DMX])+W7[JH1?I/4KJZ_""_B>.!V[<349/(IWX+0=%Q>??(A(T4Q-GCNAF(C^[$8 M?XM'JO%?[C)6A M!^QT 4-\BE81V6K?@CEB%,U45UVQQ_*O25Q35S,Z*!2(:!-=Q!ME^3[U5;K6 M$PEH9P3W81<$K9EKMQO\\@JY-W_RXV=8/-K[+&I[N:L7'5O9Z8FRM2J+J04;>|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|[FW M9JCMR3S+5OJE:FG9/%N&:F0Z.9+T#V'"SZ+>(^>0F68Y_YBV<,%6E$0;O]!+ MMBP2Z.\:2EP+ ^N%6I107C65Q((>>Y1TI0;>MAN;I;8@0_>_N':NR!T5F8(MKK=X[C&6+)ZJ2N*HLQ6L-I=ZGS",3CFFI^DXQ%-529C5EK8(<"IXT/7RU1PX M2?[P("$=V/<^_($.W'*H(4ENB#S>+5V ;:-N2&]UUC/P%6!B!)PR>.*'FMB M\A+[U(3A-J/]&4LAHX:2Z.EL!11E5._?]{0S%SQF'64Q).H6+F!H?#21CF9MO2P1MZ81M)8FUWF.5;Y/LN9:DPX+YAER/KSZIL#KU9QR8PN<09\>Z\XU M\,#=DSAGDH>WX2%19_ .,,Z-%?>[&C/|")'A_CX1HS MY\EP+N[BP27[A6$ZBH%)B&9YJ'0 MC,"N]PV4@^IW'PW+,\/W'!\^B'T\/2RDGU&;2*1Q..>GM[!KPC'4B94'8 .:4 MC#M=!=@L26#PM5^J'Y-4.N,+ORJ%@FIAEBN_1E\7-%]=SQG%:VHPLO]KJ;X MN#;K?+0HK(2%;C@;*[/'BK!5F5WD)7%QHDO#T3B;8/Q;IQBO=D+++4?<4X2D[MF4^A;T=6&,S\:W#CKU8 XF,W?C"GPC%_L#4E(=DZ,NB>;#+8I]YC(((@_+%& M\O#"]:DE7!=!7*]!{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

%>TR\PZ39T8W&]QH]64;;501WNM,F>=NO?A"[_BW,TM6..P MT@)NN.IH")#Z=!_EB83N]0^>"H@SR8OO MHF7S'/P]]O%K;GF[A(+Y5EPF%MU]\DB\L(8XJ4%P@HV11@M6GOK?@;-8AL >XX#3!5K)L>T]>X*@&7=$ MFSD9/-5D16I*')P*U+ SJ1]YX;,9 G;Z-M%F3A5JO*Q(H=:.V5KF$>TN")T5MCOBJ<4CCK:LA6IK3GT*DW6=!CISLB&E\II32$!TBE*8XT,G"7*![9]KB \2N M^.D@@TUR"A&=XN[R&G+_MM*C'_"=HO)5\GQ#;!]=Z0(58;)3N,A,+-\U7(IY M*E-?@JC=DS)G>>AO ,MXPZRC,7#$Z4X1TXX!N!O$X,AX M\DIDDCB5 1DB,8UQP45]"H5V3+[=0.%7T_'PHCOQL(T))V1'}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|\K?@%*(D+>=:\]++*@D(AK*DPT0!MU=Q^I) M!0+SC;_#@LH#@2$WML"U7T"N@0?FCN68[N3- Y I^--*RRLN>:\\@3J+"XJ_8 M!]X0ARJXQLS!ATO*V:FLF)+";G:,XB93DE,_9 5?=?("ZPA:2S, XP4$)"=9 MD>#215^HKE*H$))IX0#7B."N-P4\JAW'PW+,\/W\!^BF\8.2^5H_#H8CLZ* MAO"V0=W-X"VQ!M @>;/;L[AOPY\:NJ7M'MCWW^7FN:,A!Z"Q(Y?%*5"+|;I M%=<8]=0^D.?=N^5&2'8X=21>>J,PN6\N4L%WSR6C$Z7T3)7,RZ^O6F.#$F;$ MYDX?S=ASO2UO@/4F57L]*@77(T*QQ+ODR$Q6R7NX?.B5#V!555,27,>6,R_2M*MBF$ER>T;$7.MC,3]R&*/FP?/+CRHW]Z/A:*B (WFKP)*.8P8CE;:@D8X"8/VT\#=?@&7'?3UX@8,&/8.FC8C, M7JQS&L@N+RXNB^:QI%$C:=7(-XM(2@C"_V#/VK__?U!+ P04_" ,@F99 MXMJ*=L_< 0 _'18 %0 &=B:6\M,C R-# Y,S!X,3!Q+FAT:>R]:7?JNK(NM_/W^"K_9]]R]UK@ATQT&YFKNH#%]:QP(7SR,+<"X S=TO_Z5;$,@(80DD)C$ MYXP]5S!"EJJ>*E652J6__]]2U[YL&S%-/]Y+W&'_Q<#AF3*BC'ZY[]H+EL] M_??__?1G_QCKF="H:6 U8E]! M6,92Y!$(?D+@=\D[_"X5QV*QH*^,,,.?FL;O39,[XO'+;- S^IH@?C&_2)RD ML?AOBOQ-Q[%FI;&E_^,J,K!$:[69!OP1>AM.)NY(.IYZVIH#UER1 %8V!U@I M]QL3DT,")"DBAC,,':,3DA0;$,-D;$C%4_* @OV(M-_'V(&T@O0RI-^N'1N) MXO2?F['C3'__^C44[<&=:8U^!5]X0[X)&H\&BKEMB3[<2:,NM0*IMFB]M9;_U@MJT)7[U:E5.&@-=C"F&I8B& M]/@KV*?L;'^X^XKX+__+35-EZ<1L(.V]!'Z^&YGS7XH!AP,0.7\YEFC80]/2 M10?2'G9$Q&-X,D81FWYLRWE.)OAPCT3*\[6I$]3.VS;-+3!\D53,+_CMJGR5 M(U1]2A\9*/O$V U''^]V=- M."(FF88#5;_W 3?QYS5%-S\^O=O1W$T\,_?OS;__M]:L:F/+JW\[E98]9SDM2%C2)AC3CG]3^-3Y"[[T%_QZKXVLV%--7/TV M3 .@!LKR-^H-6/Z?BBP#P_L3-JA#!6@IDC_#IG$[?DJ5\>[>-?J.-5NLNRH]RV!0D.. MQ0@2JHC/'&\N6+?\ 3?A"TPY#Y_9VP$S#TNJ)677!5QO.,[,X;C)8IX6:#3@_M%O698TW#@8#5Q]#B^N-&>D'2^BP.SDQRJPPS1';6$.!K?4-1L\,(0\Y8H MH>%@KJ'X^3A'P('!5X6+5FPQZ(%;$%)VIPQ$/0BWQ@G:ZM*FNDV2G!8AV=& M",QV:H\?\NV)DJJ:.H4'I5Q+'(RDEL2V;C 92(H.A_C/#;Z99[!0_N8<4U)+ MMNT"&?8.S0Z?-9PWJ#I8>%\%3"IZ8BCDLI6E;O3P$CZK@9)H,1-[(8R@(&P(-ML)GQ24RB?"91:",:40 4?X (E9$T7MK>FHN6LZG#0Z:5B"VC]%FHFU R&Z"Q+MAE0#^@!8W@-,HC'R6Z%/-<50=%/_;:-35-')C^_MN-*&7(5FBF&#],@"7LN6\(F<4O7A0/*.61/7;-+8YK;>B*>OJ!T/A\?=M MGU]V:?YL$_O &]*=MH3$4M"#(@)2F09B^6!,Y,5K-..I-<|\=9/9% ^BH,JL&T &E. !FV,J@#:.FB(C6'6 M1#I1G!@EU.$JG,3#(C:3B;)5OCB>7PLJN^>U(2L183XK2MJ5QGMVBL4ZXNZQ+UA4F_0ZJ=RYX@6;T*;&R#8>^K<5]X-UT%&)7(E!V:FQ,.6SN3P MIJ]MZUKG?C#OC#OI(^K[!%,]@6EGFNM27-MZ=WD_9IG4><%9X!S?X&L@:-.;"Z0!F-X>,T_%L< =_*:A@@ M,"H:?6#TFU558;OWJVK;=,3FI/-LD6;UJ6:N AB*(<'4#>-.5P1X:L6D(UV M!_:E[7Z/5L:ZZ3P 9SM>6./6\$CU([8(WO"*KN"3A>K)#BDUU:6<5J/]M963\] IB%;"'(H'>?W:Q<=]9#0YX\.*HX+R8R/8ON4$QZ5V;(9W 0+0/. MRH8C]*"04S37>:(=BJFU8BG/]3K+-9S>TIGV)T8=:?L!G'FC9C@7UQ+?B&MB M+*OSD\Y]+4+..JFO2NN:;2#M^E&LU,U]2&6FL%K+FE+GGY4556KS$M5_I(1)O M?80F#;#__1M%HG[;7I),@'S(E._4?SFGQM;052Y"9Z-O9@>FGIL$QF]6]HR M,GA^/>G3^VB;KN5]\D)\OP-&>W,XD=%;SNA&GL^M='9GGS[X'ES^_K[U\'7_'O M9FS;D?PZ-.VII\^WHW:@"XV"0_\B!L3P1 PGMOULO]O23]YIFHI1^.,K_&\V MGS)T1!!?AHC$3OAGM@PCJPXAH2+%,;YRHR/ALR!8F&3='Q&:+"!$G(H(Z74=0Y]<1;XIM7IBE;YTW/IUW/+$NKX;!7I.N%*N^RTDCBBKUULQ_)TAMDZ53M>C99>NJ/MOPT";>"(B@'DC:$:X"#;6U3CR27'\%DHA"F[4\N0SK7;78?G>DXP^%N[SH'5 M<_/-9_,W+@RJJ35&12T96G"J.J 5L5NAE++G6^2G;X%J]+BTO4A)\[>)^M=,K?G-N2Y,JNAC)Z&LX8'-H!V6QLY>KCSKPS7^&5IE=;3"F!+$=:X[.FK%7*6A,\#*[=<_ILG945CNG9)XU@AH7)NZCYU1.,VR8%?S.#C2UHA7Y_VE52QS+I:Q$F,*HH'?*URI[@7Z_3+Q)[,I-.5[)"V3=?I#VTH_W-?O M]-$CG>)/%KWS ,@4Z_# KB[:5>:=J"A"O2O)3*)6VY7@I#?I7E)K]SM2.HL*YHFL01H&?$IRS59.EVL$*7EZMI5W:>N:.2%@A%O9?#O):W<+-783H:N MX-UXG<]/TA5RT:MZQ?8%2UHV'WRFI8:J]W8.E>+LZ0KZGS#96ODY-I%_*O7 MM#/#X'R)Q<7$@K#8X<+A5\FBHDY=,5GAKMTKO6CJ6_@R'YYSE7-'^?9H*DFXMJW&&CC+)R&!\[5M$G\C54&S_/6=K'=P_+&-\NZ 6)N6!.,2&13X=">M5A?^? M<[4\H-/WK87KL-RJN2CR,W'1 9&P7E4 \#E7;.L\,U<9V<3).)?A2^EQKT%% M7+TN+_@Y6^=VSFZ"8?(!;Q&-L2M79E6CQ]=S.4,#51WNIJ8G&?AV= MSL+LC$W7%@TY;SGHB/IG'VYH!:*9-UY+&HNU-]! Y-MOMG0+O"(-2 MDR]HI?@HE9]7:VYHU?,!5K]CTE?"\>?V\@?%FDZ,>KE,=D*R@)#UHB981&P9 M6K,YG&)}^1RJ\\AUEY-()5+='$Q%V_QW52;(OC0KL^AENNSL?S$L_'G 0#; M2!:'NF#G5:;"%>MR/#FR>A$ 3@9 >,[-OURQ{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}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|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{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|[&UEVO>3O)VIALM3!0*Q5TEP2O]Y8[X0UOK.E&CMSX610^,PTT+;,]'F8>MKZUKBHI<,K+B5'%$+4!+CU;R^I@M=_GL,I./Q2)7GH26I_JZ(P?!\7)TRC_1 M(S\'4MBDH1%ZAQ7X52Q=3Z6[Z:F>"ZU>"3M2PNI#G0,I)3M?DGU%(;1,*+W$O?&>L6'(5NE96PZJ;AO=7 MTS)'EH@V6G5@28JH*6M_N]7;*:WNW1>_(@VIG:K5.FI,?2#=;*47&X'0:?&0 MW1?_0:*?$^3[5]%29\R$O2QN.0#?*+\'L;5Y>L5UK(<)3H[MKM9^T/I%.G1* M,62(?3>Y(ZQNL/IFH!K9:6L^R%L*2X)6MK'FI5YL&3JG.Y1 C5#Z=I3F%+'-_8Q4=8?K'W'\#*

M8QSO(%@NK#=.@MDE8XC4Z3'$71USAF@S(Q">7L&1DGG\X(D?ZOM1&-.&X8H: M1"[N!/Q+V!B<;^RNHLS,[8=&W1 MD"'Q.PM(N)5W!*
.^"Q%Q#M!O@FZ&+3=O. _@TAV*HV2'N!+V5]RF"S!P;KO*4;)G=23 M9&#CT]_*1%FE+GB"3/:U$)DTKAOK92^QTB M$3I^;W>L7¥KC1I,=G.2W0L-
+A1NK2'=G84,+N@)0G7> I>]P7T*6@]S.,U/:LR/)S,XXSNG0?0I03X@9&D M2<$!C5GH"!>&¥.4GB'O-+BB1=;S<4ZLS5E\[9FZ:M1J@$SKO\,OL@J\0A;-%
MU;]M^/)>3Q988T4E>#'5Z'1R1J50*8?.N(G"EU'X\O*[.X^JGEV)XU0CU4RQ MH*WUTU]+&*9C%U?E;YO\$R7¥T>*R75<3HS458H?
UK]%D6QFHNVQ<"M5^HQU M\R^.CT[ZZ]MD(47+G=]5KUE9)(92B5E_)<3FA6W$%59!M)UAV-&ZM1S9D42ZUG;U1LDR:) MQ&_XDP^\4'&
+N!BYT&X-U(6V#N'ZKFL]G/A>=S])92](./O&]JE:(K.4*¥ PRVM%23I64IM$EAFP!:=JKM.'7QG\¥@-OM?¥BZ2O!TJM2¥QC-^[C>4MD$EQ:(MBO'"3#
<_^LAL87L!,.W)F%;B=7S6G($JWW;4ZHL(0K]X^PMSRAQ*FH>> +9) M;=GBJ[@DX7JR0XI-=6EGE4<0R=X/=CNKNSJ 2L.TWHFS9[]'#W/ .'7%.-3M
MJ0*SU\6O_='OT>67LOP-^S)=2P*V_W$,1-G3// '_X_.\%L9Z5!!:.:+R]A" MD9WQ;P+'_^>OJ2C+BC&*:6#HP"=W5/SQF:6.QH\/3=NKTP%?
I'G%^_ZZ>=*O M-5*.F&-.?Y/$'3-U_H)#CXV!UP=-W"7B\-'.B^&OIYO?#J%6B@U%7=%6O_;.M@3:QC=7! FN;NFC\]]9_ O]K0UTV .]?7FM;60/8$7J-]^+?
\$\,_8*_D O M$+&Q!8;_W/RGT\C"C_94-/9>Z?W]VS M7=3\;A?^>(-'-_]VQ($&,'.(H>P@ MJ+XAOU OD*XB_-_T 'TE#8C6[X'IC(.1^:2-03(^CC8@[>/#?9X\
((7_I21] MTA^M!?9 ,+!Y9^!1";(N[@_]YWA;.&0-/XI=|&/OUZX893HB9O I,2$G" ' M I48X ()(&1!),640";30RG)#(DA*=[XI#D/:5%
)O9D3M#A]1U3/TWL?,(MX0Y(1]M;3-24D?$;));0#ZR_H+T%)>/S-$K--39&Q_^#>_VV^1QU0B*9/OGZ$ MUU\'(80&B\;V"Y^!JB]K,%5L9*!I4K+_'B@SM
]CE__E/DL2IO[;X MFIZ+>,\[<1#Q0Q.Y^9>OESIL#N,ZZ0[+_?UK$-)A&;]G5A./6G5_&OOC[J:Y8JE>
MZ#3]MUCN+GL'!52<3FW'NJ.8WD_I73T:0#*QO]P0=T0*Z*^]M9W1#$1)'5FF M:\@QR=1,Z_=&_#<[']M222&?@=PQ\E=\Q&;^#/?L*!:XA!MA2$1-
=QT3O]-<+ M_]^/HRY^1M;E& ^T:YG$*F@]P\)Y5HTA8X#*TT4+Z/N<*,T3D.LE ^9TS)1<% MGU"4Z\9;5>JB90F95%7K\/PLQKH%)B6-#&X5\RXU.C9@
H^U?&3M#3A"FH^T M8-$FDW"=']DD)3A4DVG:.!PNVJ0L2$DYF2!Q0)'#0:.!H^[_H2,)$3BZ7:7¥-MLS.B%B.D?
JS@KEJ(Z4'+710[GHFTF9V_F$HH4#FUP>_-'[MD1;9A,%ED^$B^ M9;5G+7ESV#.5O"=[QLQS6P9_9F$ZUF9@.]1%S^7-\SFP' 4:5H$$03H'75!W
MJ=3_["KPX%V0#>1S.VNG>Q-V.=3,Q69=W'R.+2QQ^GM@ 5&-+2"97K6HM]^+ M VB2N$Z
@F>3W&7&+T<^:78IYDKG]LNQ$%O/Q<)SNR"HSWWU.42NA///C;)$ MBLN$WH'A6"Y4?A?1JRU7M. 2H*W:8&I:SLU&HN7E.JU1]1[.BFZS4$I,V_.Q
MD(8OPP]@ALZ<&!D HPO8=Q*ATIW=]XI;Z[_YS^I!,T6G9P'%/'9$/EA5J6> M<>K8ZM+BT^'T.VZX^8&VVV6AWL':B2,OYAATO8-
U&A@TSSK0!OL_R$8_"^"PAIM MC(C_(?_I/VCDL4Z1Q79LN*W]ELYV,/@UD:)H;&L5/0+[EZ=,+P/+72Z'QGH_ M;J"\[)% <\6T,&<,L-D&\9@?ZL2
(0/YD"&S*XDRJDT*.QW+XFH%'79@7$@@ MF]Z@6#\]NV/Q-#J;;7!XB^)UCF.K6;XX&.NM-U& U/'V]GS44?AMY]FON45 M&\KP
R1<'CZQ=^9%9SI)68HE"ZQ.=_1$<\E]SOWH3?-"8SELUQU0+Z'R?AKM MK4QO0B;Q%$T!:2BDY"0AT,,4$))X4H;/27) 0]T)$N)3ZZLW&=1'R7:)PRMC
MJ2L6E]G^ #+BT?J*+*ZP6261Q15NBVLH:O:E3"[OA(E'VBMX MK&V9XU%U7!T/1N>QN>AO:7-
UVNDZ5T*6U7A+ ^>/HMBOW_=J$M9QZ&_GGWM:JU$3A4DVG:.!PNVJ0L2$DYF2!Q0)'#0:.!H^[_H2,)$3BZ7:7¥-MLS.B%B.D?
JS@KEJ(Z4'+710[GHFTF9V_F$HH4#FUP>_-'[MD1;9A,%ED^$B^ M9;5G+7ESV#.5O"=[QLQS6P9_9F$ZUF9@.]1%S^7-\SFP' 4:5H$$03H'75!W
MJ=3_["KPX%V0#>1S.VNG>Q-V.=3,Q69=W'R.+2QQ^GM@ 5&-+2"97K6HM]^+ M VB2N$Z
@F>3W&7&+T<^:78IYDKG]LNQ$%O/Q<)SNR"HSWWU.42NA///C;)$ MBLN$WH'A6"Y4?A?1JRU7M. 2H*W:8&I:SLU&HN7E.JU1]1[.BFZS4$I,V_.Q
MD(8OPP]@ALZ<&!D HPO8=Q*ATIW=]XI;Z[_YS^I!,T6G9P'%/'9$/EA5J6> M<>K8ZM+BT^'T.VZX^8&VVV6AWL':B2,OYAATO8-
U&A@TSSK0!OL__

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{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|>W+O%W M!G?(I9?_H8M/F;^N2Y?I*IZH68K,B8X54LY]).&%O8"'*!@N/7SL"WX*$V7 M1M+Y4L='8K,UM!HWN2W%,RC(]?;Q9J# 9.$M(GJSRI3H;R7?D MWH&Q+((F\YUOQ<7S\|+"<2[L&;27U! BY0X@+0&V?;GA\(*%/Q_9W3^7&#1 M*0#%T+$60H?OQZ23PTY>\T;RLABH$49$C3HI/$L1 M;V11__'$< M/L$,2$M+,>*>O'EJPKGNI9 MI_'&=O?G2D:4HOPHT=I&-6\LVXO47"?\VLIHX1^H3IS7[<0]S;RYXBJ1S(6S M=I6XLG5LE\51T)EFB9:DQ?Z]\(NX_O6/\VW^?N#2^R?!"N\]CF1M??]O^,_]MPR5#$*0J-]+9O) 9!C^]TE],F>H?C]D?* H<3SJ?_/XJG_/B(@R3M\N3C5 $1D.DOO(=H4Q9N%,;*)1B:>V>]E>'/>I.?PT*\- MZU6GCG.NKJH FGYGW)V*_->(`7(W*6W3>*I5FS4XX$G\^4BE-S-I.*:(2/3/Q=JJ,#.DIA)"<(GG+$>0N:DXY?CO\?"AI;F$JF!H\G-\,$*O/ MY#M$,30_A,1(A-"<$%L-3H?D^8)UAU6FO%(%/#F2':,*04Y=FKQ(TY8I%ALJ MOPK"D8G%0V-OU.UYI7"DWB^MYNN"D)I&STPLWAU .:BE,AL,:<[Q$KE=5I1M M)WIFXO4ETO]D[8YYA42,NPM*984E16(Y$3):I&=*YV\R9/>,)CB%1&I&AV! M3(XLYLW6@![O>MS6T]@YA:&:B7<$*CER->/+S*@$+W3-W>9LTZHQ$,D*=`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s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}] 2^F/+*#:Z/^@"\)HZ%4 M$29J(=\)YX3>_4*)+(Z=\&Y"ROS5:1";/R4T7%IJ+AO%N/3J4X49ITV(>_]FM#%>"(UMM?D"5)#+.S?> R<& M,"6&C?,*5ZO38-P3I%3 X&Q+$*^9I9<4R8%_#N38N;8 MYKT3PL.Y!SXEIZ(5*E#F&+(@$_"&OQ/7ELUX" M4?D$_FV^JP(.,Q33T=KE4Z_EOOO$@\PQDGGW'T^";)P]LS7?$-+?1"I(WC:7 MCC)7+%=;*_'--=!4 Q1(!TTU4A9DOVW/8:IV'335 %%,<&:DPAY(&1"F*-0$ MSH,+GP?7\)D_>IW.6[C5DC8WRW>I7]GKT,U!DS*:<*G7MZN] @?Y6U9 Z+/4 MKTS5EG_'$,/Q+]6E:BN_2Q%)5)6MFC1:K>!\B6MXU!@3H9X,2>\)YBDBF:LM! MB2$2+Y9J4>[@'F=VK*RXB"TXY0(RVJ7_'9??Q2C]_1W ,'_6)9DKJ+6X+ M-(X%.;6N:R1>%=$ GKMF?#"?LMYBROP3^^Z1TI/ UE^1Y?OWK;>-/ZIGYEL[M(4'@"@2N;L-1"0)7(' % E<@< 4"5^ \N+; U;|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|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|\ ;.^39N*X3!9RRM^WK,.:A2B'7A)E]VWM^G@);/IU& MVJ45"?S3B@3S@ZOYDOHR$*3MTW3MO:MEN)"8$#I /;)H?566]1D2+,_1P"+ MY%GC*<-2)P&)$\>9KB &#_3OZ]6_7Z@C"K1QH(V?)+)V.PIX+RIAZQ[O08$4OMW^GTTM;=5]3TR_:0/O8)'1=&/JJR=J6\=2&+[W98*2\NM81[#?#2.6W%VV&F M?4.DS%J1/^B_4M=S-:\'8XJ*#--THYWU-'7JT9=R$Z]'5YZUOL"F*[*

=/VC MT"#D9Z6&)'\0MR0U_;FC)E&^(NYF^$L.6HSHRP|Q9PJSCZ<@,'9_8>H*>LQ MQ.N\74[IM|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{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|>V>=4'0L]7$^0!SV[XN;%ZRBAF0/>QN' M+ ^MB:Z8BJF?0LZ C('!<@I%@&%#/%:2[842I+N!=+?K2W>[!'%[9*?A&8]% ML3,F=,>9(OQ0F;1RGLFO5IH:'XO46\?BU66_A73(&"&YKB%]ZMQ.OM1T' -9 M<)=P[UUV^\^IFGU;1O_VR02QE^] [,']J>D@"1K^$L^\,/K\|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f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|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{#,31ZRB MDWR.7]5+XURA/D=MIQ,-35*K;ZZZVFI:YGUT4V[,\I2: <1/30"QJ7M6P5%M M"29WF.(BP^%(P=5H:!*)R=\Y)M&.+257[>?WBL $8N@(/Y']FWTMZ M?NIP2%JH27^.Y]R_]?.T9*\|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

MP/1W:W^P%GG#*)<6(A>H]#_.UX4XQ:AXKT:Q_EQXN-5Z^;AR:LX{GXF+V@H MZG0*:X5M?P'W6HS"M=8C?*
Z5W(J0@[GY]FQ+,YP6(0ZSFY@$"!@#Q%8!XO:,:. MAF\@>F?R2Z[5ZXR&N!PP$O[%$I=O@<5]+8LN==CX)Z PX0TWPJ[2:Q6T"%8 MT$26HDY8!N=
I0T8<)++IQR#A$:0!DG/YN!:5)HSOOK_GH++US8B;^\X!"M43@P? M../837)0XJK01YF-=]_7D,']&M" P!V'"*,-6-8\M,C^;Q>XQFWW\BAWN?*
#0"\BQ1=]",4[ZRU-E+I£_-JZ,?'A45-K MJC%DX'>_2!K)DB1VPG#0]\:-.,)9S\]B!J0 =4Z5S3+NS'HZSLQQL=N<;;^3F M?:US8C_$')UH8POJ:
*[A\>>"2M3$\X*P@%O0H4@+C61Q/MI]%BCY3US2YEBR M^6A/I: L%>*U<'/ATIC MM9QO%'&1(U<]QD9901U4*
*P$5J.HE6Q=U.:S79_L&#,L>BA"/A]J4KM_\Z MQ*SW2I7A@BLMRTM;'C/D(F##D8F9ECD*KW*589TC56NAR<5V<4(§XTB+*
MPVDGX,123=3KZTYIK$M^M2L.K2GM^@L M87-D\+V5/]"+-54@DLLG77E)%^@R!)%JØVNCXGC3:VI!..#)!]$VN..5+Q4&5$QO%
M7$&S>%+CV7!DDE"-\8XOK*B XK9V93I">]/2V(}>GR04.ZQ/_&9MR'-#QV3% M?-MHU4;1^Y.$,DAEOIMR[;XN8N5>H4
7];A+"95<_@05IYN1M>1A0XOC0GJI.1 HTP,7HHDB#5A)50324IF$/SP[DB MKZ#IMA$(=/+],^S70QT#8-7BKLEX*
*X#H24V'$D\'{GUE>V{J.S&W+:_:D!3 MEZ3%?B?]8)Z8*4I2BK$6)$A'MW1Y480DR1E%#TW.U"Y)[.!@H(ZNC*V*7*DK*
*M99CJA,=H8J9Y$!(&=E/AN%8A6.UR3113<+S_S|Z;-B>N)O/#[_^20M%SYXF9 MN.#1PMIG[HE@$1@P.V)V$$MO?B MB(M?:2=9Y(]HQ!2 4)" BULG_ZI*HG%!N-N-*
*QB!:R*FCXT+J2J7 M7V5F967"D44))R;:I M"5RGCJYD'BU,Z;;G1:'3Z/(@/!F5NS.EG_>&'BV,7:9J3E1KT$)^$BFH+\NE M7._ABYY'"W.8T;!G))5 MD;!)P'T-*
*#CU:U[JB]">%;DK5I'S5Y%/A?JS9Q$\]6E%)%U8SKJL5T=S6EH64U)X8E6>+3ST&%]SZPU77$A*G"^-FWR^TWXI M-),>ZWD$L,-TOYM?*
*E9L*KXZSS_DFF&Z&NO?<+<+ZU18]$\QW-V13UZ69#7YN M?S@TZV+0+AM[Z3-3:17&!KNQ\S[",A@ZA^Y(&/L-^!/??:/I?R+3S[&V;_6?*
MQG@FX84RBA1U<>+Y)GSF4#>76W-R^WL8>5X_!Q:0M/ 2$N&OF6GC0XZ?%M E M1UV-_TK53\XNU0:6";NNN -PN]F4?^,^DY<&<F[?
*Z^;9T'XRV'^(KOIPO/$OXEO"%X!CA MRZ_7_R5\N0U?/JHR3/*<(SPY=>+^Q*^W"H^=KZ$,.$+P3''EU^OL4SX+!DZ(=!8Y*D'S;'GY?*
*M*Q17[\EWGXH2W/LDU4&4K^G5=U]BER:T$YX%U239U].'__6!_?)8\ M]%,R^95=9GY%AL[5!3NXMGRYTE_!E9-':FYV7^!Z]?9E!%R#I3I_CJ7)I_@7*
*MM$,-ALB0E.MW]):#33$2<]D/*2(QEYL[CL3>NRM3YO9^8N*)N6[!UDN[B;N"_M>-_!2[R]?-Q=' '7//L.LO% $80@4^#.X@5D3WV\\,"%$;)E.F]W3^+U?*
T=_ M[:LHME.QR>M$,],#4YOFS_50:_PN]?M!-=&^PX6R^VMV7OS=E#1[[!]$.$@ MKLYI$-E7=OX.,G(#TXZ[:N29'*+?F3STT1 MX0]"-*
(Æ]>)B/H7:I_\:R)C09QS|M]'!'+@]$JJV1W#(APQ1_*O*Z MF!!OFGC37WZ,QL0^JX0QIM8@=F$MK@&H,KP\[%-\88"%*H)9@YN6D9Q=(AB M:9:*
[A(X.)%D;6=#74G[^0Y8!& ZO3:1/DR0MZ9(APU=)#14%,J:%=]#(,2'O M!T@5]K+QB"\E3X!U](\B7E\N8U?I.&;C<)>H)NRF,1"GST)UG"BO2ZE8IXJ:
MBQXW'6-8D6-0US'VC[NG+^RL70/#1(^N&E6IHY3F+T:I?MBUC/Z=IF5X)577 ML='<(%W/&.ZJ:CU_K-6@6Q/_Z.)D-1.AJ*<-?J MH4XT[S)W!H*%*
[I=IO([O3X&HOQ>#\,OA9/+-T%LAKNS12-AY+1\2XIU!N-) MOY5"?;JB/_Z.7:\Y,L&1"Y2Q>$0+>M@(KR979R8=/EW8[M:5UK+HHQ(2\TYX+JJ)N9ZF#
(&?P, + MJF/]B/#"$2])9,UN. &F/,]/XE3V;E)"/#@RI+/,2';=2TW(J M,>4Q'L1__,TFV% D>6QN!/C]B-I;<+U4^80,@+^%JN#;((THU4",,8#'UJ?J
MC"EH"%)E>1.D"@U_O-3ISSHR07;=H$" MYPU948,D-7Q^X*NO/M=!OFGC37WZ,QL0^JX0QIM8@=F$MK@&H,KP\[%-\88"%*H)9@YN6D9Q=(AB M:9:*
fN2T,%FV)7+R5U<_OEYB#U^],0,4JU)=T%QR"U-Y#R+-=().N+ M%9\)1PUS\ (D-Y]"(!7|\3=SO: O4;6@E4!_)(I=O4#Z8X'3^0.I=;3%R+%L
M;2+D8]6((5RV$9F.OARH-FQOH]9?^}6#>N#BC04^.AT"8$J 1TY-A2-7O&(MBNC>Y7K#$HK];M?6&Z 5O@O,_D44Z&9G+(1B
*2K!1Q3HGL3AHVZ8A&*_VZ?R MX>UE9]1V>J##B?"'7F"QA@ZHSQ_P5/(3-JZNT,49TY4=GK7$CFJ!9*&]@.?!\ZPK#@CY8J.T!Y=9I!,N.#@AG?*
*\TJ*S<."%SN[M:.P4#]++2$E*L"I#G.F-02JXUHGCS7J29M?M-?AA-;IB/%2/$WS,6/] MOVA]O)OI67PIAT%*
<9MHTFU0%>|F&ZZ7!$IHA"93HF2!)GD%5XEM<6'DX(@;Q M=@RQ00(N-+>XO?%P1 SB51&B>0$7FEM<;'@X(@;Q%L7-K?\O/+GX4XM]W5_K
M<6Y1S JQ:"M13877PT@"!0[1Z<8')OO=7<1 -$1EMHXN8T#!!1;%-VLUDNE- M[E>0,XKS9Q3XW[1D P7-
#A@V7M>)4PF%';:>5ZD>K54SP_DLGIBXG5@+IK] M\3=#QT.QO+6RF8D"DJL6W^V]!4EONO5) J$8N0[PZ$<$'VS^>\\B/73=",K_ E!?G-*
:E9&QW5DRJ-_(>V M_-VEM N&!>##$-D"A1I)JV!24$3A> XXTT %E JFU(,& 3?)J26+[-6+K1!Q(MFC5)LR;)(B3-.I 4"V":-5&@6T=+'"<7N.M\WT$=%O]SL-
KL0ZYMA>6WQF:X. MH6]+[M5-
*>#N5@7UJUB4Y@V"]Q+SBPMHQOH8S*X56X\2:XV!$%Q268VR*2JHX$;0U[YIRJER(S858TMO3XQ_LZ8^0OPTI0^F0@"3E-BA(*
*M\DZ>]L"T%&"%O>__9&8KRC9U5;'^0>/_!0M\2!YWH(3JW3SN&PK5PQ'YW3SO M[ZNY).'C;GG@1'._($^<:"[1W(NG)Q/_8+T9:*Y1',OGMY,-*
*/<++TI\#K+E'-M1]V<$$;\@+9T@XI>=._P:F.5S'#LNF763[N@SFFM/K5RKZ(%9_%? [.YRS?\[M>/6&)4!R "->I*_"/<"=;I=5M2G*H)I@Y>)?*
Y__[!Q.B_.#KD_8!X]=__#$B-MYQL>;Q"$0ZBB&*ZZ*9 &#D*ZJPIVQHA%RP[!Q$$FUZTO7X9OKVO)9F$O+*
*M%OA\V76D*KKV&AID/8GBJIG9D"8:%+>X$&N_]*5I4IXU5^^#(>]JL>BH20; M#R7/]J1^^*?;2=97']'<6G.4>A_+G>&\8A0\:L&Q]?*
*CQ._7K!O#G1=8MC>3 M$P8*XT32D6YL&-,ZM8[1:,;:O00W0D@1_?'WMRG_+4 X9_4/#Q T 0@_@0@ MSE?4H0T[,]MPSPMZG95BC835?AGU_[#*
Y4=@(2W+7.@2886TWH@S,4BL=4B MA< B <$BE@@Q-$L@XXJ'1 \.&?X938 AX_I1C#_$C%^^6K&>*./G56Y>%.:_ MFTB+H_RT5?S#=A!O\>/=L$C-*
ZDU,8=TI" . ^/2Y)E7C\N8^!!-V.B%PQO/N] M020()ONU0<0 +B(@E<_BK$-8G_&IAKR9: MM953\AVQ;=(%'-% IT)1+A9BDL>-X@AN7/!,Y^%Q@PL*
*.@;*7UEK:G)4J96C M6F?@@!H][G33_0MK_%M%'RA\MM>M@)PVC>]MR?/84%Y6=:SH\1]_LQP32C+'_M:!L*;$Y/_X,HVE]+-_Y[($"R!=2@$;]33^\ON!*
(]I=1TEHB^V_\)_MMV1-24!;.$L9_O5XBAU[E M;WT[_<_+;?#O4IV-;'>T':XGWD[]_QW.?7_N'Y9-W;1^;K>F@T6-O7-7%M)Q
>6$#2PM(0OO>GI"^EM;V-TB6?=H<5/W>[&Z("Q=!/7/2?U,'/B!I'1)Q MJ_ !P?Q-,:R#H?/3_]KV,]RC[3XT;1S> ^FD!Z*]"]Q0]_=5S,5\<<_:399YB*
M2!C@K_["(LQ3/'HE3KTQ-+@!7_XK46,+;93_:%4S)^TR]#/_#N M?P1!#9=<@W"50?LN1&=L$]' GM65#%!PY",^]GZI-U_^)HG1Z3V_@CW7OE? M:*
*3UOQ2+O_GO-TQXP\VIT;/C)?KHG<=?BRV?A ()FQAB1)*X2"PAB=(R&(D MF>3$003]]D0&$C>(1I-Q^H?'CZ_!VW,9$WE@*
"^KA4JK)A2:IUUNA+>YW0S,"O:39@ZG#&UGS)6#CAI"LYZ:> ^6>_N9_ZM@0"/# M=&UH5=O_#M+$!$-R%>C6%\]JR,_/)S8YVT'7U-ID&0E>1@7*
:O$Q,@0>B3) M ?$83(1'\9B#/P_\.5:VKH/T8)IQATG4J<]3BG5S7.#RLMJB1+"WHZ$'D^X MH.3UA!#.U/+"E+-*
RDUA=9{'AM6DM,X;Z3DOK7K/PU2X,&T44G!D].W(_DI7-MFCU!2_.JN,FE[+#BK$!=Y$3Z[4BW5]PVV!$7%=AYV$H55W.]9-;%R/'(?\U*
*M99A.31*F]7GX65AS/3J.1A[.,Y7N,IM)DS/I9A08B<2D5V*R(SCR:)XI(:5-*
MV/HX3Z_3;7V=>P;I2C@E1H_?/A]D7Q;EV:PJ=%X&HW]EGXV,G4Q=CS2Z0V! ME$MD&"W#SY93.9G93#9U,7X\ @Y>KA:3YM#9X2N\1\--*
*=4".TU*B2HME:>SB2H4&LGT"*7O'0V=R;%< MJ6"WNG15$[MPERFG9@P.:1\/G7<9T&3[U!+=:;HD:KN9FC6\NJ]5\-_4BE\HCD3W!K1=UG(^,EM,,*
MG^\T7GH+ADY(+U!-3W"KUNSS]'A-1\#+[,7D\U!/3W!K>=F+YL,+SH# M,;XNC5<:+ ^732SCT!+=U=&&MAP@CX1-7%M)Q*
RSK!K8H;GCX2%.6(GN"6_E4)[R)-RH1H3JM M<[W)IJ/->#0$]Q*=?1D^IF=Z%I>JU?YF)VOY>DZBA(=$ZL6J92[RBHF9,:=
*MM+Y9N88.6<"=X%9Y/7^.MR*5'AU+TB^9\"RZR-='(G>"6S0/DK5.8BS0F5K! M[H+H9-!QX= -3W!HSHZCN. HC5)6: ->L.H?*
("L9H[P:UF?]IU:B,FQ0,]/17S MN6A,Y^%33W"+Y^(O=:4Z@GS7*6M],U:H]J 3SW!K5QIX%:KSPE;BTTJ*JL+ MB5D8S35VC-*
*>+C=2.V8R5%-19IS#.I>ARC]NCH4>`'7_N6>O!,I+@I2B[&LUG M&TE*P*>>D $GI_;J:H?A=.1VLSVGPN-61O.]80.&,U$K0Q>YR5-$MMJ<]2K MSL/L"*
T]FBL[FQ;3FE">T9)]%A.%,.L4-3ST:[ZL-4]JIF&1>=S4 O9:H&) MA>'0$Y+5G"B-49VWEG!HHLV^M!%HX"B"NUK'LOIX('0D M/'0[*
;^;M>\D>W%1_;;@SUV>8X#!(ZU M?:O_.;SCGXM9SO.05?VW'`#@3MV\'P3/G,(+>2M(;7|/8Q"VC\]?W\)B?"A MG^W;9Z|<.6D +7/7N;8C]\M";^3
*'T0\/G38X_8V4*RA" ^WXDOT;(5LPI?; M\"7YP4$IX/.18>[!-P&K7S,V:-X=.J.;%2;&EKFE#)G.-?*
M&%$HJW!*V3_O%@MAMCIZI2!4;&ONL=UNKSN]R)#,O"EEKZ$#-XF\^W)X 5"MOCT9DH&O7_X[9+@_;^6B_0T"Y7A\X=9VRS5?*
Y@KR5]SV"E:AM,AAH;2(|.06 M$LODT!H6*ZG3@3&];>)BY\N0_%JA-$E>#;JK2+I/SSMY+;<8-;.5R%,B-R/ MOQF&#K&)ZQ1!#)B?]X7[[0-*
HZA=L&.'2U""4-%2MH59=T4#3I(Q:KS%M>*L M4)9I[H%#8/I5:>4B6L[7K:Z8U(6@#R351U0AF]"H$_1SS+RL%V4[*X:[[G7 MQ+5^8-*
=Z>Q1ROQ[S;P'@Z_,?XA_L'[\2@W9V"AHD. M)!M0#K"FJH%-#.+UWJG7>ZOH[2W5\\M[F%['11X-5//GOB]I:Z^-U>$+4M" M:.!#FK..\X1C\-*
R+L5/I6A^%>4VV9:3$F/(<8XF0W0B>HV?,1M_AYKOKV3 M?7_MBC? ,A6LM;^MY6^5NUR+%IV"VC7H=7@\-Q;BIIE@1E"Y8QZO<2NH2S4=*
*M#IJO[1DLN&A0>"!Y)5VF.V#8WGUXL$(_^) $P?Z;AWH![%C7K4F2$NX&L5> M4T_@6B^=CV0*HMVA.XFXLZGE=2>]28EQ+]H?*
*BD3.]5(GX0023KBS<,+]&3&7 MT?.WYN2B"VM5$V+3N=*1HI/(T!U!/8?V"Y,(L4GNXN;++6V5+)A9D&*>?0(Y*
M2$E3$TYX%SFD#_4O298M3+E_H_)YD)3U9U2 M_U)46X8S=OZ-CGS@TS3@%TD!LFOA!(00RE,@,1020[G;&,K1HI]HRXOV+0=,W*".VADM&UB*
M(8XY[M-TN6S@(D_B;!\@PC+UZ/ =$2 MSC]&4"'"6/ ZS_G&]YBUM(MSRBL17[C2^0A)9[CX0@Q6PNLUS3NW2G/TBY,M= ME>\36)52ZFM['1$:6@:+*
*(ES+5](+.:N8C$DB^7N@S9_ MHN>%A@C,<:>YIE6Y4)W/YXGZ8H4K=4.CA/VPM=.]QVTR8\D8P;>]OA!BV\"Q M\9&1KDI8'\CE$!*7>:RX#*FO0,*
(1WS8<E@>ZW); #-0% M/E,@?C?QN^_&[WZ\0P/90JGD6>#]MV"D9!P>M!L[#6T W!>^)EG(N#QAF6=3 M:]):-M))'FACA4VV,],Y7T?=;J 'SH;8JQX:?"\-*
*(%XX\<(_UY/" MP.@.AIH:768S?5,SM.42Z?MWN%]BVS,M8$B&;.-UWZW3?WWG"R=MR MQ_#FJ6EA.K/,A=4J8.!1^DIK BGBORD;:*205TN22?*
3TR&9CV9+[28.NH8C-(YDR0Y MXF'",N2B2M#LD.MIM3WH-=.I7L30\FZN,QVZO4L,Q%J-KL>&(O0#7V+QS91=_M#HE?D P+4=@D<-M/CJ4(!8
M^2%&U@8!/9[-5(I",Y46;4'L&+7>2&2BWIE4_$0*.XG>/\'3TYALUY@@48'OI ME.?S@&&&<^R,L;0JOY;T6J7:J#YKBR4"#&A412!@7#[#]+86%(IIP.60LX) MZP0KK//UD>BOCNM@Y:OL=&^'3D>9-1$0 9,T"&LEL[;JI3(OT;0!/:V89\4D M(C3)K"$A'!+"^?
*(0SGL*_*YYL4CVB9GJKHVS=GKR'*E6_D7K,FH_0G'/'S$ M9MG1,VD-4F7>?CPS&.GR5R^A;)5UYJGK>>@[=GDRC%CW&?Y<#Z5LQ?YDIVJ*
M06C#55GC9TL%D$#+ P9:'CM-YN%-FV/-?ZOPR1(0X9M1MX1*F(L=->F*LF+>6 M2.'Q^1-WHN7B78=*($4L%YS-B3FX?4LB"2"0B(H7V"?*
()U\V>O=]OQ\'P+> M_^V<^<(F%LGNJA"Q^?6+YI@]N9QNHQ@++N>:#$7/]Z4D.1828_DN.GX#2^1" M.NZZC%-
)AX=934K);8%EIRTSLD0ZCI)X0S'NN){\X_2>],V8;;H198$%,%P2 M@'GL_S)C_DFEM!6KQN>6I^#P?&@4@/*9F;R&7;]]M@75G!G*9'!U5T9-L1$
MCP^Y2;3FL:,U)"WF>X1UCF'B+3J$9|)S\9E/.7183T;+O1?CN3%;(G1-&3"1-M4"3^:"DP;Y*(MT&<-0GA_(D=9%H*L,+>X)_;,$79IJXJU#]H_+]O1A/?+HQ*
*M3;ZWA?0Z*7#K,J|-64H1-=NMF'&&U:K6C$]E*L:(7RSA?/&95@AB_D*7=8J M(AQ;"(1U+AEBL_OHT8SG.IFGX<1A0:#6.YEX>@CIX11 Q^,)9-*
*G"V'=>9C) M*U-;.0XE2_:8JAIUMCQVUS@VZ]^F AYW7M+:CQ[QW MS3(7J@*4]%J FG\ G_LJW^>@LRKR87OY$BEI^=ID:LML)\=-('0RV:!B0W&2*
M2'23T-2M->FVB4:W7GVP<.2Z%MAE<&1CY1S5?I8LH;1QFI&Z7.AEDQA'T$E? M//2/Q1^E8H__BL&K5RP!DA,X2UV!?T0$I8:ZN;2IH65.H3V&ND.]-
L9^_O<_M@\M R'>->#T!@8M:>ET[7,27"$9-X$6T#OWX[U7U%Q+'DLHV17W!49>O+/&*
MB:]@[JHS5$"/>/$/G4!";O#D]:XJ&7+3,E002U0\W6VIDNXV2>_5=L3 M1K/6G4JTH:PMH1/K"47WV3(:%6@T<]XU8VC?$]_[FZ6%//8EGD?SG?]()^^/1
*M9U<=/6\;?*G/<_VY7,U,6BFD_3@Y-L$\F,<,.0:F4/%=8AM2XPMLG&\':0Y MT>/GL%W9I/'U-_?5M*
*FUM#K\'50;Q62AU1OF+'[*93OAXJK2C!D0U7#I6R9R MQ?)OWTOL;Q]A(!V]B%=],Y.1'^FY=DY'S6&0Q704K(P4F.-H=NQ1DC+OT,K MHA.A&CA0*
*PYNK&@#^V;5(O@6)U)!(3:#,FK> ^6GFGLLV=QIZ"NIG8SPZCW;;F M)L:,]M-D%M&68:"B1.*XB1<(T)$Q#PC2!#=/\HNHW^>?YB,U,%MJ:*
*MSO)]4V^!^G"$5!]%:)++14/+1LAK*DN.3X_I&S;>#L8!?TKFT.1/@'*X'C]A MY\U7Y'5U^(M8QTG&L-B+E_-TJ6" *E>>MOC.4F1C7MR&>D=C-=*
*[EZLVW05J$8";5.UGQA;W:O\]*/SK9GQ;|&6XS&0CA M=-QL!P>S2E8(_49-A-C(Z>FK'.D#1$K-21H M$NB$%W*EYLX|>>|5_ND/.M"PQY(%*-6V7;AW*
*&@@V*1?\8,G:9!ZK'?]GK^;-MN.8?YE:'3<>4M8*OS!FDRZ=]KZ[*XUBX$YG3,:.RGDMUIR?+=9'%M5<_SE0C MSO@#9F^0VJL/Z77_)C(T>Y-*
!=%Y5!5YJE%7!'"%LB75LB9$!5P\[7O;D_Y_KT M[1O9G$Y-1 J07]AJ&&2> 3S6+U5G3#EC0)5-!5B&1#6Q\;3->J52(PL_*XOT:D_3?W?
*@F1UF.%0@.=Q*CUD'A8=\&QGM/S<*,]B MB_E\G5BB97V%&?6]M.3VD0YRM>?K\T ^CPP9=:,WC"D_XZ>3>:V4X&=R-'^9 M;+)?*
A8M76=T[56U58K1AVM#=I27.RQ$T9.&5A@!2Q9M;&1Y5E7 MV@RMVFMBR#=KM1\E %++Y;X]!0^C6MM0ULVB1RE8]C>5]559.X!YO1AKE M<
E,M?.RT]D4N)>LW(>XA\NGLO$$B2Q]K\C28]\+NK6)=,U4V5]4A>.N89;Z]M7,_YF+0:E34N(B;22Z3PV- YQ@YTSS&CEK3"8;"QJ;.74S,_P$990)
*<!2KM2,0EHL3+M"'6$ M'+A=XK'+];"M?@YO)IU*AR7!)7(?B=Q'>HS@U#LW"G);M3]['\GE!^-&;%$S MA%@Z%^NW*QD0GT.G%=*
<99NCCGHHD2D4N(WW;RT@/%N7Z(^1HV^%2IMC)R72F ML+1:\5&\SV12"#E0N"L:BD,%)",@Z&SOH,X&/H[N:)TQQE3CWQ%ZM/Q*UEW$%?*
*C#6#)&H %]5WXX!+)S[MJFV>%2\]HD)]&96<)=_M<1-ZU5U !Q570(XD0A'VK(]*HEMWE2KU0)?'"LSP^7)$,"H#H:83R[96Z_#Y*

*M>5YG)AFA5VVG$!"@!//$N5+H=QZH\EZ1^66CB)(<:@#@@PP4P4)=(3#Y20"+ M!+!(.M:.)RRQ>I09%B4O(#QMU(WTHFTK--\AJV/)Y8C**XVN@W^GH#3;G=8 MMN5X*ZY)HMAK]LO-S7H$[:JHWZJ:Y53FSZX\PT?O:.RIHUF_9X !^/'E3:]OAY)'>5H'ZSBP7 M2M"D-=<54ZX>$P2.LJB^-PAPXEI3DZ-*K1S5.@,'U.AQIYON!P<$DN;SO"P7 M+%$+.Z-|<33*BFT>@P R@)(A.G]<>/E@0:FS)WQ-=S;S4M@EG5)46]9-V[7P M)3Y($FPH'11^AO;2/NU*-3RN0I)=M@QAT.@7G-C5HWB6P;O9]\YR+UR_,& L M#5!,Y5$D.WA7V'Y1LN_/UW_5C?)T4VV4L:*["NY@0$FR#)GBV.A2%^[PA(;" M#RT7_AVL4 8VZ?5TMXDJEW/R'|I_^H4E9D*#4L>*9>B.M"PM N&[%H64-*N M4S&='G!]DGK]VFGSRK#]-,@^>U M;2Z<%\+3]D",8WU'[8D^S&]!#W!G%\1@F TA*ZU!$WNCD4>#?&[!+XF'A5WY1 M;[]^\H&9&-9X1*MML- QP$&E*9S#&IV(&*8#7X8J\'9J_#; (TO2J9EDX58< MSAC8J .'H.:!(DX) ^PIE3N*Z0?ZP"AJL._ "7#GBZX+HN1UY%M6>ZM$:."#O[Z MO3GI]@'"8T\,ST]J/WOZUT7S/XJZV/X+_]D^2]:!9"'@';\1>PX]V!]/:/J? M5\'2UT+$1K;[QDZ(DF^G_O\.Y[!?",*RJ9O6S^T9\\&B?(*R>&<8@? (ID6 MEH;PO3\E?2FM[;VWE'S;I>K\W!U3E_;?L9WD1V'Y[VBL\)<1DM=0'0TU\|%_/%,6<_6>C1(-& O_H+BS#0 MR;L2I]XH-[?GRW\E;FRAO>D? K6KFI'2BGZ$6P$U'_^L08/V/4#&Q@5=S/H.V M.@.5 O.%53H4V+.BBDD;AF3 M+!]Q!V*OETU@FY/] ,]O**_[Z_J8@"5JFY<)_QY V M,^!"=]GVOP!?ZS,><=+AV!S:8NY"W^IKR;B,JE.K8> $(.(ZI?NHC|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|\R%0^M[/_,%.K%. M3OW,M)%]B6>!,3SCL(P^FH.D0#/%!M#9D7"--ZP(?LL">QL8Q<>!|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}KO&/X-I4;^0V["R:95(-O?]+,^ M[\0UR?BI5#S1M;VEI.?A.X/1%>=<,)_:'OV"'5\^PHEHWH8$O6P("=@9V]*= MVI&<\JB-Y\,WH#5SD*V\/7:%N("L&^D)Q4*A\D:W46UDI:2VT=_#8-DN^AO: MX8KMQ1Z@5XDH%YY*&KX)84%569J6YI\#FM[UBWU\%ZS@7HS=-6S1>"OR[G_@ M^P8'T?$G]NDJK6ABH>UDPQ!MX+^LGR HX_3 ;6(U7*5NFAI^[NZ=WDML%8K9 MZS=@6-I.!0FS8=;E'#O7VX!>QS,L&P0:7GRS@3PKG0LIPLT.OP<<)AN1',4[&H%D: M,[V0:N(?#\;@]>?W\|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

*M,1{6W=|J|"Z/O5-Z'D=4=F0YF>W598%,A+(0(LE?NA0%P=Z8+T;'0O-VF^PE-MZ7GU6/;&9MB_1=6{8F(M-!O(#6?^\R--L%O#Z+=7A*P)*
SY.HXM#%+W+HOS- M#;0^BF!O>('KU-N!ZZ%HA?;>^T6K";]$A)(5FGZW6?$^Z):[$;?O6?[W;*1>H<8]Z;:E^03]4X!_L+"1?O@]*MD!+5D
M5>_OU#>K8_3SL]R=BM93V\:TC"%<_-X>2)2F|NGG9\3\:T^J$U4NC:8 M$\):+,Y4"=XIB?WZ$\=NX..%;OU5X//*?>]{8M&D
MW^06T[3"2\S&.@8IM^9(W.=+IIW+P5(7_=2A.Z *?+YG0&DP;>MK*QY?2HRD-M+,>U1KFD#B$HP3S%D40B'F)2B$E7P*38?03@
3#I_.6]>V)2CG97NDYG*6DE M"5*7;_0$:OWQE.F?QJ3BH++!-M'!G2]F-\3K6[R?JFV\624-S:.4E*C30@Z! E0)QY)Q"]MSS[F +NI MCA1%P[2PFU>.O?
>)YPU1,%PH/A,*&V+IZUB*=/C=91;BR[>I\IYB M;>["YTB\U*\W^LL>ZN__LZ4D@02?XG1+00T1Z31*_>FOPQB'8[?]O'$(UW
M;9H>15L&O8KW$G&X1G26B8O6V=40+6Z7Z397%U1*;/WJ64*SC8>`34\OWFX!3W6&*PUF#&I8=*]6G M[;S8_WA0R$<==.04[[:Y;8J4E'E]GK;&Z6%Z
S,$7]]!=V_-^F[&SD_#HS!(M[18;U_"D]01^MW5I"?AI.R(;)7K%GK$Q9/9J^U0*5V2.Z8UX"ERTZU6B+F* MRY,.@*A;^-SNK6XA2-
T;I,*HM8<%6ANZVZLQF)$*V)&)2H9(B?5[P-2,56-MMYN=1E1R,\UOSP2#6D&[:A;N-'NK6XA2(4[NW!G=Z6=W7L]8^.Y13=C8S5) MK?
*5ZKPQK\WR[AP@T?4\8W>(:0/#CX9Q;3_DV.&KD3"$O4^?!S0AJKTW3B.Q M7O*KP2B+]X9]LTK7LUK=NOV=2R(ON?
6&LR&E]&478B13P>;G6D2NK0R$?QL MH-JJEV 65O4\\F*JF>9?(+CMX M+4SI)&*M)R13P+,",:!XL1)LP4.N!7$P?1IM6?
M/&D^N40Y$B%8M7)P2^;MTG M5FM94=5B>3VL4[5%=[#8)*[RU29UVEDVGR(XGL MY
TUELX4LBPT8*"W*!5))!,_8[JCAZD>U.@C*4*/>X/B:*>;GX$1@?&;%WL M);.MG&%&L]JT9FOSAG-SWQ-OUTAU2!H=J<:,2PEAEFKSV0[85%_?]W1OY?
J> M)MN]J1:&4WTO#]7'$4K:ZN*D4X]-:)&VC&)QVJ%:SD6$NMH^;;0S857^QG@.<"H,J0IP*MWCA%N\S6[SW>LKP;"(?C]OI M+JZ(E7)FV)EU"06"T?
4\93?5G/Y"-(+;A9H1!EA=&RCO5Q_B$8@0P.N=J?"S ML1:I-,+9EO$1Q.VP7*YC3:=UO%606O'E7*JKK=O?48QM]>U0'Q%QNE6EQM?
K>_%LCNX(3[!+*ZI9B11+,?:"F4WQ\U) MB9ZL2.L^(1VM[6B<'E?++!.G'\28QN6R!M\!V!8&D(7HJ#HAKQU(;K=SG7W M673#ATUE,C7-,F6S1"^6=V?
RL']?@P:%MEL#N61V:`>X3C!VLE]J%K(W<*_MM1#=='@#=PDWH7[<)?:_;3ZNN5\MA>BM0^6Q^-*GV^[4!"PTTZ/:+13*IGY=H
MK*]9C!P&NWW]2<@QT,0 T'":/9/Y^^#M=0NHW'VN/QM5\YHL,X#&"#:S\)8Z MPLSLW.!12[\GHIA;MIRH7L5)HIV7DJM.9DC=WH.W-J@AM9H4LWB-
S-3X34[1 MR+@#2?3K3PJ :(P(SW$?S#)\0(W^>O1Z,6;N[G-]@!WO#0MIO@W,RM%89YV: MQ)=2B^P+*[)=E^O*E:Y*O&5WV[&7:|
(F*8EF]%ET7=HFXHDE1+6PCF8(:@]8 M://NHS*3?,%<4R5F7!XWR;48=^]8B'.YH_MS>CE;BJ*FNGF=5L;.^M,K! C>
[,L:'GR=I,2J9$R<7*XDK'&]9ZT;I09 M6"WVY.UI/J^O%[TX3_>X>B*?PMMD-@Y;GKP]V1+R^>]&=_%6I\O0--#I:);>P MY5(-)>=$OAI MTVG?
T9*5%=.@\VRFT\AF8F'P'=CTA*)VS%U,A8XJTJMZ572F3&N[F:%> Y(>MJ=)[K$2NN&9(HI23I61-5&;JO+EUILYSZ&H;F@[6-KX*(.AF(9-
O]ERQOZT^'AR@96;9D[7.^6)I%P3U<\>!_!+E;\A)/ M6$ 0#*QN&!]0(X*IO(4@XZN1Z_D0+KP?TM<438OG,$W-K 4/5BA9UAQH(Z"Q
MW4M63B6D.&O3N)TO#JE:D4GW9KE5!'W[U*8310Q0MW9&.'G_CF(X[_M"X[<,H*W^KT1WHS>=CZ73#\EDI<""SAQ?:9_#?0I*D*2!+\'87V[>^9P3-2
MU_%$^(^NF2*4J=\&+P/A6O//^O1M7/3BH"DS,S79MOAG$[V*4@%92.S4Z@N, M&C"UW;^2W-@1Z9 OC\
<7XBD6\N41^4(\)4,@>T#&A$#VF'P)@>Q!^4(^)2^& M>H:, ^11CWAG]JJ!?#NTHF2#HY<7#MYP+XV'V(3![==LU";[:UAL% MU9FY46HHF!DE-
DF6S>W'HUY>'%')T$SS3-A+A4Y9+6U6'M$UGBTM^N75."\[MTQB\5T'$(XEX[!K!>B%,_'"<\)QJ?R=.$.0TA@[T8U\)%-LHSV7J';U,)=O#
M>RH_/$HWW<#!=%H)I<+%\])O61-Y7!:G<^['0 42004Z43FZVZQ/H 3 M,*\IN@TLQ[UYA((_3$VP',;XBDQU#[9QN"'@W7/.7YG=_(!Z(_!LT_8/8$6 M[1J
QCU?A7Q\G#J$AH $7B)'D[^R?4_>^J^Z^=&?X8W?^,+?,&Y3?[[48]TV!2U$KC MUE9Y:;=[],?O8[Y,^]^E@2 M-E4I"P C^3I@?
#_/4)UG3'ZAR1PF*KJAK=$=U\SF?Y&O/L9X!8ZA-X$9#O] MJ1RH3W ;AIM12LJQ#9JT MBR@&(P$B&?R2DSM4_+]4\4-
OT.1YJ>_LC;38[J"\IIJ6H;MB8NH>D6;>-#-T!EU_ M_H/@*R?,ZD.5;>BMGW%]9&5B=7:_5Y"S5(MV=JZRY);BM=N
MZ$[2J4W*T=B,0.^:7;47#K'RCB5)SN+I6'1 MG"W=4*5)VI06N;Y@TIV*R7:EI3AE1UFO/F,\$8EG+]5#_A&>I3]P#7]C69:U
M%5MF8*H\CM<-0%ZO!CB,/&(4#P,*+P'LN(H'&I1E9[-J2@F\&T01-MV:J7RV()"-D M\M2, ^B>$G1!V[F&-/2"='@%VKF?!71%WJ))Y*R9,MJ=/1=JH?
VR:UKIV8>_5\ MB$PDF3D]1?SG>SJ?DN@57U7G\>_=@-Z]]L2M4@;<>YX/L"F]O9NIR9]#J<1R MG1:SO7I%:LF+?CR3KV:R
Y0+'QI)2,X<J5+@X623#LDX4 MAR%-B4@]^J-.:"@S?/,.5_.K->K0'Q$ M=>\PS.(EQO;&;W18^0BR'}6*L!8&[]V\4T65QO3PXH6)\2K'<]A1FD@.KAJ8
MPY@W+M59; P3EF;U:#R9YY="=3:,3KCCR]F)=TCP6\SMG20G/4EN,@:LX-Z< MI=?$PL)K)3$7S[:D8=7L@,7JZ31^!-
LE@/R__=MJP"^5+/CUO0J@*'477:5 MI%HLUY-+2JI9W,Y__8D]I5^D5P0S>%/G69BC6':?L"N*<@R)\M5XX\MRI) W ML>F
B^GY]%;IT4FY9PV*G69[L[D#;\BR-4YD8DE.SA?FK!B-=N,5:PYE^?2> MS$UE^1F]K/G &O/#V!3\D6399FU2,Y[H^EDVJ?=7< G
M1.O$M%W!=Q.VMDT@T?,)*P:UL\"X M65[4K8#.!]0 P_#(.2F$*E5Z?3-S\+UI!0GJO1UV=N:5<(QK49-WW#RF;(E7 M>8.106<.EE\P.LP$E8EE$1-
,K*7!Q8S,!#S<$1U0SZ,+H@J@&=0Q2%#,FU!$%D1@0T@.[9TX)O?H5%'Z,7-G-W,WC"ACR025G>E:2#+U^++1
[T_8T8[@T(DNH/]!8]Q#4$C3M]C7$:A@ M8&P]FRVOZ.VOZSV22""N<,_+(427++95729&[@!W?OU)GMDOO)DY.V-,A/88O/WK#\Y7E+.W9YX" MYA?
AVLYOJ, '4!11]:C@&RL"7/8TK*D!34O%/,%"SYZKW'I08N.@D @+K D# M>FH6OD6R\|- 8^0:E41>3+-,Q@-'TX4(1+/RX/GZ,]*#N"PRI^FO$[\/@=
MS,JOOD(BY]&8H$SZO?.Z11#QAG^%$O\"SOX M'9+CA):P0N !Q8Z*!/]/'=<)##Y\I=B+SQA+TW^3Q!,\0SFHDQ@GGE*)*[']MF8T:VS/F?QD,;-T
5OQ7OY4_FTP<_@X$$$BK?%3+P?_HU\^JL4(E #67/8N MP_M.&.:/=X#MCRKGGRY"]M?7?7/-RBZS*S*G54UU2C2]W]1JM@YI>C*.M\W-
%E].ME.%6LQ)/1:GDS*QV=+!TSL\5758L?4TXL\3F%QCNC;&RZ/%MT MN5N3UU;'F]\IL598">U4)MIESA==WDH;9L')
(YPT2H5$>R&+$G&VZ'*_L8P! MRR79I/BA6TEU\F*,BD=MQ=%Y*.7A2SZ1B+M&UEM3\7-%EV9*M=';$ M9:E5M%*:VS6VG+'FYXHN[_+#3;
(:KTIXU%FH(UR6]/R@;PTD MN[3BE)]X,.:;[+FBR]7)+*.OA*%%)[DY+RRF^^S?=Y :3F@-+?<>>M\R,J=9[UA(K4]V]RE>6
M;B_OYIQS4ME+CJTE[5I+EJG5W/>6>FS[7C: M=,[)4BN3FL;Y42,IKH977)5E;=;GS0ZJR:G7-\ MS^8[J80YT!5*W"SZ'2J1T4?6V6+;_:I%Y4+=
M:Y4J/ES3WE^>.OF$+?/%#*\G:M[*W03>'KS:=\>:;)\&EE5@3K*Y_?T.F+PG M^>V+5??8!<_9.M\23L4\&1&GDF [DR)8K-OTK23P=O5C,B8$LL?
D2PAD#\J7L';U M@]2NOE\!U^#=2*GAO'O0Q,T3PGC(OKWDX4_A.1C6C9PLM_HWY)CY%@; 6 MJQK6PWY.@[!*:U@/^Y P'R;#-
ZZ'_=[\O7F=_ANB:UCI.@35L/3UVX5H=V2B MZ++F\EYL(:^:^T#W&:_R@OB%.?T?C (/E!'@VU]\"RL@7>$^*^6K9I='M_0/
M3@GSW]'FF>MN2FF96AE3+D>YU25?D+G9MJ5TO$+6\4@"OY2_.U3O4+W#@D6W MN\GZ$?UV&$L1L_'AEF*&JK1<%;14E<_Z]:=C$1(_O=GV/3-
K/+-2-L"&@P'# M!F_RC,$ND(7"\6M>UKRRU/QAU.F/LO#_DCR0806B^UL>L&#M;U_G*%_ENK[& M956NL-
>W(.CK9:32K%F'GE8&$M43HG&#GZDEB?(K2B?Q,+5&]+AA7M:OLRF^.M4G.Y[G8>]SG)I91?Q28RA=L8^P$Y:"),UD#?ZAO1#[T8M:H+I%EI2*S-J^-
RUFO1G(Z M]O56QX-9T2UXK3;<*?W552+":LC?THX)-EI(A=]TW$R,6E8_L^X:4HER7'+; MJBS$1=:K6AP/@TE"7 BK%O\$<^C]P-!6F$&C65RMI=[
:4RX19I1$## X7L+R+E\$8_>NB'"K -A[S_,!T.G:QS\'\ 0V:L\1ZPQ4C>="!ALM=V-4 M*66L!(JH#86-7TPX&2$R]=
)$^IZ6.7EL2R1CRI[H5G(F]E15I*&D8E MM^C.O3+#1#*2(!^YVLMSK?UX;JVK#?9,2N"C\5=4K*FMO8O,4"XB^]QJ&(,9 M_%H$;]<$,#R#L?BYR&(Z3-
WNY65#&=-WR<.]FT@S%Z7"!L-EYEYY 'OW20/" M"OOA1(-G+PH1]AC#D+._LW]CF]%Q8T-QC%1$G" 8D.9L'KH',68WE9QBQ7-M]^=RT %\C[@J-
+/I[N'3\&.99W9]PB$M>$73%X#'#)8]2&07O!4EVF94%?" M19FV#9[;)UR&'3J:(8'.O8S]C X>W 5LWC9?2L*Z+:!3_ED=[F(BXDFOF]O
M^#K=M:1ZQ7DIL_9A]0SP1U ^([HD\Z4!OIE03+]+:Z=I?%FL'*7")M^!"EW>-MRRZ-,IH#0/ CY_.:0$]!3+7$MI^!@Z3DD4_,W\;5@>_[*'>YDH>9 IVZ;3
MU;2YV93H9,_$>UL=&"]K.=S*G,#%OU"!@6ZEZ*6?W\DH MC/+Y'UQ5-($&&#P&]'4NP@47]!F]D[& J_R40N,%LP;Z#(#-&1WC3%R0'>4 MF'[7!$
"Z%HS8$6*!0]K%;", >D*OY_SD:!J!+R$@*I \.ZS$:'*)?!<7O9& M:MKLXN!YA-7@59YD@F]U\#8+E;H G 8C,-W9TD_NCTH.H.=W-S/1!58X;*]>
MBGI0U,.$P&/X5S:#^BD (!8B>-Z;+H*(N5^7P."]6BLP4SLL&6!G<3 K.^G+!&%XS&;X'F%004@O&H"_->S!KKQ&B". M1ER&/2\,5!L"T%4T#BK6'$Z.
WKL*0*_X5G;>ONL'DS00C:\+^GI 2BX/&.\6/_AQBE0CR =1BP; M:]ZKM] 2(*Z?YD*U&E0KFB?%F-1CI76C,2 [Z7$GS(5ZVURH+^8&(9[BL3 9
MUQGI.'CNI8+Q_BQI'A>>XF&JN@=,51=_(D*VW%DWR-13)E2.ATX7^-H:[D7.4 *H"*QYKJ[8^<-M@EJ,1RX$B"_(,XP\"4ZY1/Z*Y]",-I->AZ\N"^U[=@-
UA8@&>]XF;$ G/XHNR_+P6.ST.K[ME:,? 2#O@2]ZA.;CV[>^*)*3D?=-M0 !(!%0%79_!QBB^;I1TWZZ7LB>/DC[V]58Q\T8L>B[
M;8ETX\NIG&"8\L#/04(2E_*@A1'Q[QML81]DIXH]CRG@\87Y8JP=BN7>!?C] M]VUMB)*,-33%IB;0 M8K5S=IGY]%'X?*.P$!M>2C\V+_HU]_C!?
<1;Z.HA^I*PD:D:CP-8=]U4.[MET%QO1;X@39S-BA9.:FUGQ@C?EA; K^2++L MLF3QK57G@F1"UD/IA/$W)]^I6CVB:667T4+"VEH#+IC<[.
(F\GLKS_7HDC] M+$4&7$S/I[=*CT[*/6M0[#3;F\TE7;TB1;I\8T"P>(J4DIK9B8)5;%MV.K_^_MJ-J9A>39!Q9"N[D*= ->(G8N=U8G#4.4WH&C,B_$.5Z<+
(_M09->58\#KO&GR M?,L#,75>AS'\YFFX=UQ , 8#0LA"&UI&02):(#!^+]:"0=4_1.I]%42$#+]B!>&C MM>^^SLP\'I!%;<&LX<>@-X3>\.(-O-W#O?
@4!B\EHHL^7Z\7AS;63-/ O%0D MIV]0& KL.L"X6;XEM-!4^AJ%)G(V)ONUB7FZQ*/1_54OJ%OVC&#!TN8IO+/ M41.#.SG_SAJ:L";XQ[XO3_JMU_Z?KTX
Y5]8G E@V\^V(^G[8W1P;=[<+F M!L_X=^7@G^_-1IRN[]OA<32-GC)I!AN7I1@7IC XL G3Q2N8MGT L&(.(M+M+"CAE%LR%IGM\Z_>]-
S0<23;QE)X.2 M;1W%I"'LVI.]D!K-74*_ HVCM MLR91PUQ+.J+VM$RYEA$;XPS+;$H.V%P_G4;Q(/8O#+H$YO<.QHJZ?\+Z"_X. M@^"'"<2785DH
^!5$"H]!-^]'YO; M0.] M)VWV XCR0_BY5GPK $]68O_'!M8,;B>7"-@_L4H6#(>,.)VJQF1>AX% M_W^.@OGW5CXGTLS?@?NLX-9^9<,2.1)F_-1[RX!(X
7_V9DAW%-?Y:IS%,L M.!CYO?/ Q=#ZBC_%$Q_"#GZ'Y#BA);PK=D"QH^MB_F/'\:"#U^YT^_S!MZ, M)(DG>#D-
%+4GUB<>$HEKL2J9V9&:, ^8_V6PA0'1XK_ZK?Q9<_C5'7O?,S@$ M+.,]=K]MOUIG#NP\79161-@K(N!^M3]K]A\<\.2&U]R5 '?;?L 7V?P$DPR?_ M>
<:$9]S<.V9WO-2M%[L/V.+LDJM/9F.BJ9=GN++FRO:**#3K$P?8-?@OCP"[MEEIMP[6Y:*F.E\K+7)N4F<6P!UN2SUMN2[.2H"8W.:J4+HX;3$(D&
<)FR.&W5$Q4X+)8$]:QJKT4JCG&R6ZU2A&9ZMA9VD)':#?/VDI M)G+Y96*N+_%6JE90V$2S-"O#'"8G+1?,BK5Q1V9P99O58HD16YL 'F5.6[J#
M<5ZE5YD$O8I;DK#I;0O)SGQ*X&=>3V7&O$K.);RF&,N8*!9Z\B8+FY{0?EZ8 MSJ{L-V;QO-X2Y[FEWJU[!KKL%?"B9YAXV1!J#0RPVVS-NG IB>]Y@8N
MTZ/GU IWMQE[N&#_^7(.!G"&I9M$*B4I;&M16)5E1=4R<$M!F\N5]O$6661 MD^_L24RL9S19J"M,(5D895]PYKMAL!1]NJ;8XR);S_*)S3E=;B[0P
MFL[&==QV-%V2AKW1-C<'+4^F)&5;%NL:\3J>;VZW;G)>3<4[4/]/II2;SH>X ME.INJ&3*C4,J*9 M[9 GVITJ/
0_F7QSK(QO2G^.PWOBMJH)8(E6C8W('M#R9?)RR34J12VE[18RKD\D\.HXW89^]R0.[S?>^.9.M@\->9OK^\|=$T4;YF?
Q3=4@5GV7IN>B%\)\<>?D)S6";D^5A4E]G\#VHF! MS8.+4B/M=DZ7=G PC8,.*Z B UO<[>;.'16\;5^]P40GC.DG:3)_8_=R_ 59 MO=P&8Z$-$;*]3KV!
<68YSO4KV0W>8\M&MC9;Q@:":WA'R]3QT;)W'@",I.#. MV[M"'S^*V;<3BZ_(:0#L$_@A2N#X0>C$G^+DW27F4L]#SV0">5U]3HRJNP;B M@C[1CN#?
7N8^N/N(^9$7_WR9\-J[AG>X58#L@WO/^TOR7GL+[(.%1<>.3F-N M%0>,.]JSP5 '"^Q_:.H%$,#Q#G&91_DK4)D@Q,-8& K/FZ6]92Y"3=H3I>
M(@(BDHE=JO+S 9"[-:(E?L#*?4.DNNDDOZY>T&O&?PA$]P.B@LTWP3SZ#B^O M><_@/G=)@:_CBYBE="6Q5:IWU;)3;\^S7CZ!5.2SA14?T=9*AF;5-
S>KOAJ_M0MOJ^T :M*;ZCG8&R2[)7*PITQ-I:I4<&CEM7F+'KG^_/QW!$Z^6('EL@RH5 M&E2A016BSP.@#_1@GL&?3%*]-
1K#6(:NQ0N9B27,F/C8OT.?CI"I+]f0W7L1 M!NQ+AY94:$F%EM0WQK*B9I_S3643<[SM-#E&$D?Q55T=]2GDS%OB;3 MY4LR]0BVXNXB=7)O-
_Y,,_"HVSR8QLP003=E>!X.IP;[9%0S>MKO>^)WKV-$ MWCT/Y WCV.X^U|"P? :W+P#M&4!E77%1:.<6&ZKEEO+Z."<7I5P'WE]&AB01 M2>.GD/I]?
(7WR$3^_'JWP$S0Q+=_QCY$6CT,XPRT&?>SV;U8AZIT$A[_"/M M!]E@H8GU&";6CP+G+*U1+R.F]!Z'UZPX)Z2T@FR2*),+VKNF\-27>.Q>02!--
Z(<677%L5F\7E_R\[&9?MD6TS*#Q,DH0]M^MQ 4 M?,$,K]8&S %WDE?."R=|'ASU^]MF"XO'GE+W3(\49@OS%^4P6=@C\(%X2EZI
MQQLRXE:,P)_(>,B)1^!$!:(A(T)&'&-3XD5D-.[,VF,^/D0S BQ*9'841H M-S'*)T*5"!D1,B+$!NMQXO.G@Z^Z_\(#[L]=|<]\T*73BM:30WMP33\G4M\X M?
2F+.*JR\D6YPU_;BOPH17]_%,7N&_R62EJPBKG;Q:B=]YZO3X(OR_Q_J6D MZ2&*?DUJ?8)X2G]O8(4'RE\D&Z]9Z#\3.S\N.^03D?CNLA,+U]V[R%Z(.R'N
M_,VR$_MX$1C?3KMWP&GKV?T&&-/I50;:O>?VW7P#'H+?^J@M? MNVC)U-EHR6)CF+ TJT?CR3R_%*JS873"?56$*XRO/)<:6$GV3(-(C*15@N@O
MM=R@AS;*^N^8V77*SI%#RBQM[T42J0\8L90]Y._L0B9!J_ANZ3]IKG M&^K^H^C^W[ONO^^6Q#5U?[G5UEV[."](-DFVLMI0Z??
#M#]S|_\4@<)\)U M/]3\4/>_7O>?K?OG2&"-^6%L"OY(LNRR9/&M5>>ZNL^IE9*Z3-HR%1W:LZ9*.M5D;5/%SW"?
+7GTPD'2>_*#'6/4[[!XPAHGM17^^L"%'J=90*TS!\'A[_VC0, MM_6/!$AQ"2I[ZS7;8@IT#"=K%\!6LRB>U@VQZ9
JQU^_2"R=DL5YT#K$G^^I..7;++)PL/L$&L>F82A M77-+_\];L$9HQ-AU?U9@:*9<*!>M83Z3FCD :S+PV"=QL2)D:-F$;//() S1 MYI8>I[>@C3/
S5&#I%1\-6,7G#-+,6T36C;0X41&$E_M?"<)FO=)W? M/1_;#7WK=Y_K T#A31Q*ER"P;I?7O4VN/:#S<3P_YYBI1);\$MQ$)).YHL$5 M@D8(&N\.Q+G[7!\'-*

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|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`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`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{4KH:WX_V' CMY=/9^:OOLZ'0'\$L5>_D5RQL* ML:;J-/<^[UYF]__N:[NSNO+Y< MV3NL%V_&U\FA?L2*SSHP^[ZV$?+3W-WI_7CS[=+Q

MH;'5!#/-P.[#O3ZNNJ-W2!Z1E,-;*!I F)&PG :EZN\FL/B\E@/RE[B;L,= MX)$@ZW9YB)%/U99(ZVODCK >GB)ZJ %TO+L+8""C@6:!/H6B]>"%6DKN@"0\
MZ441H" >&NL]"XQ5!R@*?"QF3C<]J MFCN5&*')Y(O[Z[W.1/]Y51P=W)Y7_M4::M^;C=O2#EQ9F;[RA_/E M:Z-_8!\.SG*5(ZUY_?
7V\@=V^2A,7UGLU\N]OEWL[PV+6NU[Z638>_R-%;V6D^:J5:[Z]J7[GAH-R>9J-C[X W2BL#]ELKW.]^;DU^U'*CTXU-
OWVV+BX6_!X$.4X>GB$42'T/M=7V,'7H1<%(T"5X,= M*SS-!04[^1D.NH(.!H'P?E!6I'7$02:H FEN"?T/NY;*YX40ZHK0H,0)N (Z MY8U]# NL5QMQO0-
@DQ"^\E&P)\"\#S#8#;9_UGV:N[5/%_O63[=YO+<[=+[N MG;2NNB7]XM5G6S_%2ROY,W,9[DW/OA["Q@QYW%.MYTNE!&KY1SS#VAC!6
MSF3BVT(8LEB2;HWP/&OC+0V#VXSZ?DL0\&?/E!?-GGD2&HU\L[I- MLV>63%#,>"5UO!++!*87687;0_G/F+SU4OLK ;S'A/&MDG7KS-F:)^)25K1\
M(TOCYE>_Q2;74K;M^&NU5Q6!*6]GOV(2(0\WW^D-Y\ILW0V_W)SU&R>3HYW:
M[=DSTPAEJ[47QF4_3>8_8+HAOJ#Q*R1QW))S>74CJF3:S=\'O9^_#H:#6KW; M*9__^%JOG$::0A:>4Q[]LOWL4-#>3VTL^-737\Z*O0NV=[Y__];^\=#L
MCX_$M*]RO:(6ZK5U.BZLIJ4R+A9J[=US\8*FBLESL3<>3 SMH7U>8.;/R7&I M97[_^>LB;5R\\S!H6#<7^U\+VLWOGV?6N'Q@C7!
<3@5G]A7K3;6\M'/*VW.O MKB+U]JZEC#R[W<<,IO"AX5OPHU(JEI+UK](HHQ*T-/R2623J,R)Z(9\&^^[N
MQ66Y_+6P^^ODZU7..3FNW:7.ROBZWZ^=-7*YO<']MZ-+UVT.K=Y(3-(HEM52 ML:H6BFLUD4S<'4XI^R;K+*>1?1,T,1:S[V/[[*3]Z:PXO-EM?
#KZ/;SZ=N5= MIXY];YOUWW=UYU-E[V@R^E7X?7=^^HUA!^@*-8"NUU[M&,!X6UW77MWN>+I0,@TBH_?IIO]E;W3;OM&_#[^5ZUB_!D?W-
U]OVC^K5]TK3%-'C[^@ M-JHUM5!>UF$YTOAPJ]))IXL54M#5,9HP$NMN7Z5DY+FY+BEIC[01N1XJ@EQ+
MJK_)!DW%K$%3UJ!I>QHT\6JONVZE5F^Q:OVN66FU[RJ-9O&N66QI=X5RIU(J M-[1NL]J-U(<=NFQ8.M%,C;>^>6-<1;?/VN#_]7G$+RH M<0?
JCM0Y=:*;U4*;Q0K..>69LI7OG'I.+&!EFDGEK++EAU\BJIO<1,1' !&R ML;@0V!-KFQUG&&H-\[SWBL5B695F3M2@@P<^'%YD>'ZM%=7CBGHM?
!GBNX4 M5">&-<:TU>ZU.Z(ZK5"K\'K^6=@9^+>8#7PWC:6A5%].&T'(0LKP*P/[%-! M+2^QJ%<9ZX#NT#KYLX:S! AOE.T5\\]AJSC]H%>%1F7Q)1?
L')>*XUUQ/RQ M9@>+@#&3TJ3)A7O!:!T9#-,V8Z9]V\V+1?[F8Q&(,,09LQPV ,6_$"?$#J MA:?9L -C H2.;9ZPZ&T?
D,FYJ%C(75!_JNG+5+_D^64+TGDU\9 WG6[S[A>\ M:GZ']YB*+@LT8>Z(5A3Y6G1$YE7-?FD@OABWFE2MK MR"3EA&D8'2B-
:N,EF!;R$K8P<=%#@M<_#=TP_89?.%TPCC#!7F-\#S0RC_4F M5 X8+;[FCV-4*8B]0W.&90VHYTX ?RJO!ZJUC#&6\CN#.>P1*4M'D%#O$ZR\
MI^8\P:K=ON4P^45H[Z*A Q)ZJ?#W);Q%V><7T4?%O[%F,^#4!;"AW441CTN5 M;2FH*4W':GM\8YQ. LSO[?(^%!IOQ",%"F\'T]&
[7;A;RBQC$M1LR@L!CFU; M;Q':B4CTX0PZ!]]J8G:VM.[(2+4BS!QGL:,8YI MC7F7_!BS5@M;*KMT$!=?0V$GY8"74\&VTZ[$/0L1Q>3 NR5/1 I-8'
MH0KB/ICM<"&I]'"F'X>P3OI!D,?X\LY0U*9+]!L9*.F01T&N,1^"0[5%^/7 M'39FAC4BUGBP\'M8O&A#0;U
B#ZP5PKPLXL<[_C]+EH,J&LL>DTPDJ;>!_Q1 MI3-2*RU;-"ZQM1'S$ H@/ W9/BC6!KW/HQ>R(&P0VW)?:")H MBJW(?##*[M ME#8SC!P
HL=P0X8^PB8CFFGQQH.(0$!5VST^/5M+&E8]>KKGB10L8[:"31\KWCI_,?3)@RL:$'[["B@E'$'G7B(KQR:'5@JS9O>.3XP Y1+'7W(FO(MHU<"<>H=@ !
['$F[(4WR$#="AIF==@0:-;EC0<"8/G8QGY7RO44I1!:P'2S M>2\Y(&"'@3ZWE@$8T MEZ$V!JC2.FR$O0%-
E]9+C3Y=2YBOO*4AWJ.U:9ES%^G(G9!V'PX]D^7N/1U0 M\5DL5;^GG["UF-YFR3(OJ&,+J33$O8@V$+_,D O5>(_*Y$* EJ!*^&H-MIW&#GRQ$_^#;R;'@-
N1T1C^%N5=(0,-"AU=SB$N0LQ0# M92R):=0$8822"D=%@1WX>C97'&P$;NF0<;J%!Y)4X!87M2[BJ $ F(XEV^_1 M?>*;2=;S)A"P0/X"C[K%A102EPK
H#?83&W4E,!U#[/4$KL@VK M,K&S'3:O P!?[EVI0D]VO+:O6+"#J5@EO($B[7EEI<8AX1Y%B!%JY@]O(3;I MC$G*XF*G0 #KW4>)"%>@T0%BR?!
IL.U#IN2/-@>EVO,T,/H27Y7 MI"?1($M,$ITM)"P?CG,N;'UA3[84;]SK*#U/[Y#U'&KD0D"?T9=A%8#R7/8/ M%H"VA, %R@:BT5QK9.ED$9)U(+Z!R[]
<[3I^*B&D5QJV#9 V1B M\2#X41>"K0O^!#&:J2R/KL#=8WULH=D.Q;8Y5 0%[DTOHHE-8P$:R.;A8W M&3S7$K(G,"-
Q;;#LH.LI]O6B%75":WS6VKB0Q,@*7QI"A9LI!#O#Z@'D8 44 M=*:V-[J%'O-O.7^U^/'?U,OY%(PZ*C7& M,W\U%)K B_^/779EE E6+CE8.
Z:WRR2ZRR@#(K9^=%-+B!F.PXC.4L/&)G8 M?X'-PKV=.=EC4%5&@+C-/^T%(DHY16*[>Q"+.<_,ZT19!8!A:T0FZ+0%+@^1 M??" .8:*#*X9&
(@5S^2R+9!AX9;3XJW4P_$-'W:6LL/.[+!S>PX[$]#JF@FR M'ZR\SA(9IZ+CY7CB7,Q7(]2,U;6L 4EBH250Z(P:O.0V.7A/E?:OBBE@F-Q
M+3<"Y#D6J'/]%@O6 KAYH7:WLK6X8G4+S#/@6!(A?) M)K3D)/&XIFRH# O$(*STT(3#=,^C^TA]F,A)YPL83)#'+50R[8G'_D?V,4] M;(IRG4#*0\340T:
<'UR8JRI0EL_7$;JYJHK@ZF$5K9"<00FZ_;MG3,0HE(>I MF0$:KAKM=]G9GDXL/=WHT&@#;16JR!&R*9P3I8B@^3! XQ;;1^.LEDBS97^R
M3:29]UDPQ*57!T/M"+"V?WZYVL9YB,_,MB7;0>*5-+M'\KN[/Z^@>[;1]Y5'74ILW'/=I0?R6]7S/>KZ_FY[O":J'$PHJ
M<;]O5C_L8KM9,,B#LZ5C$"F@Z)4=J3-"C!N^-O0][?S$ZN#L)=[(6%[(,'5 M/B&-'LS*X3$R&D:10C^($';N(X=_?'8%.O0\E,S;;U@:
MG7C2818UGJ8)'E8+=TS&G=B\H$1RI^<-)!)!13%S)C+CB(;3S.PC.9&YXD!X?6PIZ-)IQAM M&J+H,IY6,PR%L.6\)DGM8GJ2/FS1G!0OZ-BMRUED?
(2#^(5/=7A@8L@#3_"7?"SL5.9526^X\K[E[DQ/%8.P6?Y^Z:CE)X!I#E,MWT-T%2 M=.)GG88V+$YX K^2A]3QUVMQ\S5E=R3%#8$:Y-/XQ!X6ZD38Z@[
TA!&A.0? MFF1'PS2[-JS&YQGN+\%#_Z@4\@699,6-OI&FDP_Q1SU?]2?(ZZ1,Z2M?CG4] M&K4P.Q@/$02X[.EB:)9XL"_G/C^*.8;2BMX+KP"4W7-
T'@XPA&WXNC@5O)Y MP(4AJ8=)93W,^@%_0PTQ&]^-H\'30^^@O $^$(?O N'+Y39/5F!,3O3A@@+/ MJZ-?Y\%K\J=?1@)"P?
HH$VF(TR@H._E!V*WDT[3(PM-=@Y.OA XH+33Z;&L" M)C\HL(_$SK:&YS,]?NB!1[(YD>/1 ?AR.P);'/-Z2?DA-INA?0/,A%SK!&PW MEXE"!S A$3 K&*8M:,
[647G-I7"'=%4@O<5" BDN9,Q?,G DS@_G[&&Y9 GG MO;+@A: _;TO>P#1+VGLCCSPE_8!;G]V W WGS\R"1O4D?@#B+.KS"F M3+MY9H5_Q"R8
8_W+!*0E \5#;/)Y*802I\0>'*"96]_\%.YJBQB@A(LG- MT.%0[TQ]N"H.9R5]9,)L-)"Z@,E>SPSFQ@I0C,E"%0#+O:\9IXYJ:95SV2+* MOS;BJ"T(2--!+-
\OH*%6U46VJY7I5#,D)U6/X?:?P ?Y3D?\QC,L#4W_4 M\L5*,/.&3VO&3)@>+*J'KI3?R2]XIUP+],:4!@B%X19L,FK@^8&,"-*E ?:& M3^W*V:E==FJ7G=]]P
SFQB]WHD09&G?L?(G$;NP7B%,]P7.6/4C60BF@? M>!21GLH-"BJ*Q)C&=D1M1")UFA_I$BU,')L1C)6#3)<3L'S42KJ*K'"Q'R: M*]W//H4?
1M)H%L%P41%:*-8"TT0:0!BQ=C59'H+S[P1"_0) !"4=FG&;REY2 MF!+4>*A!>(G7*@H7DD=Z^$+GV6Y^+I@:C@SYYMNT=8:AZ#%EZJCA.*M(SYG-
M*U;E4'6Y*%ADMRMO\8LL@U'KAD:YS4 .&C],:"-\ 5858I6=9G!/W!^] M'9IA:&(P"[POCXD,+OX(;B&*48#Y1?3Q/>@[I66H
87.T$%6\$33SLQ'(,SZ]@HZX[J'WH MM>$/1B0.;+_!^9_<8A272-MSV1VP">#_^E]J8+>O\X*0E*4GE@I_A;UQ>FKT M&I)G#S8&=$T0[AB8PQ(A2@L'AA
5BYJ;\#D*&74E26+H4V2>!&DIZ.?1S%GSL\'R+:<@VU5*AH(*IO3)@IZY_+<"JG)IY M*FC.FN$,.==9%&G/@7PQ7XY ?E. W_%ZH/^#/)&HMVLN96 N%
(+\E[G<=)6 M#G %BX2@#?^J6)Y@++/R0.R*/@2!.^MOP7=G162R5*[G"Q%XY96;D;#2,!5[MPC=$Q\93RZ9MAU(:>$D0IE9$-NT'=*
[U,25TY"0JB8"33T,[6)>V>'9TP26 M:&Z-RK7SHX[UU* ':7]EWSX5H::E"D\WSJ@\T;2 MKJ""6$G8,(^Y2[QF@Z-]W62QQ]TX!VRRWRE1J5CS"CE=UP684
MCR5;BL?K9/31\=IHG()\FSERI)BZ)T8USYP]8M0=*T"MX.@'"VXZU(W"D9:4 M>"9WE^!]G M-M-,M M?
S2+^4IP]"%BVA0XED0\^S+53XDF_T0D.?/:72I!6B54 MG=%41E,.8P.%AR'(5*?0O68(=V*^_".O(?#]P)"7LRJ$(!#76PDY>Z%$:F8S*",@_D0U34?285!
[Y$AEA(U%^ M?HFBJ4_E)6#:MS&*%8UTR=86)D-9AC;^/7]J.O@>PV((+Q:=X28P4?)8="GEA MY<8R&?@V(^08TU6*+5"Z1'D>A<]4W;")U,]1/ MGZO'
MRB=A HM <9E(S2O[GHVY(U/+FCT+C23=81%NJ#28GS3Z!Z$:];'FZ3 B)3*Q MQ-905_Z@U M;'8:/3L.;$Y5ST^PJ !(Z\96I-W3,Q>-\8&X_8$FQ&#> %?-(
MM%1B3#D@=,**M!%0?QCUBSE!Q3-:/$*>PA.71VPZ:U$V<:4V(ZU05Q.1(AW* MR^NPEAND3#OJ5$JE&NK(I!E<##JRT2"ONB*4VUB#Q(^HPV>
3Z7LW7+>:&$> MEB9+$C4]FG"%**%VA:&43H(ISWKR&GF)33D9/#6^C9G4>*#4,QI70H;Y@;P-3 MJ Q]J%/))'58Q%P+OW.(. *;UA-XT4(M,97?
$1RD30FHQ'CS$VMK7I")9^+(M/6P"N6#QHS&?4U4+EMZA;) ^NS>E24O ;4A9DA-C<^1S8>&_HI6D2OMIB MPY-
[>99%)Y#)9%,R,=RB&T@40&CP IZU@W 7!P/1#)Z\LH>=[/6N7)R\TY<) M4ZPO% @JS19KX\@5^3SL/1TEW)D+.$^$(> 8F86I5#%14C*4;T%98:9<@$1
M+HTD#H1%HLN3WG%& 6\[SKO?\HYL';]F< Z!6Z\\'FK.G,G;H$5_*"='Y]W4 M*_E&7AS8:2-2,Y/U-MZ$3"G.@- MU]>,KF@,5P^Z;K>
(5&G%#G>P'#%WJ6\]\-[L@>Z80[C32Z/)'C2 RAN.0OGU M2 I46,#I37FP+:PTI[YV*-R(I=%B& --RG;M(I%)Q@<="T23S;MZHT;DB2=\ M
(LCY)K10([ICDM$IS"(OK"]G)9%>#@'-""Q(U]F9$1L^H!!K1 ;<(7S.J M$S2.K[#PYTOD=1CP68_7;^A@ +5=64^T:'B7%4T<#!D5?BU)8%9<,7]0$*4L
ME_X^U@$H';P9'[8KUG@IX9T7^;R;G)8SS50A0;_K]XBG*7"PJ;E#X>)>7:3% M]Z+USM%+N_-J$-*RN'6BB6?
D;W+;4O2_$94>LSR_I@/ODN7\@94E7=UH$_?IC6YD)-2ZF#]J;D? ; M7=GBA5PNJG[;P+J>90 ^N3!)K:&",2);ASK(B(QLV6$T*/(+Y;E&79&@38,(
MH03MW.>T1@UUJ.9C6G@3A"Q#]EV%!?T(GM\UA.@O3%I@IP-Q(KFUP(0'HYK< M9JL]R'&;#
(,@V,O*EV\\&QP==T'IO+$#&XX,:X)=;IC9TWJ\V=S"VE4YMR7+ M=O(XILV;5-!',@R*II$8 M(1BU_ED6?_HSW&]SI31OP&%%@V_S^BTSV?+]-8JY[*9S?
9.^H/=#JH21) MR1T^@B&A51$- 0].4AQ;L^W=HQ#$=C4JO8"]"(2>[:6(. M.;)9#E1$I!DMDD)>Z&\M^%*!M M<[R#>BACP-?);S*-23#+XNB,3)+Q'?
\LB/J$7T@!>VJ!KR#?,^R>*8#CHO1 MVWSR32O4P"?2R2IL&*W0X8R.@3&2;W=$'%]TC0ZZQ5SSH3OTJ8S]4\=H?@7= MQ=OA\D@87R_U^8-
PGD*!#^J%#N@MN+,YH, $LLU.*.#7#%%8"&P9N+.?K0Y MT@77;T3-I2R_@H#&#\;G6I$JV8;\?.[RS'DJ/J/.E*-&C>8 K^$F<%*:SQK* ML[2)J0"\7V\
[*/1OB9P,0;Z$60I* N[;M@4&_1#3=T=&:,*J/+_TBZ\5*HO$ M*;,>;@2?@HMS@+!$ZD4;Q^!2I^"Y;3">1M"R-A@\RRH\4CLTO0PQM"A7,#13 MUC\I4!?
[&R'6$GQIXN!!X8X2S(2)$']\A$] M_*$:WJ_*%!7NC(@3/.JJS8\RA#01A_I!)0W/DN99DF*HUI-5SBO7W'"1L:#_
MC'C(PL0C'-4L)EG[B3[X0)V^$0.WULL,FI<*%.U%[L]PS8YSWI6%DKVBTX
M>SACGD]B61I+X.,4Q5P[&OS\0'$*WCOP]+.JY"C5ATZ$^.V9WY81G!!@+3'$ M'M3*B$U36T0.!].:4/FV:>2WS C*""HCJ*E4L07ITO,-@%B5?T:,&3&&[
MHAEA2[0FY?EGFIPD>@)K%FQ@!@B 13T36;I^6#(0O/-Z.7B%&;8*WQ)'>S M[0\=DKGOT6X7JQ?C9!2<4?!4 TW>()JW:&6F#8@.C^]#*2IJ*Z:
(;O;4B89" M[\JKY#SHS";,:&Y:A?N-7NG ??%G2^C2AZ /%"-0W3RSM"%CM: MEXE\<']TL#^<7HNDOJ-;G1.I:
[PLA%K8^W,XJ;LKCGNG%M#6R#.D],XLA8SF MUZ-YS!Q@RN7>E>C_0B5!$=M4MNH/5;OR7C(9-674-$5-H3X2D?I//]M#G#^%
MYK_:W$X,>41J1G\9_3W#:A3U9*)^4HQ U0SXQ=8>@N2-\#&=T)3"A,QT9T9M M+Y-V&
(,.SM2MF5JJD##,Z"BC(WYVWV;ZR!699J+%B!QD/:>U26CJU4W^"H= M6+S#[6?,T=P)#2N+I!Z)$ ZY%Z&'>F[?XL716Y?=7\NR^[/L_BR[/U,*;TPI M+#
(N5$4V.@\:G,NNYCPOAYJ=CS27TBM !708ML$0/V*S"IL/U7)%DE.@'>9W M1"?JI#.!D,J00]YIM.NJ@7T_)PE>W3=!WO8F60_LC-:G:=UOT..WOF&=<&"4
MQU!QJK'!;'F?B*@"@-H3/UJZ.,G)3S3*^DUFM#AS=.H/T0X.45' ^3V'P@V^ M0IZ=ZK?(P.8'W. .?+WI7+=%;Q'G#O(TU>_5X?A=$:2S@/DJ0=:R''+]]C*W
M=[/.4!)GFX >5._K"!5D8]8'FNVCAL1(40Q@([.:E92/[P34]BW'^^ CF^6 MU701A$PG,,[I2$$G/3-
O]EOHF=A2@!]D\CQQKKQUFG[]DMZ7"34M.5@\$3OI MMB4K+&U^XY*D6TFP1];V<)U^;UO9/U)D:L@Y]B$W/KH_O^=$7ED%"IKA6'[6
M/*I*1HDA2'],%!])A4@K4F3/4P,OGG!IV:+-)O43Y%!"^"6R90=D_>+Y^WC?>)7%1KY#3=T^6!F$_OOPC.QKR%/^$&KG4B+ M%U^A-: BW=ILRI>E=?
LR)-2(9::^1]IBH4WC1U=L K\O.T==N4-]SR-&_,!Y)8T#EQ$$V/=T;G' M^[&O=SK,)$>]42J4_PZO]&W&ZNM9K#Z+U6]/K#X%BN+U.
[HN:^"*&>6Z$ZA8 M%ZB*]XAGC:U_+<6&9!NN251$#- ;HO/XF_DFO 1QJ$6S-(C6W.+'5]QCA)WG M!,175#G/")#RM:%H$V(-^;;-!4-
4D,YRWJRB%/>A:*]_J=9R M+,-S-R-/IA@4Q%]U61MCNF]U*@@;'E.!W0586!@QSA?*&5[2B)=ZAI<4XJ69 M;U0SO*0/+Z5\O9+A)7UX 3E6RO"2/KR
'*MG>$D?7HKY6B;'4HF7S$Y.(UX: M^48SPTOZ\%+(%S-_/X5X ?U2R_"2/KPT\YE;F4*TE#)S+)5X 3&6\4L*\0)B M+%/[*<1+YE:F%2_E+#R60KS4\]7,3-
X<7JA<(EHH\Z+3X\2 T'@&$%8BR)6" M36]INVW+P__[T/UP[HV>#7?+,DL,C]G8O2H #_H'47FIVT07+CMA2EV\^'7 MBKPSG$:$Z2Z8K7+"DU3V9I-
41,+E?UK/(9QU-7^BM+1VXN5&8[GO$"0\C+H] M++9+]68QL=!3L(BY?S1K&8KVX5 MS,O3$H!2; 9I,G#CY6,9W-;SYM\.5[X6$Y8R8EJ+ M">L9W-
8U_C(F3(>]\,:)25C8&=S6"N"\9;B]EJRJO6TP):4;,_MT[=A8IAKG
M%&EDQ+1>$44&M\P^C04HYS,P23"0]_;8IUA5ZX58K9M,'2QOE9)QRPI]2]+*+F6U4,J,I]C#96_=>'JJ M?
45:R;E84FOU6>MI*W(4S_PA:W),UM:F*\9>ZI)0LN'*@NK=Y [.\/FF<9_* MQ+\X*3N9PYG447;B"7FO3MFI/*V,N3PQ9;M[?RWU[BTB5S
MF&:W^S26M,/&S+!&.(;]+74-KAGYYOIE;29-& MNF#"8W!;QRW5IEIMQMB(Y_UFBB5-&^F"B8C9;1V_9.98?.&ZC&%F@WQ;QS + M%,P;3VLK-
N@=UY:K&8HUTR#KC6>UB=VE)BXX"Y>D^239M+>D=[^!<^&J6BG' M7E*9&H9*.%"8/@I*-F\NZ=UOX%RYK%8+Y>Q<^;7RZI*FH&3S[I+>_4;.I0NU
MZO;FY15+J;'H%B3]J4U3B2;R);WY#43ARQ6U6HZ]!#4U#)5PK#%]))1L)F#2 MN]\ Q7*:K$6HTN4F73+4P63)J%D4PF3WOT&7**B6J[-
ND1O*=.0OX(R#;NV M-92!1LM<,\#XWC@]Z99J,4<"WZ!;5:RKC4:;[K?MA!RPBW0UB1DU";5 M>HR$_#[/?
9/60C"QMZ>550LJY5ZC('B]YL>MQ5DG'A_LW7MBF)#;93BE,?O M-W%M6P@YX3YGZU)RH: 6*Z7,LGCCKAFVQJRYXP_3&-
Z5[(!F92!8;N;E"W8[G9/.4Q1GM6V4';Z^H]MFK*SX[+T MJJYWUEDLFW+XJIE(6T'9:6P9MGEC)!/963.P;:3LS!C)VGREFK+?4E9-;2;@ M0WWI==-E-G-

M2"J^CL?LW!84;5>LNR#|_!E&H =@3@T3M)FHT8BVXG2%I=J$; [F=T@WMTZ% MM4,Z4\C!

*[B7[+'<8H%)46U;AL+JJPZ<2LUPLN'MV_OG;1Q"%E{C'P)_] J;+ M>[1KU_J#7&3;-26V,5FW;O5.*7\1L">L M/=VOH:!H2-HJU\FG#JK-?*

JX'3[XTXB^^59LG\H_A/_J__V?=_/*X@WQ\RO_%JD>(!3G4$PB^CL*O/H?'_^HGHC&/[__YV)V M%W_M/A53+(RXF"\^G'S_?KCA[/^-W?DQZ>?.O_\Q_#*

*[/?@"&_(\$6^\EH)3 MPD9$BI1@O=I^/7B#$NF24:C1[KDZ^FGWZM*K MJ81P1,JQG9HK9=^5K?:2<]H\NZ6JK:CGUMINV\UOH&2;*J2F;>DQV;LV=^1/*

M(W>K14?2#9@WA14,.)K? M6G0$UM)"1_W.[+#J5\4:JWXFN*>E'PWAGZ)<$307BT]fGNW+'R9^>YV(WL)S M5O0GOWC=?*

*7_OAV]_V7@76(A]&:9.]@+DUSJ:H5C*I$L1R'>CJZAW5JRGLYAVM7EQCW>>B#?:^MT.\\BN3@^)1%*,Q.\D^P^K<_DR ^WO@Y*

*MONWXE7*GQG$\C]Z]?7MS.JU:S>W4 MW*:..$ZGAK&RNM-I=.JMMU[.;32Q],'P$+=Z,M=40>,KL;3JU@, M#,.E@-*

UDE$2QU=%BGV&Y34/P(5RA(V%A"I+_'IJ5F.__G;5?6-]_'ABO?9G M@R") >QZ68[LZWYF]-ZVFO52?. JH4_5I1O[Jj(:Y_ F6 M"-*

A6K58[:>/[;G5JKO.0"MC+V7LY7G1\K'UIUOJSU)_OEC]^6CAD37Z<_D\ M9:D_#XQ=2_U9ZL_[Z4\7_,]2@98]\4J4/<9.*!.FUD)T01/[+S^K*0_?*

U2PU9:DI2TUY#+*J3KVU)C+-PY=3VW_O?]Y4?KJ[@-9L'T#CRK&%'34GB7PKL4WML*[R^7 M9Z7P+H7W 0AO]4"POJ>(92&W=H@Q4M)L N0,-*

\XWQI_O)02A[+6I"J^8;)P T$P M4#3<<8J 4G7>+$B+MX3$>##

*<8_%!;_/MEH/A#4#W;*PSZC]HJM]%@DX/,Z8\VF^*%>G/L)GFNR,GC\&Y")'[C('#R^5[V.XVSQ.(O5$" ML9= [*MY];EUC%2PZZ)?';;<1K/G.%5LPCCL]_J-*

*3JW7'S;JPWJ_*CS7R\&N M7YW_>M']^NWR[*K7;-6;G>I^,=?7P1$ORLAL:'L1?XN?^V(<_6&H16H1GO8] M7_-@#\[G5]JLHC]..;N+0DVEQ-)1*

VEJ1\]M4SDQNRJ-W@PHT;=?3D6DR&W M:)'<5)AOH#>',IG!4_1",+/' ?6O?^:X])GC7._8[?]>[;UNGVW+13H:5?"1 MUK[V40-

*C#OWZZ]G%V25U4+7>GW^V3C[;JT)B"S%X,AVW3J1NN:);O*EFUUH/ M\Z9ZTVX[FUZU93QPNTGNA;ZG(I;OK(O@FOMW-QD^==DIK:H4U]4G$X+C>*

*&7#[\E.1*7P?3G" M=Y&V;$_AO^_M3<A;FE7O2!*LR6U!+=2DOCED/AU$:P.6M'=P2!(9C&VE5YA6#U6 M)<:JRLL.A*

*'*81S@,)YGXK+YD(E+,]RO#,Q9#$N:'1MS5EM4^,X$OXK.J9F!ZIB.V^PE,-0 M!2%SFZKA99EPM_M1MN58A6-*

Y)3DA]^NW6Y(3YV5FF%M8EBH"D5M2=S_=3[?D MLW]YW]C(:\&SA/PRN?Y,$A%7,U9H$DM&-8PNN,[(1)0E+<@UDY+G.;F4/)DR M0CIM_\3O=

*(_]MN>=G\%:0S=)%"'I=(*3H-ON]DG[..QUPWZ7W%V3PX?)\,A(M7]T.)[_?*

C>RV=P^7G\=#)A\|DY!0G.=L_.SH/YK92.1+._/$CXG2B|SJO%@1N64%YX69=AKEWH M,P-

*XO"7SY"UXHK.PTVZ_'Y0T27@QJ7*6ZO#8/SU=#TD^S59CPIH62I93S>*<, MUVZL&N>,RC 2.AML;*

*[!O9EG/2T6AO93.>+X,/TSXC"ERPQ;D7LQH|:%E1^"O M8I*G'P9&6O'_L;#3!?,T>](>S?D4%D==!];^T)F.TO4^"5=E3I,"_* M1?*

*S8G(_FV^^\2""RS!K6BMZ)\R2N!T[?4-T](@\+FZX(9GT4B3V#*Z"GC$=>D MU_$[Y"R(8(WR)6QO;]H>@[Y,UL9W^Z4F[?4QJKZI\Z;2P]'}9/QI/+R8C&]O*

*MR.TG;BXF9#)+?DR M&AKM>^TN6C#Y942^7-Q?7MR,OGBWOWT>_4XNAA-\TFV#Q&L8X:+F^-COE*LX MQ"#=@F+<(O]F(DW)=7PE"E%-*

LQ:)F&3I.2#;G;.$TJ3.NR\5E8|/OB3WK\12 WF23T+.2GK7.6D/.FWO5_N?2,&^_M@DF**4\NN2!#X0_>RIJN3RZL.E1/9DOR6(A%S]*

*HM*Q1TIJ2"%"@$%!-8"]* M"T*+):D*+2L&&D.I,*4&+*-D!M\DISE):0Q#BH@9Y!+65FY'H& Q4XK*)8K, MZ".#?1MK*AA+0!G8,L?*

*0QCU0(.82ZAN(0<53H$G")%ED/,Z(JO!C/7\!H>,6 M00-F7 $/(WG;BBB9*EEL%,1U2U!-)&#F'*8E)%HVW?!F((6^ 1(C*2_ #>C1 MM=DM0*

C$X;%L/.=%"@%[X\7<5XEL":XMF%C"V#A&,0E> 9!1;"A55BAYARF MMK:&P$A,$6NA1)6# $ E2A?GRN@34Y61-!<+5>,HV90K#6V!)A0'K=Z@9;L!

MAZJ5V='VS1#I^V2RH?Y/[TZ[G9\'ROG<,16&&5 9AZ_&L#&ADAD7@DMXE#,T ME3# +'[,A^A47<^'%BQX_,PARK3&$AQ>T(YD(#

*M;>MY5.V[^Q*W96I2=ANEL!&:O8T_2""MOAJQ=_Q^\?Y, ^UW_U,!Z2)USKIB" MD@MV&3KY/@8M9+]85NKY4Y!R(@8.=#M9$A.5A*

4@[N=8X/.>0DZ)$SA/3W:LJ4CSA5'(T@%NN->Q2X$J50OXS M\;P,69K<@YX<%((NVTPJH>;QN,HI4@:89918\RC,L*S<+";P7\10$+(;YK/D*

MU;+X.8A'1V03[&?'_P[FS\^<9T,/X3+G"2)%9R:D#&H@FC NH 'T&9O$W!">IF=?:O>L_;#E=@3%/]H+T RF(;"KBN)+HI09U[5EU)I2& M<3R*

*P5HJAH7^L-T^.?S*E!3@AN38DG;*0Q_$3+>,C711K?0ZLEIE5*UX'M/* MA =+#-\8?S@N6$)/_,ARUSIOR;?^LHM>-22^>PP_G\[+',T2^HH;JTC'A.P*

MB>0Z^!&+'Z#]G2]J4HU"I=5"JA73F@%8<@:'(,W8-^@E$L#E^#SAH)]9Y!#P MAFQ6R!;P%^M]':3LCXJ#^B8@JR(V+?;1/Z)SNH##

*I8U#IA@6X<-8LP9.-$1 MY*J#63#ZB(QGRXKA/%.0S:&O(CC\$#2NV:_]]XDH0E.5&R5(U^%T951F)8 M0+5K6=I5P+FJFH$?P$W&&.=-*

>X]8;TZI40T),&S$4^9\@^!9VZ0[UT"<=F92Z6#)XN,F&SC&X@#M:T%V=UKV1O4!%%?#FV-S[?3S FU>\ MX3;MGULA@JADTHM%GM-

2L;#^IZD#+IW9&I&\<4;_Z;]]FHW.9MMHDTW,K+ MZ1):E)!66KB+WG[[/9JB)?PFM2IS9&*H9IRE9/3$X@H[<')K>XE7V=R V%D!>7AGST; ?*

*3O['VU!%YB,K-]5O38] MX0'4EL PXPGXR@36:;?=VXPLHXS]S.2*F6C\.)5P_DN0G80,ZXANO #;?.#2 MI+N5-G4.-%^\N9'F>[?M-WHE5"XO@OK_Z-*

*4BVD<\$3%]NGIWZW_[[./3O6 M-J^N!)M"\^KQ_$)02P,$% @ #()F64*_5.:\" 5!\ !@ !G8FEO*

M+3(P,C0P.3,P>&5X,S%D,BYH=&W566%OVS@2_2N\%+N; +9D.TXN<-(CN/L M!FB3;.KB;C]2$A41D44M2=GU_?I[0\JV8KMM>IML>P7JV-

2(G)DW\V9(GOVC MW1X7&2]BD;#?)N_?L43%U504EL5:<(O1N;09FZBRY 5[+[26>!&/= M3G <='M'0:?=/C_#7/Z)54,6+*

<;'H>]3J_/.D>#P]Z@WV5W]]G^Q\GHP$E? MWHXF?]R-_;)W'R_>78_87CL,_W4X"L/+R;5_T \Z73;1O##22E7P/ S'-WML M+[.V'(3A?#X/YH>!T@_AY#[,

[#3OA[E21@2)3?;.SV@$GX(GYV=383F+,ZZ-_ML&_W/DZNVB>0L-+FXOPL7/[ULI%%N=GB9PQ8Q>Y>+LWY?I!%FVKRL%AI[2G*

M>#/$XPV93^VY3&PVZ'8Z/YV6/$ED\=#.16H'1\)R7I(RX=L-.:\;0,M_-+R(_AKA);1+Z=. MVLC_B$&WASG[&H/:.']XG'8FC8QD+NUBD,DD04?

GYSTNL>"ZT&D;':ZZ99=]KZV&;43H8]5T\'12M:YE7X^T\Z_KN>FFC^_Z1YW3E]H M\GUU:7?H^'D^O:&W5ZQN_OKF]'UW? =N[]^&>(K

MOMU>06)_[<9\0R][S[>?_@XO)FPR2WI,!XY[0\[/:)@\MN8?1C>7PQOQA_: MM_]^-_Z##4<3>M+K=%X'"5D@QD%!1T$C(BF)-J"X;K'WW-

H,L]\H_5@5W+18 M)K2(%BP6VLITP65&[8#]+1H>;RG8#=@UR_A,,"UF4LQ1?6PF#?N]XAH Y0MV M+TJE+6H2NU)ZZO.MVVG_[K^IE/T]"J$Y<1[*

*D(J-5'#ZO:S!>R"&U=!V73! M'@LUSP5J;6/&P4I'E+]*82F#G# M:PF+%DTW?#>0#K\ DF"I+. &\NC:[!80@C@>Z\9S6:0(2!]XLHCS*L&<<&W#*

MQA9@D13$)3Q#H!+8Z,6]4 -4.,QM+(S 25V5;)%'E$!4]]SCW#A]8FXREN9J M;I8X;Q@=C46W91FG0:\WM&PUX#!+9;.T 6Z(] ,V>;(^E>[N/T]-[?.;J2C,

*M5)I*_'2&73.NA7,A7'"*C7)"I3_"W*)(J[OJUR8FH(.>;M[M"\._$],4H\? M)7[\P$TLJJK$7NO M'QSMQK3?"TXAB5"X3MVDR561D*

*M(KF69(#T7.O8I;"9*D/\Y^+9.+)TN8>M#A3"YL6]5*+FR;C*.5$&S')*K'D4 M;WA6;A83?(L$"2*K\;Y(7BV+GX-X=,">@OWL^_"_/F9\VSH$2XSF1"BW& S*

M2HS!#;!ZA[!S'6R=#F"0'*_HR!VW;4L!.!#QSG>Q\X3T4;==,,3TJ3:HK#1V M4<"![JD$<*YTX!5P%??#-3 [\\424%%@D@N[8XP E"7(X/1U-A[? '5<)_=X*

*MQO/*90 Y0Z0IZAFVA04:D>VZM"+V9V2T_[F[5#EX\2*RT?B"&*G*?EZ#YW . M7TD+JO;IUUL8%BW["!>QPGL"^IRZR;\C.,F2>;W=V_ZCEK,N,.*

]3I"^(06) M354<5YJ\U"N':-.E:;8IQT8YC(Q)GK3=_ML_S.O(.;R:$A72N./DBX;ID: MZ:);Z77@M1UZ[PAW_K++GK5D/CJ/O#H M?^VPW-*

8L6491:QWQE(!-)-?!3UA_^UO5=F5:AR5UBIM5DSK!C#E%)L@\07 MZ"52X')ZGDCHYR;9!][(9D-L@;]4[Y=!*OZL)-1W 5D5L6NQ#WZ(SFF(S0*5 M-*

*0E,J*YC!C&6 DZL"7+5P^P=2<(3 MO&C$*D<^"V-=1O$*L$"U:WG:->!<4TWA![C)&5-ST\XMUG>GU&@)"9@SU0C% M%APD7/;*

*Q6XW7&/1\L0CBYG*9X+8I^ /|;9>UPDGIF6N%@)/YYGR6<:?(UD M7H2:@Y?TV9)@3K8(YA*V#]@-M)A&4.2XQ=S=P0NM_>73X;7@X?&30[GUP2\=*

*M;;N@[=]Y/%P>N_;MGB!"50K=CE>>|-&*P_-+4@;;._)E2@^6^=FP\.F#.NE[&R2PS.CF[6L]TKQ\W;Q<+5%G MVQ&ZE<'(2]/H_+9G$CW7<3;"_+G;WS^?*

_!5!+ P04 M" ,@F99-.Z(2P\% %$@ & &=B:6\M,C R-# Y,S!X97@S,F0Q+FAT M;=58;7/:.!#^*WMT>DUF\!LO&6HH,\0X+3--H,37<@C]|;>R*

M(36DG70N2.^2F?"BE5;/KK3/LWCPAV'X;4+2D$;P+KA^#Y$(BS5-%822$H6C M&Z82"$26D12NJ92,<[B4+%I1 ,W6R12%QS'NK!;=JL#

M=M=MM]Q."V;7<+8(O/-R]GCJ!9]F?K7M;"Y?N)!P["LO]N>98V#<67HF+8#

M@21HSA03>&6Y=\TH@$HE;F6M=ELS$W;%')E!7,K&O=L;@0.34C%36& 5V" MKY1$P\&:*@)A0F1.U9O&(K@R>CA#,<7I<&#MWZNY2Q%MAX.*

*(W4&NMIR^;:R) M7+'44")SVW:F^KC20O/1G'MCPR*5N(YMO^QG)(I8NC(XC97;-7N];T.2K9*' M,5&%YDK*B6)W5/NN>0TY)=)="I7TCS?*

*XWLILORX6J3)BLF9\Z[X*V)KF<$,W M,!=KDKY]5B/XGE/)XE?]BJ.-TJT#]?.!=V?V!EIW"N72IZKPS"*

*MV0J1ZT0<;C=8'FRRH66NEH)';/3O$[9D"MHMTX&!M1P^#:P0*X#*/Y6)U-@ M?_O_&4C/GP>3]XDW"B;3&YA>@?=NXE^!_]'W%L'D+Q^'T.K/?UL*

OX!YMIC? M+D8W 013<'JP,&]-SX1;WRMC<-I=N_E_@CNZA=%X.@O\,=21[_&^MB]TWH-W M/MR.YI>C&__6F'Y\]

*fW^"D1=H2]NV6T\2#TLCG,7M=LU:'3FM1Q=HTH2W5,0Q M7(=CD8IBE30AI%*Q> M9(?."(.IBUF*VJK'T7U4DG6Y.!6.R'89 M*

[]])X$GNJ&M8UH?:...!VVIB[X#TM:$]$BU)9;6^:6A%T]))EISN/2R%C*@T M0L$YR7+J[C_4,5R@ZZ2J8RUE.N68Q4.AU.

*.9;*L+;V5P'[X;&TDR=XE=T&=C@PGYJ;@_V.DR%[Q0M*\[#+UW#=TI5!TEK,_Q>ANU M*!X3\.X0-0;'U&2%H%@$+_^SR[X','LOA2>*

[H$V/\P7U'XQW+L:O@3&WW!ZH+_MH->RVP<5\!N+|-=!55WH[E5%^D7J@CC%Y3^-+OXXX$W"'%#7RC(3414HMJP?G M

*%BY=2R/)SV(_^;FV3[@UF=P;(]ZE6MS;#X7\#.46Z;;LE)[O831&/L"[!$T M(<,TCAEV7L\EF+.99-A29-A3/(KA_+D$<8."679_%U7S=X3;*N5^SVI/3;O_*

*M@FB3AWYC2<+/*RF*--*MCY#NGAU]/JL/#3O*:%U1TJY/Z[H\+=B/UIP7'SR$R MLJ)&U7"0&$G+)7>"1;N#[?7.5N?EGL>J,:N4Z^KY1OG 9/@/4$L#!!0 (*

M R"9ED>3O4B'P4 % 4 8 9V)I;RTR,#(T,#DS,'AE>#,R9#(N:'1M MU5C_3]LZ$/]7_#IM ZGYUA;4I:52">U6"5K6!KVW'YW$:2R<.',<2M]?_\[Y

M4D)A&T^#"9!($_M\][FS[SXG#__2M$D2X<0G ?KB7IRC@/MY3!)?$&PA-$-*

*ME1%R>9KB!%T0(2ACZ%308$T0LDS]6+61W.W:O@RXOT,&5ZQP6TF<+Q_UV.2G-7EZ=GL\8&<9DWD*M2,K4-HS-9J-ONCH7:|-*

*=&I&,6<]@G&=$#V30&@W5 M"#P)#D;#E$B,_ B+C,B3U!4[U?H@(;ED9#0TZM2UN/!=C0,Z W*Y);1DU:,*

*MQ9HFFN2IW353.8"5!DSOR=QJ&QK(R+9,_T@Q4% D[7&2"CM([W?OQL2=!WM MQGCIFBT(PY+>$*7[)Y8;%D*

PK<5"GD@MQ#%E6_NC2V.2H3G9H"6/T(QZE%&YM2,.:'0!@0_O^AVS.Q@: M2A#BD#X2"Y\1+&R/RVBP'Y;'_/U]_:]^/#..C8'!;C?5ZY42G(K-@=-

*#2\T+5=7X[F+ MW 6R^NA*7^F.CE83I_#'ZAZ9[=<$=[Q"X[/%I3LY0TWD-=Y/YK&*N_ME@E;C MY>EX/EEIBW_.)]_0V''53,P*$%3+N(*B;E]+=]*

UV>2$(&5<71*.7*XCD(N"BW?2RV(0(0"@ BH8P^^ MN^!'06YASL"$S^.440A\09=JH2#?.$C\7 M4!M!S>06B"H!C]V\M3YU>P@G02%'$T

7EWA]V$U,$\|&$Y3E?O2HCR&F*A"I M()G'TU;"&(@D.3ZN(%5^/ M!/"9CNC/V:DAV+]7]>^827%2D:XG+47$BO&QQTBMP>,B($+S.6,XS8A=OS0Q

*M'(/JJ$QDQ64JY!#%^_RNP-UG]R*YE"F-X2W/I8USR2OV[I7D+44-HU)OE2[* M8$>_*K=\S*J* TU D_\;@:ELUT%J,'%#-0=U(>.;FLKK;VTC<&I[T+Q=:QL(*

MR"]|DMT\]C+.X$.&S X'AK#2\>5N!J$Q4&2U?5"D#1 +TSB[]= M/7O(A\]R1E\8XP_..TP^L3?[@TGX=%!EPU@]9:_>0B7$7 M@@+P%)#?

*^;#:A;'O\SR18+UVZ?"M^#0':BSZO..RS7NEN)]YL.N*WO#P_D1%$YT] MVJ@YH'GS5(TT+Y[V+Y92O"9;V03B$(C&QC>'-D4$L! A0#% @ #()F64MY"'T(R*

M#@ :<$!4 (!F1 &=B:6\M,C R-# Y,S!?8V%L+GAM M;%!+ 0(4 Q0 (R"9ED"00! 4RX +_A @ 5 " ?X> M !G8FEO+3(P,C0P.3,P7V1E9BYX;6Q02P$"% ,4 "

*,@F99O DJMO=7 M "2#@4 %0 @ &$30 9V)L:RTR,#(T,#DS,%)L86(N>&UL M4$L! A0#% @ #()F62."1"WA/0 *U\$!4 (!KJ4 M &=B:6\M,C R-# Y,S!?*

<')E+GAM;%!+ 0(4 Q0 (R"9EGBVHIVS]P! M #\=%@ 5 " <+C !G8FEO+3(P,C0P.3,P>#$P<2YH=&U0 M2P$"% ,4 " ,@F99"K;\I (!/'0 & @ '$P (

*M9V)I;RTR,#(T,#DS,'AE>#,Q9#$N:'1M4$L! A0#% @ #()F64*_5.:! M" 5!\ !@ (!BLD" &=B:6\M,C R-# Y,S!X97@S,60R M+FAT;5!+ 0(4 Q0 (*

R"9EDT[HA+#P4 42 8 " M 4'2 @!G8FEO+3(P,C0P.3,P>&5X,S)D,2YH=&U02P$"% ,4 " ,@F99 M'D[U(A\% !0% & @ &&UP(9V)I;RTR,#(T,#DS,'AE ?

*>#,R9#(N:'1M4$L%!@ * H I@(-O< @ $! end XML 69 gbio-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001733294 us-gaap:CommonStockMember 2024-07-012024-09-30 0001733294 us-gaap:CommonStockMember 2024-01-012024-09-30 0001733294 us-gaap:CommonStockMember 2023-07-012023-09-30 0001733294 2024-11-062024-11-06 0001733294 us-gaap:CommonStockMember 2023-01-012023-09-30 0001733294 us-gaap:RetainedEarningsMember 2024-09-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001733294 us-gaap:RetainedEarningsMember 2024-06-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001733294 2024-06-30 0001733294 us-gaap:RetainedEarningsMember 2023-12-31 0001733294 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001733294 us-gaap:RetainedEarningsMember 2023-09-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001733294 us-*

gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001733294 us-gaap:RetainedEarningsMember 2023-06-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001733294 2023-06-30 0001733294 us-gaap:RetainedEarningsMember 2022-12-31 0001733294 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001733294 us-gaap:CommonStockMember 2024-09-30 0001733294 us-gaap:CommonStockMember 2024-06-30 0001733294 us-gaap:CommonStockMember 2023-12-31 0001733294 us-gaap:CommonStockMember 2023-09-30 0001733294 us-gaap:CommonStockMember 2023-06-30 0001733294 us-gaap:CommonStockMember 2022-12-31 0001733294 gbio:TwoThousandAndTwentyStockIncentivePlanMember 2024-01-31 0001733294 gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember 2024-01-31 0001733294 gbio:TwoThousandAndTwentyStockIncentivePlanMember 2023-12-31 0001733294 gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember 2023-12-31 0001733294 gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember 2024-01-012024-09-30 0001733294 gbio:CertainEmployeesDirectorsAndConsultantsMembergbio:ServiceBasedOptionsMember 2024-01-012024-09-30 0001733294 gbio:TwoThousandAndTwentyStockIncentivePlanMember 2024-01-012024-09-30 0001733294 us-gaap:LetterOfCreditMember 2021-07-31 0001733294 us-gaap:ContractsAccountedForUnderPercentageOfCompletionMembergbio:CollaborationAndLicenseAgreementMember 2024-09-30 0001733294 us-gaap:EmployeeSeveranceMember 2024-09-30 0001733294 us-gaap:EmployeeSeveranceMember 2023-12-31 0001733294 2023-11-012023-11-30 0001733294 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001733294 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001733294 us-gaap:ConstructionInProgressMember 2024-09-30 0001733294 gbio:LaboratoryEquipmentMember 2024-09-30 0001733294 gbio:ComputerEquipmentAndSoftwareMember 2024-09-30 0001733294 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001733294 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001733294 us-gaap:ConstructionInProgressMember 2023-12-31 0001733294 gbio:LaboratoryEquipmentMember 2023-12-31 0001733294 gbio:ComputerEquipmentAndSoftwareMember 2023-12-31 0001733294 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001733294 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0001733294 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001733294 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0001733294 gbio:ModernatxIncMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMember 2023-01-012023-09-30 0001733294 us-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001733294 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0001733294 us-gaap:ConstructionInProgressMember 2024-01-012024-09-30 0001733294 gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember 2024-01-012024-09-30 0001733294 gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember 2024-01-012024-09-30 0001733294 gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodTwoMember 2024-09-30 0001733294 gbio:ShareBasedCompensationExpectedToRecognizeOverWeightedAveragePeriodOneMember 2024-09-30 0001733294 us-gaap:ContractsAccountedForUnderPercentageOfCompletionMembergbio:CollaborationAndLicenseAgreementMember 2024-07-012024-09-30 0001733294 us-gaap:ContractsAccountedForUnderPercentageOfCompletionMembergbio:CollaborationAndLicenseAgreementMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember 2024-07-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember 2024-01-012024-09-30 0001733294 gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember 2024-09-30 0001733294 gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember 2024-09-30 0001733294 gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember 2024-09-30 0001733294 gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember 2024-09-30 0001733294 gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember 2024-09-30 0001733294 gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember 2024-09-30 0001733294 gbio:TwoThousandAndTwentyStockIncentivePlanMember 2024-09-30 0001733294 srt:MaximumMembergbio:TwoThousandAndTwentyStockIncentivePlanMembergbio:AdditionalFrom2017PlanMember 2020-06-11 0001733294 gbio:TwoThousandAndTwentyStockIncentivePlanMember 2020-06-11 0001733294 2023-09-30 0001733294 2022-12-31 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001733294 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001733294 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001733294 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001733294 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001733294 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001733294 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0001733294 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001733294 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0001733294 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001733294 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0001733294 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001733294 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0001733294 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001733294 2023-07-012023-09-30 0001733294 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0001733294 gbio:ModernatxIncMembergbio:ThirdLiverOrNonLiverProgramCommercializationOptionLicenseMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:SecondNonLiverProgramCommercializationOptionLicenseMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:SecondLiverProgramCommercializationOptionLicenseMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:FirstNonLiverProgramCommercializationOptionLicenseMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:FirstLiverProgramCommercializationOptionLicenseMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:CtlnpTechnologyAndResearchLicenseMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:SharePurchaseAgreementMemberus-gaap:BeneficialOwnerMembergbio:CollaborationAndLicenseAgreementMember 2023-03-012023-03-31 0001733294 srt:MaximumMembergbio:TwoThousandAndTwentyStockIncentivePlanMembergbio:AnnualIncrease2021To2030Member 2020-06-112020-06-11

0001733294 srt:MaximumMembergbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMembergbio:AnnualIncrease2021To2030Member 2020-06-112020-06-11 0001733294 srt:MaximumMember 2024-08-012024-08-31 0001733294 gbio:AtMarketOfferingMember 2024-08-012024-08-31 0001733294 gbio:ActiveLeaseMember 2024-09-30 0001733294 2021-07-012021-07-31 0001733294 2023-01-012023-09-30 0001733294 srt:MaximumMember 2021-07-012021-07-31 0001733294 gbio:ModernatxIncMembergbio:SharePurchaseAgreementMemberus-gaap:BeneficialOwnerMembergbio:CollaborationAndLicenseAgreementMember 2023-03-31 0001733294 2021-07-31 0001733294 gbio:AtMarketOfferingMember 2024-08-31 0001733294 gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember 2023-04-30 0001733294 gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember 2023-03-31 0001733294 gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember 2023-03-012023-03-31 0001733294 gbio:ModernatxIncMembergbio:CollaborationAndLicenseAgreementMember 2024-09-30 0001733294 gbio:ModernatxIncMembersrt:MinimumMembergbio:CollaborationAndLicenseAgreementMember 2023-03-012023-03-31 0001733294 2024-09-30 0001733294 2023-12-31 0001733294 2024-07-012024-09-30 0001733294 2024-11-01 0001733294 2024-01-012024-09-30 shares iso4217:USD gbio:item gbio:product gbio:security pure iso4217:USD shares0001733294--12-31Q3false0P10YP12Yhttp://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense 0066205550667535O8P2Y1M6D-0.06-0.0610-Qtrue2024-09-302024false001-39319GENERATION BIO CO.DE81-4301284301 Binney StreetCambridgeMA02142617655-7500Common Stock, $0.0001 Par ValueGBIONASDAQYesYesNon-accelerated Filertruefalsefalse667928222165700066446000163113000197918000221200000396000042720004294000191254000272618000150420000160100681663000-571377000104442000203128000248784000374758000755400021460001570400030260001508800002186200045811000656940009181000116410011690000-595960000254380003350300013453100010316800O-17884000-31357000-118827000-100142000257100030910008541000871600O-15313000-28266000-110286000-91426000-0.23-0.23-0.43-0.43-1.66-1.66-1.43-1.436673846866738468659070006590700066583266656832663951508631951508-15313000-28266000-110286000-91426000059000190004500079000-14714000-28247000-110241000-913470006670273470007820300O0-280000-666350000115407000968013000130004109 4-16000-16000375200037520005990005990O0-15313000-153130006675350870007857790003190O0-681663000104442000657842507000762228000-23000-5079250002542870001437O6-130000-130000600400060040001900019000-28266000-282660006592795670007681020O0-4000-536191000231914000662055507000774224000274000-571377000203128000225173100031000369414-172000-172000156027247000247000114490001144900045000450005000-110286000-110286000667535087000785779000319000-681663000104442000595054376000727335000-83000-444765000282493000585937510002255500022556000455463-448000-448000107681367000367000182930001829300079000790000-91426000-91426000659279567000768102000-4000-536191000231914000-110286000-91426000-590850000114490001829300037550003938000631200066990008400024000221200000265000-694000-1408000-2799000-479400028400O0-931000-790001386000-9526000-2633000-12154000044474000-7236000-1992000-72779000-277670002023000281700014900001158810002959670001420000002910000002424500O-778400001790000360000002780003670001720004480001060003574O000O-484280001890007223700098863000238090000990520004700013300004500079000 Generation Bio Co. Notes to Condensed Consolidated Financial Statements (Unaudited) 1. Nature of the Business and Basis of Presentation Generation Bio Co., or Generation Bio, was incorporated on October 21, 2016 as Torus Therapeutics, Inc. and subsequently changed its name to Generation Bio Co. Generation Bio Co. and its consolidated subsidiary, or the company, we, our or us, are innovating non-viral genetic medicines to provide durable, redosable treatments for potentially hundreds of millions of patients living with rare and prevalent diseases. We are developing two distinct and complementary platforms that we believe will enable highly differentiated therapeutic applications. Our first platform is a potent, highly selective cell-targeted lipid nanoparticle, or ctLNP, delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. The identification and optimization of new ligands to target new tissues and cell types is an efficient, flexible, and modular process, which we believe will allow us to rapidly expand our portfolio. Our second platform is our novel immune-quiet DNA, or iqDNA, a partially single-stranded DNA, which is a variant of our closed-ended DNA, or ceDNA, designed to enable long-lasting high levels of gene expression from non-integrating episomes, while avoiding innate immune sensors that have long prevented DNA from use in non-viral systems. Underpinning the iqDNA platform is our highly scalable capsid-free manufacturing process that uses our proprietary cell-free rapid enzymatic synthesis, or RES, to produce highly pure iqDNA at scale. We are headquartered in Cambridge, Massachusetts. We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, we have funded our operations with proceeds from the sale of instruments convertible into convertible preferred stock (which converted into convertible preferred stock in 2017), sales of convertible preferred stock (which converted into common stock in 2020), and sales of common stock in underwritten public offerings, “at-the-market” offerings, and in a private placement, as well as collaboration revenue under our collaboration with ModernaTX, Inc., or Moderna. We have incurred recurring losses, including net losses of $110.3 million for the nine months ended September 30, 2024 and $91.4 million for the nine months ended September 30, 2023. As of September 30, 2024, we had an accumulated deficit of $681.7 million. We expect to continue to generate operating losses in the foreseeable future. As of November 6, 2024, the issuance date of these condensed consolidated financial statements, we expect that our cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months. We will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We may not be able to obtain financing on acceptable terms, or at all, and we may not be able to enter into additional collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of our stockholders. Arrangements with collaborators or others may require us to relinquish rights to certain of our technologies or programs. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, pipeline expansion or commercialization efforts, which could adversely affect our business prospects. Although management will continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations when needed or at all. The accompanying condensed consolidated financial statements reflect the operations of Generation Bio and our wholly owned subsidiary, Generation Bio Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB. 2016-10-21-110300000-91400000-681700000 2. Summary of Significant Accounting Policies Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the measurement of proportional performance of the performance obligation of our collaboration agreements, accrual of research, and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and other market-specific or other relevant factors that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Unaudited interim financial information The condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission,

or SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of our financial position as of September 30, 2024, the results of operations for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024 or any other period. Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. Updates to our significant accounting policies are discussed below. Employee Retention Credit Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, passed by the United States Congress and signed by the President, we are eligible for a refundable Employee Retention Credit, or ERC, subject to certain criteria. ASC 105, Generally Accepted Accounting Principles, describes the decision-making framework when no clear guidance exists in GAAP for a particular transaction. Specifically, ASC 105-10-05-2 instructs companies to look for guidance for a similar transaction within GAAP and apply that guidance by analogy. As such, forms of government assistance, such as the ERC, provided to business entities would not be within the scope of International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, but it may be applied by analogy under ASC 105-10-05-2. We accounted for the ERC as a government grant in accordance with IAS 20 by analogy under ASC 105-10-05-2. We recognized a $2.3 million ERC upon completion of an analysis providing reasonable assurance that we met the conditions set forth in the CARES Act and it was reasonably assured that we will receive the employee retention credit. We recorded the ERC in other long-term assets on our condensed consolidated balance sheet as of September 30, 2024 related to labor costs recognized during 2020 and 2021. The ERC was recorded in research and development expenses and general and administrative expenses proportionately in the manner in which the qualified wages and related costs were classified. We have filed for refunds of the ERC and as of the date of this Quarterly Report, we have not received any refunds. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the measurement of proportional performance of the performance obligation of our collaboration agreements, accrual of research, and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and other market-specific or other relevant factors that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Unaudited interim financial information The condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of our financial position as of September 30, 2024, the results of operations for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024 or any other period. Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K that was most recently filed with the SEC. Updates to our significant accounting policies are discussed below. Employee Retention Credit Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, passed by the United States Congress and signed by the President, we are eligible for a refundable Employee Retention Credit, or ERC, subject to certain criteria. ASC 105, Generally Accepted Accounting Principles, describes the decision-making framework when no clear guidance exists in GAAP for a particular transaction. Specifically, ASC 105-10-05-2 instructs companies to look for guidance for a similar transaction within GAAP and apply that guidance by analogy. As such, forms of government assistance, such as the ERC, provided to business entities would not be within the scope of International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, but it may be applied by analogy under ASC 105-10-05-2. We accounted for the ERC as a government grant in accordance with IAS 20 by analogy under ASC 105-10-05-2. We recognized a $2.3 million ERC upon completion of an analysis providing reasonable assurance that we met the conditions set forth in the CARES Act and it was reasonably assured that we will receive the employee retention credit. We recorded the ERC in other long-term assets on our condensed consolidated balance sheet as of September 30, 2024 related to labor costs recognized during 2020 and 2021. The ERC was recorded in research and development expenses and general and administrative expenses proportionately in the manner in which the qualified wages and related costs were classified. We have filed for refunds of the ERC and as of the date of this Quarterly Report, we have not received any refunds. 2300000 3. Marketable Securities and Fair Value Measurements The following tables present our marketable securities by security type: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> Fair </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.48%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:58.48%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> 319 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 178,155 </td></tr></table><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> Fair </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.46%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:58.46%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> 197,644 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,918</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our marketable securities by contractual maturity as of September 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less than one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 162,932 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 163,113 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Greater than one year but less than two years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,904 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,042 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 178,155 </td></tr></table> Our marketable securities as of December 31, 2023 consisted of investments that mature within one year of their purchase date. We assess our available-for-sale securities under the available-for-sale security impairment model in ASC 326, “Financial Instruments - Credit Losses”, or ASC 326, as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on our available-for-sale securities is the result of a credit loss. We also evaluate our available-for-sale securities for impairment using a variety of factors including our intent to sell the underlying securities prior to maturity and whether it is more likely than not that we would be required to sell the securities before the recovery of their amortized basis. During the nine months ended September 30, 2024 and 2023, we did not recognize any impairment or realized gains or losses on sales of available-for-sale securities, and we did not record an allowance for, or recognize, any expected credit losses. The following tables present our assets that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques that we utilized to determine such fair value: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at September 30, 2024 Using: </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.93%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:57.93%;background:#cceeff;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 5,460 </td></tr><tr><td style="vertical-align:bottom;width:57.93%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,155 </td></tr><tr><td style="vertical-align:bottom;width:57.93%;background:#cceeff;margin:0pt;padding:0pt;"> Totals </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,460 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 178,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,615</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements at December 31, 2023 Using: </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 38,210 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,210</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,918</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Totals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,210 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 236,128 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> Fair </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.48%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:58.48%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> 319 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 178,155 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> Fair </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.46%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:58.46%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> 274 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 197,918 </td></tr>
</table>17783600031900001781550001976440002740000197918000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> Fair </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Less than one year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 162,932 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,113</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Greater than one year but less than two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,042</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 177,836 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 178,155 </td></tr></table>16293200016311300014904000150420001778360001781550000 The following tables present our assets that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques that we utilized to determine such fair value: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at September 30, 2024 Using: </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.93%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total </td></tr><tr><td style="vertical-align:bottom;width:57.93%;background:#cceeff;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">5,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 5,460 </td></tr><tr><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 5,460 </td></tr><tr><td style="vertical-align:bottom;width:57.93%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.93%;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,155 </td></tr><tr><td style="vertical-align:bottom;width:57.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Totals </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 178,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 183,615 </td></tr></table> - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at December 31, 2023 Using: </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.21%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">38,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 38,210 </td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"> U.S. treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 197,918 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 197,918 </td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"> Totals </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">38,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 197,918 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.83%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 236,128 </td></tr></table>
546000000546000001781550000178155000546000017815500001836150003821000000382100000197918000019791800038210000197918000 style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4. Collaboration and License Agreement Moderna Collaboration and License Agreement In March 2023, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Moderna to collaborate on developing treatments for certain diseases by targeting delivery of nucleic acids to liver cells and certain cells outside of the liver. Under the Collaboration Agreement, the parties have agreed to collaborate on preclinical research programs relating to lipid nanoparticle, or LNP, delivery systems and nucleic acid payloads, with each party obtaining certain rights to intellectual property used in and arising out of such research programs. Each party will be solely responsible for its own clinical development and commercialization of products under the Collaboration Agreement. Moderna will reimburse us for the internal and external costs incurred by us in conducting the research programs, to the extent consistent with such research plans and budgets. Moderna has exclusive options, upon payment of option exercise fees, to obtain worldwide, exclusive, sublicensable licenses under specified company intellectual property to develop, manufacture and commercialize (a) products comprising LNP delivery systems and nucleic acid payloads that are directed to (i) up to two liver targets, (ii) up to two non-liver targets and (iii) a third liver or non-liver target and (b) Exclusive Targets, which are Independent Program Products (as defined below) that include messenger RNA, or mRNA, that are directed to gene and protein targets in any of certain agreed-upon immune cell types, referred to as the Cell Target Types. Subject to the exclusivity obligations described below, each party has granted to the other a worldwide, non-exclusive, sublicensable license under certain LNP-related intellectual property arising out of the non-liver ctLNP program, or the Joint Collaboration ctLNP Intellectual Property, to develop, manufacture and commercialize products comprising LNP delivery systems and nucleic acid payloads directed to gene and protein targets in any of the Cell Target Types, or Independent Program Products. Each party is obligated to use commercially reasonable efforts to complete the activities assigned to it under the research plans, and Moderna is further obligated to use commercially reasonable efforts to develop, seek regulatory approval for and commercialize at least one product directed to each target for which Moderna exercises its exclusive license option in at least one indication in the United States and in specified European countries. We have agreed not to, directly or indirectly, alone or with, for or through any third party, develop, manufacture, commercialize or exploit (a) products containing mRNA that are directed to any of the Cell Target Types, during an agreed-upon exclusivity period, which may be extended by payment of extension fees, (b) products directed to any liver target or non-liver target during the option periods for those targets, (c) products directed to any liver target or non-liver target for which Moderna has exercised its exclusive license option or (d) products containing mRNA that are directed to any Exclusive Target for which Moderna has exercised its exclusive license option. Under the terms of the Collaboration Agreement, in April 2023, Moderna made an upfront payment to us of $40.0 million, and paid us $7.5 million in prepaid research funding. In addition, we are eligible to receive up to $1.8 billion in milestone payments upon the achievement of specified development, regulatory, commercial, and sales milestone events, research term extension fees and exclusivity extension fees. Subject to reductions in specified circumstances, we will also be entitled to receive tiered royalties: (i) ranging from high-single-digits to low-double-digits on sales of licensed products that are directed to any liver target or non-liver target with respect to which Moderna has exercised its exclusive license option, and (ii) in the single digits on sales of Independent Program Products, including the exclusively licensed Independent Program Products directed to the Exclusive Targets. In consideration for the non-exclusive license granted by Moderna to us under the Joint Collaboration ctLNP Intellectual Property, we have agreed to pay Moderna tiered royalties in the single digits on sales of Independent Program Products that include mRNA, subject to reductions in specified circumstances. Royalties will be paid by each party, on a licensed product-by-licensed product and country-by-country basis, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; or (iii) ten years after the first commercial sale of the applicable licensed product. In addition, in connection with the execution of the Collaboration Agreement, we entered into a Share Purchase Agreement, or the Share Purchase Agreement, with Moderna, pursuant to which we issued and sold 5,859,375 shares of our common stock to Moderna, at a price of $6.14 per share, for an aggregate purchase price of $36.0 million, which closed concurrently with the execution of the Collaboration Agreement and resulted in Moderna becoming a related party. Under the Share Purchase Agreement, Moderna has the right, subject to certain terms and conditions, to purchase up to 3.06% of the outstanding shares of our common stock (on a post-closing basis) in connection with a future equity financing of at least $25.0 million by us. Moderna Agreement Assessment We assessed the promised goods and services under the Collaboration Agreement, in accordance with ASC 606. At inception, the Collaboration Agreement included one combined performance obligation, which includes the license to the ctLNP technology to target indications outside of the liver and the related research services to develop such technology, as the two items are not distinct in context of the contract. The Collaboration Agreement also provides Moderna with options to receive additional research services and options to receive exclusive licenses. The options to receive exclusive licenses allow Moderna to develop and commercialize product candidates that utilize our ctLNP and ceDNA technology for targets within the liver, as well as utilizing the ctLNP technology to be developed as part of the Collaboration Agreement and our ceDNA technology for targets outside the liver. These options are considered to be a priced at a discount to its standalone selling price and therefore are considered to be material rights. The initial transaction price included a $40.0 million upfront fee, premium paid over the fair value of the common stock of $13.3 million in connection with shares issued and sold to Moderna under the Share Purchase Agreement, and estimated revenue associated with the payment for research services, including $7.5 million in prepaid research services. We utilized the expected amount method to determine the amount of reimbursement for these activities. We utilized the most likely amount method to determine the amount of consideration to include in the transaction price related to any variable consideration related to exclusivity fees, and milestones, and the royalty payments are constrained based on the royalty constraint. No amounts are included in the transaction price related to these elements.
We initially allocated the transaction price to each unit of account as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">Performance Obligations (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Standalone Selling Price </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;width:21.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Transaction Price Allocated </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> ctLNP technology and research license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;margin:0pt;padding:0pt;"> 42,576 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> First liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"> 7,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"> 5,677 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> Second liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"> 7,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;margin:0pt;padding:0pt;"> 5,677 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> First non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"> 11,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"> 9,488 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> Second non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"> 11,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;margin:0pt;padding:0pt;"> 9,488 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> Third liver or non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,987 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 96,050 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#ccceff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#ccceff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 77,893 </td></tr></table> The transaction price was allocated to each unit of account based on the relative estimated standalone selling prices, over which management has applied significant judgment, of each element. We developed the estimated standalone selling price for combined performance obligation and each of the options to receive licenses primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program and an estimate of the costs to provide services including a reasonable return. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, the probability of success and the time needed to commercialize a product candidate pursuant to the associated license. On a quarterly basis, we measure proportional performance of the combined performance obligation over time using an input method based on cost incurred relative to the total estimated costs by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is then applied to the transaction price allocated to the combined performance obligation and each of the options to receive licenses. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. All allocated consideration for the material rights is deferred until such time that Moderna exercises its options or the right to exercise the options expires. Upon exercise, we will determine the appropriate revenue recognition methodology and any other implications on the accounting treatment for the arrangement. During the three months ended September 30, 2024, we recorded additional revenue related to a change in estimate due to revisions in the research plan resulting in a reduction in the estimated timeline of future research services and total estimated costs. The change in estimate resulted in a $6.8 million decrease in the allocated transaction price and a $3.8 million increase in collaboration revenue, a $3.8 million decrease in deferred revenue and a $0.06 decrease in net loss per share, basic and diluted, for both the three and nine months ended September 30, 2024. The following table provides a summary of the transaction price allocated to each unit of account, in addition to revenue activity during the period: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:32.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Performance Obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Transaction Price Allocated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revenue Recognized During </td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revenue Recognized During </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Deferred Revenue </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.69%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">Three Months Ended September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> ctLNP technology and research license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> 7,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 14,549 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> First liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 5,388 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 4,526 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> Second liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 14,549 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> First liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 5,388 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 4,526 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> First non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 9,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 7,565 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> Second non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 9,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 7,565 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> Third liver or non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,734 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,976 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 42,707 </td></tr></table>
140000000.07500000180000000058593756.1436000000.00.030625000000.0140000000.013300000075000000 - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-

wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Performance Obligations (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:21.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Standalone Selling Price </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:21.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Transaction Price Allocated </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> ctLNP technology and research license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;margin:0pt;padding:0pt;"> 42,576 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> First liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"> 7,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"> 5,677 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> Second liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"> 7,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;margin:0pt;padding:0pt;"> 5,677 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> First non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"> 11,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"> 9,488 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> Second non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"> 11,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;margin:0pt;padding:0pt;"> 9,488 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;margin:0pt;padding:0pt;"> Third liver or non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td

*style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,987 </td></tr><tr><td style="vertical-align:bottom;width:48.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> 77,893 </td></tr>
</table>525000004257600070000005677000700000056770001170000094880001170000094880006150000498700096050000778930000-68000006800000380000038000000-3800000-3800000-0.06-0.06 The following table provides a summary of the transaction price allocated to each unit of account, in addition to revenue activity during the period: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:32.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Performance Obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Transaction Price Allocated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revenue Recognized During </td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revenue Recognized During </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Deferred Revenue </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.69%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30,*

2024 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> ctLNP technology and research license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> 7,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 14,549 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> First liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 5,388 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 4,526 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> Second liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 5,388 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 4,526 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> First non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 9,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"> 7,565 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">Second non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;margin:0pt;padding:0pt;"> 7,565 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;margin:0pt;padding:0pt;"> Third liver or non-liver program commercialization option license </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,734 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,976 </td></tr><tr><td style="vertical-align:bottom;width:32.69%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,554 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 42,707 </td></tr></table> (
4040900075540001570400014549000538800000452600053880000045260000900600000756500090060000075650004734000003976000739315
style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">5. Property and equipment, net Property and equipment, net consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.56%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Laboratory equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"> 14,859 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Computer equipment and software </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 1,422 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 1,447 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Furniture and fixtures </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"> 1,293 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"> 1,293 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 20,909 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 20,865 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,030 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 38,279 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 45,494 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (22,269) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (19,695) </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 25,799 </td></tr></table> Depreciation and amortization expense for the three and nine months ended September 30, 2024 was 1.2 million and $3.8 million, respectively. Depreciation and amortization expense for the three and nine months ended September 30, 2023 was $1.3 million and $3.9 million, respectively. In July 2021, we entered into a lease agreement for a manufacturing facility in Waltham, Massachusetts, or the Seyon Lease. On January 31, 2024, we notified Waltham CenterPoint I Investment Group, LLC, or Landlord, of termination of the Seyon Lease due to Landlord’s breach of its obligations to us under the Seyon Lease and returned possession of the premises to Landlord, effective January 31, 2024. On February 14, 2024, Landlord sent us a notice of the termination of the Seyon Lease due to our non-payment of rent. On February 20, 2024, Landlord served us with a complaint, filed in Massachusetts Superior Court, or the Court, with respect to the Seyon Lease. The complaint sought declaratory judgment that we unlawfully terminated the Seyon Lease and also asserted a claim for breach of contract damages. Following receipt of the complaint, we filed a counterclaim against Landlord asserting breach of contract and violation of Massachusetts General Law Chapter 93A. On October 29, 2024, the Court determined that although we did not have the right to terminate the Seyon Lease, Landlord’s subsequent termination was effective, and that we had alleged sufficient facts to state a claim for breach of contract and violation of Massachusetts General Law Chapter 93A by Landlord. We will continue to vigorously defend our rights with respect to this matter. During the nine months ended September 30, 2024, in connection with the termination of the Seyon Lease, we recorded a non-cash charge of $6.2 million in an impairment of construction in progress. For additional information, refer to Note 7, Leases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,543 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,859</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,447</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,293</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,865</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,030</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,494</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,695)</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,010 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt

0pt;"> 25,799 </td></tr>
</table>1454300014859000142200014470001293000129300020909000208650001120007030000382790004549400022269000196950001601000 0
style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">6. Accrued Expenses Accrued expenses and other current liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.56%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued employee compensation and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"> 13,208 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Accrued external research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 600 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 1,169 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"> 654 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"> 908 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Property and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 33 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 838 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 405 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 406 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,529 </td></tr></table> . In November 2023, following a review of strategic priorities and a determination by our management and board of directors to implement a strategic reorganization, to invest in our ctLNP delivery platform to develop wholly-owned programs for extrahepatic cell types and to develop our iqDNA platform for our lead program in hemophilia A and other programs, we announced a reduction in our workforce of approximately 40%, or RIF, and implemented reductions in operational expenditures including Good Manufacturing Practice readiness and manufacturing expenses. We completed the RIF during the second quarter of 2024. In connection with the RIF, affected employees were eligible to receive one-time severance benefits, including cash severance, temporary healthcare coverage, to the extent they were eligible for and elected such coverage, and transition support services, subject to each such employee entering into an effective separation agreement, which included a general release of claims against us. We offered a retention bonus to certain affected employees if such employees remained in continuous employment with us through their respective separation dates and executed a general release of claims against us. Below is a summary of accrued restructuring costs recorded and included in accrued expenses and other current liabilities during the year ended September 30, 2024: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:27.98%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Severance and Benefits Costs </td></tr><tr><td style="vertical-align:bottom;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,291</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash payments</p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,055)</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restructuring expenses</p></td><td style="vertical-align:bottom;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments</p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (402)</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September 30, 2024</p></td><td style="vertical-align:bottom;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:27.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 214 </td></tr></table> During the nine months ended September 30, 2024, we recorded $0.4 million of restructuring expenses in our condensed consolidated statements of operation and comprehensive loss all of which was classified as general and administrative expense. We did not recognize any restructuring expense during the nine months ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"> 4,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"> 13,208 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Accrued external research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 600 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 1,169 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"> 654 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"> 908 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Property and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"> 33 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"> 838 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 405 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 406 </td></tr><tr><td style="vertical-align:bottom;width:68.56%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,529 </td></tr></table>450500013208000600000116900065400090800033000838000405000406000619700016529000040 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:27.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Severance and Benefits Costs </td></tr><tr><td style="vertical-align:bottom;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,291</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash payments</p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,055)</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restructuring expenses</p></td><td style="vertical-align:bottom;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments</p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (402)</p></td></tr><tr><td style="vertical-align:bottom;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September 30, 2024</p></td><td style="vertical-align:bottom;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:27.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 214 </td></tr></table>529100050550003800004020002140004000000 7. Leases We lease our office and laboratory space under a noncancelable operating lease that expires in 2029, or the Office and Lab Lease. We have an option to extend the Office and Lab Lease term for one additional term of five years at the greater of the then-current base rent or the then-current fair market value. Exercise of this option was not determined to be reasonably certain and thus was not considered in determining the operating lease liability on the consolidated balance sheet as of September 30, 2024. We posted a letter of credit in the amount of approximately $2.1 million as a security deposit. The letter of credit is subject to increase if we were to sublease any portion of the leased premises. The Office and Lab Lease does not

include any restrictions or covenants that had to be accounted for under the lease guidance. Future lease payments for our noncancelable operating leases as of September 30, 2024 and a reconciliation to the carrying amount of the operating lease liabilities presented in the condensed consolidated balance sheet as of September 30, 2024 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:75.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (remaining 3 months) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,935</p></td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,838</p></td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,059</p></td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,275</p></td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,535</p></td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,834</p></td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted payments due under operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,476</p></td></tr><tr><td style="vertical-align:bottom;width:75.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,673)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,803 </td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">Current operating lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,707</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,096</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,803 </td></tr></table> The following table presents our costs included in operating expenses related to our noncancelable operating leases: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:43.72%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,280 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"> 9,842 </td></tr><tr><td style="vertical-align:top;width:43.72%;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 528 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 832 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,575 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,542 </td></tr><tr><td style="vertical-align:top;width:43.72%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,384 </td></tr></table> Net cash paid for the amounts included in the measurement of the operating lease liability on the condensed consolidated balance sheet and operating activities in our consolidated statement of cash flows was $5.7 million and $9.6 million for the nine months ended September 30, 2024 and 2023, respectively. The weighted-average remaining lease term and weighted-average incremental borrowing rate for all leases as of September 30, 2024 was approximately 5 years and 7.1%, respectively. The Seyon Lease commenced in December 2021, when we were granted access to the facility, and monthly rent payments began in September 2022; the total rent payment was expected to be approximately $104.3 million for the 12-year lease term. We had an option to extend the Seyon Lease term for two additional terms of five years each at the greater of the then-current base rent or the then-current fair market value. Exercise of this option was not determined to be reasonably certain and thus was not considered in determining the operating lease liability. In connection with the Seyon Lease, we provided a security deposit of $3.6 million in the form of a letter of credit. We paid an initial monthly base rent of approximately $0.4 million that increased annually, up to a monthly base rent of $0.6 million. We were obligated to pay operating costs, taxes and utilities applicable to the facility. We were responsible for costs of constructing interior improvements within the facility that exceed a construction allowance of $26.0 million provided by the landlord. As previously disclosed in our most recent Annual Report on Form 10-K and in this Quarterly Report, the termination of the Seyon Lease is the subject of pending litigation with the landlord. As of September 30, 2024, the landlord has collected $3.6 million from our security deposit in lieu of rent payments and has fully utilized such deposit. In connection with the termination of the Seyon Lease, during the nine months ended September 30, 2024, we recorded a material impairment loss of non-cash charges of $45.8 million in an impairment of the Seyon Lease right-of-use asset, $6.2 million in an impairment of construction in progress, and the write-off of $3.9 million in tenant improvement allowance receivable from the landlord. In addition, during the nine months ended September 30, 2024, we recognized $3.7 million in accretion and other lease related expenses, which resulted

in a $59.6 million loss on termination of lease in our condensed consolidated statement of operations and comprehensive loss. Accretion and other lease related expenses related to the Seyon Lease will continue to be recognized in loss on lease termination on our condensed consolidated statement of operations and comprehensive loss. As of September 30, 2024, as we have not met the criteria to extinguish the lease liability pursuant to ASC 405 Liabilities, and we had $62.0 million in operating lease liability related to the Seyon Lease on our condensed consolidated balance sheet. Additionally, in accordance with ASC 450 <i style="font-style:italic;">Contingencies</i>, we have assessed the probability of realizing a material loss contingency for the potential losses, including obligations to pay any future variable lease costs, under the Seyon Lease. Based on this assessment, we have determined that it is not probable that we will be obligated to pay any such amounts. As a result, we have not accrued for any amounts related to the potential losses, primarily variable lease costs, such as common area fees and other charges, as they relate to the Seyon Lease.</p>trueP5Y2100000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</p></td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (remaining 3 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> 1,935 </td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> 7,838 </td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> 8,059 </td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> 8,275 </td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> 8,535 </td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,834 </td></tr><tr><td style="vertical-align:top;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total undiscounted payments due under operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> 37,476 </td></tr><tr><td style="vertical-align:bottom;width:75.11%;margin:0pt;padding:0pt;"> Less imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,673) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,803 </td></tr><tr><td style="vertical-align:top;width:75.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"> Current operating lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,707</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,096</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,803 </td></tr>
</table>1935000783800080590008275000853500028340003747600056730003180300057070002609600031803000 The following table presents our costs included in operating expenses related to our noncancelable operating leases: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:43.72%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px

solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:43.72%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,280 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"> 9,842 </td></tr><tr><td style="vertical-align:top;width:43.72%;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 528 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 832 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,575 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,542 </td></tr><tr><td style="vertical-align:top;width:43.72%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,384 </td></tr></table>1467000328000044010009842000528000832000157500025420001995000411200059760001238400057000009600000P5Y0.07110430000059600000062000000.0 8. Equity As of September 30, 2024, our amended and restated certificate of incorporation authorizes us to issue 150,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per share, all of which preferred stock is undesignated. In August 2024, we entered into an “at-the-market” sales agreement pursuant to which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $237.0 million. Upon our entry into this sales agreement, we terminated our prior at-the-market program pursuant to a prior sales agreement that we entered into in August 2021. At the time of termination, approximately $237.3 million out of an aggregate of $250.0 million remained unsold under the prior sales agreement. As of November 6, 2024, the issuance date of these condensed consolidated financial statements, we have not issued and sold any shares of our common stock pursuant to the August 2024 sales agreement. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of our stockholders. Holders of common stock are not entitled to receive dividends, unless declared by the board of directors. 1500000000.000150000000.000123700000.023730000025000000.01 9. Stock-Based Compensation Stock incentive plans Our 2017 Stock Incentive Plan, or the 2017 Plan, provided for us to grant incentive stock options or nonstatutory stock options, restricted stock, restricted stock units and other

equity awards to employees, non-employees, and directors. In May 2020, our board of directors adopted, and in June 2020, our stockholders approved, the 2020 Stock Incentive Plan, or the 2020 Plan, and together with the 2017 Plan, the Plans, which became effective on June 11, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the 2020 Plan is the sum of (1) 2,547,698 shares; plus (2) the number of shares (up to a maximum of 7,173,014 shares) as was equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2017 Plan that remained available for grant under the 2017 Plan on June 11, 2020 and (y) the number of shares of common stock subject to outstanding awards granted under the 2017 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021 and continuing until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 4% of the number of shares of common stock outstanding on such date, and (ii) an amount determined by the board of directors. In January 2024, the number of shares of common stock authorized for issuance under the 2020 Plan was increased from 16,813,962 shares to 19,462,688 shares. Upon the effectiveness of the 2020 Plan, we ceased granting additional awards under the 2017 Plan. The Plans are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions on any award under the Plans are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted under the Plans with service- based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock as of the date of grant. Prior to our initial public offering, or IPO, in June 2020, the fair value of our common stock was determined by the board of directors. Subsequent to our IPO, fair value of common stock is based on quoted market prices. As of September 30, 2024, 790,738 shares remained available for future issuance under the 2020 Plan. Shares subject to outstanding awards granted under the Plans that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right will be available for future awards under the 2020 Plan. Grant of stock options During the nine months ended September 30, 2024, we granted time-based options to certain employees for the purchase of an aggregate of 3,693,074 shares of common stock with a weighted average grant date fair value of $1.87 per share that vest over a weighted average period of approximately four years. Employee stock purchase plan In May 2020, our board of directors adopted, and in June 2020, our stockholders approved, the 2020 Employee Stock Purchase Plan, or the 2020 ESPP, which became effective June 11, 2020. The 2020 ESPP is administered by our board of directors or by a committee appointed by the board of directors. The number of shares of common stock authorized for issuance under the 2020 ESPP automatically increases on the first day of each fiscal year, beginning with the fiscal year that commenced on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lowest of (1) 1,302,157 shares of common stock, (2) 1% of the number of shares of common stock outstanding on such date, and (3) an amount determined by the board of directors. In January 2024, the number of shares of common stock authorized for issuance under the 2020 ESPP was increased from 2,115,792 shares to 2,777,974 shares. As of September 30, 2024, 2,204,771 shares remained available for issuance under the 2020 ESPP. Stock-based compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.81%;margin:0pt;padding:0pt;"> (in thousands) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:47.81%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"> 2,874 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"> 8,608 </td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"> General and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,232 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,130 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,685 </td></tr><tr><td style="vertical-align:bottom;width:47.81%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,293 </td></tr></table> As of September 30, 2024, total unrecognized compensation cost related to unvested time-based stock options and restricted stock units was $14.7 million, with $13.2 million expected to be recognized over a weighted average period of 2.1 years and $1.5 million expected to be recognized over a weighted average period of 2.2 years, respectively. 2547698717301400.041681396219462688P4YP10Y79073836930741.87P4Y13021570.012115792277979422047714 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.81%;margin:0pt;padding:0pt;"> (in thousands) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:47.81%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"> 2,874 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"> 8,608 </td></tr><tr><td style="vertical-align:bottom;width:47.81%;margin:0pt;padding:0pt;"> General and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,232 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,130 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,685 </td></tr><tr><td style="vertical-align:bottom;width:47.81%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,752 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,293 </td></tr>
</table>1520000287400044520008608000223200031300006997000968500037520006004000114490001829300014700000132000001500000P2Y2
style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">10. Commitments and Contingencies 401(k) Plan We have a defined-contribution plan under Section 401(k) of the Internal Revenue Code of 1986, as amended, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to contribute a portion of their annual compensation on a pre-tax and/or after-tax basis. In September 2020, we adopted a match program, beginning on January 1, 2021, for employee contributions to the 401(k) Plan up to a maximum of four percent of the employee’s salary, subject to the maximums established under the U.S. Internal Revenue Code of 1986, as amended. Indemnification agreements In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and our officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims. . Legal proceedings We, from time to time, may be party to litigation arising in the ordinary course of business. On February 20, 2024, our Landlord served us with a complaint, filed in the Court with respect to the Seyon Lease. The complaint sought declaratory judgment that we unlawfully terminated the Seyon Lease and also asserted a claim for breach of contract damages. Following receipt of the complaint, we filed a counterclaim against Landlord asserting breach of contract and violation of Massachusetts General Law Chapter 93A. On October 29, 2024, the Court determined that although we did not have the right to terminate the Seyon Lease, Landlord’s subsequent termination was effective, and that we had alleged sufficient facts to state a claim for breach of contract and violation of Massachusetts General Law Chapter 93A by Landlord. We will continue to vigorously defend the action and our rights with respect to this matter. As a result, we may continue to incur costs and expenses relating to this facility, and we may remain responsible for payments under the Seyon Lease, which may have a material adverse effect on our business, results of operations or financial condition. <p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.
0.04 11. Net Loss per Share <span
style="background:#ffffff;">We have generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. We excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: . <table
style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td
style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> . </td><td
style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> .
</td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> . </td><td
style="vertical-align:middle;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"> .
</td></tr><tr><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> . </td><td
style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> . </td><td colspan="3"
style="vertical-align:middle;white-space:nowrap;width:38.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30,
</td></tr><tr><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> . </td><td
style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td
style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td
style="vertical-align:middle;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"> 374,076 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,179,349 </td></tr><tr><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> Stock options to purchase common stock </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,215,012 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,676,685 </td></tr><tr><td style="vertical-align:middle;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,589,088 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,856,034 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:38.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"> 374,076 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"> 1,179,349 </td></tr><tr><td style="vertical-align:middle;width:57.22%;margin:0pt;padding:0pt;"> Stock options to purchase common stock </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,215,012 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,676,685 </td></tr><tr><td style="vertical-align:middle;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,589,088 </td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,856,034 </td></tr></table> . 3740761179349132150129676685135890881085603 4falsefalsefalsefalse